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the ‘PROSPECT’ research group that studies the relations between dietary protein intake, nutritional
security and cardiometabolic health, combining metabolism and physiology in clinical trials and the
analysis of dietary intake of populations (at UMR Physiologie de la Nutrition et du Comportement
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Preface to ”The Effect of Diet and Nutrition on
Postprandial Metabolism”
Humans feed themselves by discontinuous inputs that give an essentially dynamic characteristic
to all nutritional processes. Metabolism is constructed according to a nutritional system:
The individual’s endogenous metabolism works on a fasting basis at a steady-state to ensure
physiological functions with consistency, but this situation results in molecule/nutrient losses that
must be compensated for by food intake. In the postprandial phase, conversely, the nutritional
system must ensure the correct use of the influx of nutrients, by regulating flows while maintaining
circulating concentrations within acceptable ranges. The postprandial phase is, therefore, the critical
nutritional phase during which the body ensures its repletion while putting its homeostasis
under pressure, and manages metabolic disturbance according to “hemodynamic” type processes.
A decrease in good postprandial management capacity compromises the nutritional status of an
individual, on the one hand, and, on the other hand, indicates alterations in metabolic health,
i.e., a loss of metabolism flexibility and adaptability. The effectiveness of nutrient use in the
postprandial phase appears to be a major determinant of long-term nutritional status for many
nutrients. If we consider the resilience of the body to environmental stimuli as a central and
modern definition of health, then we can view the smooth course of these postprandial processes as a
definition of nutritional health. The efficiency of nutrient use and the time course of the activation of
nutrient metabolism is modulated by the characteristics of the diet, patterns of intake, nature of the
meals, individual genetics, phenotypes and health status, and all other lifestyle characteristics.
Changes in postprandial metabolism have been considered to be potential early markers in the
pathophysiological course, leading to the risk of pathology development. They are sensitive to diets
and the complex nature of meals, which can alter the allostatic load, and postprandial deregulations
are predictive of the risk of chronic diseases.
With this Special Issue, we aimed to expand and add to the research on the importance of
postprandial metabolism in nutrition. The book begins with two long reviews of the literature
to understand the appearance of markers of altered cardiometabolic health in the postprandial
phase, as well as what is known about its modulation by nutritional intakes, with a detailed review
on the importance of modulation of postprandial lipemia. This is complemented by an original
research paper on the nature of dietary lipids. Another article focused on the likely important
mechanism of postprandial regulation, which is the appearance of low-grade endotoxemia, while
another contribution has tended to rule out the possibility that arginine methylation processes, which
lead to the appearance of cardiovascular risk factors, may be operating in the postprandial phase.
This set provides a rather important overview of the presentation of postprandial processes and their
determinants. The global and exploratory understanding of postprandial changes in metabolism is
also addressed here, with metabolomics data allowing comparison between “normal” postprandial
situations (i.e., after a standard meal) and situations resulting from an acute or prolonged nutritional
challenge. Other data help to understand the re-organization of inter-organ flows in response to
overnutrition, particularly during the postprandial phase. The last part of the book presents studies
that account for the effects of meal composition on postprandial phenomena. It includes several
studies that have focused on what has long been the poor relation of the nutritional regulation of
postprandial metabolism: proteins. These studies illustrate that proteins themselves, or depending on
their relationship with other nutrients (sucrose, lipids), may (1) have different levels of effectiveness
ix
in postprandial repletion in subjects with anabolic resistance, (2) modify postprandial metabolic
responses in healthy or at-risk subjects, and (3) limit metabolic deregulation leading to ectopic
lipid deposition—a highly pathogenic phenomenon. These studies illustrate the current vitality
of this topic, which is decidedly modern because it offers a consistent conceptual framework for
understanding the relationship between diet and health.
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Abstract: The purpose of this review is to provide an overview of diets, food, and food components
that affect postprandial inflammation, endothelial function, and oxidative stress, which are related
to cardiometabolic risk. A high-energy meal, rich in saturated fat and sugars, induces the transient
appearance of a series of metabolic, signaling and physiological dysregulations or dysfunctions,
including oxidative stress, low-grade inflammation, and endothelial dysfunction, which are directly
related to the amplitude of postprandial plasma triglycerides and glucose. Low-grade inflammation
and endothelial dysfunction are also known to cluster together with insulin resistance, a third
risk factor for cardiovascular diseases (CVD) and type-II diabetes, thus making a considerable
contribution to cardiometabolic risk. Because of the marked relevance of the postprandial model
to nutritional pathophysiology, many studies have investigated whether adding various nutrients
and other substances to such a challenge meal might mitigate the onset of these adverse effects.
Some foods (e.g., nuts, berries, and citrus), nutrients (e.g., l-arginine), and other substances (various
polyphenols) have been widely studied. Reports of favorable effects in the postprandial state have
concerned plasma markers for systemic or vascular pro-inflammatory conditions, the activation of
inflammatory pathways in plasma monocytes, vascular endothelial function (mostly assessed using
physiological criteria), and postprandial oxidative stress. Although the literature is fragmented,
this topic warrants further study using multiple endpoints and markers to investigate whether
the interesting candidates identified might prevent or limit the postprandial appearance of critical
features of cardiometabolic risk.
Keywords: metabolic syndrome; postprandial; endothelial function; oxidative stress; nuts; berries
1. Introduction
This review focuses on the kinds of diets, food, and food components that affect postprandial
inflammation, endothelial function, and oxidative stress, and which are related to cardiometabolic
risk, including metabolic syndrome (MS), and ultimately, cardiovascular diseases (CVD) and type
2 diabetes. Although this review gathered a very large number of studies, it is not intended to be
exhaustive; rather, it emphasizes the food and food components that have been studied the most,
and the data that together help us to understand the impact of nutrition on cardiometabolic risk, as this
can be studied during the postprandial period.
Metabolic syndrome refers to the clustering of a series of risk factors for CVD, whose prevalence is
rising markedly at a global level [1–5]. Because MS is an important risk for CVD and type-II diabetes [6],
considerable attention has been paid to analyzing its links with environmental factors and diet.
MS has been characterized from a clinical point of view using the following criteria: a high waist
circumference; raised plasma triglycerides, plasma glucose, and systolic blood pressure; and lower
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HDL-cholesterol concentration [5,7,8]. From a pathophysiological viewpoint, the heterogeneity of
MS is considerable, but there is now consensus regarding the importance of a few related features
that are major components of cardiometabolic risk. MS is mainly considered as being related to the
development of resistance to the action of insulin in different tissues and on different metabolisms [9],
linked closely to the onset of systemic low-grade inflammation, which in turn is associated with
the development of abdominal fat [10]. The third element in the triad is the initiation of vascular
endothelial dysfunction. Indeed, endothelial dysfunction is closely associated with insulin resistance
and it is the manifestation of a pro-inflammatory and pro-atherogenic phenotype in the vascular
milieu [8,11]. Nutrition, and in particular western diets, have been implicated in the onset of this
cardiometabolic risk; for a review see [12–14]. Controlled studies in animals have provided further
evidence that insulin resistance, systemic and adipose tissue low-grade inflammation, and vascular
endothelial dysfunction, as promoted by western diets, are early features of this cardiometabolic risk
cluster [15].
From a mechanistic standpoint, a growing body of evidence is tending to confirm the rationale for
a close association between insulin resistance and endothelial function. Firstly, it has been suggested that
endothelial dysfunction is the earliest manifestation of diet-induced cardiometabolic risk, even before
the onset of insulin resistance and a systemic inflammatory state [15–18]. Secondly, endothelial
dysfunction may be largely driven by an impairment of the action of insulin on the endothelium,
so that this dysfunction could be considered as a vascular feature of insulin resistance, itself promoting
a pro-inflammatory state in the vascular milieu [19,20]. In turn, macro- and micro- vascular endothelial
dysfunction limits the action of insulin on the peripheral extraction of nutrients by limiting the
perfusion of insulin-sensitive tissues [21,22]. Endothelial dysfunction and insulin resistance would thus
interact in a reciprocal relationship [20,23–25]. Abnormal nitric oxide (NO) production or signaling and
endothelial dysfunction, triggered by excessive exposure to high-fat and high-sucrose foods, may be
one important mediator of diet-induced insulin resistance and cardiometabolic risk [26,27].
2. The Postprandial Period as a Metabolic Challenge Eliciting Pathophysiological Features
Related to Cardiometabolic Risk
A very large body of evidence has demonstrated that a metabolic challenge with a high saturated
fat and high sucrose meal results in the transient appearance of low-grade inflammation and endothelial
dysfunction [28–40].
The level and chronology of these phenomena are closely associated with the postprandial rise in
plasma glucose and lipids [35,41–44]. Postprandial inflammation has been characterized at a systemic
level [38,45], in blood leukocytes [42,46,47], in the visceral adipose tissue [48,49], and at the vascular
level as an increase in intercellular or vascular adhesion molecules and proteins measured in the plasma
ICAM-1 et VCAM-1 [32,50]. Other postprandial changes associated with inflammation have been
reported after a high fat meal (HFM), such as changes to markers of angiogenesis (vascular endothelial
growth factor-VEGF) [51]. Postprandial vascular endothelial dysfunction has also been repeatedly
documented using integrative physiological endpoints such as macrovascular reactivity to acute
changes in shear stress (particularly using flow-mediated dilation of the brachial artery-FMD) [52,53].
Although the underlying mechanisms are not fully elucidated, the dramatic rise in plasma glucose
and triglycerides (and more precisely chylomicrons and their remnants) are considered to be the
trigger factors for the activation of inflammatory signaling pathways in leukocytes, endothelial cells,
and possibly other cells or tissues [35,48,54–56]. Postprandial oxidative stress is one mediator of the
effect of metabolic stress on inflammation and vascular dysfunction [57,58]. Early evidence for the
contribution of oxidative stress was provided by the finding that pre-treatment with high doses of
vitamin C and/or vitamin E blunted postprandial endothelial dysfunction and inflammation [32,59].
As we also discuss further below, the initiation of low-grade endotoxemia is considered to be
an important mechanism [47,60]. Lastly, of importance to our understanding of cardiometabolic
pathophysiology is the fact that postprandial inflammation and macro/micro- vascular endothelial
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dysfunction are all the more important if individuals present at baseline with markers of dysregulation or
cardiometabolic risk factors [21,61], and dysfunction increases when the meal challenge is repeated [62].
At the molecular level, considerable importance has been given to NO, primarily because it is
well-known as the pivotal molecule of vascular health, and endothelial dysfunction can be explained by
alterations to NO synthesis and/or bioactivity. More specifically, regarding postprandial deregulation
the role of NO in the insulin-mediated peripheral extraction of nutrients is becoming increasingly
well-established [19,22,63–68]. Furthermore, high fat and high sucrose meals impact NO synthesis
and/or NO downstream signaling [26,69,70], and studies have confirmed that impairment of the insulin
sensitivity of the vascular NO production pathway may explain the impairment of glucose extraction in
the muscle [20,23,24,71]. Finally, because the NO pathway is more sensitive to the oxidative/redox state
at many different levels, this pathway may mediate the effect of a postprandial increase in oxidative
stress on impairment of endothelial function and the initiation of vascular and systemic inflammation.
The final picture is that the postprandial occurrence of low-grade inflammation and endothelial
dysfunction is extremely relevant to the pathophysiological influence of nutrition on cardiometabolic
risk for the following reasons: (i) low-grade inflammation and endothelial dysfunction are well
known to be pivotal to the initiation and progression of cardiometabolic dysregulations, as discussed
previously; (ii) their postprandial appearance is directly related to the degree to which energy nutrients
challenge homeostasis and are concurrent with deregulations at the cellular and molecular levels;
(iii) their postprandial appearance is graduated according to the basal level of metabolic regulation
and in line with the existence of risk factors for CVD and type-II diabetes; and (iv), the level of the
postprandial rise in plasma triglycerides, and glucose after a meal challenge is considered to be a potent
risk factor for CVD and type-II diabetes [72–74]. Finally, the current paradigm is that repetition of
these adverse, silent postprandial events is a mechanism for the initiation and progression of metabolic
dysregulation, CVD, and type-II diabetes [36,73].
Accordingly, the postprandial state following a challenge meal offers an interesting, practical,
and relevant model for studying the impact of nutrients on metabolic dysregulation, and the initiation
of cardiometabolic risk factors such as MS.
3. Fatty Acids, Carbohydrates, and Postprandial Adverse Effects
As mentioned above, there is very convincing evidence that a challenge meal containing both
saturated fatty acids and sucrose triggers a vast corpus of inflammatory phenomena and endothelial
dysfunction features during the postprandial period. A smaller, yet still high, number of studies
have also reported similar findings when the challenge meal only contained saturated fat or simple
sugars [75–78], although some studies using a single macronutrient were negative [75]. It should
be noted that these studies differed markedly in terms of the methods used to study postprandial
metabolism [74].
3.1. Fatty Acids in Challenge Meals
In contrast, the literature is less conclusive regarding the role of the type of fatty acids in the
challenge meal [79]. It should, however, be noted that olive oil (as compared to oils rich in palmitic
acid, or to milk fat) induces a smaller increase in plasma inflammatory markers, does not result in
activation of the NF-κB inflammatory pathway in peripheral blood mononuclear cells, and generates
less postprandial endothelial dysfunction in healthy individuals and/or those with risk factors [80–82].
When supplementing a high fat meal, fish oils have also been shown to be beneficial to postprandial
vascular function. In a postprandial model combining a high-fat meal and a heparin infusion to
increase postprandial non-esterified fatty acids (NEFA), the standard high-fat meal with saturated
fatty acids (SFA) impaired flow-mediated dilation (FMD) whereas the addition of fish oil to this meal
conversely improved FMD 4 h after ingestion [83]. In another study, the introduction of fish oil as
part of a high-fat meal improved (endothelium-independent) microvascular reactivity and increased
postprandial plasma nitrite concentration (a marker of nitric oxide synthase activity) [84]. Fish oil
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enhanced eNOS expression in cultured endothelial cells exposed to triglyceride-rich lipoprotein isolated
after the meal. When associated with fibers, unsaturated fatty acids (unSFA) blunted the postprandial
expression of the inflammatory genes usually found after a high SFA meal; that is, the postprandial
circulation levels of IL-1β, IL-6, MCP-1, and IFN-γ did not rise after an unSFA and fiber-rich meal
when compared with an SFA meal [85].
An antioxidant and anti-inflammatory effect of olive oil or monounsaturated fatty acids (versus
saturated fatty acids and low-fat meals) during the postprandial state has also been reported when the
individuals had been receiving diets of a similar composition before the postprandial challenge [86,87].
The underlying mechanism for the effect of SFA on systemic inflammation has been documented.
Studies have suggested that SFA increase the intestinal absorption of lipopolysaccharide (LPS), which in
turn increases postprandial endotoxemia and the postprandial inflammatory response. For instance,
in individuals with metabolic syndrome, a meal rich in SFA raises plasma LPS concentrations when
compared to other meals rich in monounsaturated fatty acids (MUFA) or low in fat, and high in
complex carbohydrates and n-3 fatty acids. After the SFA meal, the increase in LPS was correlated with
the gene expression of IkBα (an NF-kB inhibitor) and MIF1 (a pro-inflammatory cytokine) in peripheral
blood mononuclear cells, suggesting partial mediation by these pro-inflammatory pathways [88,89].
Finally, a high SFA meal could be involved in causing postprandial endotoxemia and also affect
other mechanisms, including intestinal absorption and clearance rates of LPS, changes to intestinal
microbiota, and intestinal barrier function [88]. However, it remains difficult to assess the significance
of endotoxins in plasma, as LPSs are highly heterogeneous. Indeed, stimulatory, non-stimulatory,
and inhibitory LPS molecules coexist in plasma, and assays cannot distinguish or quantify them
separately [90].
In contrast, the literature remains scarce and still inconclusive regarding the effect of different
types of saturated fatty acids, or the role of various unsaturated fatty acids [91–95].
3.2. Carbohydrates in Challenge Meals
There is quite a large body of evidence to suggest that sucrose and glucose loads induce
postprandial inflammation and endothelial dysfunction, related to the postprandial increase in plasma
glucose [75,96], although there have been some negative reports when these loads were given alone
(i.e., without saturated fatty acids). To our knowledge, there are no data regarding the effect of other
simple carbohydrates. Given the relationship between postprandial plasma glucose and postprandial
dysfunctions, the glycemic index (GI) is expected to be an important factor in the adverse effect of
carbohydrates, however, findings are scarce and conflicting [56,97,98]. For instance, nuts have shown
potential to manage post-meal glucose when consumed with high GI food content [99] but not with low
GI foods [100]. Also, the acute ingestion of low-fat milk has been shown to protect adults with metabolic
syndrome from endothelial dysfunction when compared to rice milk (high GI). The postprandial serum
glucose peak was higher after rice milk and correlated positively with an increase in malondialdehyde
(MDA, a biomarker of oxidative stress mostly related to lipid peroxidation) and a drop in plasma
arginine, suggesting that cow’s milk may limit postprandial hyperglycemia, which in turn may decrease
lipid peroxidation and enhance NO bioavailability [101].
Although most studies have resorted to using experimental artificial meals containing high
amounts of simple ingredients such as milk cream and sucrose, postprandial inflammation and
dysfunction are not the result of an experimental artefact because they have also been evidenced
following the consumption of “real” energy-dense meals, such as those supplied by fast-food
outlets [46,102–105]. In contrast, some foods, such as orange juice and certain meals considered
to form part of a prudent diet (e.g., meals rich in fibers and fruit, or light regular meals), do not induce
adverse postprandial effects [106–110].
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4. Relevance to the Effect of the Type of Dietary Protein
As mentioned before, some carbohydrates and fat sources do not appear to elicit any adverse
effects during the postprandial period. Although dietary proteins are the third most important energy
macronutrient, their effects have been little studied.
Indeed, we previously reported that a mixture of 50 g amino acids (based on the total milk protein
composition, and with or without a supplement of l-arginine) did not increase plasma markers of
inflammation or induce endothelial dysfunction [111].
In a pioneering work, Westphal and colleagues showed that adding dietary protein (milk or soy
protein) to a high-fat meal prevented postprandial endothelial dysfunction [112]. This effect could,
however, be explained by a quantitative effect of protein, because a high intake of protein (as compared
to fat), (i) slowed down gastric emptying and decreased postprandial exposure to fatty acids in the
meal [113], and (ii), raised postprandial insulin, which in this context could have anti-inflammatory
and anti-atherogenic properties [114]. However, specific effects of protein quality or specific amino
acids have also been documented [115]. The same authors reported that a “dietary” amount (2.5 g) of
l-arginine alone (and not phenylalanine or leucine) prevented postprandial endothelial dysfunction [78],
confirming the results of a study that used a massive dose of l-arginine [116]. The issue of the dose
was raised in one of our studies which consisted of supplementing overweight adults with a low dose
of l-arginine. After a high fat meal, reductions in the FMD and fRHI (a reactive hyperemia index
that is another measure of endothelial function) compared to baseline were attenuated by arginine
supplementation in individuals whose plasma arginine concentration was below the median [117].
Likewise, in a validated rat model [70], we showed that rapeseed protein (an arginine- and cysteine-
rich protein when compared to milk protein), and the supplementation of milk protein with l-arginine
and l-cysteine, prevented postprandial endothelial dysfunction [118]. Using this model, we were also
able to show that rapeseed protein markedly reduced a postprandial increase in the production of
reactive oxygen species (ROS) in the aorta [70]. Indeed, dietary arginine and cysteine are known to
impact critical metabolic pathways (notably glutathione and nitric oxide) and may exert favorable
effects on the initiation of cardiometabolic risk factors such as insulin sensitivity and endothelial
function [119,120].
It has also been reported in overweight/obese individuals that neither a palmolein nor an olive oil
diet impaired postprandial FMD when consumed in a high-fat, high-protein meal rich in l-arginine [121].
These results were not in line with the findings of a study that could not find a protective effect of
proteins on postprandial endothelial dysfunction and low-grade inflammation, apart from a decrease in
sVCAM after a protein mix compared to maltodextrin. However, the protein mix that was used during
that study was not high in arginine, and this might have been the reason for the discrepancy [122].
Other plausible mechanisms (other than the arginine content) could explain the protective effect
of milk on cardiometabolic health and endothelial function [123–125]. For example, acute dairy cheese
consumption has been demonstrated to improve NO-dependent vasodilation compared to non-dairy
products (soy cheese and pretzels) when eaten with non-dairy sodium. This suggests that dairy
proteins may protect against Na-induced reductions in NO-dependent dilation [126].
5. Foods, Nutrients, and Other Dietary Substances That May Protect against Adverse
Postprandial Effects
The adverse postprandial effects of a high-saturated fat/high-sucrose meal have been used to
determine whether adding a nutrient or dietary substance to that meal might lower or prevent
the postprandial inflammatory reaction and endothelial dysfunction. Because high exposure to
triglycerides and glucose have been convincingly proposed as trigger factors for adverse postprandial
effects, numerous studies have addressed the effects of dietary factors on postprandial increases in
glucose and triglycerides. As with the addition of protein, some foods or ingredients may basically act
through their added weight/energy, slowing down gastric emptying and modulating plasma insulin.
Furthermore, the kinetics of digestion and the availability of carbohydrates and fats differ depending
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on the type of food or the structure of the meal. For instance, the unique physical structure of nuts may
explain their role in postprandial regulation. Indeed, the effects of processing on nuts have been shown
to affect the postprandial glycemic response [127] by breaking down the nut cell walls and increasing
the bioaccessibility of intracellular lipids [128,129], leading to prolonged gastric emptying. Likewise,
we have shown that interactions between macronutrients within a meal may modify the kinetics of the
absorption of meal fat and result in a different challenge for postprandial metabolism [130,131].
Several nutrients, micronutrients, and phytochemicals may affect postprandial blood lipid
concentrations after both acute and chronic consumption, as recently reviewed in detail by
Desmarchelier et al. [132]. Among many examples [133], a blend of antioxidant spices added to
a high-fat meal lowered postprandial insulin and triglycerides [134]. Nuts have also been described
as improving postprandial FMD [135,136], glycemia [137,138], and triglyceridemia [139]. In contrast,
in many cases, certain nutrients and other dietary substances that have been shown to reduce the
adverse postprandial effects of a challenge meal, did not affect postprandial plasma lipids [140].
5.1. Adding Nuts to a High-Fat/Carbohydrate Meal Prevents Postprandial Endothelial Dysfunction and
Oxidative Stress
Glucose fluctuations have been shown to alter endothelial cells by inducing markers of oxidative
stress and DNA damage and the onset of a metabolic memory [141,142]. However, it appears that
glucose fluctuations do not impact FMD shortly after intake (within 2 h) [143]. Beyond fluctuations in
glucose concentrations, evidence has shown that it is the acute consumption of whole macronutrient
meals that has the most influence on FMD within 6 h of intake [144].
Nuts have also been involved in improving endothelial function when combined with a meal.
In healthy overweight or obese men, the acute consumption of a control shake significantly reduced
FMD whereas a peanut shake, matched for nutrient content, did not significantly decrease FMD 4 h
after the meal, regardless of the patients’ baseline cholesterol concentrations (total cholesterol -TC or
low density lipoprotein-LDL) [139]. The peanut shake reduced the triglycerides area under the curve
(TG AUC) by 32%. The impact of nuts on postprandial lipemia still needs to be clarified, as the results
regarding improvements to postprandial VLDL, HDL, cholesterol efflux [145], and TG [139] are not
always consistent [146].
There is some evidence that consuming walnuts improves postprandial endothelial function
after a meal challenge in overweight or obese and hypercholesterolemic populations [135,136,147].
When measured with FMD, endothelial function improved over baseline by 64% following daily
consumption for four weeks [147] or 24% after acute consumption [135]. In normocholesterolemic [135]
or moderately hypercholesterolemic [136] populations only, a walnut meal has been shown to prevent
postprandial endothelial dysfunction as assessed using both FMD and RHI measurements.
To determine the walnut component to which the effect on endothelial function could be ascribed,
Berryman et al. [136] studied the effects of separated nut skins, de-fatted nutmeat, and nut oil derived
from 85 g of whole walnut in mildly hypercholesterolemic individuals. The effect of walnut oil on fRHI
differed from those of the skin and whole nut, and this might be related to its fatty acid composition.
This is in line with the results of a study that compared two types of walnuts which differed in terms of
their polyunsaturated fatty acid contents [148]. Finally, when compared with olive oil, which is quite
low in polyunsaturated fatty acids (PUFA), the acute consumption of walnut with a high-fat meal
improved endothelial function [135]. Taken together, these findings suggest a beneficial effect of plant
PUFA, or in fact α-linolenic acid (ALA), on endothelial function.
Nuts have favorable effects on certain inflammation and oxidative status indices [149]. English
walnuts contain the highest antioxidant content [150], and in healthy young adults the acute
consumption of a walnut meal increased postprandial γ-tocopherol, catechins, and hydrophilic
and lipophilic oxygen radical absorbance capacity (ORAC, a measure of the antioxidant capacity),
while decreasing some markers of oxidative stress, such as MDA, when compared with a refined meal
matched for energy nutrients [151]. These results suggest that walnuts exert antioxidant activities in
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both the lipid and aqueous plasma fractions. However, when comparing the antioxidant capacity
of plasma regarding different walnut components in individuals with mild hypercholesterolemia,
this antioxidant capacity (as assessed by the ferric reducing antioxidant potential, FRAP) was higher
after the intake of walnut oil and skin compared with intake of the nutmeat [136].
Phenolic antioxidants may be more effective in MUFA-rich nuts, such as almonds and pistachios,
than in PUFA-rich nuts [152]. One study reported that, in healthy individuals, the acute intake of
almonds induced less protein damage during the postprandial period than parboiled rice/mashed
potato, cheese, and butter meals, whereas the total antioxidant capacity did not differ between the
groups [153].
As for the effects of pistachios on inflammation and oxidative stress, data are scarce in the acute
setting. Nonetheless, several studies have shown chronic effects on various markers of oxidative
stress in individuals with metabolic syndrome [154], hypercholesterolemia [155], and prediabetes [156],
or in healthy populations [157,158]. By contrast, in obese people with metabolic syndrome, the acute
consumption of pistachio meals had no significant postprandial effect on RHI [159]. It is still difficult
to interpret the overall effects of pistachio nuts on postprandial inflammation and oxidative stress
based on the results for various markers in isolation because many antioxidant components have been
studied in plasma and tissues and there are few data to infer their final possible combined action.
However, one study found a significant increase in blood antioxidant potential and lowering of MDA
concentration (an indicator of lipid peroxidation) after substituting pistachio nuts for 20% of daily
caloric intake for three weeks in a healthy population [158].
A review concluded that pistachios are singularly rich in nutrients and substances that exert
antioxidant and anti-inflammatory effects that may be beneficial to cardiovascular health. There is
evidence that three key nutrients/phytochemicals in pistachios could mediate these effects: carotenoids,
γ-Tocopherol, and phenolic compounds [152].
5.2. Adding Fruit to a High Fat/Carbohydrate Meal Prevents Postprandial Endothelial Dysfunction and
Oxidative Stress
The protective effects of extra virgin olive oil on postprandial oxidative stress have frequently been
described during the past decade [160–162] and these effects appear to be comparable to those reported
with walnuts. Indeed, the acute consumption of walnuts and olive oil in a high-fat meal by patients
with hypercholesterolemia caused similar reductions in postprandial plasma concentrations of soluble
inflammatory cytokines, adhesion molecules, and oxidized low-density lipoproteins. Only E-selectin
levels fell more after the walnut meal than the olive oil meal. The authors concluded that both walnuts
and olive oil preserve the protective phenotype of endothelial cells [31].
As are olives, avocados are a fruit that is specifically rich in MUFA (oleic acid) and n-6 PUFA
(linoleic acid), and in this respect have also been studied recently in terms of their potential postprandial
metabolic and vascular impacts. In overweight/obese individuals with elevated fasting glucose and
insulin, the partial substitution of meal carbohydrates with avocado increased postprandial FMD [163].
However, the control breakfast did not result in a significant reduction in postprandial endothelial
function as might have been expected. However, this result is important on practical grounds because
the introduction of avocado in the meal represented only ~15% of the meal energy. The effect on
FMD might, in part, have resulted from the effect on postprandial lipoprotein profiles, such as lower
post-meal VLDL with avocado, which could be ascribed to the exchange of carbohydrates for MUFA.
The avocado meal also caused a smaller increase in postprandial plasma insulin [163].
Because of their particular composition of nutrients and other substances, berries have also been
studied in terms of their benefits on cardiovascular health [164]. In a well-designed study, Alqurashi et
al. showed that in healthy overweight males in an acute setting, an acai-based shake (vs. a control
shake) consumed alongside a high-fat breakfast significantly improved postprandial FMD [165]. Acai is
well known for its high flavonoids content; however, the mechanism underlying the reported benefits
of Acai still needs to be elucidated and further research is required to understand the degree to
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which this effect could be extended to other berries. Additional positive findings have been reported
for other berries such as blueberry and raspberry, and possible mediation by polyphenols has been
considered. In healthy males, the acute consumption of processed or unprocessed blueberries caused
changes to the profile of polyphenols but not the amount, resulting in different patterns of increase in
polyphenol metabolites in the plasma but similar improvements in postprandial FMD [166]. After the
consumption of raspberries, increases in plasma urolithin metabolites were found to be associated with
improvements to endothelial function [167]. Interestingly, plasma total nitrite concentrations have been
reported to rise significantly during the 2 h following intake of cranberries, suggesting that polyphenols
increase postprandial circulating nitric oxide and mediate the maintenance of postprandial endothelial
function [168].
Berries are rich in phytochemicals, and particularly phenolic compounds (2/3 flavonoids such
as anthocyanins, catechins, quercetin, and kaempferol, and 1/3 phenolic acids such as ellagic acid),
which are considered to be potent antioxidants inasmuch as they are able to scavenge ROS, chelate metal
ions in vitro, and act synergistically between themselves and with micronutrients such as ascorbate and
tocopherol [165,169,170]. The effects of berries on post-meal oxidative stress have been described in both
the acute [171,172] and chronic settings [172]. In a chronic context, berries may exert anti-oxidative and
anti-inflammatory effects by modulating mRNA expression in overweight and hypercholesterolemic
individuals. Indeed, a study showed that the intake of an aqueous extract of wolfberry fruit (goji) once
a day after a meal for eight weeks significantly decreased erythrocyte superoxide dismutase activity,
DNA damage in lymphocytes, and the expression of TNF, IL-6, and other mRNAs related to oxidative
or inflammatory stress. In addition, superoxide dismutase (SOD) expression in whole-cell extracts was
down-regulated [173].
The effects of strawberries on postprandial hyperlipidemia and oxidized low-density lipoprotein
cholesterol (LDL) have previously been studied in hyperlipidemic and overweight individuals using
a control beverage supplemented with strawberry powder at a dietary dose (equivalent to 110 g fresh
strawberries) or a placebo beverage (matched for energy, macronutrient, micronutrient, and fiber
contents) given with a high-fat test meal. In the acute setting, the strawberry beverage (vs. the control)
lowered postprandial increases in TG, HDL, and OxLDL at 3, 4, and 6 h after the meal. In the chronic
setting, after a 6-week period, the strawberry beverage lowered mean cholesterol, LDL, TG, and OxLDL
concentrations (when adjusted for fasting values) following the intake of a high-fat meal [172].
Berries reduce the lowering of ORAC that is usually reported after carbohydrate meals.
Furthermore, in healthy women, when adding grape and blueberry powder to a carbohydrate
meal, ORAC increases within 2 h of intake. When comparing the AUC for the change in plasma
hydrophilic ORAC-FL over 4–5 h after a meal, Burton-Freeman et al. found that the decrease was halved
after a grape and blueberry supplemented meal as compared to the control meal [171]. The ultimate
health impacts of such postprandial changes to ORAC still need to be determined.
Alternatively, in adults with type 2 diabetes, the addition of cranberries (40 g dried) to a high-fat
fast-food-style breakfast lowered some biomarkers of inflammation and lipid oxidation, such as serum
IL-18 and MDA, 4 h after the meal, although no significant differences in postprandial concentrations of
CRP and IL-6 were observed [168]. Postprandially, a meal composed of an antioxidant-rich concentrate
of berry added to a turkey burger and in the water consumed during the meal blunted the postprandial
increase in MDA, decreased protein carbonyls (a marker of oxidative stress on protein), and increased
plasma antioxidant activity [174].
A similar series of protective effects on postprandial inflammation in mononuclear cells has also
been reported regarding the consumption of orange juice with a high-fat meal [104]. Consuming
orange juice (300 kcal, i.e., ~600 mL, versus water or a glucose solution) with the meal, lowered the
postprandial production of ROS by blood polymorphonuclear cells and resulted in less activation of
inflammatory pathways such as mitogen-activated protein kinase (MAPK) and suppressor of cytokine
signaling 3 (SOCS-3) in mononuclear cells. As with the aforementioned study, orange juice also
lessened postprandial low-grade endotoxemia and the expression of toll-like receptor 4 (TLR-4) [104].
8
Nutrients 2019, 11, 1963
Regarding oxidative stress and the effects of fruit juice, the results should be interpreted with
caution as most studies assessing the effects of fruit-based beverages on postprandial stress used as
a control a drink matched for macro- and micronutrients and not simple water. Therefore, what was
being tested was not the fruit-based juice itself but rather the phytochemicals it contained in the context
of a drink and a high-fat meal [175].
By contrast, acute avocado consumption was not associated with postprandial changes to
biomarkers of inflammation or oxidative stress/damage to MCP-1, tumor necrosis factor alpha (TNF-α),
or Ox-LDL [163].
6. Key Phytochemicals Identified as Mediating Postprandial Antioxidant and
Anti-Inflammatory Effects
According to the same type of study design, it has been reported that red wine (but not vodka)
consumed with a high-fat meal prevented the postprandial activation of NF-κB in mononuclear
cells [176]. Indeed, the ingestion of wine with a meal has been reported to reduce postprandial
oxidative stress, although the markers chosen for most studies were of limited value [177]. It has also
been shown that the consumption of other foods and nutrients does not result in the postprandial
inflammation and dysfunction that are induced by high saturated fat and high sucrose loads.
In the context of elucidating the complex effects of wine on endothelial function and postprandial
inflammation, it was reported that combining muscadine grape polyphenols with resveratrol—a
phenolic compound in red wine that has been long largely studied for various anti-inflammatory
effects [178]—reduced postprandial increases in a set of pro-inflammatory and inflammatory markers
in mononuclear cells, such as the expression of IL1-β and SOCS-3 [179]. Because the dose of resveratrol
(100 mg) used in this study was very high when compared to the amounts found in wine [180–183],
the results cannot be used to conclude that wine polyphenols and resveratrol are candidates for
a potentially favorable effect of wine on postprandial inflammation [184,185]. However, they offer
a good example of the potential effects of combining different chemicals at neutraceutical doses on
postprandial dysfunctions.
The effects of the resveratrol and polyphenols combination were considered in detail in the
same study, and this work also provided some interesting insights into the possible mechanisms
underlying prevention of the initiation of inflammation in mononuclear cells in the postprandial setting.
The combination of resveratrol and polyphenols largely reduced the increase in the expression of the
p47 NADPH subunit, which is known to be associated with a postprandial increase in oxidative stress
in mononuclear cells. Furthermore, the supplement increased the binding activity of Nrf-2 and the
expression of some target genes. Because Nrf-2 is a transcription factor that mediates the physiological
antioxidant response to oxidative stress, this supplementation may have limited the production of
ROS yet evoked a higher protective antioxidant response, and the nrf-2 pathway might be important
in mediating the adverse effect of triglyceride-rich lipoprotein on vascular health [186]. However,
in our view, because of the delay required for this antioxidant response to take effect, it might not
generally account for the series of protective effects that appear acutely in the postprandial phase.
Other authors have confirmed that grape powder (in quantities compatible with dietary modulation)
increases the expression of Nrf-2 acutely during a high fat carbohydrate meal [187]. Another result of
importance to our understanding of the pathogenesis of postprandial adverse effects and that of the
effect of the supplement in the study by Ghanim et al. is that the supplement also reduced or prevented
postprandial low-grade endotoxemia, plasma lipoprotein binding protein, and TLR-4 expression in
mononuclear cells. As discussed above, an increase in the translocation of endotoxins from the gut
has been proposed as a mechanism for the adverse postprandial effect of high-fat meals on low-grade
inflammation and endothelial dysfunction [75,188,189]. However, such a mechanism may not strictly
require TLR-4 mediation, but rather may act through a combined interplay between TLRs [190].
Therefore, the protective effect of the supplement may be mediated, at least in part, by a reduction in
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postprandial low-grade endotoxemia and downstream pro-inflammatory signaling [179], although the
potential underlying mechanisms for an acute reduction in endotoxemia still need to be fully elucidated.
With respect to berries, urolithins and ellagic acid appear to be the best candidates for their
anti-atherogenic effects. In quantities compatible with dietary modulation, these phytochemicals have
displayed their potential to affect key processes in the development and progression of atherosclerosis
in vitro, such as endothelial activation and resulting monocyte recruitment, cholesterol transport,
and foam cell formation [191].
Some polyphenolic compounds are attractive candidates to explain the effects of orange juice.
In this regard, it was shown that the consumption for four weeks of 500 mL orange juice, or hesperidin
(the major flavonoid in orange juice), increased microvascular endothelium-dependent function
during the peak of hesperidin absorption [192]. This result cannot directly be extrapolated to the
postprandial phase. However, because hesperidin has a short half-life in plasma, its effect may be
mostly transient so it may operate acutely during the postprandial period, with favorable effects on
macro- or micro-vascular endothelial function or other related pro-inflammatory postprandial features.
More recently, in adults with hypertriglyceridemia or who were overweight/obese and subjected
to a double high-fat meal challenge, a study reported that various orange-based drinks containing
flavanone (vs. an isoenergetic control) alleviated the postprandial decrease in FMD 7 h after a high-fat
meal. The effects were similar despite variations by a factor of four in the amount of flavanone in
the drinks. However, the effect on FMD at 7 h coincided with the peak of naringenin and hesperidin
metabolites being found in the plasma, and the fraction of hesperidin metabolites assayed in plasma
predicted, in part, the magnitude of the changes to FMD [193]. Salden et al. did not evidence any effect
of supplementation with hesperidin 2S in their study sample as a whole, either with acute postprandial
testing, or after six weeks of supplementation. In individuals with a normal or high baseline FMD
(60% of the total sample), hesperidin 2S improved FMD and reduced adhesion molecules after a HFM,
when the latter was given after six weeks of supplementation [194].
It is difficult to draw any firm conclusions from the literature on the postprandial effects of
polyphenols. First, many studies have investigated the effects of polyphenol-rich foods (such as cocoa,
grape, or berries) or food preparations (e.g., juices) rather than purified and well-characterized extracts.
Again, adding a food/ingredient with a significant mass and energy (e.g., 500 mL juice) to a challenge
meal tends to affect the kinetics of postprandial metabolism directly, and the results are therefore
difficult to analyze. More recently, studies have used ingredients such as powders, and control
treatments matched for macronutrient content, which is more useful when trying to ascribe the
effects to polyphenolic fractions [172,187,195]. Second, studies have resorted to different postprandial
endpoints and markers, in limited numbers, giving rise to highly fragmented findings. For instance,
the consumption of a juice rich in blackcurrant polyphenols (as compared to a well-made placebo
drink) was shown to improve postprandial oxidative status, but in vivo evidence for postprandial
anti-inflammatory effects was lacking [196] as was evidence for a beneficial effect on vascular
reactivity [197]. Likewise, an anthocyanin-rich blackcurrant extract lowered postprandial glucose and
insulin after a high-carbohydrate meal but did not affect 8-isoprostane F2α (a stable and reliable marker
of overall lipid peroxidation [164]) or arterial stiffness; endothelial function was not measured [198].
Many phenolic compounds have shown that they can reduce postprandial oxidative stress or
acutely affect parameters for oxidative stress [164,199]. This has been largely documented for cocoa
flavanols and grape polyphenols [200]. Potential mechanisms of action have also been reported.
In vitro, a grape seed extract and a strawberry powder activated NO synthesis pathways in endothelial
cells [201,202]. Cocoa flavanols acutely increased plasma concentrations of nitroso compounds, reduced
arginase activity [203,204], affected pro-inflammatory pathways in vitro [205], and acutely improved
endothelial dysfunction [206–208]. However, for many polyphenolic compounds with interesting
in vivo effects after ingestion, the evidence remains limited regarding their effects on important
endpoints of cardiometabolic health, such as endothelial function in humans [196,209].
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7. Conclusions
As we have shown in this review, acute supplementation with certain whole foods, ingredients,
nutrients, and phytochemicals can prevent postprandial endothelial dysfunction and inflammation.
Because many studies have lent credence to the current paradigm that oxidative stress mediates adverse
postprandial effects [58], further efforts are necessary to determine whether nutrients and substances
that display postprandial antioxidant effects also reduce postprandial low-grade inflammation and
vascular endothelial dysfunction. Future studies also need to investigate other mechanisms that
are good candidates for the acute effects of nutrients during a high-fat meal, such the induction of
low-grade endotoxemia. These studies could take advantage of simultaneously analyzing the effects
on different endpoints and using various markers. It would be interesting to further clarify the
degree to which certain nutrients (e.g., some amino acids) and other substances (in particular various
polyphenols) affect potential underlying mechanisms that are directly or indirectly related to oxidative
stress, including NO and nitroso-compound metabolism, induction of the antioxidant defense system,
the delicate redox status in tissues, and insulin-related signaling pathways [203,210–213]. Further
studies could also profitably investigate acute variations in the metabolism of arginine and related
compounds (such as homoarginine and methylated arginine) during the postprandial period, and their
potential modulation by the nature of the meal [214,215].
The metabolic utilization and effects of any nutrients added to a high-fat high sucrose meal
are basically postprandial (e.g., amino acids). Many other dietary substances also exhibit an acute
postprandial metabolism; in particular, despite huge heterogeneity, many polyphenols (e.g., flavonoids)
and their metabolites display early plasma peaks (e.g., at 2 h) and a short half-life in plasma after
ingestion [216]. We can therefore expect that many nutrients and other substances exert most of their
biological effects during the postprandial period. This factor warrants dedicated investigations of their
specific effects under adverse postprandial conditions.
Finally, we can conclude that based on a very large set of data, the present paradigm is
that the postprandial occurrence of cardiometabolic-related dysfunctions, including postprandial
inflammation and endothelial dysfunction, are pathogenic to the initiation and progression of MS.
The high-saturated-fat/high-sucrose model is therefore highly relevant to preventive nutrition, and as it
is also practical for the conduct of human trials, it can be used to study the benefit of nutrients and other
dietary substances when added to a challenge meal or consumed immediately beforehand. Although
many studies have addressed the postprandial effects of nutrients and other substances, the literature
remains largely fragmented. In particular, some nutrients and substances have been shown to lower
postprandial oxidative stress and impact inflammatory-related pathways, but further studies are needed
and should involve final critical endpoints such as endothelial dysfunction. Nevertheless, we found
that nuts, l-arginine, polyphenols from berries, and citrus are good candidates for acute and multiple
protective effects during the postprandial phase, and the data so far warrant further investigations
involving multiple clear endpoints and valid, sensitive markers to ascertain the global picture.
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Abstract: Postprandial lipemia, which is one of the main characteristics of the atherogenic dyslipidemia
with fasting plasma hypertriglyceridemia, low high-density lipoprotein cholesterol and an increase of
small and dense low-density lipoproteins is now considered a causal risk factor for atherosclerotic
cardiovascular disease and all-cause mortality. Postprandial lipemia, which is mainly related to the
increase in chylomicron production, is frequently elevated in individuals at high cardiovascular risk
such as obese or overweight patients, type 2 diabetic patients and subjects with a metabolic syndrome
who share an insulin resistant state. It is now well known that chylomicron production and thus
postprandial lipemia is highly regulated by many factors such as endogenous factors: circulating
factors such as hormones or free fatty acids, genetic variants, circadian rhythms, or exogenous factors:
food components, dietary supplements and prescription drugs. In this review, we focused on the
effect of nutrients, micronutrients and phytochemicals but also on food structure on chylomicron
production and postprandial lipemia.
Keywords: carbohydrates; cardiovascular disease; cholesterol; fibers; food structure; lipids;
polyphenols; proteins; triglycerides; vitamins
1. Introduction
Cardiovascular diseases (CVD) are the leading cause of death in the world [1]. Atherogenic
dyslipidemia (AD), which is mainly characterized by plasma fasting and postprandial
hypertriglyceridemia (postprandial hyperlipemia), low high-density lipoprotein cholesterol (HDL-C)
and an increase of small and dense low-density lipoproteins (LDL), is frequently seen in individuals
at high cardiovascular risk such as obese or overweight patients, type 2 diabetic (T2D) patients and
subjects with a metabolic syndrome who share an insulin resistant state [2,3]. The pathophysiology
of the AD is widely explained by the blood accumulation of triglyceride-rich lipoproteins (TRL)
synthesized by the liver (very low-density lipoproteins (VLDL)) [4] and the intestine (chylomicrons
(CM)) [5]. This accumulation has been attributed to the overproduction of both VLDL and CM and to
a defective TRL removal process [6,7]. Elevated fasting and postprandial blood TRL concentrations,
which are mainly related to the increase in CM production, are now considered a causal risk factor for
low-grade inflammation, atherosclerotic CVD and all-cause mortality [8]. It is now well known that
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CM production is highly regulated by many factors such as endogenous factors: circulating factors
such as hormones or free fatty acids (FFA), genetic variants, circadian rhythms, or exogenous factors:
food components, nutraceuticals and therapeutic interventions. In this review, we will focus on the
effect of nutrients, micronutrients and phytochemicals but also on food structure on CM production
and postprandial lipemia (TRL metabolism only) in humans [9].
2. Methodological Introduction
A large number of studies have assessed the effects of acute or chronic ingestion of meals
containing different types of fat or other nutrients on postprandial lipemia but have yielded conflicting
results. A number of potentially confounding factors reflecting the lack of standardization among
studies could explain this: population, amount of fat, type of fat, amount and types of other nutrients,
physicochemical composition of the meal and fatty acid (FA) or other nutrients, composition of habitual
chronic food intake. Moreover, the measurement of postprandial plasma triglyceride (TG) response
may provide only a limited evaluation of the true impact of meals and nutrients on postprandial
lipoprotein metabolism. Studies have analyzed TG or retinyl-palmitate in a variety of sample types,
including whole blood, plasma, serum, lipoproteins and their remnants, over a wide range from two
up to 12 h postprandially [10]. Finally, qualitative and not only quantitative changes (size beyond the
number of lipoproteins, lipidomic changes) have been described in several studies [11,12].
3. Effect of Dietary Lipids
3.1. Lipid Amount
A study performed in healthy men showed an increase in postprandial lipemia (plasma-TG peak
concentration) following an 80 g fat meal compared to a 20 g fat meal with an intermediate result
following a 40 g fat meal. A parallel elevation of glucose-dependent insulinotropic polypeptide (GIP)
concentration and postheparin lipoprotein lipase (LPL) activity with a trend but no significant change
in the increase of insulin response were seen following the 80 g fat meal compared to the 20 g fat
meal [13]. Another study in healthy men individuals did not report any effect of a 15 g low-fat meal
on postprandial lipemia compared to a nonfat meal and confirmed the dose-dependent increased
postprandial serum-TG and CM-TG concentrations for moderate doses of fat per meal (30 to 50 g). The
serum insulin response was significantly higher only following the 50 g fat meal compared to the nonfat
and 15 g fat meal [14]. These results were confirmed in normal-weight and obese individuals with an
increase in CM-TG concentration following a 40 g fat meal compared to a 10 g fat meal [15] and in obese
boys with an increase in postprandial plasma-TG concentration following a 33 g fat meal compared
to a 18 g fat meal. Glucagon-like-peptide-1 (GLP-1) concentration was significantly higher after the
high-fat meal in the latter study [16]. Very high doses of fat (80 g and above) exaggerated postprandial
serum-TG in healthy men [17]. This stepwise increase in the postprandial lipemia seen with the
increase amount of fat intake suggests that the clearance capacity of the individuals is overloaded
proportionally to the amount of fat assimilated. Moreover, consecutive meals containing fat appear to
enhance postprandial lipemia [7,18].
3.2. Fatty Acid Composition
3.2.1. Test Meal (Acute)
First, it should be remembered that dietary short- or medium-chain FA have limited effect on
postprandial lipemia because they directly enter the general circulation via portal route instead of
CM secretion. It is probably why studies using dairy fats, which contain significant amount of short-
and medium-chain FA, as the only source of saturated fatty acids (SFA), generally report a lower
postprandial TG response compared to other sources of SFA or other types of fats [7,19]. In healthy
individuals, a recent randomized, cross-over, single-blinded design study, showed that a medium-chain
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SFA-rich meal (coconut biscuit) resulted in a significant lower postprandial whole blood TG response
(concentration and net area under the curve (AUC)) compared to a short-chain SFA-rich meal (butter
biscuit) and a long-chain SFA-rich meal (lard biscuit) despite identical fat and caloric content [20].
In healthy men, a study showed an increase in CM-TG concentration after an SFA-rich meal compared
to an n-6 polyunsaturated fatty acid (PUFA)-rich meal but no difference with the monounsaturated fatty
acid (MUFA)-rich meal [21]. The postprandial lipemic response to a SFA-rich meal was comparable
to that of a n-6 PUFA-rich meal when consumed with n-3 PUFA in one study conducted in healthy
individuals [22] whereas, the increase of the n-3 PUFA content of a SFA-rich meal fat meal did not
acutely change postprandial TG concentration in another study performed in subjects with a metabolic
syndrome [23]. In overweight men, a difference in the postprandial serum TG concentrations between
an SFA-rich meal and an n-6 PUFA-rich meal was only seen in the late postprandial phase [24]. Four
studies showed different effects of SFA compared to MUFA consumption on postprandial lipemia
showing either an increase [25] or a decrease in healthy individuals [25,26] or in overweight and obese
subjects [27], and one no change in healthy individuals [28]. In healthy individuals, another study
showed a decrease in postprandial lipemia following a stearic acid-rich fat meal compared to other SFA
(palmitic acid) or a high-oleic acid sunflower oil [29] but there was no difference between a high-oleic
acid sunflower oil and a stearic acid-rich fat meal using cocoa butter [30]. Consumption of six different
test meals rich in stearic, palmitic, palmitic plus myristic, oleic, elaidic or linoleic acids by healthy
individuals resulted in a relatively lower postprandial lipemia response with long-chain SFA than did
the intake of the unsaturated FA. The significant differences in LPL activities between groups did not
explain the postprandial response that could be due to slower or less-efficient absorption of long-chain
SFA [31]. Moreover, no difference in postprandial lipemia was observed following an oleate-rich meal
(cis isomer) and an elaidate-rich meal (the trans isomer of oleic acid) [29]. Thus, most studies have
shown that meals enriched with different proportion of SFA, MUFA or n-6 PUFA do not elicit marked
differences in postprandial lipemia [7,32,33]. In healthy individuals, an n-3 PUFA-rich fat meal (fish oil)
lowered postprandial lipemia compared to an SFA-rich fat meal (palm and coconut oils) [34]. However,
two other studies did not show a difference in the incremental area under the curve (iAUC) plasma-TG
after an SFA-rich meal compared to an n-3 PUFA-rich meal [28,35].
3.2.2. The Habitual Diet (Chronic)
Postprandial lipemia may be influenced by the habitual diet [7,19]. A short-term consumption
(25 days) of isocaloric diets rich in SFA, n-6 PUFA or n-3 PUFA in healthy individuals resulted in greater
TG and CM concentrations following SFA compared to n-3 PUFA, with intermediate concentrations
with n-6 PUFA. CM from subjects on n-3 and n-6 PUFA diets were more susceptible to lipolysis
in vitro [36]. After 15 and 29 days of dietary intervention (SFA-rich or n-6 PUFA-rich diet in healthy
young men), postprandial response analysis suggested no change in the clearance of CM remnants
but a prolonged accumulation of VLDL in individuals fed with the SFA-rich diet [37]. Two other
short-term studies (six or four weeks) showed that n-3 PUFA supplementation (2.7 g/day or 4 g/day)
in healthy subjects resulted in a significant reduction in postprandial TG compared with the control
diet without supplementation [38,39]. In the second study, the supplementation with n-3 PUFA
suppressed the increase in TG content in CM as well as in VLDL [39]. In contrast, consumption of
a low-fat diet with n-3 PUFA (fish oil) supplementation for 16 weeks in healthy individuals led to a
significant increase in postprandial TG concentration following a fat-rich test meal compared to chronic
consumption of a low-fat diet alone [40] and another study did not show an effect of a six month n-3
PUFA supplementation in fasting or postprandial lipids compared to n-6 PUFA supplementation in
moderately hyperlipidemic subjects [41]. In healthy individuals, an eight-week study of diet rich in SFA
or MUFA (olive oil) showed a significant reduction in plasma total- and LDL-cholesterol concentrations
but a higher postprandial plasma TG and TRL-apoB-48 concentrations with the MUFA diet [42].
In contrast, a 16-week moderate-MUFA diet or high-MUFA diet following an eight-week SFA-rich
diet (reference diet) in healthy individuals resulted in the reduction of postprandial apoB-48 response
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without change in plasma TG concentration, suggesting that the CM formed carry larger amounts of
dietary lipids per particle [43]. Similarly, a three-month SFA-rich diet compared to a MUFA-rich diet in
healthy individuals did not show a difference in postprandial TG concentration but a reduction in both
groups receiving a n-3 PUFA supplementation (3.6 g/day) versus placebo [44]. In this study, neither
type of diet nor n-3 PUFA supplementation affected serum LDL size, but this parameter was measured
in fasting state. Furthermore, in a cohort of 1048 subjects, hypertriglyceridemic (fasting serum TG
> 150 mg/dL) participants had higher number of LDL particles, higher concentrations of small LDL
particles and lower large LDL particles in baseline compared to normotriglyceridemic (fasting serum
TG ≤ 150 mg/dL) participants. Following a high-fat meal challenge, both groups displayed similar
patterns of change in LDL particle size concentrations with a small decrease in total LDL particle
number, an increase in large LDL particle concentration, a decrease in small LDL particle concentration
and no change in LDL particle size [45]. In another study, healthy individuals consumed three different
diets for four weeks: a Western diet (38% fat of which 22% SFA), Mediterranean diet (38% fat, 24%
MUFA) and a high carbohydrates diet with α-linolenic acid (ALA) (< 30% fat of which 8% PUFA).
Consumption of the Mediterranean diet led to a decrease in the postprandial number of TRL compared
with the other meals and also an increase in TRL particle size compared to the high carbohydrates with
α-linolenic acid diet [46]. In the Medi-Rivage intervention study, a postprandial test was performed in
individuals after either a three-month low fat or a Mediterranean-type diet (with SFA intake reduced
by about half whereas MUFA increased). The consumption of the Mediterranean diet only lowered
fasting TG concentration and both diets reduced TG and apoB-48 levels 5 h after the test meal. The
overall 5 h postprandial apoB-48 response (AUC and iAUC) was lowered after both diets but this effect
was more marked after the Mediterranean diet intervention [47].
A two-week trans FA-rich diet compared to a MUFA-rich diet (oleate) in healthy individuals did
not show a difference in postprandial TG after a test meal [48].
Concerning the mechanisms, the reduction of postprandial lipemia following n-3 PUFA
supplementation could be due to a decrease in CM synthesis/secretion and/or an increase in clearance.
Several studies have shown an increase in LPL activity [44,49–51] and hepatic lipase activity [51]
following supplementation with 3–5 g/day n-3 long-chain PUFA suggesting an effect on CM clearance.
On the other hand, some studies are more in favor of an effect on CM production [52,53]. It is
important not to forget that the reducing effect of n-3 PUFA on VLDL production [53–55] could also
influence postprandial lipemia by the major link with CM metabolism. A lipoprotein kinetic study
has examined the effect of the addition of n-3 FA ethyl esters (4 g/day: 46% eicosapentaenoic acid
(EPA) and 38% docosahexaenoic acid (DHA)) to a weight-loss program for 12 weeks on postprandial
apoB-48 kinetics in obese subjects after ingestion of an oral load. Compared with weight loss alone,
weight loss plus n-3 supplementation significantly decreased fasting TG, apoB-48 concentrations,
postprandial TG and apoB-48 total AUCs as well as postprandial TG iAUCs. This improvement
of the postprandial profile was due to a decreased apoB-48 secretion in the basal state in the n-3
supplementation group without a significant effect during the postprandial period (3–6 hours) and no
change in the clearance rate compared to the weight loss alone group [56]. A crossover study (but
without a lipoprotein kinetic analysis) conducted by the same team showed a significant improvement
of the postprandial lipemia after a fat load in a group of patients with familial hypercholesterolemia with
n-3 PUFA supplementation (8 weeks; 4 g/day: 46% eicosapentaenoic acid and 38% docosahexaenoic
acid) compared to no supplementation [57]. A review mainly focused on stable isotope tracer
methodologies and compartmental modeling studies examined the mechanisms of action of dietary
FA on lipoprotein metabolism [58]. Concerning n-3 PUFA, their effect on TG concentration reduction
can be explained by several mechanisms: inhibition of diacylglycerol acyltransferase, FA synthase and
acetyl CoA carboxylase enzymes; increase of FA β-oxydation via a peroxisome proliferator-activated
receptor (PPAR) mediated pathway; inhibition of de novo lipogenesis by suppressing transcription
of sterol regulatory element-binding protein-1c (SREBP-1c) gene; degradation of newly synthesized
apolipoprotein B by stimulating the post-endoplasmic reticulum presecretory proteolysis pathway.
28
Nutrients 2019, 11, 1299
In vivo studies have confirmed that n-3 PUFA decrease the pool size (PS), the production rate (PR) of
TRL-apoB-48 and VLDL-apoB-100, the fractional catabolic rate (FCR) of TRL-apoB-48 and increase the
FCR of VLDL-apoB-100. Regarding n-6 PUFA, one lipoprotein kinetic study has shown after three
weeks of n-6 PUFA supplementation a decrease in the PS of VLDL-apoB-100 due to an increase in FCR
compared to a medium-chain FA supplementation. This effect could be due to an up-regulation of LPL
activity and hepatic uptake of VLDL consequently to PPAR-activation by n-6 PUFA [59]. Lipoprotein
kinetic studies on the impact of SFA on lipoprotein metabolism are lacking. One study did not show
any effect of a four-week supplementation of medium-chain TG on TRL-apoB-48 and VLDL-apoB-100
metabolism in obese, insulin-resistant men [60]. For MUFA, one study conducted in twelve adults,
has shown a decrease in PS and PR and an increase in FCR of VLDL-apoB-100 after a three-week
MUFA-rich diet compared to a carbohydrate-rich diet [61]. Only one study has examined the impact of
trans-FA on lipoprotein metabolism with no effect, in postmenopausal hypercholesterolemic women,
on TRL-apoB-48 or TRL-apoB-100 metabolism [62].
3.2.3. Clinical Trials and Recommendations
A position paper from an international lipid expert panel concluded that n-3 EPA and DHA could
be used efficiently as dietary supplements to reduce plasma TG (by 18–25%) whereas, their effects on
LDL-C and HDL-C were clinically insignificant [63].
Despite the potential positive effect of n-3 PUFA on fasting TG and postprandial lipemia,
two meta-analyses of randomized controlled trial, including a recent one (77,917 subjects; EPA
supplementation doses between 226 and 1800 mg/day; mean follow-up: 4.4 years), did not show any
effect of n-3 PUFA supplementation on mortality and cardiovascular events [64,65]. The most recent
and larger meta-analysis of randomized controlled trial (112,059 subjects; 12 to 72 months duration; n-3
PUFA doses ranged from 0.5 g/day to > 5 g/day including EPA and DHA or ALA by supplementation
or enriched food or dietary advice compared to placebo or usual diet) showed that increasing EPA
and DHA has little or no effect on mortality or cardiovascular health and that low-quality evidence
suggested ALA may slightly reduce cardiovascular disease and arrhythmia risk [66].
However, a recent randomized, double-blind, placebo-controlled trial (REDUCE-IT) involving
8179 patients with established cardiovascular disease or with diabetes and other risk factors, who had
been receiving statin therapy and who had a fasting TG level of 135 to 499 mg/dL and a LDL-C level of
41 to 100 mg/dL with a median follow-up of 4.9 years, showed that a high-dose treatment of 4 g/d of
EPA is accompanied by a significant decrease of 25% in the primary endpoint (cardiovascular death,
non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, unstable angina), of 20%
in cardiovascular mortality, of 28% in fatal and non-fatal strokes, and a non-significant decrease of 13%
in total mortality. More patients were hospitalized for cardiac arrhythmias in the EPA group [67].
Regarding dietary fat intake, the European guidelines on cardiovascular disease prevention in
clinical practice advise: SFA to account for < 10% of total energy intake and should be reduced by an
increase in PUFA; trans unsaturated FA as little as possible with preferably no intake from processed
food and < 1% of total energy intake from natural origin; fish 1–2 servings per week, one of which to be
oily fish; 30 g unsalted nuts per day [68]. The recent American guidelines on the primary prevention of
cardiovascular disease recommend: the replacement of SFA with dietary MUFA and PUFA; the intake
of trans FA should be avoided: a diet containing reduced amounts of cholesterol [69].
The European guidelines for the management of dyslipidemias recommend reducing TRL levels:
to use supplements n-3 PUFA and replace SFA with MUFA or PUFA [70].
In line with the most recent meta-analysis, supplemental long-chain n-3 PUFA are probably not
useful for preventing or treating cardiovascular disease, although they can help to reduce serum TG
and raise HDL a little [66].
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3.3. Dietary Cholesterol
The data available on the impact of dietary cholesterol on postprandial lipemia are limited.
In healthy individuals, one single meal containing 0 or 140 mg cholesterol with a fixed amount of
fat (45 g) elicited comparable postprandial lipemia whereas important doses of dietary cholesterol
(280 or 710 mg) significantly increased postprandial lipemia compared to the lower amount [71].
A cholesterol-rich meal (1 g) compared to a cholesterol-free meal elicited increased postprandial
CM-cholesterol and CM-TG in T2D patients and in matched non-diabetic control subjects. The
increase in the postprandial VLDL-apoB-48 concentration was significantly higher in the diabetic
patients (10-fold) compared to control individuals (three-fold) but the postprandial VLDL-apoB-100
concentration was not affected by dietary cholesterol, suggesting that intestinal CM production rather
than their clearance explained these results [72]. However, chronic consumption (eight weeks) of diets
varying in their amount of cholesterol (from 128 to 858 mg/day) by healthy individuals had no effect
on postprandial lipemia [73].
To summarize, it appears that postprandial lipemia increases dose-dependently with the amount
of dietary fat or cholesterol (at least above 15–20 g of fat and 140 mg of cholesterol) after a single
meal. Acute test meals enriched with SFA, MUFA or PUFA do not generally elicit markedly different
postprandial lipemia. Despite conflicting results, habitual diet studies show postprandial lipidemic
responses to be in the order SFA >MUFA > n-6 PUFA > n-3 PUFA.
4. Effect of Dietary Carbohydrates
4.1. Effect of Chronic Consumption of Dietary Carbohydrates
High carbohydrate diets and especially highly digestible carbohydrate enriched diets have
commonly been shown to alter lipid postprandial metabolism and to increase fasting plasma TG
as a result of both intestinal CM and hepatic VLDL TRL and their remnants accumulation [7]. In 2
groups of normolipidemic and moderately hypertriglyceridemic subjects, Parks et al. compared the
effects of two isoenergetic diets: a control (35% fat) diet for one week followed by a low-fat (15%
fat) and high-carbohydrate diet for 5 weeks. Low fat/high-carbohydrate diet resulted in increased
fasting TG concentration and decreased VLDL-TG clearance rate in both groups and increased fasting
TRL-apoB-48 and TRL-apoB-100 concentrations in the hypertriglyceridemic group [74].
The monosaccharides have been extensively studied. As described by Livesey et al. in a
meta-analysis, effect of fructose consumption on lipid profile was different depending on daily ingested
amount: significant effect on postprandial TG was not evident unless> 50 g fructose/day was consumed,
and no significant effect was seen for fasting TG with intakes of ≤ 100 g fructose/day [75]. In 66
overweight or obese men, the consumption of fructose sweetened beverages containing 75 g fructose
per day for 12 weeks while continuing usual lifestyle and diet increased significantly fasting plasma TG
and postprandial TG (AUC and iAUC) response after a mixed meal but did not impair glycemic control
or incretin hormone responses during oral glucose or mixed meal challenge [76]. In contrast, another
meta-analysis on the replacement of glucose or sucrose in foods or beverages by fructose (11 trials;
length from 2 to 10 weeks; doses of fructose between 40 and 150 g/day) found no difference in fasting TG
when fructose replaced glucose but a slight significant reduction when fructose replaced sucrose [77].
In a meta-analysis of 10-week to 26-week randomized trials of sugar-containing soft drinks, Bray
concluded that plasma TG increase was due to fructose rather than glucose in sugar-containing soft
drinks [78]. However, in a randomized control clinical study, Campos et al. showed in overweight
subjects that substitution of high sugar-sweetened beverages providing large amounts of mono- or
di-saccharides by artificially sweetened beverages during 12 weeks did not decrease postprandial
TG despite of lower energy and fructose content of the meals [79]. Stanhope et al. showed, in
overweight and obese subjects, that the consumption (eight weeks) of fructose-sweetened beverages
significantly lowered glucose and insulin postmeal peaks and the AUC compared with the baseline diet
(energy balanced diet containing 55% of energy as complex carbohydrates for 2 weeks) and with the
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consumption of glucose-sweetened beverages. Only fructose sweetened beverages diet consumption
resulted in increased postprandial TG suggesting that the specific effect of fructose, but not of glucose
and insulin excursions, contribute to the adverse effects of consuming sugar-sweetened beverages on
lipids and insulin sensitivity [80]. Glucose supplementation had no effect on postprandial TG response
as confirmed in 2 other studies of the same authors in young men and women [81] or in overweight or
obese subjects [72] but a specific increase in fasting plasma TG concentration [82]. Despland et al. found
a slightly decrease in postprandial blood glucose but no difference in postprandial TG plasma nor in
hepatic insulin sensitivity in eight healthy male consuming a diet containing 25% energy as honey or
pure fructose-glucose compared to an isocaloric starch diet [83]. Taken together, these studies suggest
that isocaloric inclusion of fructose in mixed meal has inconsistent effects on postprandial TG despite its
greater stimulation of de novo lipogenesis than other monosaccharides such as glucose [84]. However,
in a systematic review and meta-analysis of controlled feeding trials, Wang et al. showed no significant
postprandial TG increase when fructose was exchanged isocalorically for other carbohydrates in the diet
but a significant postprandial TG raising-effect of fructose in studies in which fructose supplemented
the background diet with excess energy from high-dose fructose compared with the background diet
alone (without the excess energy) [85].
4.2. Effect of Acute Consumption of Dietary Carbohydrates
Both amount and nature of carbohydrates in a meal may alter postprandial lipid metabolism.
In healthy individuals, a high-fat/low-carbohydrate meal yielded a postprandial TG iAUC increase
and an apoB-48 plasma iAUC reduction compared to a low-fat/high carbohydrate meal. This suggests
difference in size and composition of CM depending on the meal composition [86]. In healthy
individuals, the addition of 50 g or 100 g oral glucose to a fatty test meal diminished postprandial
lipemia in a dose dependent manner compared to the meal containing fat alone. This effect was not
due to increased clearance of TG from the circulation but appeared to reflect delayed gastric emptying
and decreased hepatic secretion of TG. Starch ingestion had no discernible effect on postprandial
lipemia [87]. Likewise, the addition of 75 g oral glucose to an oral fat meal delayed the gastric emptying
and postponed the CM response compared to the fat meal in healthy individuals. The postprandial
iAUC of serum TG and VLDL-TG were reduced but the CM-TG iAUC remained unchanged. The
postprandial reduction of VLDL-TG iAUC may be due to the pronounced FFA depression during
the glucose-induced rise in insulin [88]. In contrast, in healthy individuals, adding oral fructose as
a monosaccharide [89] or as a disaccharide in sucrose [90] to an oral fat load led to an increase in
postprandial lipemia.
In healthy individuals, physiological ranges of postprandial hyperglycemia and hyperinsulinemia
as generated by starchy foods (white bread, pasta, beans) did not induce noticeable alterations in the
overall postprandial TG response but delays and exacerbates postprandial accumulation of CM-apoB-48
in plasma [91]. Likewise, in healthy individuals, the intake of a standard fat dose meal (0.5 g/kg body
weight) accompanied by either low-carbohydrate meal (17 g as lactose) or a high-carbohydrate meal
(136 g of which 60 g was sucrose) did not show a difference in plasma TG or TRL-TG postprandial
concentrations but a biphasic plasma TG response seen with the high-carbohydrate meal largely
reflected the TRL-TG or CM fraction, which would tend to suggest a biphasic pattern of absorption.
Higher insulin and GIP responses were seen with the high-carbohydrate meal [92]. Moreover, in obese,
insulin-resistant subjects, the consumption of a high-glycemic index mixed meal, compared with a
low-glycemic index one, increased the postprandial rise in plasma insulin and the accumulation of
TRL-apoB-48 and TRL-apoB-100 thus increasing postprandial TG concentration as well as modifying
the kinetics of peak occurrence. Thus, adding various digestible carbohydrates to a test meal can elicit
a biphasic response of postprandial lipemia [93].
Besides the effects of dietary carbohydrates on hepatic VLDL metabolism [74,94], their effects on
intestinal CM metabolism remain to be clarified, but have been reviewed in a recent paper pointing out
the intestine as a contributor to carbohydrate-induced hyperlipidemia [95]. Oral fructose in a mixed
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meal can stimulate hepatic but also intestinal de novo lipogenesis, thereby increasing TG availability
for CM and VLDL synthesis. This mechanism was increased for CM but not VLDL when glucose
was added to the meal with a concomitant decrease in fructose oxidation and gluconeogenesis from
fructose, suggesting the addition of glucose to the meal committed more fructose towards intestinal de
novo lipogenesis [96]. In a lipoprotein kinetic study performed in healthy individuals, TRL-apoB-48
(CM) and TRL-apoB-100 (VLDL) metabolism was assessed after intraduodenal infusion (to avoid
change in gastric emptying) of intralipid plus saline or glucose or fructose under pancreatic clamp
conditions. Glucose markedly stimulated CM-PR with a moderate increase in CM-FCR resulting
in net elevation of CM concentration but no effect on VLDL metabolism. Fructose significantly
stimulated CM-PR and VLDL-PR but no effect on FCR [97]. The same team performed another
lipoprotein kinetic study in healthy individuals to assess the effect of intravenous infusion of either
20% glucose or normal saline as control in a constant fed state. Compared with saline infusion; glucose
infusion induced both hyperglycemia and hyperinsulinemia (despite pancreatic clamp conditions),
FFA decrease and increased plasma TG, CM concentrations and CM-PR without affecting CM-FCR
or VLDL metabolism [98]. Several studies have shown that a fructose-rich diet induced less insulin
secretion than a glucose-rich diet, which could explain the lower postprandial LPL activity and the
reduction in TG clearance after fructose compared to glucose [99].
At a cellular level, both luminal and basolateral glucose enhanced CM secretion with a greater
effect of luminal glucose and a greater effect of luminal glucose than fructose [95]. In Caco-2/15
cells, basolateral exposure to glucose increased apical cholesterol uptake with increased expression
of Niemann-Pick C1-like 1. This elevation of cholesterol uptake was associated with an increase
in the transcription factors SREBP-2, carbohydrate-responsive element-binding protein (ChREBP)
and liver X receptor (LXR)-β along with a fall in retinoid X receptor (RXR)-α [100]. Moreover, in
Caco-2 cells, the incubation with glucose or fructose increased expression and protein abundance of
microsomal triglyceride transfer protein (MTP) and fructose, but not glucose, activated SREBP-1 and
ChREBP. These results show the link between carbohydrate and lipid pathways and suggest that these
monosaccharides may play a role in enhancing TG synthesis and CM assembly [95]. Furthermore,
several studies have shown that oral glucose compared to oral water can mobilize TG stored in cytosolic
lipid droplets of enterocytes. This storage of droplets could contribute to CM appearance up to 16 h
after the last meal. Moreover, the contractile activity of mesenteric lymphatics able to activate the
secretion of extracellular CM, that reside between enterocytes, in lamina propria, lacteals and the
mesenteric lymphatic system, was reduced with chronic high-fat and high-fructose feeding in rats [95].
4.3. Recommendations
Regarding dietary carbohydrate intake, the European guidelines on cardiovascular disease
prevention in clinical practice advise: sugar-sweetened soft drinks must be discouraged [68]. The
recent American guidelines on the primary prevention of cardiovascular disease recommend: to
minimize the intake of refined carbohydrates and sweetened beverages [69].
The European guidelines for the management of dyslipidemias recommend reducing TRL levels:
to reduce total amount of dietary carbohydrate and reduce intake of mono-disaccharides with a higher
magnitude of the effect than the replacement of SFA with MUFA and PUFA. To illustrate this point,
with a habitual fructose consumption between 15% and 20% of the total energy intake, plasma TG
increase as much as 30–40% [70].
To summarize, it appears that postprandial lipemia increases more markedly with fructose than
with glucose added to a single meal and in relation with the glycemic index of the carbohydrates.
Acutely, a biphasic postprandial lipidemic response was described depending on the glycemic index of
the carbohydrates. The chronic hypercaloric intake of fructose shows consistent results enhancing
postprandial lipemia, but despite numerous studies, isocaloric chronic consumption of carbohydrates
(fructose, glucose or starch) in mixed meals has led to discrepancies resulting in unclear divergent
effects increasing or decreasing postprandial lipemia.
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5. Effect of Dietary Proteins
In recent years, several studies have investigated the effect of protein quantity and quality on
postprandial lipemia. The main mechanisms by which proteins have been hypothesized to affect
postprandial lipid concentrations are through their slowing down of gastric emptying [101] and their
potent effect on insulin release, notably via increased incretin secretion, i.e., GIP and GLP-1 [102,103].
Insulin is a well-known activator of LPL [104] but an increase in postprandial insulin also inhibits
hormone-sensitive lipase and thereby suppresses the release of FFA from adipose tissue [105], which
could limit the lipotoxicity associated with elevated FFA concentrations [106].
5.1. Effect of Acute Addition of Dietary Proteins
Early work by Cohen et al. showed that the addition of 23 g casein to a meal containing 40 g
fat did not have any effect on postprandial lipemia in a group of 15 healthy adults [107]. In a group
of 24 healthy adults, the addition of 50 g sodium caseinate to a fat meal (1 g fat/kg body weight as
whipping cream) did not have any effect on the AUC of postprandial serum-, CM- or VLDL-TG
concentrations, although a delay in serum-, CM- and VLDL-TG peak concentrations was observed,
without any difference in gastric emptying rates. However, addition of casein led to a 20% reduction
in FFA concentration over 8 h, together with a 30% increase in insulin release [108]. In contrast, in
a group of 16 healthy adults, the addition of 50 g sodium caseinate or soy protein to a fat meal (1 g
fat/kg body weight as whipping cream) led to a decrease in postprandial TG concentration (significant
decrease at early time points but AUC was not calculated), with a 1 h delay in the peak time, together
with a decrease in FFA associated with an increase in insulin secretion [109].
In a group of 11 patients with well-controlled T2D, the addition of 45 g casein to a control
meal, consisting of energy-free soup with 80 g of fat, did not affect the postprandial TG or HDL
response. However, when casein was added to the control meal plus 45 g carbohydrates (as white
bread), it suppressed the increased postprandial TG concentration observed after the control meal
plus carbohydrates alone, with an increase in insulin, glucagon and GIP release and a decrease in FFA
concentration [110].
5.2. Effect of Dietary Protein Type
Mortensen et al. compared the acute effect of protein type on postprandial lipemia by providing
12 patients with T2D a test meal containing 100 g butter and 45 g carbohydrates in combination with
45 g casein, whey, cod, or gluten [111]. Compared to other sources of proteins, whey led to a decrease in
the AUC of postprandial TG concentration after 360 min (−27% to −31%), in both plasma and CM-rich
fraction, suggesting a concomitant lower production of CM, as illustrated by a lower retinyl palmitate
concentration in the CM-rich fraction and a decrease in FFA secretion. No differences in insulin,
glucagon and incretin concentrations or gastric emptying were observed. Using the same setting in 11
obese non-diabetic patients, the same group observed a significant lowering effect of whey proteins on
postprandial plasma TG, notably in the CM-rich fraction, with an increase in insulin and glucagon
secretion compared to cod and gluten but not compared to casein [112]. In a group of 20 overweight or
obese postmenopausal women, the addition of 45 g whey to a breakfast meal significantly decreased
postprandial TG concentrations as well as the exposure to smaller TG-enriched CM particles, as
reflected by a decrease in the AUC of the TG:apoB-48 ratio, compared to the addition of 45 g glucose
or casein to the same meal (−21% and −27%, respectively) [113]. In 11 obese non-diabetic subjects,
Homer-Jenssen et al. did not observe any difference between the addition of 45 g of four whey fractions
(alpha-lactalbumin, whey isolate, caseino-glycomacro-peptide and whey hydrolysate) to a high-fat
meal on postprandial TG, insulin, glucagon or incretin concentrations although whey hydrolysate
led to a smaller decrease in postprandial FFA production compared to the other proteins [114]. No
difference in postprandial TG concentration was observed in a similar setting in 12 T2D subjects [115].
33
Nutrients 2019, 11, 1299
Mariotti et al. provided 10 healthy overweight men a high-fat meal plus 45 g casein, whey protein,
or α-lactalbumin-enriched whey protein and observed a lower increase in postprandial plasma TG
concentration following the meal that provided casein (AUC decreased by 22%), with no effect on FFA
or insulin. As supported by their in vitro observations at pH values similar to those observed in the
stomach during digestion, the authors hypothesized that this difference was due to the low solubility
of casein at low pH leading to potential phase separation in the stomach, hence slowing down the
digestion and absorption of fat [116]. These results are in disagreement with those of Mortensen et al.
and Pal et al. Mariotti et al. put forward that they studied healthy individuals and that the components
of the meals they used were pre-mixed, therefore allowing more interaction between the nutrients.
When providing a pre-meal consisting of 17.6 g proteins (whey, casein or gluten) 15 to 30 min before a
fat-rich meal to 16 subjects with metabolic syndrome, Bjornshave et al. did not observe any difference
with regard to postprandial TG or FFA concentrations [117]. The authors hypothesized that the lower
protein dose used compared to Mariotti et al. may explain the discrepancy between the results of the
two studies. The same group also provided 12 matched subjects with and without T2D with 17.6 g
whey proteins 15 min before a fat-rich meal or during the main meal. Although the whey protein
pre-meal led to an increase in insulin, glucagon and GIP concentrations in both groups of subjects
and a decrease in gastric emptying rates, the authors did not observe any effect on postprandial TG,
apoB-48 or FFA concentrations [118].
5.3. Effect of Chronic Addition of Dietary Proteins
Mamo et al. investigated the long-term effect of a diet enriched in proteins from lean red meat,
in place of carbohydrates, on postprandial lipemia [119]. Twenty moderately hypertriglyceridemic
but otherwise healthy individuals consumed for six weeks two isocaloric diets (14%, 53% and 30%
energy from proteins, carbohydrates and fats respectively vs. 25%, 30% and 35%) and then received a
fat tolerance test meal. The protein-enriched diet led to a decrease in CM production, with a lower
postprandial apoB-48 concentration, but no difference in fasting plasma or postprandial lipemia was
observed. In a group of 52 patients with abdominal obesity, Bohl et al. did not observe any long-term
effect of the addition of 60 g whey compared with casein to a high-fat test meal consumed daily for 12
weeks on postprandial TG or FFA concentrations but whey addition led to a decrease in CM production
compared to casein addition, with a lower postprandial apoB-48 concentration [120].
To summarize, although the effects of dietary proteins on gastric emptying and FFA release seem
well established, their effect on postprandial TG concentrations remains unclear. Nonetheless, at least
three studies have pointed at a greater decrease in postprandial TG caused by the acute consumption
of whey proteins compared to casein, the two most studied protein sources. Of note, one study has
observed an opposite effect but it was the only one where food components were pre-mixed, and
therefore not physically separated from the fat source, thereby underlining the potential effect of food
structure on postprandial TG concentrations, as further discussed in chapter eight of the present review.
Long-term studies that investigated dietary protein consumption suggest a possible decreasing effect
on CM production, in particular by whey proteins.
6. Effect of Dietary Fibers
The effect of dietary fibers on postprandial lipemia has previously been reviewed [7,121]
showing that some sources of fibers, particularly soluble fibers, at the level of 4–10 g/meal, can
decrease postprandial TG and cholesterol concentrations following a mixed meal. Several interrelated
mechanisms have been put forward, including slowed gastric emptying, alteration of TG hydrolysis,
through increased viscosity decreasing the rate of hydrolysis or inhibition of pancreatic lipase activity,
alteration of mixed micelle formation, and possibly that of intestinal secretion of CM [122] but also
modification of insulin secretion [123].
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6.1. Effect of Acute Consumption of Dietary Fibers
Cara et al. showed that enrichment of a high-fat meal with fibers from cereals, i.e., 10 g oat
bran, wheat fibers or 4.2 g wheat germ, led to a decreased postprandial serum TG concentration in 6
healthy male adults compared to a low-fiber control meal, while only wheat fibers led to a decrease in
postprandial CM-TG concentration. Rice bran did not have any effect on postprandial TG concentration.
All fiber sources led to a decrease in postprandial CM-cholesterol concentration [124]. In another study
involving six ileostomized subjects, oat bran added to a test meal (43.8 g fat) was shown to elicit a 37%
reduction in postprandial CM-TG concentration and a 43% reduction in postprandial CM-cholesterol
concentration compared to a low fiber test meal, although the limited sample size did not allow for
these differences to reach statistical significance [125]. This was accompanied by an increase in ileum
excretion of fat and cholesterol. Dubois et al. observed that the addition of 10 g pea or soybean fibers
to a high-fat meal did not result in a decrease in postprandial TG concentration in six healthy male
adults but both fibers led to a decrease in CM-cholesterol and -phospholipid concentrations [126].
However, Sandstrom et al. showed that consumption of pea fibers by eight healthy adults in two
consecutive meals (containing 7.4 g and 9.3 g fibers respectively) resulted in a reduction in CM-TG and
intermediate-density lipoprotein-TG concentrations compared to a low-fiber meal [127]. The meals
provided in this study had less fat (19 and 43 g), and hence more carbohydrates, than those used by
Dubois et al. (70 g), which could partly explain the discrepancies between the two studies.
Kristensen et al. showed that addition of flaxseed fibers to a test meal containing 50 g fat led to a
decrease in postprandial plasma TG concentration in 18 healthy male adults (with 22 < body mass
index < 30 kg/m2) [128]. The difference (7 g dietary fibers) with the control meal was more marked
with the meal that provided a high dose (17 g) of flaxseed fibers from mucilage than with the meals
that provided 12 g dietary fibers from whole flaxseeds or low dose flaxseed mucilage. The addition
of mucilage also led to a decrease in postprandial insulin secretion. Khossoussi et al. showed that
addition of 12 g dietary fibers from psyllium husk to a standard meal (total fiber content = 15 g) led
to a 21% decrease in postprandial serum TG concentration in 10 overweight and obese mean [129].
Moreover, apoB-48 concentration was lower 1h after consumption of the meal high in fibers compared
to the meal low in fibers but the difference was not significant over a 6 h period. Resistant maltodextrin
(5 or 10 g added to a test meal containing 50 g fat) has also been shown to elicit a decreased postprandial
serum TG concentration in 13 healthy adults [130]. Kondo et al. provided 11 healthy male adults
with moderate hypercholesterolemia 200 g yogurt with or without 6 g partially hydrolyzed guar gum
together with a high-fat meal containing 43.5 g fat [131]. Ingestion of fibers led to a 15% decrease in
postprandial serum TG concentration and a 23% decrease in postprandial remnant-like lipoprotein
particle cholesterol concentration.
In contrast, some studies have shown no effect or even an increase in postprandial TG
concentrations following acute consumption of fibers. For example, Bourdon et al. observed no effect
of a barley pasta meal enriched with beta-glucan (15.7 g fibers versus 5 g fibers) on postprandial plasma
or TRL-TG or -cholesterol concentrations or postprandial TRL-apoB-48 concentration in 11 healthy
men [123]. Redard et al. observed a higher postprandial plasma TG concentration in females, but not
in males, following consumption of a high-fiber (15.4 g mixture of oat bran and guar gum) versus a
low-fiber (0.4 g) test meal [132]. Likewise, Ulmius et al. observed an increase in postprandial plasma
TG concentration following consumption of meals enriched with fibers from oats, rye bran, sugar beet
fibers or a mixture of these three fibers versus a low-fiber test meal in 13 healthy adults [133]. The
meals providing fibers not only differed in their soluble fiber content but also in their insoluble fiber
content and they were mixed with a blackcurrant beverage, hereby raising the question whether the
way fibers are added to the food matrix can influence the postprandial response measured.
6.2. Effect of Chronic Consumption of Dietary Fibers
Maki et al. studied the effect of adding oat containing β-glucan or wheat cereal products to the
usual diet of 27 healthy male adults for two weeks on their postprandial lipemia following consumption
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of a high-fat meal [134]. Both dietary treatments were matched for their energy and total fiber content.
The postprandial serum peak TG concentration was lower and the postprandial serum TG concentration
tended to be lower following consumption of the oat treatment but the postprandial FFA concentration
was higher. Of note, Cara et al. did not observe any difference in postprandial serum-TG concentration
following consumption of a meal containing 10 g β-glucan vs wheat fibers in healthy individuals [124].
Dubois et al. compared the postprandial effects of an oat bran test meal (12.8 g fibers) following
consumption for 14 days of either an oat bran supplemented diet (23.8 g fibers/day) or a basal low-fiber
diet (2.8 g fibers/day) in six normolipemic men [135]. Although it did not reach statistical significance,
probably due to the low number of participants, the oat test meal following chronic consumption of
oat elicited a slightly greater postprandial CM-TG concentration. However, the authors did observe
significant differences in the postprandial concentrations of other lipid classes: postprandial plasma
phospholipid, as well as plasma- and HDL-free cholesterol concentrations were increased while
postprandial HDL-C ester concentration was decreased. The authors thus concluded that chronic
consumption of oat exacerbates the acute effects of an oat meal on postprandial lipid concentrations.
Wolever et al. provided 33 dyslipidemic participants for four months either a high soluble or insoluble
fiber diet. The postprandial CM-TG concentration following consumption of a standardized fiber-free
fatty liquid meal did not exhibit any difference when all subjects were considered but subjects with the
APOε3 phenotype had a greater postprandial CM-TG concentration, due to an increase in the rate of
fat absorption or CM synthesis or both, after soluble vs insoluble long-term fiber consumption [136].
Bozetto et al. provided 20 overweight/obese subjects with T2D with a high carbohydrate/fiber diet (26 g
fibers/1000 kcal) for eight weeks and showed that participants exhibited a lower postprandial plasma
TG concentration as well as a lower TG concentration in the CM+VLDL fraction following consumption
of a test meal rich in saturated fat after the dietary intervention [137]. In another study using a relatively
similar design, the same group also observed a decrease in postprandial CM-cholesterol concentration
in T2D patients [138].
To summarize, most studies show that acute addition of soluble fibers to the meal leads to lower
postprandial TG concentrations. Several interrelated mechanisms linked to lipid digestion have been
implicated (see [121] for review). However, studies on this matter are relatively old and have thus not
taken into consideration the possible effect of the interaction between the gut microbiota and fiber
consumption on postprandial lipemia and more research is therefore needed to investigate if some
strains of bacteria are associated with altered postprandial TG concentrations or lipoprotein profiles, as
has been for example shown recently in the case of postprandial glucose concentrations [139].
7. Effect of Micronutrients and Phytochemicals
Some micronutrients, e.g., vitamins or trace elements, as well as polyphenols have been shown to
modulate postprandial lipemia. However, mechanisms underlying these effects have not been fully
elucidated and it is possible that not yet studied vitamins or trace metals, e.g., fat-soluble vitamins or
selenium, or phytochemicals other than polyphenols, e.g., carotenoids, might modulate postprandial
lipemia as well.
7.1. Niacin
The term niacin (also known as vitamin B3) refers to all molecules with the biological activity
of nicotinamide. It functions in the body as a component of Nicotinamide Adenine Dinucleotide
Phosphate (NADP) and Nicotinamide Adenine Dinucleotide Phosphate hydrogen (NADPH), which
are involved in many metabolic processes, including glycolysis, FA metabolism, and tissue respiration.
Its effect on fasting blood lipids is well established and pharmacological doses of niacin have been
used for five decades to treat lipid disorders and try to prevent CVD. Indeed, niacin diminishes fasting
blood TG concentration, likely by its inhibitory effect on VLDL production in T2D patients [140],
as well as LDL-C concentration, and raises HDL-C concentration in hypercholesterolemic patients
and in subjects with diabetes and peripheral arterial disease [141,142]. Nevertheless, its role on
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postprandial lipemia is still controversial because the only 3 studies dedicated to this topic showed
different results. Indeed, in a first study, niacin treatment did not significantly changed CM kinetics in
subjects with isolated low HDL-C [143] while in a second one, which was performed in normolipidemic
men with hypoalphalipoproteinemia, it significantly diminished it [144]. In a third study performed
in T2D patients, an intermediate effect was observed with a decrease in the postprandial secretion
rate of apoB-48-containing particles without a significant change in iAUC of postprandial plasma
TG and apoB-48 concentrations [145]. The reason for this discrepancy is not known but it might
be due to the form of niacin used, i.e., crystalline or another formulation, e.g., extended-release
or sustained-release [146], as well as to the characteristics of the subjects. Although it has been
shown, in lean and obese subjects, that niacin reduces FFA mobilization from adipocytes, perhaps by
suppressing lipolysis [147], and diminishes the liver formation of TG via noncompetitive inhibition of
liver diacylglycerol acyltransferase-2 (DGAT2) [148], mechanisms that explain its role on postprandial
lipemia have not been elucidated until the results of a recent study that give an idea on the potential
mechanism. Indeed, in a study, which was performed in statin-treated T2D subjects, it was observed
that extended-release niacin reduced postprandial secretion rate of apoB-48-containing particles [145].
However, a recent meta-analysis of randomized controlled trial (39,195 subjects; median duration
of treatment 11.5 months; median dose of niacin 2 g/day in monotherapy or in combination with other
component versus placebo/usual care or other component alone) showed no reduction with niacin
in mortality, cardiovascular mortality, fatal or non-fatal myocardial infarction nor fatal or non-fatal
strokes but niacin was associated with side effects [149].
7.2. Zinc
The pioneering studies on the effect of Zinc (Zn) on postprandial lipemia in rats were published
in 1977 by Koo and Turk [150,151]. These researchers described in detail the consequences of Zn
deficiency on lipid absorption in the rat. They notably found that the rate of TG absorption markedly
decreased, with a huge accumulation of TG droplets in the mucosa and that these droplets were
unstable and coalesced. They also observed that cell cytoplasm exhibited prominent cellular changes.
They deduced that the enterocytes were not able, by an unknown mechanism, to secrete lipid droplets.
They suggested that this was due to the failure of these cells to synthesize proteins required for the
formation of CM, i.e., apolipoproteins. Later, it was found that marginal Zn depletion significantly
diminished apo-C and -E concentrations in CM [152]. The nascent CM were also irregular and larger
in shape and size. The same team further showed in rats that the CM from marginally Zn-deficient rats
were less efficiently taken up by the liver [153]. This likely explained their delayed clearance from the
blood. One year later, the same team showed, also in rats, that marginal Zn deficiency also significantly
diminished CM-apo-B concentration [154]. About ten years later, Reaves et al. showed that the plasma
ratio of apoB-48 to total apoB protein was significantly lower in Zn-deficient rats than in Zn-adequate
rats [155]. They suggested that this is due to the editing of apoBmRNA that was impaired by Zn
deficiency. Indeed, apoB mRNA editing is performed by a Zn-containing cytidine deaminase [156] and
this enzyme determines whether apoB-48 or apoB-100 is synthesized. The same team later focused
on the intestine and found that Zn deficiency modestly, but significantly, diminished intestinal apoB
mRNA editing in hamsters [157]. Nevertheless, another team did not observe significant modification
of apoB mRNA editing in rats upon zinc deficiency [158]. This suggests that this effect, if existing, is
not very important. Nevertheless, the demonstrated inhibitory effect of Zn deficiency on the intestinal
synthesis of CM in rats and hamsters has also been observed in Mongolian Gerbils [159], suggesting
that this is a general phenomenon in rodents and, we assume, in mammals. Unfortunately, to our
knowledge, there is no data in human. Zn deficiency has apparently also another effect on CM
metabolism via a reduction of their lipolysis efficiency by LPL. Indeed, Zn-deficient rats exhibited a
reduced LPL activity in postheparin serum and adipose tissue [160,161]. Koo and Lee suggested that
this was not due to changes in the enzyme activity per se, but to Zn-deficiency-induced compositional
alterations in CM, which modulate LPL activity. The key role of CM composition on LPL activity likely
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explains why the effect of Zn deficiency on LPL activity was observed in rats fed coconut oil, but not in
rats fed fish oil [161].
7.3. Copper
Although there are few studies on the effect of copper (Cu) on CM metabolism, the two available
studies performed in rats suggest an effect of Cu deficiency. In the first study, it was observed that
Cu deficiency significantly diminished the activities of both endothelial LPL and hepatic lipase. This
might explain the lower clearance rate of CM, which was observed in the beginning of the postprandial
period in the Cu deficient rats [162]. The second study showed that TRL isolated from Cu-deficient
rats were more fluid than those isolated from control rats [163]. This was apparently due to their
low cholesterol/phospholipid ratio and their high TG content. The authors suggested that these
modifications could affect the metabolism of these lipoproteins. Thus, dedicated clinical studies are
required to assess the effect of Cu deficiency on postprandial lipemia.
7.4. Magnesium and Calcium
A pioneer study performed in inverted hamster intestine showed that a very low concentration
of Mg in the intestinal lumen impairs the normal secretion of CM by the intestine [164]. Conversely,
a clinical study performed in healthy individuals found that both the CM-TG response and the
postprandial blood concentration of apoB-48 after a fat load were significantly lower after a meal that
contained a Mg supplement (500 mg) than after a control meal [165]. Thus, as for Cu, further clinical
studies are required to conclude on the effect of Mg status or Mg supplementation on postprandial
lipemia. Concerning Calcium (Ca), a clinical study has suggested that dairy Ca, but not supplementary
Ca carbonate, can attenuate postprandial lipemia in healthy moderately overweighted men [166]. It
was suggested that this was due to impaired fat absorption because high Ca intake increases fecal fat
excretion. However, further studies are needed to confirm this finding and to explain the different
effect of these two chemical forms of Ca.
7.5. Polyphenols
The story on the effect of polyphenols on postprandial lipemia unusually started with a clinical
study that found no significant effect of acute dealcoholized red wine, which is rich in polyphenols,
on postprandial lipid metabolism in dyslipidemic postmenopausal women [167], suggesting that
these polyphenols, at the tested dose, do not significantly affect lipid absorption and CM metabolism.
However, a study performed in human Caco-2 cells led to an opposite conclusion by showing that
red wine polyphenols significantly impaired the secretion of apoB-48 by these cells [168]. Conversely,
in the same cell model, Vidal et al. did not find that wine polyphenols decreased the secretion of
lipoproteins, contrarily to apple polyphenols that decreased it [169]. Tea polyphenols were also shown
to decrease postprandial hypertriglyceridemia in rodents [170,171] and in men with mild or borderline
hyperTG [172]. It was suggested that this was due to a decrease in TG absorption via an inhibition
of pancreatic lipase activity [171]. However, as observed in mice, this could also be due to the fact
that tea polyphenols decrease bile acid reabsorption, which results in lower intestinal bile acid levels,
which might further decrease lipid absorption [173]. Interestingly, coffee polyphenols also inhibited
pancreatic lipase activity, resulting in a lower postprandial increase in blood TG concentration. A study
in mice suggested that this effect was apparently due mainly to one species of polyphenols among the 9
species that are recovered in coffee, i.e., di-cafeoylquinic acids [174]. Cinnamon extract, which is rich in
polyphenols, was also able to diminish the secretion of apo-B48 and TRL in a fat load test performed in
hamsters. Furthermore, it was observed that cinnamon extract reversed the expression of the impaired
Insulin Receptor (IR), Insulin Receptor Substrate 1 (IRS1), IRS2 and AKT serine/threonin Kinase 1 (Akt1)
mRNA levels and inhibited the overexpression of MTP and SREBP-1cin rodent enterocytes [175,176].
In another study, an anthocyanin-rich extract purified from a Haskap fruit significantly reduced the
postprandial TG response measured in rats after a fat load [177]. Finally, a clinical study performed in
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overweight/obese subjects and components of the metabolic syndrome showed that subjects submitted
to eight-week supplementation with a diet rich in polyphenols had lower postprandial TG response to
a fat load than subjects who consumed a diet poor in polyphenols [178].
To summarize, it appears that some polyphenols, but not all, could significantly impair either the
absorption of lipids or the intestinal secretion of CM. Nevertheless, additional studies, preferentially
clinical ones, are required to identify which polyphenols and, at which dose, can significantly diminish
postprandial lipemia.
8. Effect of the Food Structure (Matrix)
Although the study of the effects of single nutrients on postprandial lipemia is paramount in
our understanding of the mechanisms involved, this approach bears limitations since human beings
consume foods and not isolated nutrients. Indeed, most foods are complex, heterogeneous matrices
and are defined not only by their qualitative and quantitative molecular composition but also by the
organization of their molecules at multiple spatial length scales [179]. Moreover, the initial structure of
a food is greatly modified by digestive processes, be it physical (e.g., mastication, antral grinding) or
chemical (e.g., digestive enzymes, pH) ones. Hence, numerous interactions exist between the different
components of each food and with other components from co-consumed foods. Jenkins and colleagues
have long acknowledged this complexity in the case of postprandial glycaemia with the introduction of
the glycemic index in 1981, which considered the postprandial effect of both nutrients, such as mono-
or di-saccharides, as well as that of foods [180]. To date, such an approach has not been developed
in the case of postprandial TG although guidelines have been proposed to assess postprandial TG
concentrations in a standardized fashion [181]. Yet, several authors have pointed at the greater
efficacy of food-based approaches in the prevention and treatment of some chronic diseases, including
CVD [182–184], and thus advocate to switch the focus from nutrients to foods, for easier translation to
the public but also to take into account the inherent complexity of food matrices. Numerous studies
have shown that the distribution of FA in TG, the organization of lipids as oil droplet emulsions
differing in their size and interfacial composition, the degree of crystallized fat or the permeability of
the food matrix to digestive enzymes can influence lipid digestion and metabolism [185] but only a
few studies have specifically investigated the effects of food structure on postprandial lipemia.
8.1. Effect of Dietary Lipid Physical State
Fats and oils in foods can be present either as a continuous phase or as emulsions, i.e., two
immiscible phases dispersed as droplets, but they are also characterized by their crystallized/liquid
TG ratio, which varies with temperature. Vors et al. provided nine normal weight and nine obese
subjects with an identical breakfast containing 40 g milk fat either emulsified or non-emulsified [186].
Importantly, the two fats used had similar melting temperatures. The emulsified fat led to an earlier
and greater CM-TG peak concentration, greater apoB-48 concentrations in all subjects, as well as larger
CM size and iAUC of the CM-TG concentrations in obese subjects. Garaiova et al. also observed
a 60% greater iAUC of the postprandial plasma TG concentrations following consumption by 24
healthy volunteers of a standardized meal comprising 30ml of an emulsified n-3-rich PUFA (EPA +
DHA = 28% w/w) oil mixture compared to the same meal but with a non-emulsified oil mixture [187].
Nevertheless, only the postprandial AUC for plasma n-3 PUFA concentrations was affected by the
emulsification, i.e., AUC for postprandial plasma SFA, MUFA and n-6 PUFA concentrations were not
significantly different, strongly suggesting an increase in the absorption efficiency of n-3 PUFA with
emulsification rather than a modification of postprandial CM metabolism.
Clemente et al. investigated postprandial TG concentrations in 8 T2D overweight patients after
they received three test meals, identical in volume and macronutrient composition, but with fat
originating from different sources, namely milk, butter and mozzarella cheese. No significant difference
was observed in the increase in plasma TG concentration over the 6 h following the meal although the
meal containing butter elicited a significantly delayed plasma TG peak time, not due to differences in
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gastric emptying rate. Unfortunately, it is not possible to conclude from the study design if this was
due to the dispersion state of lipids (relatively small native milk fat globules in milk, aggregated milk
fat globules dispersed in a protein matrix for mozzarella cheese, relatively larger fat droplets for butter)
or to differences in viscosity (butter, mozzarella cheese and milk being respectively solid, semi-solid
and liquid) [188]. Tholstrup et al. did not observe either any difference in postprandial plasma total
TG, CM-TG and VLDL-TG concentrations when they provided 14 healthy young men with butter,
cheese and milk [189].
8.2. Effect of the Droplet Size of the Oil Emulsion
Fats and oils in processed foods are mostly found as emulsions, and usually as oil-in-water
emulsions. The initial oil droplet size has a major impact on lipid digestion, with smaller droplet size
leading to faster digestion rate due to increased surface area. Armand et al. fed 8 healthy individuals
with either a fine (surface-weighted mean diameter = 0.7 μm) or a coarse (surface-weighted mean
diameter = 10 μm) emulsion and they observed a higher gastric and duodenal lipolysis, a slower gastric
emptying, confirmed in [190], and a later postprandial serum- and CM-TG peak concentrations with
the fine emulsion, but no significant difference was observed in the AUC of the postprandial serum- or
CM-TG concentrations [191]. Tan et al. also studied the effect of emulsification and oil droplet size on
postprandial TG concentrations [192]. Fifteen healthy Chinese males received a test meal containing
olive oil as non-emulsified, finely emulsified (surface-weighted mean diameter = 0.7 μm) or coarsely
emulsified (surface-weighted mean diameter = 10 μm). The meal with non-emulsified oil elicited
the lowest iAUC of the postprandial plasma TG concentrations (although only with a trend against
the coarse emulsion, p = 0.07), associated with the fastest gastric emptying, in agreement with the
above-mentioned results from Vors et al. [186]. Moreover, a higher iAUC of the postprandial plasma
TG concentration was observed following consumption of the test meal containing the fine emulsion
compared to that containing the coarse emulsion (similar surface-weighted mean diameters as in
Armand et al.) [192].
8.3. Effect of the Interfacial Film at the Oil-in-Water Emulsion Droplet Surface
The formation and stability of oil-in-water emulsions in the gastro-intestinal tract is influenced
by the presence of emulsifiers, such as proteins, polysaccharides or phospholipids, which can in turn
modulate oil droplet coalescence and hence fat digestion rate. Proteins differ in their emulsifying
and stabilizing capacities, depending partly on their solubility, their hydrolysis rate by proteases and
their displacement from the interfacial film by bile salts (see [193] for review). These characteristics
could explain some of the differences observed in studies comparing the effect of protein sources
on postprandial TG concentration but this has usually not been evaluated, with the exception of
Mariotti et al. who observed in vitro a phase separation with the casein meal used in their clinical
intervention study which they suggest could partly explain the associated lower increase in postprandial
TG concentration [116]. Keogh et al. fed 10 men and 10 women (mean age = 59 years) two emulsions
(iso-viscous, iso-caloric and same mean droplet size), containing 30 g of fat, differing in their emulsifier
composition (namely sodium sterol lactylate or sodium caseinate/monoglycerides) [194]. Emulsions
stabilized by sodium caseinate/monoglycerides elicited lower postprandial TG concentrations at 90
and 120 min compared to sodium sterol lactylate (no AUC calculated), with a concomitant faster gastric
emptying and lower secretion of the gut hormones cholecystokinin, GLP-1 and peptide YY.
8.4. Effect of the Positional Distribution of FA in TG
Dietary TG can vary in FA chain length, degree of unsaturation but also in the distribution of FA
on the glycerol backbone (stereospecificity), whether in naturally occurring TG or from technological
processing by food industries, a technique termed interesterification. The isomers thus formed can
lead to TG molecules with different physical properties, including melting temperature [195], digestion
rates and biological effects, including postprandial TG concentrations. Dedicated reviews on the effects
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of interesterification on lipid metabolism have previously been published [196,197]. Berry reviewed 10
cross-over studies investigating the postprandial effects of stearic and palmitic acid-rich fats, the two
major SFA in human diets, where test meals only differed from control meals by the stereospecificity
of the TG sources and not by the FA composition. No conclusion could be drawn when only the
positional distribution of FA was considered but she suggested that interesterified TG with higher
melting points, i.e., crystalline at body temperature, led to a decrease in postprandial TG concentration,
due to a slower assembling of micelles, leading to a slower rate of lipolysis in the gastro-intestinal
tract [196]. This hypothesis has been confirmed in two subsequent studies by Berry’s group where fat
test meals containing interesterified palm olein led to lower postprandial plasma TG concentration
compared to palm olein in healthy men and women [198] and in men aged 40–70 years with fasting
plasma TG concentration > 1.2 mmol/L [199]. In these two studies, interesterified palm olein was
characterized by a higher proportion of palmitic acid in the sn-2 position and a higher melting point
(4.7% solid fat content at 37 ◦C whereas palm olein was fully melted at 37 ◦C).
8.5. Effect of Fat Localization within the Food Matrix
Berry et al. showed that a test meal containing 54 g fat provided as whole almond seed
macroparticles elicited a 74% lower postprandial increase in plasma TG concentration compared to the
same test meal containing almond oil and defatted almond flour (identical macronutrient composition)
in 20 healthy adult men [200]. Oils bodies in almonds, as in many nuts, are found within thin-walled
cells. These cell walls have been found to be highly resistant to digestion since almond microstructure
has been shown to be only marginally affected by mastication, leading to low lipid bioaccessibility and
hence lipolysis rates [201].
8.6. Effect of the Meal Consistency/Viscosity
The effect of the addition of fibers on postprandial TG concentrations has been specifically
addressed in the dedicated chapter and is therefore left out of this section.
In a recent study, Dias et al. investigated the effect of three meals differing in their structure
and form, namely solid, semi-solid and liquid, while having the same nutrient composition, on
lipid digestion and postprandial TG concentration using an in vitro approach and a randomized,
cross-over, dietary intervention trial in 26 healthy adults [202]. They showed that the liquid food
elicited significantly higher postprandial TG concentration compared to the solid food, while the
semi-solid food displayed an intermediate figure though not reaching statistical significance. This effect
was partly attributed to the larger oil droplet size exhibited by the solid food compared to semi-solid
and liquid food before and in the earlier stages of in vitro digestions as well as to the fact that solid
food showed phase separation during gastric digestion together with a lower release of FA during
intestinal digestion.
To summarize, food structure, whether native or manipulated, can significantly affect postprandial
TG concentrations and can even override the effects of macronutrient composition. Lipid emulsification,
particularly with a smaller droplet size, interesterification leading to TG with lower melting points
or lower meal viscosity all elicit higher postprandial TG. Additional research is warranted to better
characterize how manipulation of food structure can impact on postprandial TG concentration, e.g.,
effects of emulsifier type on the stability of oil-in-water emulsions. Nonetheless, consumption of foods
with specific food structure, e.g., nuts, or technological modification of food structure certainly constitute
relevant approaches in the prevention and management of elevated postprandial TG concentrations.
9. Conclusions
During the last decades, many clinical studies have highlighted the fact that healthy humans
spend most of their time in a hyperlipidemic postprandial state due to the repetitive consumption
of fat-containing meals and that this process is exacerbated in hyperlipidemic patients. Postprandial
lipemia is characterized by the accumulation of both hepatic apoB-100 and intestinally-derived
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apoB-48 TRL in the circulation, which participate in atherosclerotic plaque progression. Accordingly,
postprandial lipemia, in both its magnitude and duration, has been shown to constitute an independent
risk factor for CVD, which confirms the central role of dietary modifications in the treatment and
prevention of CVD.
Indeed, we have shown in this review that chylomicron production and postprandial lipemia
are highly modulated by both habitual diet and single meal nutrient composition. Despite conflicting
results between studies due to different methodological approaches and many potentially confounding
factors, we have summarized in Table 1 the main acute and chronic effects of food components as well
as food structure on chylomicron production and postprandial lipemia.
Table 1. Effects of nutrients and micronutrients on postprandial lipemia.
Dietary Components Postprandial Lipemia Level of Evidence
Fats
Amount ↑ +++
Type (acute) SFA =MUFA = PUFA ++
Type (chronic) SFA >MUFA > n-6 PUFA > n-3 PUFA ++
Amount of cholesterol ↑ ++
Carbohydrates Acute
↑ (fructose > glucose) +++
↑ (glycemic index) +++
Chronic ↑ (fructose/dose dependent) +++
Proteins Whey proteins (acute) ↓ ++
Fibers Soluble (acute) ↓ ++
Micronutrients
Ca supplement ↓ +
Niacin supplement ↓ ++
Zn deficiency ↓ +
Cu deficiency ↑ +
Mg supplement ↓ +
Polyphenol supplement ↓ +
Ca, calcium; Cu, copper; Mg, magnesium; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids;
SFA, saturated fatty acids; Zn, zinc; +++: convincing; ++: probable; +: suggested.
Postprandial lipemia increases dose-dependently with the amount of dietary fat or cholesterol
after a single meal, over a certain-amount threshold. However, due to interactions between long-chain
fatty acid species and physico-chemical properties of fat structures, especially fat droplet characteristics,
it is difficult to identify the acute effect of FA species on postprandial lipemia. Despite some conflicting
results, studies of habitual diet show postprandial lipidemic responses in the order SFA >MUFA > n-6
PUFA > n-3 PUFA.
Although dietary fat has received the most attention, other nutrients and micronutrients can
modulate postprandial lipemia. Dietary proteins could apparently display some effect but it depends
on their nature and the few studies available do not allow us to conclude on their effect on postprandial
lipemia. Carbohydrate sources added to a meal have been shown to modulate postprandial lipemia in
relation with their glycemic index. Added to a fat-meal, glucose, and more markedly fructose, can
noticeably increase postprandial lipemia. Chronic hypercaloric intake of fructose but not isocaloric
consumption of carbohydrates (fructose, glucose or starch) resulted in constant increase postprandial
lipemia. Some minerals (Ca, Zn, Cu) and some polyphenols, e.g., tea polyphenols, have also been
shown to modulate postprandial lipemia but the number of studies is limited and the mechanisms
suggested deserve more investigations. Dietary fibers, especially soluble fibers from various origins,
can lower postprandial lipemia when added to a fatty meal in sufficient amount. Mechanisms involved
are not fully understood and new studies should thus be performed to evaluate the possible interaction
between the gut microbiota with the effect of fiber consumption on postprandial lipemia. Finally,
nutrient composition alone cannot explain the effect of foods on postprandial lipemia and it is now
clear that the food matrix is a key factor influencing fat digestion and hence postprandial lipemia.
The potential mechanisms of action have been reviewed and summarized in Table 2 but are not
fully understood. Further studies and particularly lipoprotein kinetic studies in humans are needed.
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Table 2. Potential mechanisms of nutrients and micronutrients action in postprandial lipemia.
Dietary Components Potential Mechanisms
Fats MUFA ↓ PR and ↑ FCR VLDL
n-6 PUFA ↑ FCR VLDL
n-3 PUFA ↓ PR CM; ↓ PR and ↑ FCR VLDL
Carbohydrates Fructose ↑ PR CM; ↑ PR VLDL







Alteration of TG hydrolysis
Alteration of mixed micelle formation
↓ PR CM
Micronutrients
Ca supplement ↓ fat absorption
Niacin supplement ↓ PR CM
Zn deficiency ↓ TG absorption rate and PR CM
Cu deficiency ↓ LPL and HL activities
Mg supplement ↓ PR CM
Polyphenol supplement ↓ TG absorption likely by ↓ pancreatic lipase activity
Ca, calcium; Cu, copper; Mg, magnesium; CM, chylomicrons; FCR, fractional catabolic rate; MUFA, monounsaturated
fatty acids; PR, production rate; PUFA, polyunsaturated fatty acids; VLDL, very low, density lipoprotein; Zn, zinc.
Dietary approaches based on food nutrient composition and structural interactions represent
relevant approaches to control postprandial lipemia.
A better understanding of the factors and mechanisms regulating chylomicron production and
postprandial lipemia, and particularly diet, is essential to try to modulate their increases and thus
reduce the risk of atherosclerotic cardiovascular diseases and potentially the risk of total mortality.
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Abstract: Background: Postprandial lipemia (PPL) is a cardiovascular disease risk factor. However,
the effects of different fat sources on PPL remain unclear. We aimed to determine the postprandial
response in triglycerides (TG) to four dietary fat sources in adults. Methods: Participants completed
four randomized meal trials. For each meal trial, participants (n = 10; 5M/5F) consumed a high-fat
meal (HFM) (13 kcal/kg; 61% of total kcal from fat) with the fat source derived from butter, coconut
oil, olive oil, or canola oil. Blood was drawn hourly for 6 h post-meal to quantify PPL. Results:
Two-way ANOVA of TG revealed a time effect (p < 0.0001), but no time–meal interaction (p = 0.56),
or meal effect (p = 0.35). Meal trials did not differ with regard to TG total (p = 0.33) or incremental
(p = 0.14) area-under-the-curve. When stratified by sex and the TG response was averaged across
meals, two-way ANOVA revealed a time effect (p < 0.0001), time–group interaction (p = 0.0001),
and group effect (p = 0.048), with men exhibiting a greater response than women, although this
difference could be attributed to the pronounced difference in BMI between men and women within
the sample. Conclusion: In our sample of young adults, postprandial TG responses to a single HFM
comprised of different fat sources did not differ.
Keywords: postprandial lipemia; coconut oil; butter; canola oil; olive oil; lipid; triglycerides; dietary
fat; saturated fat; cardiovascular disease
1. Introduction
Cardiovascular disease (CVD) is a major public health concern and the leading cause of death in
the United States [1]. Traditional risk factors for CVD include smoking, physical inactivity, poor dietary
habits, overweight/obesity, dyslipidemia, diabetes, and hypertension [1]. In addition, emerging
evidence has given rise to consideration of postprandial changes following single, high-fat meal (HFM)
consumption as substantially impacting CVD risk [2]. In fact, postprandial triglycerides (TG) have
been identified as a stronger predictor of CVD risk than fasting values [2]. This is partly because
individuals are in a postprandial state for the majority of their day [3]. Adverse changes that occur in
the postprandial period include increases in TG [3], oxidative stress [4], inflammation [5,6], oxidized
low-density lipoprotein [7], and decreases in high-density lipoprotein (HDL-C) [8,9] and vascular
dilation [9], all of which have been shown to contribute to the CVD pathology.
Postprandial lipemia (PPL) is the rise in blood TG response following a meal [3]. Several
studies have shown that an altered or reduced ability to clear TG in the postprandial period (thus,
a large postmeal TG response) is associated with CVD [3,10–12]. The connection between PPL and
CVD has been demonstrated in a case-control study in men with coronary heart disease (CHD)
compared to healthy controls and in the sons of men with CHD compared to sons of men without
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CHD, where both disease-case groups exhibited significantly greater postprandial TG levels [10].
Similarly, data examined in women have revealed associations between greater postprandial TG and
apolipoprotein B-48 (apoB-48) concentrations and CHD [2,12,13]. Moreover, in the Women’s Health
Study and in the Copenhagen City Heart Study, both large prospective cohort studies involving
women, nonfasting TG concentrations were significantly associated with increased CVD risk, even after
adjustment for various confounding variables [2,14]. It has been suggested that the mechanistic
connection between individual PPL and CVD is the subendothelial penetration and retention of
circulating TG-rich lipoproteins (TRL) [11,15].
Given that HFMs classically used to study PPL contain >50% fat [11,16], and the variability in
different dietary fat sources ability to increase or decrease CVD risk, it is logical that the source of
dietary fat can modulate the postprandial TG response. Several studies have found a reduced PPL
response following meals rich in monounsaturated fatty acids (MUFA) and polyunsaturated fatty
acids (PUFA) compared to meals rich in saturated fatty acids (SFA) in both healthy adults and those
with characteristics of metabolic syndrome [17–19]. These findings are in line with classical dietary
data showing that certain sources of SFA are generally associated with CVD [20,21]. Meanwhile,
Schwingshackl and Hoffmann [22] found that MUFA and PUFA can induce a greater PPL response
compared to SFA. Given these findings and classic dietary data, the effects of different dietary fats on
PPL have been inconclusive to this point. Furthermore, since the effects of a given type of dietary fat on
CVD risk can also depend on the source of the fat (animal- versus plant-based SFA [23]), it is reasonable
to suspect different postprandial responses based on fat source, even when those foods are comprised
of similar fatty acid contents and types. In support of this concept, recent data from Teng et al. and
Panth et al. examining the effects of animal- vs. plant-based SFA have yielded inconsistent and
contradictory results. Teng et al. observed a lower TG response after the consumption of animal-based
SFA (lard) when compared to plant-based SFA (palm olein), while Panth et al. observed a greater TG
response after the consumption of animal-based SFA (butter, lard) when compared to plant-based
SFA (coconut oil) [24,25]. Considering the rising scientific data on ketogenic diets and low-carb
eating patterns, and their recent popularity regarding the treatment of several phenotypes associated
with CVD (diabetes, obesity), it is pertinent to understand further how various sources of dietary
fat affect cardiometabolic health. Furthermore, considering the inconsistency with regard to current
postprandial data, and that PPL is an independent risk factor for CVD [2], determining how various
types and sources of dietary fat consumed may modify individual postprandial TG response would
be valuable.
Therefore, the primary purpose of this investigation was to determine the effects of commonly
consumed sources of dietary fat as part of a mixed meal on PPL in young adults. Specifically, this study
compared the postprandial TG response to plant-based SFA (coconut oil), animal-based SFA (butter),
MUFA-rich olive oil, and MUFA-rich canola oil.
2. Materials and Methods
2.1. Participants
Ten individuals (5 M/5 W) participated in the present study and were recruited via online survey,
email, or flyer from the Oklahoma State University campus. Inclusion criteria were age 18–40 years,
no evidence of dietary intolerances that precluded consumption of the test meals, no chronic disease,
and not taking any lipid or blood pressure medications. The study protocol was approved by the
Institutional Review Board at Oklahoma State University (HE-17-77) and carried out in accordance with
the Declaration of Helsinki. All participants provided verbal and written consent prior to participating
in the study.
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2.2. Overall Study Design
Participants engaged in one initial assessment and four randomized meal trials. The initial
assessment consisted of detailed paperwork (informed consent, medical history questionnaire,
international physical activity questionnaire (IPAQ)) and anthropometric data measurements.
Participants were also administered various lifestyle control instructions during the initial assessment.
Meal trials began approximately one week after the initial assessment. Each meal trial was separated
by a washout period of 1–3 weeks. The sequence in which a participant consumed the four test meals
was randomized. Within each meal trial, participants arrived in the laboratory 10-h fasted, a baseline
blood draw was taken, they consumed the test meal, and blood draws were taken every hour for six
hours post-meal to determine the postprandial TG response.
2.3. Initial Assessment
The initial assessment entailed detailed copies of instructions for participants to follow, completion
of written informed consent, a medical history questionnaire, the IPAQ, and anthropometric evaluations.
Height was measured via stadiometer (Seca 213 portable stadiometer; Seca GmbH; Hamburg, Germany).
Body mass was measured using a digital scale (Seca mBCA 514; Seca GmbH; Hamburg, Germany).
Blood pressure was measured using an automatic blood pressure cuff (Omron 5 Series BP742N; Omron;
Kyoto, Japan). Height, weight, and blood pressure were measured twice and the average of the two
measures was recorded.
Lifestyle controls were assigned and all participants were instructed to follow and comply with
the explained lifestyle instructions. Lifestyle controls consisted of a three-day food record, in which
participants recorded their dietary intake for the three days prior to their first meal assessment;
participants then were asked to replicate their first three-day food record for the remaining three
meal assessments. Accelerometers (wGT3X-BT, Actigraph; Pensacola, FL, USA) were attached to each
participant’s nondominant wrist and recorded their physical activity for at least 48 h prior to each
assessment. In addition, participants were asked to refrain from planned exercise for the 48 h prior to
each assessment. Participants were given a 210-kcal snack, consisting of commercial peanut butter
crackers (Snyder’s-Lance, Inc.; Charlotte, NC, USA), to consume the evening before each assessment,
after which the 10-h fast began. Participants were given a typed copy of all detailed instructions and
lifestyle controls.
2.4. Meal Trials
After a 10-h overnight fast, participants arrived in the laboratory on the morning of each assessment.
Each meal assessment began between 6:00–8:00 A.M., depending on the scheduling availability of the
participant. An indwelling 24-gauge safelet catheter (Exel International; Redondo Beach, CA, USA)
was inserted into a forearm vein and a slow infusion (~1 drip/s) of 0.9% NaCl solution was initiated.
Once the catheter was set, a baseline blood draw was collected. First, a 3 mL syringe (BD; Franklin
Lakes, NJ, USA) was used to clear the line of saline followed by a 5 mL syringe (BD; Franklin Lakes, NJ,
USA) used to take the whole blood sample. Whole blood samples were collected for the assessment
of metabolic outcomes: TG, glucose, LDL-C, HDL-C, and total cholesterol (TOTAL-C). Metabolic
outcomes were determined by a Cholestech LDX analyzer (Alere Inc.; Waltham, MA, USA). For each
individual blood draw, a few drops of whole blood were drawn into a capillary tube and plunged
into a Cholestech LDX Lipid+Glu cassette (Alere Inc.; Waltham, MA, USA). The cassette was inserted
into the Cholestech LDX analyzer and processed. The CV for TG assessment via the Cholestech LDX
system is approximately 2–4%. Following the baseline blood draw, participants consumed the test
meal within 20 min. Water was available for participant consumption ad libitum during the meal
and throughout the postprandial period. Participants remained in the laboratory for 6 h following
consumption of the test meal. The 6-h time period began after the last bite of the test meal. Additional
blood draws were performed every hour for the 6 h after consumption of the test meal.
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2.5. Test Meals
The test meal consisted of pasta sauce, whole-wheat spaghetti noodles, French bread, yellow
onion, green bell pepper, sea salt, black pepper, and the specific fat source being tested. Each meal
contained a test fat of either MUFA-based canola oil (CaO) (Great Value, Canola Oil), MUFA-based
extra virgin olive oil (OO) (Great Value, Extra Virgin Olive Oil), SFA-based virgin unrefined coconut oil
(CoO) (Organic Great Value, Unrefined Virgin Coconut Oil, expeller pressed), or SFA-based grass-fed
butter (B) (Kerrygold, Grass-fed Pure Irish Butter, unsalted). The test meal contained 61% of total kcal
from fat, 7% of total kcal from protein, and 32% of total kcal from carbohydrate (CHO). Each participant
consumed a serving of the test meal that was relative to his or her body mass (13 kcal/kg body mass).
The amount of meal consumed was designed to resemble a typical serving at a restaurant or social
event (1–2 servings). For each assessment, the meal was prepared independently 1–2 days prior to the
assessment. To prepare each meal, the test fat was added to a small saucepan and heated over medium
heat for 2 min. Onion and bell pepper were diced finely and sautéed over medium heat in a large
saucepan for 3 min. The pasta sauce was added to the saucepan and brought to a boil, after which
the heat was reduced, the saucepan was covered, and the mixture cooked for 7 min until the internal
temperature reached 165 ◦F. Once the pasta sauce mixture was finished cooking, it was removed from
the heat, cooled for 20 min, labeled, and stored in a BPA-free food storage container at 0 ◦F until needed
for each assessment. The night before each assessment, the pasta sauce was thawed at 36 ◦F overnight.
On the morning of each assessment, the noodles were prepared separately by bringing four cups of
water to a boil in a medium saucepan, after which the raw noodles were added, cooked uncovered for
9 min, and strained. The pasta sauce was reheated in a small saucepan until the internal temperature
reached 165 ◦F. The pasta sauce and noodles were combined in a small serving bowl and the French
bread was served on the side. All ingredients were weighed (g) using a digital food scale (Table 1).
Table 1. Test fats and meal composition. Data are representative of the test meal composition for a
60 kg participant.
Weight (g) Energy (kcal) Protein (g) Fat (g) CHO (g) Fiber (g)
Sauce 257 577 5 52 25 3.3
Bread 28 78 3 1 16 1.5
Pasta 33 124 6 1 24 1.5
Total 318 780 14 54 65 6.3
2.6. Statistical Analyses
An a priori sample size estimation, using standard deviations from previous studies [26,27], suggested
that ten participants would need to be recruited to detect a clinically significant difference in the peak
postprandial TG response of 0.5 mmol/L between meals with 80% power and alpha less than 0.05.
All data were assessed for normality via Shapiro–Wilk formal normality test and analysis of
frequency distribution. The trapezoid method was used to calculate tAUC and incremental area under
the curve (iAUC). Within each meal trial, tAUC, iAUC, peak value, and time to peak value were
determined for each of the metabolic markers. These postprandial metabolic outcomes were compared
across trials using a one-way analysis of variance (ANOVA) with Holm–Sidak adjustment for multiple
comparisons. Time-course changes and sex-based differences in metabolic markers in the postprandial
period were determined via two-way between and within (group × time) repeated measures ANOVA
with a Tukey’s adjustment for multiple comparisons.
Differences between participant characteristics were compared by sex via two-tailed paired t-test.
Pearson’s two-tailed correlation analysis was performed to assess the association between participant
body mass index (BMI) and TG tAUC (averaged across meal trials).
A type 1 error rate of 0.05 was used in all analyses for the determination of statistically significant
differences. Statistical analyses were conducted using GraphPad Prism statistical software (Version 7;
GraphPad Software, Inc., La Jolla, CA, USA).
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3. Results
3.1. Participant Characteristics and Premeal Physical Activity
Participant characteristics are presented in Table 2. Ten individuals participated in the present
study (5 M/5 F; age: 23.8 ± 1.3 years; BMI: 25.5 ± 7.2 kg/m2). Based on BMI, six participants (1 M/5 F)
were healthy weight (18.5–24.9 kg/m2), one participant (1 M) was overweight (25–29.9 kg/m2), and three
participants (3 M) were obese (>30 kg/m2). One participant reported with fasting TG > 1.69 mmol/L
on two occasions. Men were significantly older (mean difference: 1.2 years; p = 0.03) and had greater
weight (mean difference: 36.2 kg; p = 0.01) and BMI (mean difference: 9.6 kg/m2; p = 0.02) compared to
women. Men had higher fasting LDL-C concentrations when compared to women (mean difference:
0.47 mmol/L; p = 0.02), but there were no differences in fasting TG (p = 0.21), glucose (p = 0.96),
TOTAL-C (p = 0.44), or HDL-C (p = 0.30) between men and women. Additionally, fasting TG (p = 0.39),
glucose (p = 0.13), TOTAL-C (p = 0.07), LDL-C (p = 0.86), and HDL-C (p = 0.11) were not different
across meal trials. Physical activity, measured as moderate-vigorous physical activity (MVPA) and
steps/day, was not different across meal trials (p = 0.84 and p = 0.69, respectively) and there was not a
main effect by meal trial (p = 0.69; p = 0.90), sex (p = 0.68; p = 0.51), or meal–sex interaction (p = 0.20;
p = 0.67) (Figure 1).
Table 2. Participant characteristics. Metabolic outcomes represent fasting data averaged across the four
meal trials.
Total Men Women p-Value
Age 23.8 ± 1.3 24.4 ± 1.5 * 23.2 ± 0.8 0.03
Weight (kg) 76.52 ± 25.23 94.57 ± 23.09 * 58.42 ± 8.79 0.01
Height (cm) 171.5 ± 10.1 176.0 ± 9.8 167.0 ± 9.1 0.10
BMI (kg/m2) 25.5 ± 7.2 30.3 ± 7.4 * 20.7 ± 1.7 0.02
Fasting TG (mmol/L) 0.78 ± 0.41 0.96 ± 0.53 0.61 ± 0.10 0.21
Fasting Glucose (mmol/L) 4.85 ± 0.32 4.86 ± 0.29 4.84 ± 0.38 0.96
Fasting TOTAL-C (mmol/L) 4.76 ± 0.91 5.05 ± 1.09 4.47±0.68 0.44
Fasting LDL-C (mmol/L) 2.41 ± 0.79 2.95 ± 0.42 * 1.87 ± 0.73 0.02
Fasting HDL-C (mmol/L) 1.62 ± 0.53 1.44 ± 0.68 1.79 ± 0.33 0.30
MVPA (minutes) 152.5 ± 17.3 166.9 ± 7.9 138 ± 24.4 0.51
Steps/day 7934.6 ± 747.7 7444.6 ± 1024.3 8424.6 ± 107.6 0.68
Data are presented as mean ± SD. p-value column indicates results of an unpaired t-test between men and
women. * Indicates significant differences between men and women (p < 0.05). MVPA, moderate-vigorous physical
activity; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein; TOTAL-C,
total cholesterol.
  
Figure 1. Pretrial physical activity. Physical activity in (a) steps/day and (b) MVPA for 48–72 h before
each meal trial, stratified by sex. Data are presented as mean ± SD. Within each meal trial, there was
no difference between men and women in physical activity in either MVPA or steps/day (p > 0.05).
Similarly, within sex, there was no difference in physical activity across meal trials (p > 0.05). MVPA,
moderate-vigorous physical activity; B, butter; CoO, coconut oil; OO, olive oil; CaO, canola oil.
3.2. Postprandial Metabolic Outcomes Were Similar Across Meal Trials
Metabolic outcomes are presented in Table 3 and Figure 2. Two-way ANOVA of TG revealed
a significant time effect (p < 0.0001) but no time–meal interaction (p = 0.56) or overall meal effect
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(p = 0.35). One-way ANOVA revealed that TG peak (p = 0.36) and TG time to peak (p = 0.23) were
not different across meal trials. Meal trials did not differ with regard to TG tAUC (p = 0.33) or TG
iAUC (p = 0.14). Two-way ANOVA of glucose revealed no time effect (p = 0.27), meal effect (p = 0.64),
or time–meal interaction (p = 0.63). Glucose peak (p = 0.76) and glucose time to peak (p = 0.48) were
not different across meal trials. Meal trials did not differ with regard to glucose tAUC (p = 0.60) or
iAUC (p = 0.26). Two-way ANOVA of metabolic load index (MLI; calculated as TG + glucose) revealed
a time effect (p < 0.0001) but no meal effect (p = 0.08) or time–meal interaction (p = 0.77). MLI peak
(p = 0.24) and time to peak (p = 0.64) were not different across meal trials. Meal trials did not differ with
regard to MLI tAUC (p = 0.12) or MLI iAUC (p = 0.08). Two-way ANOVA of LDL-C revealed no time
effect (p = 0.27), meal effect (p = 0.83), or time–meal interaction (p = 0.72). One-way ANOVA revealed
that LDL-C peak (p = 0.66) and time to peak (p = 0.59) were not different across meal trials. Meal trials
did not differ with regard to LDL-C tAUC (p = 0.62) or iAUC (p = 0.72). HDL-C results did not reveal
a time effect (p = 0.62), meal effect (p = 0.2), or time–meal interaction (p = 0.42). One-way ANOVA
revealed that HDL-C peak (p = 0.19) and time to peak (p = 0.52) were not different across meal trials.
Meal trials did not differ with regard to HDL-C tAUC (p = 0.23) or iAUC (p = 0.16). Two-way ANOVA
of TOTAL-C revealed no time effect (p = 0.29), meal effect (p = 0.07), or time–meal interaction (p = 0.82).
One-way ANOVA revealed that TOTAL-C peak (p = 0.12) and TOTAL-C time to peak (p = 0.09) were
not different across meal trials. Meal trials did not differ with regard to TOTAL-C tAUC (p = 0.11) or
iAUC (p = 0.37).
Table 3. Postprandial metabolic outcomes for the four meal trials.
Butter Coconut Oil Olive Oil Canola Oil p
Triglycerides
Peak (mmol/L) 1.7 ± 1.1 1.4 ± 0.6 1.6 ± 0.9 1.6 ± 0.8 0.36
Time to peak (hours) 2.2 ± 0.8 3.0 ± 1.5 2.8 ± 1.1 2.7 ± 1.3 0.23
tAUC (mmol/L × 6 h) 7.6 ± 4.6 6.4 ± 2.8 7.4 ± 4.7 7.1 ± 2.8 0.33
iAUC (mmol/L × 6 h) 2.9 ± 2.5 2.0 ± 1.6 2.7 ± 2.4 1.9 ± 1.7 0.14
Glucose
Peak (mmol/L) 5.4 ± 0.9 5.3 ± 0.7 5.4 ± 0.7 5.5 ± 0.8 0.76
Time to peak (hours) 3.2 ± 1.8 2.4 ± 1.9 2.5 ± 1.8 2.5 ± 2.3 0.48
tAUC (mmol/L × 6 h) 28.5 ± 3.7 27.5 ± 3.6 28.5 ± 2.2 28.0 ± 2.8 0.60
iAUC (mmol/L × 6 h) 0.3 ± 1.5 −0.9 ± 2.3 −1.1 ± 1.1 1.1 ± 2.6 0.26
Metabolic Load Index
Peak (mg/dL) 241.0 ± 105.4 208.8 ± 60.5 230.4 ± 99.2 231.3 ± 231.3 0.24
Time to peak (hours) 2.7 ± 1.1 2.7 ± 1.4 2.9 ± 1.2 3.2 ± 1.9 0.64
tAUC (mg/dL 6 h) 1185.2 ± 447.7 1065.5 ± 302.4 1163.7 ± 448.9 1158.9 ± 367.8 0.12
iAUC (mg/dL 6 h) 260.7 ± 239.9 163.1 ± 151.6 219.1 ± 222.1 181.9 ± 228.6 0.08
TOTAL-C
Peak (mmol/L) 4.6 ± 0.7 4.4 ± 1.2 5.1 ± 0.9 5.0 ± 0.9 0.12
Time to peak (hours) 3.2 ± 2.3 3.6 ± 2.4 4.3 ± 1.8 2.2 ± 2.3 0.09
tAUC (mmol/L × 6 h) 26.2 ± 4.2 24.7 ± 7.3 27.3 ± 5.0 28.7 ± 5.9 0.11
iAUC (mmol/L × 6 h) 0.4 ± 1.1 0.6 ± 0.9 1.1 ± 1.5 0.2 ± 1.6 0.37
LDL-C
Peak (mmol/L) 2.7 ± 0.6 2.8 ± 0.8 2.8 ± 0.9 2.9 ± 0.8 0.66
Time to peak (hours) 2.4 ± 2.2 3.5 ± 2.8 3.3 ± 2.5 2.6 ± 2.1 0.59
tAUC (mmol/L × 6 h) 14.2 ± 3.4 14.3 ± 4.6 14.4 ± 4.6 15.5 ± 4.9 0.62
iAUC (mmol/L × 6 h) −0.3 ± 2.8 0.9 ± 2.7 1.1 ± 4.7 1.6 ± 5.1 0.72
HDL-C
Peak (mmol/L) 1.5 ± 0.4 1.7 ± 0.5 1.6 ± 0.5 1.7 ± 0.6 0.19
Time to peak (hours) 3.4 ± 2.7 3.7 ± 2.0 3.5 ± 2.4 2.2 ± 2.4 0.52
tAUC (mmol/L × 6 h) 8.3 ± 2.1 8.9 ± 2.8 8.8 ± 2.5 9.2 ± 3.0 0.23
iAUC (mmol/L × 6 h) 0.1 ± 0.5 0.5 ± 0.9 0.1 ± 0.6 −0.5 ± 1.2 0.16
Data are presented as mean± SD. There were no differences between meals for all analyses (p> 0.05). TG, triglycerides;
MLI, metabolic load index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein; TOTAL-C,
total cholesterol; tAUC, total area under curve; iAUC, incremental area under the curve.
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Figure 2. Postprandial metabolic responses. Metabolic responses in the four meal trials at baseline
and hourly throughout the postprandial period for (a) TG, (b) glucose, (c) MLI, (d) HDL-C, (e) LDL-C,
and (f) TOTAL-C. Data are presented as mean ± SD. Closed circles indicate B meal trial, open circles
indicate CoO meal trial, closed triangles indicate OO meal trial, and open triangles indicate CaO
meal trial. Error bars indicate SD. TG, triglycerides; MLI, metabolic load index; HDL-C, high-density
lipoprotein cholesterol; LDL-C, low-density lipoprotein; TOTAL-C, total cholesterol.
3.3. Postprandial Lipemic Responses Were Different between Men and Women
When data were stratified by sex, a two-way ANOVA of TG revealed a significant time effect
(men, p < 0.0001; women, p = 0.0002) but no time–meal interaction (men, p = 0.20; women, p = 0.21)
or overall meal effect (men, p = 0.53; women, p = 0.48). When averaged across meal trials, men had
a significantly higher TG peak (p = 0.03) when compared to women but there was no difference in
TG time to peak between men and women (p = 0.87). Further, men had significantly higher TG peak
(p < 0.05) within every meal trial (Mean sex difference: B, 1.49 mmol/L, p = 0.0005; CoO, 1.08 mmol/L,
p = 0.006; OO, 1.05 mmol/L, p = 0.007; CaO, 1.23 mmol/L, p = 0.002) (Figure 3).
 
Figure 3. Peak response in triglycerides. Data are presented as mean ± SD. Peak TG responses for meal
trials when stratified by sex. * Indicate differences between men and women for a specific meal trial
(p < 0.05). TG, triglycerides.
When data were stratified by sex and the TG response was averaged for each participant, a two-way
ANOVA revealed a significant time effect (p < 0.0001), time–group interaction (p = 0.0001), and group
effect (p = 0.048) (Figure 4).
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Figure 4. Consolidated postprandial responses in triglycerides in men and women. Average TG
responses across meal trials at baseline and hourly throughout the postprandial period in men and
women. Data are presented as mean ± SD. * Indicate differences between men and women at a specific
time point (p < 0.05) based on post hoc pairwise comparison. TG, triglycerdes.
In post hoc pairwise testing, men had significantly higher TG than women at every time point in
the postprandial period (p < 0.05). Postprandial TG responses in men and women within each meal
trial are presented in Figure 5. When data were stratified by sex for men and women, there was a
significant time effect (p < 0.0001, p = 0.0002), but no time–group interaction (p = 0.19, p = 0.21) or
overall group effect (p = 0.53, p = 0.47), respectively.
 
 
Figure 5. Postprandial responses in triglycerides in men and women based on meal trial. TG responses
in men and women for each meal trial at baseline and hourly throughout the postprandial period.
Data are presented as mean ± SD. (a) TG response for B meal trial; (b) TG response for CoO meal trial;
(c) TG response for OO meal trial; (d) TG response for CaO meal trial. * Indicate differences between men
and women at a specific time point (p < 0.05) based on post hoc pairwise comparison. TG, triglycerides;
MLI, metabolic load index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein;
TOTAL-C, total cholesterol.
When data were stratified by sex for the B and OO meal trial, a two-way ANOVA of TG revealed
a significant time effect (p’s < 0.0001) and time–group interaction (p = 0.001 and p = 0.002, respectively),
but no overall group effect (p = 0.057 and p = 0.11, respectively). When data were stratified by sex for
the CoO and CaO meal trial, a two-way ANOVA of TG revealed a significant time effect (p < 0.0001,
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p = 0.0015), time–group interaction (p < 0.0001, p = 0.04), and overall group effect (p = 0.02, p = 0.047).
In post hoc pairwise testing, men had significantly higher TG at baseline, 1, 2, 3, 4, 5, and 6 h post-meal
for the CoO meal trial and at 2, 3, and 4 h post-meal for the CaO meal trial. Although there was a
nonsignificant group effect for the B and OO meal, in post hoc pairwise testing, men had significantly
higher TG at 1, 2, 3, 4, 5, and 6 h post-meal for the B and OO meal trial. When Pearson’s two-tailed
correlation was performed, BMI was strongly associated with TG tAUC (r = 0.79, R2 = 0.63, p = 0.006)
(Figure 6).
Figure 6. Correlation between TG tAUC and BMI. Data are means of TG tAUC for each participant
(averaged across the four meal trials) and BMI (kg/m2) value for each individual participant. There was
a significant positive correlation between BMI and TG tAUC (r = 0.79, R2 = 0.63, p = 0.006). BMI,
body mass index; TG tAUC, triglycerides total area under the curve.
4. Discussion
4.1. Postprandial Responses in Triglycerides between Meals
The present study compared the effects of a high-fat mixed meal rich in butter, coconut oil,
olive oil, or canola oil on the postprandial metabolic response in young adults. Peak postprandial TG
concentrations were observed at 2–4 h post-meal (mean peak across meals: 1.59 mmol/L) and suggest
that the HFM used in the present study induced a robust postprandial response. In our sample of
young volunteers, consumption of a mixed HFM containing various sources of commonly consumed
dietary fat did not result in different postprandial TG responses. Therefore, counter to our hypotheses,
the results of this study do not support the notion that various sources of dietary fat result in markedly
different PPL responses. As PPL has been identified as an independent and clinically relevant risk
factor for CVD, these results advance understanding with regard to the effects of different dietary fats
on cardiometabolic health.
In agreement with our findings, Lesser et al. examined the lipemic effects of a mixed breakfast meal
with the fat derived from almonds (MUFA) or cream cheese (dairy-based SFA) in overweight/obese
pregnant women and found no significant difference in the postprandial TG response between the two
meal trials (MUFA versus dairy-based SFA) [28]. Notably, the test meal utilized by Lesser et al. [28] was
a mixed meal, containing a heterogeneous mixture of macro- and micronutrients. Likewise, the HFM
meal used in the present study contained moderate amounts of CHO (32% of total kcal) derived from
fiber-rich whole grains, French bread, and vegetables. As part of a mixed meal, fiber has been shown
to blunt the PPL response by interfering with lipid absorption and digestion via impairment of proper
emulsification of lipids in the gastrointestinal tract [29]. In support of this concept, Lesser et al. utilized
a mixed meal consisting of 46% of calories derived from CHO and found no differences between
test meals [28]. The almond test meal contained 7 g more fiber when compared to the cream cheese
test meal; therefore, the lack of detectable differences between meals may have been a result of the
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modifying effect of fiber on PPL. Kristensen et al. found that when participants consumed a mixed
meal with added fiber from flax seed, the mean TG response was 18% lower when compared to
the low-fiber control, reaffirming the notion that fiber interferes with the postprandial handling of
lipids [29]. Consequently, in the present study, the presence of fiber and other nutrients besides fat
in the test meal may have weakened our ability to detect differences between test meals, given the
buffering effect that fiber has on the magnitude of PPL.
By contrast, some previous studies have found differences in PPL based on source of dietary fat.
For example, researchers examined the effects of mixed meals containing low (basmati rice) or high
(jasmine rice) glycemic index CHO and three different types of dietary fat sources (B, OO, grapeseed
oil) on the postprandial metabolic response in healthy adults. The TG iAUC was significantly lower
following the B (SFA) and grapeseed (PUFA) meals when compared to the OO (MUFA) meal, regardless
of GI [30]. These results contrast the findings of our present study that found a similar postprandial
TG response when comparing the B (SFA) meal with the OO (MUFA) meal.
Similarly, Mekki et al. [26] assessed the effects of various dietary fatty acids in a mixed HFM on
PPL. The authors found that, when compared to the B meal, OO induced a greater PPL response,
but a comparable postprandial response to the sunflower oil meal, concluding that B resulted in
lower PPL than the OO and sunflower oil meals [26]. These results contrast to our results, but align
with Sun et al. [30]. Mekki et al. [26] found that the size of circulating chylomicrons (CM) were
consistently lower after the meal rich in B than those detected after the meals rich in vegetable oils (OO
or sunflower oil). Although not an explanation as to why these authors found differences between
various dietary fats and the present study did not, the lower TG response in the B trial could have been
a result of greater or faster lipolysis of CM containing fatty acids from B or a reduced overall size of
secreted CM due to the calcium present in B, contributing to the formation of calcium-soap complexes.
For our present study, examining the size of circulating CM and concentrations of either intestinally
derived apoB-48 present in CM and/or endogenous apoB-100 present in LDL-C and very low-density
lipoprotein (VLDL-C) may have yielded detectable differences between meal trials. Additionally,
Mekki et al. [26] did not standardize the test meals to body weight and used a homogeneous sample
consisting of only men. These factors may also partially explain the disagreement between our study
and Mekki et al. [26].
In contrast to Teng et al. [24], Sun et al. [30], Mekki et al. [26], and our present study, another study
observed a lower PPL response following a meal consisting of 80 g of ingested OO when compared
to 100 g of ingested B [27]. However, since the OO test meal had a lower amount of total fat (80 g)
compared to the B meal (100 g), these test meals were not a uniform comparison of the independent
effects of OO and B on PPL. In another study investigating acute PPL [31], participants consumed either
71 g of MCT oil, representative of the predominating fatty acid found in CoO, or CaO (MUFA), and the
authors found that plasma TG concentrations increased 47% from baseline after the CaO ingestion,
while they increased only 15% from baseline following MCT oil ingestion. Notably, only males were
included in this study sample and the test meal was not standardized to body weight, nor was it a
mixed meal.
Despite several studies comparing the effects of SFA with MUFA or PUFA, there are very few
examining the acute effects of various sources of SFA (plant- and animal-based) on PPL. Teng et al. [24]
compared the effects of animal-based SFA (lard) and plant-based SFA (palm olein) sources to oleic
MUFA-rich dietary fat (virgin OO) as part of a mixed meal on postprandial TG. Researchers found
that the lard (animal-based SFA) elicited a significantly lower TG response than the OO and palm
olein (plant-based SFA). On the other hand, a recent study by Panth et al. [25] examined the effects of
various sources of SFA on the PPL response in healthy adults. Researchers found that the PPL response
was ~60% lower after the CoO meal (plant-based SFA) when compared to the B meal (animal-based
SFA) and the lard meal (animal-based SFA). No difference was observed between the B and lard meal
for PPL. These findings disagree with Teng et al. [24], who found that plant-based SFA (palm olein)
elicited a greater PPL response when compared to animal-based SFA (lard). Teng et al. [24] found that
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animal-based SFA (lard) resulted in lower postprandial TG when compared to plant-based SFA (palm
olein), whereas Panth et al. [25] found that plant-based SFA resulted in lower postprandial TG when
compared to two sources of animal-based SFA (butter, lard).
These findings by Teng et al. [24] and Panth et al. [25] are contradictory and there were several
key differences between the two study designs. First, Teng et al. [24] recruited an exclusively male
sample and employed a three-day washout period between meal trials, while Panth et al. [25] recruited
equal numbers of males and females and employed a one-week washout period between meal
trials. Considering the brief washout period utilized by Teng et al. [24], the effects of the dietary
fat in the preceding meal trial may have carried over to the subsequent meal trial, thus influencing
the postprandial response and interfering with the evaluation of a singular source of dietary fat.
Additionally, Teng et al. [24] utilized a meal higher in total kcal and percent of kcal from fat (~754 total
kcal; 60% total kcal from fat, 33% total kcal from CHO, 7% total kcal from protein) when compared
to Panth et al. [25] (~660 total kcal; 53% total kcal fat, 40% total kcal from CHO, 5–7% total kcal from
protein). Teng et al. [24] also instructed participants to abstain from consuming high-fat foods the day
before the meal trials and administered a low-fat meal for the dinner preceding the day of the meal
trial, while Panth et al. [25] alternatively asked participants to consume the same meal the night before
each meal trial. Lastly, the postprandial assessment period employed by Teng et al. [24] consisted
of BL, 1, 2, 3, and 4 h post-meal, whereas Panth [25] measured TG at BL, 2, 3, 4, and 6 h post-meal.
Teng et al. [24] may not have been able to capture the entire postprandial response, considering that
postprandial TG tends to peak around 2–4 h post-meal consumption and return to postabsorptive
values around 6 h post-meal [2].
4.2. Factors Influencing the Postprandial Lipemic Response
Mixed meals contain varying amounts of macronutrients and micronutrients, which modulate
physiological processes of digestion, absorption, and metabolism of fatty acids [32–34]. The use of
laboratory-derived fat mixtures and lipid emulsions in the place of mixed meals is a common feature
in studies assessing PPL (e.g., Mekki et al. [26]), particularly in those evaluating the effects of specific
types of fatty acids or sources of dietary fat on PPL. Several of the studies that have observed differences
in PPL based on source or type of dietary fat have utilized laboratory-derived fat mixtures or lipid
emulsions [31,35,36]. Considering that individuals do not consume these dietary fat sources in isolation
or as a component of lipid emulsions in daily living, testing the effects of different fats within a mixed
meal may be a more practical and appropriate approach. Our study, as well as others, tested the
lipemic effects of different fat sources in the context of true-to-life mixed meal and did not observe
differences across meal trials. If the various dietary fat sources used in this study were isolated in
laboratory-derived fat mixtures, and thus the effects of macro- and micronutrients were removed,
it is possible that differences in postprandial TG between various dietary fat sources may have been
observed in the present study.
We observed a strong correlation between BMI and TG tAUC. Men had significantly higher BMI
than women and no females were overweight or obese. In agreement with our findings, Kasai et al.
found that men with a greater BMI (≥23 kg/m2) compared to men with a lower BMI (<23 kg/m2)
exhibit greater PPL in response to a HFM [37]. In contrast, Hansson et al. did not find that BMI or
sex significantly altered the postprandial TG response to various types of dairy fat rich in SFA [38].
However, the study population (n = 31) consisted of 70% women and 30% men and therefore may not
have been sufficient to detect an interaction between sex and postprandial TG in response to different
fat sources. In addition, the median BMI was 23.6 kg/m2 (range: 21.0–25.8). Consequently, the range of
BMI may have been too narrow to establish a relationship between BMI and postprandial TG.
The majority of studies that found various sources of dietary fat influence PPL differently included
a sample of only male participants [26,30,31,33]. We also observed greater PPL responses in men for
all meal trials when compared to women. This finding adds to the notion that sex is an important
modifying factor with regard to PPL. There are well-known sex-based differences in visceral adipose
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tissue accumulation, with women generally storing less adipose tissue in the visceral region than
men [39,40]. Women tend to store fat in the gynoid regions (hips/breasts/thighs), while men tend to store
fat primarily in the android regions (trunk/abdomen), and thus have a tendency to accumulate fat within
visceral tissues [39]. One study has suggested that this difference in visceral adipose accumulation
between men and women is the primary explanation for the amplified postprandial response observed
in men compared to women [39]. Additionally, Blackburn et al. found that men with impaired glucose
tolerance were characterized by greater visceral adiposity, waist circumference, and postprandial
lipemia when compared to men with normal glucose tolerance, adding further evidence to the notion
that visceral adiposity is an important modulator of the postprandial response [41]. Further, women
with android obesity, both with normal and high fasting TG, exhibit a more pronounced and deleterious
postprandial TG response when compared to women with gynoid obesity with normal fasting TG [40],
further supporting the influence of sex on PPL via body composition differences. Considering that men
had a greater BMI than women in our sample, these findings demonstrate one possible mechanism
responsible for the marked sex difference in postprandial lipemia that we observed, as the anatomical
location of fat storage clearly plays a significant role in determining postprandial lipemia. Thus,
although our observed sex-based differences in postprandial lipemia are noteworthy, since there were
sex differences in BMI (likely indicative of differences in body composition), it is not possible to form
conclusions from our study about the independent role of sex on postprandial lipemic responses.
4.3. Strengths and Limitations
A strength of this study was the use of a “true-to-life” mixed HFM challenge, in contrast to many
studies examining PPL that use lipid emulsions or laboratory-derived lipid formulations. The meal
used in the present study was also scaled to body weight and resembled a meal that individuals
might typically eat at a social gathering. This consideration is important because many postprandial
studies utilize meals that are unrealistically high in calories, particularly calories from fat, and are not
standardized to body weight. Therefore, this study allowed for the comparison of different dietary fats
with regard to PPL in a realistic context. This study also consisted of a balanced sample with regard
to sex (5 M/5 F). Several studies similar in design had a predominately or exclusively male sample
population. Another strength of this study was the robust postprandial assessment protocol, whereby
we quantified the postprandial response serially every hour for six hours post-meal.
A limitation of this study was only measuring blood lipids and glucose. Examining the size of
circulating CM and concentrations of either intestinally derived apoB-48 and/or endogenous apoB-100,
in addition to blood lipids and glucose, may have been valuable with regard to answering our
hypotheses. Next, all of our participants were young and presented few CVD risk factors. Thus,
features of atherosclerotic development, including exaggerated and prolonged PPL, may not have
been prominent enough to detect differences between meal trials, especially when considering the
“true-to-life” meal used. Additionally, although this study found consistent sex-based differences in
postprandial TG, it was not designed to address these differences. In addition, considering that three
male participants exhibited an obese BMI (BMI > 30 kg/m2), it is not possible to conclude whether
the greater postprandial TG response was due to sex or BMI. Similarly, the lack of body composition
measurement beyond BMI was a limitation of the present study. Finally, while we conducted an a
priori sample size estimation and our study featured the same sample size (n = 10) as similar previous
studies [26,27], our null findings present the possibility that our study was not sufficiently powered to
detect differences. A post hoc analysis revealed that, given our observed TG variations, the minimum
difference in peak TG that our design could have detected was 0.54 mmol/L. Thus, while we view this
to be reasonable, differences between meals less than 0.54 mmol/L could not have been statistically
detected in our study.
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5. Conclusions
In our study, the effect of various sources of dietary fat, namely plant- and animal-based SFA,
on PPL did not differ. Sex-based differences regarding the PPL response to the meal trials were
observed and there was a strong correlation between BMI and TG tAUC, supporting the notion that
sex and BMI are important factors that modulate the acute PPL response. However, it is impossible to
form conclusions about the role of sex-based differences versus differences regarding BMI within our
sample, owing to the fact that BMI was different between men and women. Moreover, differences in
the PPL responses to the various sources of dietary fat used in the present study were not observed,
despite the inclusion of three obese individuals. It is worth noting that our null findings on the effects
of different fat sources within a mixed meal on PPL were in a sample of young adults. Future studies
should investigate the effects of these various dietary fat sources on PPL in populations at risk for CVD
or with existing CVD. In more at-risk individuals with a larger postprandial response, differences in
TG between different sources of fat may be more apparent. Overall, the magnitude of PPL in response
to a realistic mixed meal is likely modulated by several interrelated dietary factors, such as the amount
of fat, energy density, and the heterogeneous mixture of macro- and micronutrients, rather than the
specific type or source of dietary fat alone. Future studies should continue to focus on delineating
between various sources of animal-based SFA (dairy- vs. meat-based) with regard to CVD risk, both in
an acute (postprandial) and chronic context.
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Abstract: Circulating levels of lipopolysaccharide-binding protein (LBP) and soluble cluster of
differentiation 14 (sCD14) are recognized as clinical markers of endotoxemia. In obese men,
postprandial endotoxemia is modulated by the amount of fat ingested, being higher compared
to normal-weight (NW) subjects. Relative variations of LBP/sCD14 ratio in response to overfeeding
are also considered important in the inflammation set-up, as measured through IL-6 concentration.
We tested the hypothesis that postprandial LBP and sCD14 circulating concentrations differed in obese
vs. overweight and NW men after a fat-rich meal. We thus analyzed the postprandial kinetics of LBP
and sCD14 in the context of two clinical trials involving postprandial tests in normal-, over-weight
and obese men. In the first clinical trial eight NW and 8 obese men ingested breakfasts containing
10 vs. 40 g of fat. In the second clinical trial, 18 healthy men were overfed during 8 weeks. sCD14,
LBP and Il-6 were measured in all subjects during 5 h after test meal. Obese men presented a
higher fasting and postprandial LBP concentration in plasma than NW men regardless of fat load,
while postprandial sCD14 was similar in both groups. Irrespective of the overfeeding treatment,
we observed postprandial increase of sCD14 and decrease of LBP before and after OF. In obese
individuals receiving a 10 g fat load, whereas IL-6 increased 5h after meal, LBP and sCD14 did not
increase. No direct association between the postprandial kinetics of endotoxemia markers sCD14 and
LBP and of inflammation in obese men was observed in this study.
Keywords: LBP; sCD14; postprandial kinetics; high-fat diet
1. Introduction
Metabolic diseases, including obesity and type 2 diabetes, are associated with a chronic
inflammatory state and increased plasma levels of lipopolysaccharides (LPS), also called endotoxins [1].
Endotoxins are components of the outer membrane of Gram-negative bacteria, which are dominant
in the healthy human gut microbiome [1]. During lipid digestion, some endotoxins are translocated
in the bloodstream, and thereby contribute to the onset and maintenance of low-grade inflammation
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during the postprandial phase following a fat-rich meal [2–5]. Indeed, Clemente-Postigo et al.
(2012) reported an increase in the plasma level of endotoxins after a fat overload in morbidly
obese humans [6]. This includes the binding of LPS to LPS-binding protein (LBP) and its transfer
to the receptor CD14, present in both soluble (sCD14) and membrane-bound (mCD14) forms [7].
The activation of the LPS-LBP-CD14 complex leads to the secretion of pro-inflammatory markers and
contributes to the inflammatory state [8]. LBP and sCD14 are now recognized as clinical markers of
endotoxin exposure [9] and have been associated with obesity and metabolic disorders [10]. LBP is
synthesized and released into the bloodstream in the presence of LPS, and is considered as a surrogate
biomarker for the activation of LPS-induced innate immune response regarding its relative long half-life
(24–48 h) [11]. Moreno-Navarrete et al. have also shown that the increase of plasma LBP in vivo may
contribute to a vicious cycle that prevents white adipose tissue (WAT) expansion, and exacerbates the
inflammatory response in WAT [12]. It was further shown that serum LBP and sCD14 are markers
of Crohn’s disease [13]. The relative variations of LBP/sCD14 ratio are also considered important in
the inflammation set-up [14]. Furthermore, higher plasma LBP concentrations have been observed
in obesity [7,13,15] and plasma LBP concentration is associated to abdominal obesity [16]. We have
recently shown that increase of plasma IL-6 is linked to a rise of LBP/sCD14 ratio in both humans [14]
and mice [17]. More recently, Sakura et al. have suggested that plasma LBP concentration is associated
with arterial stiffness, independently of traditional cardiovascular risk factors and especially in men
with type 2 diabetes [18,19]. In children and adults, obesity and obstructive sleep apnea are also
associated with increased LBP concentrations, and the presence of both conditions may enhance LBP
concentration [20,21]. Concerning sCD14, it has been reported in mice that sCD14 presents protective
effects in inflammatory bowel disease [22]. Therefore, the literature shows that LBP and sCD14 are
important factors implicated in low-grade inflammation during metabolic diseases. We have previously
demonstrated in obese men that postprandial endotoxemia is modified by ingested fat amount with
a higher postprandial endotoxemia compared with normal-weight subjects after a higher fat load
(40 g vs. 10 g) [23]. More recently, a study of healthy premenopausal women has suggested that the
consumption of a pre-meal yogurt improves the postprandial metabolism and decreases metabolic
endotoxemia, LBP and sCD14 [24]. However, the postprandial variations of LBP and sCD14 after a
mixed meal with different amount of lipids remain poorly described in humans of different weight
status. We thus analyzed the postprandial kinetics of both markers of endotoxin exposure in the
context of two clinical trials involving postprandial tests in normal weight, overweight and obese
men. We hypothesized that postprandial LBP and sCD14 after a fat-rich meal differed in obese vs.
overweight and normal weight men, hence, contributing to different IL-6 responses after a fat load
or OF.
2. Materials and Methods
2.1. Clinical Trials and Subjects
The present work relies on two previous clinical trials performed in the Human Nutrition Research
Centers (CRNH) of Rhône-Alpes and Auvergne. The first clinical trial, called the Lipinflox study,
was approved by the Ethics Committee of Lyon-Sud-Est-II and AFSSAPS and was registered at
ClinicalTrials.gov (NCT01249378). The second one, called the Overfeeding Study, was approved by
the Ethics Committee of Lyon (RG/FL-2005-067) and registered at clinicalTrials.gov (NCT00905892).
The eligibility criteria of included subjects and postprandial metabolic explorations for both trials have
been described elsewhere [23,25,26]. Briefly, in the crossover Lipinflox Study, 8 normal weight (20
< BMI < 25 kg/m2) and 8 obese (30 < BMI < 35 kg/m2 and waist circumference > 94 cm) men were
submitted to a fat load of 10 g or 40 g at breakfast. The test breakfast contained 10 or 40 g of anhydrous
milk fat with bread and a glass of skim milk (282 kcal and 551 kcal, respectively). Blood samples were
collected from an antecubital arm vein through a catheter at baseline and at regular intervals during
5 h, following ingestion of fat load. Plasma was separated by centrifugation (1500 g, 10 min, 4 ◦C)
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and stored at −80 ◦C until further analysis. In the overfeeding clinical trial, 18 healthy young men
(lean to overweight, BMI 25.8 ± 0.8 kg/m2, age 30.6 ± 2.1 years) were submitted to an overfeeding
during 56 days. During this period, the subjects added to their daily diet +760 kcal/day as previously
described [25]. Fasting plasma sampling was performed at Day 0 and Day 56. In this article, we focused
on a subcohort of eight subjects that consumed a test meal (882 kcal) and performed a postprandial
test including endotoxemia analyses, as described previously [25]. The mixed meal contained 33 g of
fat (291 kcal) and was composed of 200 mL of Fortimel (enteral emulsion), 23 g of margarine, 9.4 g of
butter, 1 g of olive oil, 85 g of bread, 20 g of jam and 200 g of banana. The body composition (fat and
lean mass) was performed in 18 subjects. All subjects gave written consent after being informed of the
nature, purpose, and possible risks of the clinical trial. Both clinical trials were approved by the ethics
committee of Lyon Sud-Est, according to the French“Huriet-Serusclat” law and the Second Declaration
of Helsinki.
2.2. Plasma sCD14 and LBP
To measure the plasma concentrations of circulating LBP and sCD14, plasma samples were
assayed using sandwich ELISA kits (CliniSciences and R&D Systems; Nanterre, France), following the
manufacturer’s instructions.
2.3. Plasma Analyses
Endotoxins were determined using the limule amoebocyte lysate assay in kinetic chromogenic
conditions (Biogenic; Pérols, France) [15]. Serum high-sensitive C-reactive protein was assessed by
immunonephelometry on an image analyzer (Beckman-Coulter; Villepinte, France). For the overfeeding
trial, IL-6 was measured in serum using ELISA kits (Quantikine; Abingdon, UK). For Lipinflox, plasma
hsIL-6 levels were measured using a sandwich Ultrasensitive ELISA kit (Invitrogen; Illkirch, France).
The liver enzymes ASAT and ALAT were routinely measured during the screening visit (Pentra C400;
Horiba, Kyoto, Japan) in order to exclude patients if the values were not biologically normal. In fact,
as patients were submitted to a fat load, or to an overfeeding, it was important that they had no
liver disease.
2.4. Anthropometry and Body Composition
As previously described by Alligier et al., body composition was determined before and after
overfeeding by dual-energy X-ray absorptiometry (Hologic, Inc.; Bedford, MA, USA), and abdominal
adipose tissue distribution by magnetic resonance imaging (Magnetom Symphonie 1.5 Tesla;
Siemens AG, Munich, Germany) [25].
2.5. Statistical Analysis
Data are presented as means ± SEM and were analyzed with Graph Pad Prism® (version 7.0,
San Diego, CA, USA) and with R (version 3.6.3, Saint Louis, USA). Clinical characteristics of the subjects
of the two clinical trials (before vs. after overfeeding and lean vs. obese subjects) were performed using
Student’s t-test with Graph Pad Prism. To evaluate possible relationships among the various outcomes,
Spearman correlations were performed using Graph Pad Prism Software. For the Overfeeding Study,
postprandial kinetics of plasma LBP, sCD14, LBP/sCD14 ratio and IL-6 were each analyzed by two-way
ANOVA for repeated measurements in both factors (time and overfeeding), followed by Bonferroni’s
post hoc test, using Graph Pad Prism. For the Lipinflox study, postprandial kinetics of plasma LBP,
sCD14 and IL-6 were each analyzed with a linear mixed-effects model, analogous to a 3-way ANOVA
for repeated measurements, where the factors with fixed effects were time, obese status, fat load
and their 2- and 3-way interactions, while the factor with random effects was the subject identifier.
This analysis was carried out with R, using the lme function of the nlme package. The main effects
and the interactions effects were tested using marginal (Type III) sums of squares like in GraphPad
Prism. For the Lipinflox study, postprandial kinetics of plasma LBP, sCD14 and IL-6 were each
73
Nutrients 2020, 12, 1820
analyzed with a linear mixed-effects model, where the factors with fixed effects were time, obese status,
fat load and their 2- and 3-way interactions, while the factor with random effects was the subject
identifier. This approach is similar to a three-way repeated-measures ANOVA but is more robust to
missing data (we lacked IL6 data for one of the ten lean subjects). A posthoc analysis was carried
out to assess the effect of obesity on the estimated marginal means at all time points. Specifically, the
significance of the difference of the two marginal means (lean versus obese, collapsing the fat load) was
assessed at each time point with a t-test based on the standard errors of the estimated marginal means.
The five raw p-values obtained for each response in this posthoc analysis were adjusted using the False
Discovery Rate (FDR) correction, in order to correct for multiple testing. This posthoc analysis was
carried out with the emmeans package. A p-value (or a FDR-corrected p-value) lower than 0.05 was
considered significant.
3. Results
3.1. Characteristics of the Subjects
The characteristics of the eight subjects, lean to overweight, from the overfeeding clinical trial
(OF) and from the 16 subjects (normal weight and obese) from Lipinflox clinical trial are shown Table 1.
As expected weight, BMI and waist circumference were significantly higher after OF, compared to
before, and higher in the obese than in normal weight (NW) subjects. Concerning body composition,
lean mass and fat mass were significantly enhanced after OF. CRP, IL-6 and LPS did not vary significantly
in the OF clinical trial. CRP and IL-6 were higher in obese compared to NW subjects.
Table 1. Clinical characteristics of study subjects. Data are means ± SEM. Groups are compared using
unpaired Student t-test, * p < 0.05, ** p < 0.01; n = 8 OF clinical trial, n = 8 normal weight, n = 8 obese.
Overfeeding Clinical Trial Lipinflox Clinical Trial
Before OF After OF p Value Normal Weight Obese p Value
Age (year) 26 ± 2 29 ± 1 31 ± 2 0.426
Body weight (kg) 78.9 ± 4.9 81.7 ± 4.9 0.005 ** 72.5 ± 2.1 101.1 ± 2.1 0.001 **
BMI (kg/m2) 24.9 ± 1.5 25.7 ± 1.4 0.004 ** 22.4 ± 0.5 31.8 ± 0.3 0.001 **
Waist circumference (cm) 84.9 ± 3.3 86.9 ± 3.3 0.038 * 83.6 ± 1.7 105 ± 0.8 0.001 **
hsCRP (μg/mL) 0.6 ± 0.1 1.1 ± 0.5 0.38 1.96 ± 0.01 2.98 ± 0.47 0.036 *
IL-6 (pg/mL) 1.23 ± 0.15 1.43 ± 0.35 0.53 0.18 ± 0.04 0.45 ± 0.16 0.006 *
LPS (EU/mL) 0.11 ± 0.03 0.16 ± 0.10 0.59 0.19 ± 0.05 0.18 ± 0.04 0.729
Lean mass (kg) 57,3 ± 2.5 58.2 ± 2.60 0.032 * - -
Fat mass (kg) 15.8 ± 2.9 17.1 ±3.1 0.048 * - -
Visceral fat (kg) 66.0 ± 18.1 73.5 ± 16.5 0.469 - -
3.2. Postprandial Kinetics of LBP, sCD14 and IL-6 in Normal Weight and Obese Subjects (Lipinflox Study)
We evaluated the postprandial variations of plasma LBP, sCD14 and IL-6 in NW and obese subjects
during 5 h after mixed meals differing only by fat amount: 10 vs. 40 g of milkfat spread on bread.
Figure 1A,B shows that, regardless of lipid amount in the meal, the concentration of LBP in
plasma was higher in obese subjects than in lean subjects (obese status, p = 0.027), with no impact of
postprandial time. No significant difference was observed between lean and obese subjects along the
postprandial kinetics of sCD14, regardless of fat load in the meal (Figure 1C,D).
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Figure 1. Postprandial kinetics in plasma of lipopolysaccharides (LPS)-binding protein (LBP) (A,B);
sCD14 (C,D); and Il-6 (E,F) in normal-weight and obese subjects after 10 g vs. 40 g fat load. Data are
means ± SEM. * p < 0.05.
Regarding IL-6, we observed an interaction effect between time and obese status (p = 0.012) during
the postprandial kinetics (Figure 1E,F). The post-hoc analysis revealed that the significant two-way
interaction between obesity and time occurred mostly at t = 300 min. Indeed, IL-6 plasma concentration
at 300 min was on average 5.6 times higher in obese vs. lean men (p = 0.02) (Figure 1E).
There was no impact of BMI and postprandial time on the LBP/sCD14 ratio in all subjects for each
fat amount (Appendix A).
3.3. Postprandial Kinetics of LBP, sCD14 and IL-6 Before and After Overfeeding
Previously, we have shown in 18 subjects of the OF clinical trial that the LBP/sCD14 ratio was
enhanced in the fasting state after OF [14]. Here, we completed our exploration by analyzing the
postprandial evolution of LBP, sCD14 and LBP/sCD14 in the subgroup of eight subjects who performed
the postprandial explorations. Altogether, there was no significant effect of OF on the postprandial
kinetics of LBP and sCD14 (Figure 2A,B). Concerning LBP before OF, we observed a significant time
effect with an increase of LBP concentration in plasma 120 min after the mixed meal (Figure 2A,
p < 0.05). The concentration of LBP was decreased at 240 min vs. 120 min (Figure 2A, p < 0.05).
After OF, no significant increase was observed at 120 min after the mixed meal but a significant decrease
was observed at 240 min compared to 120 min (p < 0.05). Notably, even if after OF LBP concentration
was higher at fasting compared to before OF (p = 0.07), at 240 min LBP concentrations were similar
before and after OF (18.3 ± 1.9 μg/mL and 18.2 ± 0.8 μg/mL, respectively). A significant increase of
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sCD14 at 240 min compared to 0 and 60 min (p < 0.01 and 0.01 respectively) was observed both before
and after OF (Figure 2B). The postprandial kinetics of the LBP/sCD14 ratio was not impacted by OF
(Figure 2C). Both before and after OF, the LBP/sCD14 ratio decreased at 240 min (p < 0.001 vs. other
postprandial times). We have measured IL-6 plasma concentration at 0, 120 and 240 min before and
after OF (Figure 2D). There was no significant OF effect but of note, after OF plasma IL-6 concentration
increased at 240 min compared to 0 min (p < 0.05). No interaction (between time and OF) was observed
for LBP, sCD14, LBP/sCD14 and IL-6 (Figure 2A–D).
Figure 2. Postprandial kinetics of LBP (A), sCD14 (B), LBP/sCD14 ratio (C) and IL-6 (D) before and
after overfeeding. Data are means ± SEM. The effects of time (postprandial kinetics) and overfeeding
(OF) were determined by ANOVA for repeated measurements followed by post hoc test (Bonferroni).
* p < 0.05 (after OF), & p < 0.05 vs. T0 and T120 (before OF); # p < 0.001 vs. other time (after OF);
$ p < 0.05; 0.01; 0.001 vs. other time before and after OF.
3.4. Associations between Fasting and Postprandial LBP and Selected Parameters of Dietary Trials
and Intervention
We examined the association of plasma LBP concentrations with some parameters related to
obesity and metabolic disorders in subjects from both the overfeeding and Lipinflox studies. Subjects of
the Lipinflox study who have consumed a test meal with 40 g of lipids presented no significant
correlation between circulating LBP and the selected parameters, age, weight, BMI, waist circumference
(WC), aspartame amino transferase (AST), alanine amino transferase (ALT), sCD14 (data not shown).
The correlations between LBP and selected parameters of the Lipinflox postprandial clinical trial
after the test meal containing 10 g of fat are reported Table 2. At all times of the postprandial kinetics,
the LBP concentration was significantly and positively associated with waist circumference (WC),
but not with weight and BMI in all subjects from Lipinflox clinical trial (lean and obese, Table 2).
After stratification according to BMI group, this positive correlation was maintained for lean subjects,
but not for obese subjects (Table 2). LBP concentration was also significantly and positively associated
with ALT but not with AST. These correlations were also maintained for lean subjects at 0, 60 and
120 min, a trend was observed at 180 and 300 min (Table 2). Conversely, no association of LBP with
WC or with ALT was observed for obese subjects (Table 2).
Concerning the overfeeding clinical trial, we also used some mass parameters, such as abdominal
visceral fat and subcutaneous WAT depots, measured by magnetic resonance imaging [27]. As shown
in Table 3, LBP concentration in plasma was significantly and positively associated with trunk lean
mass, lean mass and waist circumference before and after OF. No correlation with subject age was
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observed (data not shown). Notably, the LBP/sCD14 ratio was significantly and positively associated
with lean mass, fat trunk and BMI, before and after overfeeding (Table 3).
Table 2. Correlation analyses (Spearman) with postprandial plasma LBP concentrations as dependent
variable after a 10 g fat load (Lipinflox clinical trial in men). * p < 0.05; ** p < 0.01.
All (n = 16)
Postprandial Time 0 min 60 min 120 min 180 min 300 min
r p r p r p r p r p
Age (years) 0.66 ns −0.06 ns 0.065 ns −0.10 0.07 ns 0.23 ns
Weight (kg) 0.26 ns 0.42 ns 0.43 0.058 0.37 ns 0.36 ns
BMI (kg/m2) 0.24 ns 0.35 ns 0.44 0.052 0.37 ns 0.36 ns
Waist circumference (cm) 0.58 0.007 ** 0.58 0.006 ** 0.63 0.003 ** 0.41 0.07 0.51 0.02 *
AST (U/L) 0.20 ns 0.1 ns 0.24 ns 0.27 ns 0.14 ns
ALT (U/L) 0.49 0.02 * 0.57 0.008 ** 0.63 0.003 ** 0.53 0.016 * 0.43 0.05 *
sCD14 T0 (μg/mL) 0.41 0.06 0.45 0.04 * 0.28 ns −0.15 ns 0.058 ns
Lean (n = 8)
T0 min T60 min T120 min T180 min T300 min
r p r p r p r p r p
Age (years) 0.7 0.02 * 0.43 ns 0.43 ns 0.35 ns 0.47 ns
Weight (kg) −0.31 ns −0.16 ns −0.02 ns 0.09 ns 0.07 ns
BMI (kg/m2) −0.23 ns −0.18 ns −0.08 ns 0.02 ns 0.05 ns
Waist circumference (cm) 0.66 0.04 * 0.60 0.06 0.71 0.02 * 0.72 0.02 * 0.58 0.08
AST (U/L) 0.55 ns 0.18 ns 0.22 ns 0.27 ns 0.23 ns
ALT (U/L) 0.69 0.03 * 0.62 0.05 * 0.68 0.03 * 0.51 ns 0.38 ns
sCD14 T0 (μg/mL) 0.05 ns 0.05 ns −0.01 ns 0.17 ns −0.02 ns
Obese (n = 8)
T0 min T60 min T120 min T180 min T300 min
r p r p r p r p r p
Age (years) −0.48 ns −0.56 ns −0.17 ns −0.09 ns −0.04 ns
Weight (kg) −0.13 ns 0.18 ns −0.27 ns 0.25 ns 0.06 ns
BMI (kg/m2) −0.31 ns −0.46 ns −0.13 ns 0.07 ns 0.17 ns
Waist circumference (cm) 0.25 ns 0.05 ns 0.13 ns −0.13 ns 0.35 ns
AST (U/L) −0.33 ns −0.27 ns −0.07 ns 0.23 ns −0.13 ns
ALT (U/L) −0.11 ns 0.04 ns 0.18 ns 0.53 ns 0.16 ns
sCD14 T0 (μg/mL) 0.22 ns 0.4 ns 0.10 ns −0.13 ns −0.29 ns
Table 3. Correlation analyses (Spearman) of fasting LBP and LBP/sCD14 with mass parameters in the
overfeeding clinical trial (n = 18 men). * p < 0.05; ** p < 0.01.
Before OF
Variable 1 Variable 2 r p
LBP (μg/mL)
Trunk lean mas (kg) 0.65 0.002 **
Lean mass (kg) 0.57 0.009 **
Waist circumference (cm) 0.53 0.02 *
BMI (kg/m2) 0.47 0.04 *
Fat trunk (kg) 0.41 ns
Visceral fat (kg) 0.52 0.03 *
LBP/sCD14
Lean mass (kg) 0.62 0.004 **
Fat trunk (kg) 0.48 0.04 *
BMI (kg/m2) 0.62 0.004 **
After OF
Variable 1 Variable 2 r p
LBP (μg/mL)
Trunk lean mas (kg) 0.62 0.003 **
Lean mass (kg) 0.56 0.01 *
Waist circumference (cm) 0.51 0.02 *
BMI (kg/m2) 0.32 ns
Fat trunk (kg) 0.47 0.04 *
Visceral fat (kg) 0.07 ns
LBP/sCD14
Lean mass (kg) 0.49 0.03 *
Fat trunk (kg) 0.49 0.03 *
BMI (kg/m2) 0.49 0.03 *
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4. Discussion
The novel feature of the present study is the postprandial explorations of LBP and sCD14
concentrations in plasma in two different clinical trials in obese vs. overweight and normal-weight
men. In the first clinical trial (Lipinflox), we have shown that obese men presented a higher LBP
concentration in plasma than lean men, regardless of fat load (10 g vs. 40 g), with no time effect
during the postprandial period. However, no significant differences in sCD14 concentrations were
observed between lean and obese men. In the second clinical trial (overfeeding), we demonstrated,
in lean to overweight men, a time effect on LBP, sCD14, IL-6 concentrations and LBP/sCD14 ratio
during the postprandial period. Only a few human studies have focused on the effect of an OF on
endotoxemia [24] and, to our knowledge, no study has been performed to date in order to evaluate the
impact of dietary fat intake on the postprandial kinetics of LBP and sCD14 in NW, overweight and
obese men.
It is now well established that the intestinal barrier function is modified in obesity, leading to
low-grade inflammation and endotoxemia [9]. Endotoxins have been described as contributors to the
inflammation observed in hypercaloric diets [5,28,29]. LBP and sCD14, two important actors in the
endotoxin metabolic pathway, are now considered indirect markers of gut permeability in metabolic
diseases, but also in other diseases, such as HIV [9,22]. Indeed, both reductions of these markers and
gut permeability were shown after 12 weeks of fish oil supplementation, compared to placebo in HIV+
patients [30]. We show in the Lipinflox study that LBP concentration was higher in obese men at all
times of the postprandial kinetics, independently of fat load (10 vs. 40 g of fat).
The relationship between inflammation and “metabolically healthy” and “non-metabolic healthy”
status remains relatively unknown, even though some studies have shown relationships between
inflammatory markers and obesity or metabolic syndrome. Aguilar-Salinas CA et al. demonstrated
that obese individuals depict similar adiponectin levels to normal-weight subjects and this may be
associated with the “metabolically healthy” obese phenotype [31]. In turn, patients with severe obesity
were reported to have higher LBP concentration, which can be reduced after bariatric surgery [32]. In a
recent study, it was suggested that serum LBP is related to abdominal obesity more than to metabolic
health [16]. Serum LBP is also known to be associated with the carotid intima media thickness [19],
suggesting that the pro-inflammatory action of LBP might be a contributor to the progression of
cardiovascular events [11,33]. In hemodialysis patients, for whom gut barrier and microbiota are
impaired, a positive association between LBP and chronic inflammation and metabolic syndrome
was reported [34]. The present study shows a strong relationship between plasma LBP and waist
circumference. It is interesting to note that plasma LBP was correlated significantly with WC only in
lean subjects. Another point is the correlation of LBP with ALT only in lean subjects. Patients with
non-alcoholic fatty liver disease are known to present higher LBP concentrations when they develop
steatohepatitis [15]. An association between LBP and ALT was noted in hepatitis C virus, and these
authors suggested that, as with ALT, LBP might serve as another hepatic inflammatory biomarker [35].
Another study has shown that endotoxemia reflects the hepatic functional reserve capacity of end-stage
liver disease [36]. Interestingly, in obese subjects of the present study, no correlation of circulating LBP
with WC or ALT was observed. Naghizadek et al., 2018 have shown that WC is important for the
association among TLR4, serum LBP and IFNβ and metabolic state only for the highest WC range [16].
This finding is not in agreement with the present study, and could be explained by the fact that obese
subjects were not morbid.
In the Lipinflox study, the fat load (10 vs. 40 g) did not modify the kinetics of the LBP concentration
in the plasma of lean and obese subjects. However, the LBP concentration in lean subjects was lower
than that in obese subjects for both fat loads. Moreover, the dietary intervention in the OF study did not
affect postprandial LBP concentrations. Umoh F. et al. also suggested that obesity might not result in
enhanced exposure to intestinal bacteria, as the effect of BMI was no longer significant in multiple linear
regression models [37]. It is well known that obesity is associated with modifications in the secretion
of cytokines from adipose tissue and liver. However, only few studies have investigated the impact of
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overfeeding on the production of cytokines/adipokines. In the present OF study, the concentrations of
LBP, sCD14 and Il-6 were not significantly affected by a two-month overfeeding (+760 kcal/day by
adding 70 g of lipids to the usual daily diet). More precisely, the fat OF consisted in daily addition of
20 g of butter, 100 g of cheese (Emmental) and 40 g of almonds. Another study of acute overfeeding
(+1250 kcal/day with a nutrient composition of 45% fat, 15% protein and 40% carbohydrate) has shown
that 3 days are sufficient to increase body weight and HOMA-IR, without affecting MCP-1 and CRP
plasma concentrations [38]. Tam C.S. et al. also demonstrated that moderate weight gain after 28 days
of overfeeding (+1250 kcal via high-fat snacks composed of 45% fat, 15% protein, and 40% carbohydrate)
in healthy humans resulted in a significant weight gain and increased circulating levels of CRP and
MCP-1, without changes in subcutaneous WAT mass [39]. Those results demonstrate that different
compositions of overfeeding diets may differentially impact cytokines/adipokine concentrations in
plasma and tissues.
The present study has some limitations. Firstly, the sample size was small, owing the cumbersome
aspects of postprandial explorations, and only one plasma inflammatory marker was measured.
However, the postprandial results were obtained from two different trials, and the timing of plasma
collection was not the same. Another limitation of this study is the measure of IL-6 in plasma taken
serially from a catheter in an arm vein. Indeed some authors have shown that the presence of the
catheter irritate the vein and cause an increase in IL-6 levels in plasma samples taken over several
hours compared to fresh samples taken from the opposite arm [40,41]. Finally, ensuring adherence to
dietary instructions given during the OF clinical trial is difficult in a feeding trial.
To conclude, we have shown in obese men that a fat load of 10 g of lipids can drive an increase
of IL-6 concentration in plasma at 300 min post-meal, maybe due to a lesser clearance of LPS by
lipoproteins. Indeed Vors et al. has shown that obese subject chylomicrons were more enriched with
LPS compared to NW, which could contribute to LPS clearance and to a lesser IL-6 concentration in
plasma [23]. This result should be confirmed in further studies with the measure of other inflammatory
markers. The LBP concentration in plasma was higher in obese subjects than in NW subjects both at
fasting and along the postprandial period (Lipinflox clinical trial), and was significantly and positively
associated with trunk lean mass, lean mass and waist circumference before and after OF. Further studies
are now necessary to better understand the relative role of LBP and sCD14 during the postprandial
phase after diets containing different amounts and types of fats in different food matrixes.
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Appendix A. Postprandial Kinetics of LBP/sCD14 after 10 g vs. 40 g Fat Load. Data Are
Means ± SEM
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Abstract: Asymmetric and symmetric dimethylarginine (ADMA and SDMA, respectively) are risk
factors for the cardiovascular and renal systems. There is a paucity of data in humans regarding
variations of protein L-arginine (Arg) methylation leading to ADMA and SDMA. In this study,
we introduced and used Arg dimethylation indices based on the creatinine-corrected urinary
excretion of SDMA and ADMA, and its major metabolite dimethylamine (DMA). The main objective
of the present study was to assess whether, and to which extent, a high-fat protein meal (HFM),
a classical allostatic load eliciting various adverse effects, may contribute to Arg dimethylation in
proteins in humans. Reliable gas chromatography–mass spectrometry methods were used to measure
the concentration of ADMA, DMA, SDMA, and creatinine in spot urine samples collected before
(0 h), and after (2, 4, 6 h) three HFM sessions in 10 healthy overweight individuals. At baseline,
urinary ADMA, DMA, and SDMA excretion correlated positively with circulating TNF-α and IL-6.
Arg dimethylation indices did not change postprandially. Our study shows that three HFMs do not
contribute to Arg dimethylation in proteins. The proposed indices should be useful to determine extent
and status of the whole-body Arg dimethylation in proteins in humans under various conditions.
Keywords: ADMA; arginine; SDMA; DMA; PRMT
1. Introduction
L-Arginine (Arg) is a nutritionally semi-essential proteinogenic amino acid. It is involved in many
pathways and numerous physiological processes [1,2]. Arg is the substrate of all known nitric oxide
synthase (NOS; EC 1.14.13.39) isoforms, which are present in virtually all cell types and oxidize the
guanidine (NG) imine group of free Arg to nitric oxide (NO) via an NG-hydroxy-L-arginine intermediate.
NO is one of the most potent endogenous vasodilators and inhibitors of platelet aggregation,
and has many other biological functions [3]. The NOS-catalyzed conversion of Arg to NO and
L-citrulline (Cit) is inhibited by three endogenous Arg derivates: L-NG-monomethylarginine (MMA),
L-NG,NG-dimethylarginine (asymmetric dimethylarginine, ADMA), and L-NG,N’G-dimethylarginine
(symmetric dimethylarginine, SDMA) [4,5] (Figure 1). MMA, ADMA, and SDMA inhibit the activity
of the three NOS isoforms by distinctly different mechanisms and inhibitory potency [6,7]. Like their
parent molecule Arg, MMA, ADMA, and SDMA exist in two forms: as residues of certain proteins,
and as free acids produced by regular proteolysis of those NG-methylated proteins. The free guanidine
group of Arg moieties in proteins undergo posttranslational methylation, which is catalyzed by the
family of the protein arginine methyltransferases (PRMT; EC 2.1.1.125) [8–10]; the methyl group for
this reaction is provided by the universal cofactor S-adenosylmethionine (SAM) (Figure 1).
Nutrients 2019, 11, 1463; doi:10.3390/nu11071463 www.mdpi.com/journal/nutrients83
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Figure 1. Simplified schematic of the asymmetric and symmetric methylation (ADMA and SDMA
respectively) of arginine residues in proteins, their proteolysis to free ADMA and SDMA, metabolism
of ADMA by dimethylarginine dimethylaminohydrolase (DDAH) to dimethylamine (DMA), and their
excretion in the urine. Proposal of the protein arginine dimethylation index (PADiMeX).
High circulating ADMA and SDMA concentrations are considered risk factors in the renal
and cardiovascular systems [11–16]. In these systems, ADMA is thought to exert its detrimental
effects by inhibiting NOS activity in the endothelium. Yet, there is an increasing indication that
free and/or proteinic ADMA and SDMA exert NO-independent biological effects that have not
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yet been fully elucidated [6,7]. As an example, mass proteomic studies identified mono- and
dimethylated Arg residues in the cardiac sodium channel, suggesting a potential role of proteinic Arg
methylation in the regulation of the cardiac voltage-gated Na+ channel, presumably via mutual Arg
methylation–phosphorylation crosstalk [17–19]. It has also been discussed that methylation of arginine
residues in proteins are essential for proper regeneration of skeletal muscles, presumably by regulating
muscle stem cell function [9].
A major fraction (about 90%) of endogenously produced ADMA is hydrolyzed to dimethylamine
(DMA) by dimethylarginine dimethylaminohydrolase (DDAH; EC 3.5.3.18); only a minor fraction of
about 10% of the daily produced ADMA is excreted, unchanged, in the urine [4,20]. Unlike MMA
and ADMA, SDMA is not hydrolyzed by DDAH and is excreted almost unchanged in the urine [21].
The urinary concentrations of ADMA, DMA, and SDMA can be considered markers of whole-body
asymmetric (ADMA + DMA), symmetric (SDMA), and total (ADMA + DMA + SDMA) dimethylation
of Arg residues in proteins. Therefore, this could be a practical way to assess whole-body Arg
dimethylation, and its variations in vivo. Previously, we and others have used Arg methylation indices
for symmetric [22] and asymmetric Arg dimethylation, including the DMA/ADMA molar ratio in urine
of healthy and diseased children and adults [23,24]. In the present work, we further build on the rationale
of indices for assessing protein Arg dimethylation by defining and using the following terms: aPADiMeX
for asymmetric dimethylation; sPADiMeX for symmetric dimethylation; toPADiMeX (ADMA + DMA +
SDMA) for total Arg dimethylation; and a/sPADiMeX for the molar ratio of asymmetric-to-symmetric
Arg dimethylation, i.e., (ADMA +DMA)/SDMA (Figure 1). In 24 h-collected urine samples, the amounts
excreted within a day can be used in these terms. In urine samples collected by spontaneous micturition,
the creatinine-corrected concentrations of ADMA, DMA, and SDMA are considered.
MMA, SDMA, ADMA, and DMA are natural compounds, and the ingestion of vegetable and meaty
food may contribute to endogenously produced SDMA, ADMA, and most notably to DMA [25–27].
Application of the above described protein Arg dimethylation concept in health and disease requires
taking proper measures to minimize exogenous contributors to urinary SDMA, ADMA, and DMA.
Previously, we found that dietary fat ingestion increased the plasma concentration of ADMA marginally
(by 6%) in lean and obese healthy subjects [28]. In 10 overweight men, we previously found that
high-fat protein meals (HFMs) acutely increased plasma ADMA concentrations [29]. Yet, in those
studies, we did not measure ADMA, DMA, and SDMA in urine samples.
The aim of the present study was to apply the above proposed indices of Arg methylation to
a human study, and to test the hypothesis that dimethylarginine methylation in proteins would increase
after a HFM. We measured, by fully validated and previously reported gas chromatography–mass
spectrometry (GC–MS) methods, the concentration of ADMA, DMA, SDMA, and creatinine in spot
urine samples collected in previous study [30] before, during, and after HFM meals consumed on three
occasions by the 10 healthy overweight volunteers.
2. Materials and Methods
2.1. Ingestion of High-Fat Protein Meals by Healthy Overweight Men
The urine samples analyzed in the present study had been collected in a previous study, reported by
us in detail [30]. The study was conducted in accordance with the Declaration of Helsinki, approved by
the Ethics Committee of Saint-Germain-en-Laye Hospital (Reference #08001), and authorized by
the French Ministry for Health (Reference 2007-A01296-47). All participants gave their written
informed consent prior to enrolment. The study recruited eleven healthy overweight (body max index
(BMI)> 25 kg/m2) men aged 21–50 years, with enlarged waist circumference (>94 cm), and without
any established illnesses. This sample size was set taking into account 10% attrition, and considering
that 10 individuals were necessary to detect medium effect size (Cohen’s d = 0.5) of the treatment on
the primary outcome of the clinical trial (postprandial endothelial dysfunction). Volunteers had no
regular use of medication or nutritional supplements, were not heavy smokers or alcohol drinkers,
85
Nutrients 2019, 11, 1463
and had no moderate/high level of physical activity. They had blood hemoglobin >130 g/L, and no
hypertension. The volunteers had the following characteristics: age, 34 ± 9 years; height, 178 ± 3 cm;
weight, 96 ± 6 kg; BMI, 30.2 ± 1.5; body fat, 24.3 ± 2.0%; waist circumference, 96 ± 3 cm. Three HFMs
of the same nutritional composition, but differing in the protein source, were tested in a randomized
crossover design. Each period consisted of a postprandial study separated by at least two weeks.
The test meals consisted of a mixture of 233 g cream containing 40% fat, 45 g sucrose, 45 g protein as
protein isolates, and 160 mL water. The composition of the meals was as follows: energy, 1200 kcal;
fat, 93 g (70% energy); carbohydrates, 45 g (15% energy); crude protein, 45 g (15% energy). After the
overnight fasting (9–12 h), the subjects ingested the meal, and spot urine samples were collected before
the meal (0 h, T0) and 2 h (T2), 4 h (T4), and 6 h (T6) after the meal. One subject chose to withdraw
from the study during the first session because he felt nauseated after the meal. The urine samples
collected during the meal were also analyzed and considered in statistics.
2.2. Measurement of Urinary ADMA, DMA, SDMA, Creatinine, and Quality Control
Creatinine, ADMA, DMA, and SDMA were measured by previously reported fully validated
methods based on gas chromatography–mass spectrometry (GC–MS) methods [22,24,31,32].
Urine donated by a healthy volunteer served as a quality control (QC) sample, and was analyzed
alongside the study samples within 8 runs. The following analyte concentrations were measured
in the QC samples (mean ± SD): 10.7 ± 0.02 mmol/L (RSD, 2%) for creatinine, 21.3 ± 0.4 μmol/L
(RSD, 2.0%) for ADMA, 36.2 ± 1.27 μmol/L (RSD, 2%) for SDMA, and 243 ± 18 μmol/L (RSD, 7.4%)
for DMA. These results underline the reliability of the GC–MS methods in the measurements of the
study samples.
2.3. Measurement of Inflammation and Cardiovascular Biomarkers
The biochemical parameters apolipoprotein B 48 (apoB48), monocytes chemoattractant
protein-1 (MCP-1), myeloperoxidase (MPO), non-esterified fatty acids (NEFA), reflexion index (RI),
soluble intracellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1
(sVCAM-1), triacylglyceride (TAG), tumor necrosis factor-alpha (TNF-α), tissue plasminogen activator
inhibitor-1 (tPAI-1), and the physiological parameters reflexion index (RI) from pulse wave analysis
were measured as described elsewhere [30].
2.4. Statistical Analyses
Statistical analyses were performed, and graphs were constructed using Origin 7.5G, GraphPad
Prism 7 (GraphPad Prism Software Inc. San Diego, CA, USA). Distribution of variables was tested
by D’Agostino and Pearson omnibus K2 test. Normally distributed parameters are presented as
mean ± SD or mean ± SEM. Non-normally distributed parameters are presented as median and
interquartile range (25th–75th percentile). Correlations between variables were assessed by Pearson
(parametric) or Spearman (non-parametric) statistical tests. Repeated measures one-way ANOVA
with Tukey’s multiple comparisons test was used to test the effect of postprandial time on the urinary
parameters. p-values < 0.05 were considered as statistically significant.
3. Results
Considering all volunteers, meals, and time points (n = 124 values), the urinary analyte
concentrations were 40.2 (22–57) μmol/L for ADMA, 55.2 (31–76) μmol/L for SDMA, 348 (180–536)
μmol/L for DMA, and 11.9 (6.7–19.6) mmol/L for creatinine. The creatinine-corrected excretion rates
(μmol/mmol) were 3.39 (2.50–4.15) for ADMA, 4.48 (3.33–5.78) for SDMA, and 29 (21.7–37.0) for
DMA. The other values were 32.8 (24.6–41.1) μmol/mmol for aPADiMeX, 37.9 (28.5–47.0) μmol/mmol
for toPADiMeX, and 7.26 (6.27–8.20) for a/sPADiMeX. The concentrations of ADMA, SDMA, DMA,
and creatinine correlated strongly with each other (Table 1a). The creatinine-corrected concentrations
of ADMA, SDMA, and DMA also correlated with each other (Table 1b).
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Table 1. Spearman correlation coefficients between the concentrations (a) and creatinine-corrected
excretion rates (b) of the analytes in the urine samples for all volunteers, meals, and time points (n =
124 values). toPADiMeX is ADMA + DMA + SDMA for total Arg dimethylation.
Table 1a ADMA SDMA DMA
SDMA (μmol/L) 0.939, p < 0.0001
DMA (μmol/L) 0.900, p < 0.0001 0.923, p < 0.0001
Creatinine (mmol/L) 0.842, p < 0.0001 0.886, p < 0.0001 0.883, p < 0.0001
Table 1b ADMA SDMA DMA
SDMA (μmol/mmol) 0.811, p < 0.0001
DMA (μmol/mmol) 0.652, p < 0.0001 0.765, p < 0.0001
toPADiMeX (μmol/mmol) 0.755, p < 0.0001 0.842, p < 0.0001 0.981, p < 0.0001
At baseline, many of the plasma clinical chemistry biochemical parameters correlated
moderately-to-strongly with each other (Table 2). All of the found statistically significant correlations
were positive, except for NEFA and tPAI-1. The strongest correlation was observed between IL-6 and
TNF-α (r = 0.847, p < 0.0001).
The correlations found between plasma clinical chemistry biochemical parameters and the
creatinine-uncorrected urinary concentrations of ADMA, SDMA, DMA, and toPADiMeX at baseline
are summarized in Table 3. These parameters correlated with TNF-α and IL-6, with SDMA showing the
strongest correlation. The BMI value of the volunteers (range 26.9–33.4 kg/m2) was found to correlate
with insulin, sICAM-1, sVCAM-1, and E-selectin (Table 3). At baseline, the urinary concentrations
(μmol/L) of ADMA, SDMA, DMA, and toPADiMeX, or with a/sPADiMeX, did not correlate with the
BMI values. The creatinine-corrected excretion rates of DMA (r = −0.354, p = 0.051) and toPADiMeX
(r = −0.324, p = 0.076) only tended to correlate with the BMI (not shown in Table 3).
We did not observe any postprandial changes in the indices for the individual HFM (data not
shown), and so the dataset of the 3 individual meals (n = 10) were collapsed to a single dataset (n = 30).
The urinary creatinine concentration, the creatinine-corrected excretion of ADMA, DMA, and SDMA,
and their indices aPADiMeX, toPADiMeX, and a/sPADiMeX are summarized in Table 4 for all three
meals. Statistically significant overall time effects (ANOVA) were obtained for creatinine (p = 0.0021)
and DMA (p = 0.019). Statistically significant time effects were obtained for creatinine (T0 vs. T4,
p = 0.0007; T4 vs. T6 p = 0.0011), ADMA (T2 vs. T6, p = 0.0006), DMA (T0 vs. T4, p = 0.0027), SDMA
(T4 vs. T6, p = 0.0499), and aPADiMeX (T0 vs. T4, p = 0.0290).
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4. Discussion
In blood and urine, MMA is present at much lower concentrations than ADMA and SDMA.
For instance, in healthy humans, the mean creatinine-corrected excretion rate of MMA was reported
to be 0.017 μmol/mmol, and the ratio of the mean clearance rates of MMA, ADMA, and SDMA were
reported to be 1:69:71 [33]. This may be an indicator that MMA, the first PRMT-catalyzed product
of Arg-methylation in proteins, is immediately methylated to form ADMA and SDMA proteins.
Other ADMA and SDMA metabolites from Nα-acetylation and Nα-oxidation pathways occur in urine,
yet at much lower concentrations than ADMA and SDMA, such as 0.013 μmol/mmol creatinine,
and in the range 0.011–1.03 μmol/mmol creatinine for the ADMA metabolites, respectively [34,35].
Consequently, the urinary concentrations of ADMA, DMA, and SDMA are useful for the determination
of the whole-body NG-dimethylation of Arg residues in proteins.
In the present work, we propose the use of the Protein Arginine Dimethylation indeX: aPADiMeX
for asymmetric, sPADiMeX for symmetric, toPADiMeX for total dimethylation, and a/sPADiMeX
for the asymmetric-to-symmetric (a/s) dimethylation state (Figure 1). We applied this proposal to
(1) investigate potential postprandial effects of HFMs on protein Arg dimethylation; and (2) to test
potential correlations of the indices with clinical chemistry laboratory biomarkers of inflammation and
vascular functions, such as IL-6 and TNF-α.
The ADMA/SDMA molar ratio in our study is close to 1, and is almost identical with that reported
for healthy subjects [33]. However, this ratio does not mean that asymmetric and symmetric protein
Arg dimethylation rates are equal. This is because ADMA is metabolized to DMA, of which the
excretion is about 10 times higher than non-metabolized ADMA in healthy adults [24,33].
The creatinine-corrected excretion rates of the ADMA, DMA, and SDMA measured in the
present study at baseline, are within ranges reported by us and others for healthy and diseased
adults [24,33]. In our healthy overweight men, the average baseline creatinine-corrected urinary
excretion rates (μmol/mmol) were 3.59 for ADMA, 4.48 for SDMA, and 26.9 for DMA. The baseline
indices were calculated to be 30 μmol/mmol for aPADiMeX, 37.1 μmol/mmol for toPADiMeX, and 6.7
for a/sPADiMeX. These data indicate that DMA is the strongest quantitative contributor to the proposed
indices. The whole-body asymmetric dimethylation of proteinic Arg is about 7 times higher than the
symmetric in the healthy overweight men of the present study.
In urine samples from 14 healthy non-overweight men (age, 41 ± 11 years; range, 26–60 years;
BMI, 23.9 ± 3.3 kg/m2) from previous work [32], we measured creatinine-corrected excretion
rates of 29.6 ± 3.9 μmol/mmol DMA, 2.74 ± 0.51 μmol/mmol ADMA, and 2.99 ± 0.44 μmol/mmol
SDMA. The Arg dimethylation indices were calculated to be 35.0 ± 5.2 μmol/mmol for aPADiMeX,
38.0 ± 5.5 μmol/mmol for toPADiMeX, and 11.8 ± 1.6 for a/sPADiMeX. In urine samples from 5 healthy
non-overweight women (age, 42 ± 10 years; range, 28–56 years; BMI, 26.9 ± 7.8 kg/m2) from the
same study [32], we measured creatinine-corrected excretion rates of 42.5 ± 5.8 μmol/mmol DMA,
4.2 ± 1.2 μmol/mmol ADMA, and 3.91 ± 0.6 μmol/mmol SDMA. The Arg dimethylation indices
were calculated to be 46.7 ± 6.6 μmol/mmol for aPADiMeX, 50.6 ± 7.2 μmol/mmol for toPADiMeX,
and 10.8 ± 0.8 for a/sPADiMeX. Statistically significant differences between men and women were
found for DMA (p= 0.01), ADMA (p= 0.003), SDMA (p= 0.022), aPADiMeX (p= 0.007), and toPADiMeX
(p = 0.0046), but not for a/sPADiMeX (p = 0.95), suggesting potential effects of gender on whole-body
asymmetric and symmetric proteinic Arg dimethylation, yet not on their balance.
In previous studies, we found that HFM taken by the same healthy overweight men is associated
with considerable postprandial changes in many circulating biochemical biomarkers, including Arg,
L-homoarginine (hArg), and ADMA [29,30,36]. The present study indicates that HFM has no
appreciable postprandial effects on total asymmetric and symmetric protein arginine dimethylation
(toPADiMeX), and asymmetric-to-symmetric protein arginine dimethylation (a/sPADiMeX). However,
we found some significant temporary changes on ADMA (decrease, between T2 and T6), DMA, SDMA,
and aPADiMeX (increases, all between T0 and T4). At baseline, circulating TNF-α and IL-6 correlated
with urinary creatinine-corrected SDMA excretion. Previously, we found no statistically significant
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changes in circulating TNF-α and IL-6 upon meal ingestion [30], suggesting that these factors may
not be responsible for the observed changes in SDMA excretion. The results of the present study may
suggest that the HFM themselves did not contain appreciable amounts of ADMA, DMA, and SDMA
(not investigated), and did not exert appreciable effects on dimethylation of proteinic Arg. As creatinine
excretion changed relatively strongly, an effect on the glomerular filtration rate (GFR) of the kidney on
the excretion rates of ADMA, DMA, and SDMA cannot be excluded. In renal transplant recipients
(median estimated GFR of 43.5 mL/min/1.73 m2), the mean ADMA-to-SDMA molar ratio was found to
be only 0.6 [37].
The non-invasive measurement of ADMA, DMA, and SDMA in human urine provides a relevant
approach to estimate the extent of proteinic Arg dimethylation and the relative contribution of
the asymmetric and symmetric dimethylation, which can be translated into the individual PRMTs.
The proposed indices may provide valuable information of the status of protein arginine dimethylation
in health and disease. In healthy overweight men, HFM ingestion caused temporary changes
in creatinine excretion, and creatinine-corrected excretion rates of ADMA, DMA, and SDMA.
However, these changes do not indicate changes in the total protein arginine dimethylation, and the
balance between asymmetric and symmetric protein arginine dimethylation. Of note, asymmetric
dimethylation tended to increase after HFMs.
A limitation of our study is the small number of participants. Strengths of the study are the
closely controlled, repeated postprandial testing on the same volunteers, controlled meal composition,
and validated methods for measuring arginine metabolites in urine. Urinary DMA is by far the greatest
term of the indices proposed in this work. Further studies on larger cohorts are warranted to assess
potential differences in methylation profiles of proteinic arginine in various conditions in health and
disease, and to assess the effects of gender and age. In studies addressing the in vivo protein arginine
dimethylation in non-closely controlled studies, subjects must abstain from ingestion of DMA-rich
food, notably fish [24–27].
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Abstract: Although peripheral blood mononuclear cells (PBMCs) are widely used as a valuable
tool able to provide biomarkers of health and diseases, little is known about PBMC functional
(biochemistry-based) metabolism, particularly following short-term nutritional challenges. In the
present study, the metabolic capacity of minipig PBMCs to respond to nutritional challenges was
explored at the biochemical and molecular levels. The changes observed in enzyme activities
following a control test meal revealed that PBMC metabolism is highly reactive to the arrival
of nutrients and hormones in the circulation. The consumption, for the first time, of a high
fat–high sucrose (HFHS) meal delayed or sharply reduced most of the observed postprandial
metabolic features. In a second experiment, minipigs were subjected to two-month HFHS feeding.
The time-course follow-up of metabolic changes in PBMCs showed that most of the adaptations to
the new diet took place during the first week. By comparing metabolic (biochemical and molecular)
PMBC profiles to those of the liver, skeletal muscle, and adipose tissue, we concluded that although
PBMCs conserved common features with all of them, their response to the HFHS diet was closely
related to that of the adipose tissue. As a whole, our results show that PBMC metabolism, particularly
during short-term (postprandial) challenges, could be used to evaluate the whole-body metabolic
status of an individual. This could be particularly interesting for early diagnosis of metabolic disease
installation, when fasting clinical analyses fail to diagnose the path towards the pathology.
Keywords: peripheral blood mononuclear cells; postprandial metabolism; high fat–high sugar diet;
minipig; adipose tissue; biomarkers
1. Introduction
Peripheral blood mononuclear cells (PBMCs) have been widely used for more than 10 years
now as a valuable tool to provide reliable biomarkers of health and diseases [1–3]. Although very
recent studies have approached PBMC metabolism from a more functional point of view, such as
metabolomics studies [4,5], most of them are based on transcriptomics analyses only [1,6,7]. Very little
is actually known about the functional, i.e., biochemical-level, metabolism of PBMCs following
nutrition-related interventions. Previous studies showed for specific individual white cell populations
(such as lymphocytes and macrophages), these rapidly dividing cells had all the necessary biochemical
machinery to utilise the most abundant energy substrates, such as glucose, lipids, and some amino
acids, particularly glutamine [8]. More recent studies based on enzyme activities carried out on
dogs, cats, and cattle confirm that PBMCs have an active metabolism that could be similar to that
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of other organs [9–11]. However, very little is known about PBMC metabolism in minipigs, as most
of the studies are focused on immunological approaches. Only a few papers have explored the pig
PBMC transcriptomic response to diverse conditions, such as mitogenic stimulation, [12], growth
performance [13], stress [14], or leptin administration [15]. Thus, functional metabolic studies are
lacking in minipigs, especially with respect to nutritionally-related metabolic diseases.
An aspect of interest in PBMCs is that they circulate permanently and through all body parts in
the blood stream, being subjected to any variation of this fluid composition, including those related
to fluctuations in circulating nutrients, substrates, and hormones [16]. All these molecules can then
potentially impact PBMC metabolism and deeply modify their gene expression profile. On chronic
exposure to a modified nutritional environment, PBMC transcriptomics have been used to discover
valuable biomarkers of many metabolism-related diseases, such as diabetes [17], obesity [3], or insulin
resistance [18]. Despite the current knowledge about the capacity of PBMCs to be imprinted at the
long-term molecular level by altered nutritional conditions, it is not clear whether PBMC metabolism
could be representative of nutritionally-induced short-term and rapid modifications in blood or tissue
metabolites and metabolic activity. The postprandial phase (i.e., the period that follows meal intake)
represents one of the most challenging phenomena in whole-body metabolism taking place in healthy
conditions; it occurs every day, several times a day. Following meal intake, body metabolism must
adapt to major changes in blood composition: the increased levels of circulating nutrients could be
harmful remain elevated for a long time, and on the other hand, levels of several hormones increase
for just few minutes after the nutrient arrival. As do all the other organs, PBMCs must adapt to these
changes [19]. More importantly, while the contact of most of the organs with circulating nutrients and
hormones will depend on vascularisation and changes in blood circulation, PBMCs are directly and
permanently affected by the blood, as they are surrounded by the fluid. Changes in blood composition
may be then particularly sharp for PBMCs, forcing them to rapidly adapt to these changes as suggested
in transcriptomic-based postprandial studies [20,21]. For example, this has been demonstrated in
studies on humans [22] and rats [16] during fasting, at least at the gene expression level. Whether this
flexibility to adapt to a meal is compromised in PBMCs as has been shown for the whole body and
individual organs during the onset of many metabolic diseases, such as diabetes or obesity [23,24],
remains to be elucidated.
The main objective of the present study was to determine if PBMC metabolism at the biochemical
and molecular levels could adapt to different nutritional conditions known to alter the profile of
circulating metabolites and hormones, and to induce major changes in whole body metabolism.
We submitted Yucatan minipigs to different nutritional challenges, including a meal test (a meal
regular or high in fat and sugar, HFHS) and long-term HFHS feeding. In the first case, we aimed at
determining whether PBMCs were able to adapt rapidly to changes occurring after meal intake and if
their metabolic adaptive capacity might provide information about the capacity of the individual to
handle the meal. In the second case we aimed at studying the long-term metabolic footprint of HFHS
feeding on PBMC metabolism and to compare it to the metabolism of other tissues, including the liver,
skeletal muscle, and adipose tissue (AT). For the postprandial challenges, the biochemical approach
(enzyme activities) was chosen to explore the short-term adaptation (hours). For the long-term trial
(months), both enzyme activities and mRNA levels were assessed to explore the metabolic adaptations
installed in the fasting state during HFHS feeding.
2. Materials and Methods
2.1. Animals
The study involved 10 female adult (6 month-old) Yucatan mini-pigs (30 ± 1 kg). They were
housed in subject pens (1 × 1.5 m) in a ventilated room with controlled temperature (21 ◦C) and regular
light cycle (L12:D12). They were fed once daily with 400 g/day of a concentrate feed containing 17.5%
proteins, 3.2% fat, 4.3% cellulose, and 5.2% ash (Porcyprima; Sanders Centre Auvergne, Aigueperse,
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France) and had free access to tap water. All procedures were in accordance with the guidelines
formulated by the European Community for the use of experimental animals (L358-86/609/EEC,
Council Directive, 1986).
2.2. Experimental Procedure
2.2.1. Postprandial Meal Test
The postprandial meal test trial consisted in the ingestion of 400 g of a regular (control) or a
high fat-high sugar (HFHS) meal after an overnight fasting period. Five animals were involved in
the trial, consuming first the control diet, and after one week of wash-out, the HFHS diet. The HFHS
diet consisted of a regular pig diet enriched with fat (12% butter) and sugar (10% sucrose). Animals
ingested the whole mixture in no more than 10 min. Blood was collected though an arterial catheter
before (T0) and then 2, 4, and 7 h after the meal.
2.2.2. High Fat–High Sucrose Long-Term Trial
The HFHS trial consisted in the ingestion of an obesogenic diet during two months. Five animals
were involved in the trial and were fed twice a day (500 g). Arterial blood was sampled through a
permanent catheter after a fast of 24 h (day 0) and after 7, 14, 30, and 60 days of diet consumption also
at the fasting state. Liver, skeletal muscle and AT samples were collected during the catheter surgery
procedure (before the trial) and by the end of the 60 days. In both cases, minipigs were under deep
anaesthesia and samples were immediately frozen at −80 ◦C for further analyses.
2.3. Analytical Procedures
2.3.1. Blood Treatment and PBMC Collection
At each point, 10 mL of blood were collected on a dry syringe (without anticoagulant) and then
gently transferred to a tube CPT™ tube (BD vacutainer) containing a polyester gel and a density
gradient liquid (FICOLL™ Hypaque™ solution). This filter allows cell separation during a single
centrifugation step. Briefly, blood was centrifuged at 1650 g during 20 min at 20 ◦C. After centrifugation,
the plasma was collected and quickly stored at −80 ◦C until further analyses. The layer containing the
PBMC was collected (buffy coat), washed twice with PBS solution and centrifuged at 300 g during
15 min at 20 ◦C. After washing, the PBMC were pelleted, the PBS discarded and cells suspended on
RNLater™ (for further mRNA analysis) or a lysis solution.
2.3.2. Plasma Insulin and Metabolite Determination
Glucose, triacylglycerol (TG), lactate, and urea levels were enzymatically measured using
commercial kits on an automotive ABX Pentra 400 (Horiba Medical, Grabels, France) test system.
Plasma insulin levels were assessed using a commercial ELISA kit (Mercodia, Uppsala, Sweden).
Branched-chain amino acids (BCAA) were assessed enzymatically as described in Polakof et al.
2017 [25].
2.3.3. Measurements of Enzyme Activities
For enzyme activities, PBMC were immediately homogenized on the lysis solution (20 mM Tris,
pH 7.4, 250 mM sucrose, 2 mM EDTA, 10 mM β-mercaptoethanol, 100 mM NaF, 0.5 mM EDTA).
The homogenate was centrifuged for 20 min at 10,000× g and the supernatant immediately used.
Enzyme activities were determined by spectrophotometry using a microplate reader (Infinite® 200 PRO
NanoQuant, Tecan, Grödig, Austria), based on mini-pigs methods adapted to PBMC [23,25,26],
including hexokinase (HK), pyruvate kinase (PK), glucose-6-phosphate dehydrogenase (G6PD), malate
dehydrogenase (MDH), lactate dehydrogenase (LDH), glutamate dehydrogenase (GDH), glutaminase
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P-dependent, branched-chain amino acid aminotransferase (BCAT) and aspartate aminotransferase
(AspAT).
2.3.4. Western Blot Analyses
Samples were homogenized as described above and for each sample, total protein lysates (4 μg)
were subjected to SDS-PAGE, electrotransferred on a PVDF membrane and probed with the indicated
antibodies: total serine/threonine kinase protein kinase B (AKT) and phospho AKT at serine 473
(pAKT) and total eEF2-α and phosphor eEF2-α at threonine 56 (peEF2-α) (Cell Signaling Technology,
Ozyme, St Quentin-en-Yvelines, France). After washing, membranes were incubated with an IRDye
infrared secondary antibody (LI-COR Biotechnology, Lincoln, NE, USA). Bands were visualized by
infrared fluorescence using the Odyssey imaging system (LI-COR Inc. Biotechnology, Lincoln, NE,
USA) and quantified by Odyssey infrared imaging system software (version 1.2).
2.3.5. PCR Analyses
Total RNA was extracted using RNEasy Mini Kit® (Qiagen) and mRNA levels were determined by
RT-PCR. RNA quality was verified on 1% agarose ethidium-bromide stained gel. cDNA was generated
from 500 ng RNA using the High Capacity cDNA Reverse Transcription Kit (Life Technologies,
Villebon-sur-Yvette, France). Real-time PCR was performed in the CFX96 Touch™ Real-Time PCR
Detection System (BIO-RAD, Hercules, CA, USA) as in [23]. Primers were designed so that they are
overlapping an intron (Primer3 software; Whitehead Institute for Biomedical Research/MIT Center,
Cambridge, MA, USA) using known sequences in nucleotide databases. Primers sequences are
available in [26].
2.4. Statistical Analyses
Data from the postprandial challenges were analysed using a repeated measures two-way ANOVA
test (time and diet as variables). The PBMC and plasma parameters from the HFHS trial were analysed
using a one-way ANOVA test followed by post-hoc Holm-Sidak. The p-value significance threshold
for all factors was set to 0.05.
The differences between the D0 and D60 HFHS trial in liver, skeletal muscle and AT enzyme
activities and mRNA levels were analysed using a Mann–Whitney nonparametric test using for the
post hoc analysis the Student–Newman–Keuls test (SigmaPlot 12, Systat Software, San Jose, CA, USA).
The p-value significance threshold for all factors and ions was set to 0.05. p-values between 0.05.
3. Results
3.1. Short-Term Control vs HFHS Postprandial Trial
Glucose (insulin, glucose, lactate), lipid (TG), and nitrogen (urea, BCAA) metabolism were
evaluated before and after the control and the HFHS meal based on plasma hormone and metabolite
assessment in order to evaluate the postprandial metabolic phenotype of minipig followings the meal
(Figure 1). Plasma glucose levels increased (between 2 and 4 h after the meal) after the control meal
intake, recovering to basal level 7 h after the meal. No changes with time were observed following
the HFHS meal, although plasma glucose levels were lower between 2 and 4 h than after the control
meal. Plasma insulin levels showed a very important variability among individuals to put in evidence
a time effect. However, 2 h after the meal, a tendency (p < 0.081) to have higher levels than before
the meal was observed, which is in agreement with the changes observed in the plasma glucose
profile. No differences were found among the animals consuming the different meals. Lactate plasma
levels, a good indicator of glucose utilisation at the whole body level, increased significantly after
both meal tests. However, the increase observed in the control group was more important, at least 2 h
after the meal. Plasma TG levels increased also after the control and HFHS meals, but the maximum
values were different among the groups. For the control group the peak was observed 2 h after the
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meal (+355%), while for the HFHS group it was delayed up to 4 h (+281%), most likely reflecting
differences in the meal digestion and absorption. Postprandial urea plasma levels (indicative amino
acid catabolism at the whole body level) showed different patterns: while in the control group levels
steadily increased up to 151% at 4 h when compared to the fasting point, in the HFHS group no
changes were observed. While BCAA levels after the control meal slightly increased (+12%), following
the HFHS meal, their concentration was reduced up to 25% 7 h after the meal intake, suggesting their





























































































































































Figure 1. Plasma parameters in Yucatan mini-pigs fed either a control or a high fat–high sucrose
(HFHS) test meals. Results are expressed as means + SEM (n = 5) and were analysed using a repeated
measures 2-way ANOVA test. Different letters indicate significant differences between sampling points
for a given meal test. * Significant different for a given sampling point between the control and the
HFHS meals (p < 0.05). BCAA: branched-chain amino acids.
Enzyme activities involved in glucose and amino acids metabolism in PBMC (Figure 2) were
assessed in order to determine if they were affected by the meal (postprandial period) and its
composition (regular vs. HFHS). We aimed also to explore if such changes could be related to
the circulating metabolites and hormones described above. Two opposite profiles were observed:
enzymes which activity increased after the control meal, including those participating in the glucose
phosphorylation (HK, +300%), glycolysis (PK +400-600%, LDH, +150%), pentose phosphate pathway
(G6PD, +200%), and amino acid catabolism (BCAT +125%, GDH, +140%); and enzymes for which
activity was inhibited by the meal, such as those participating in amino acids metabolism, including
glutaminase (−50%) and AspAT (−50%). For all of them, the response to the meal was further
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blunted when the HFHS test was performed. MDH activity (enzyme involved in the Krebs cycle)
was not modified by the regular meal, but it was inhibited (−75% at 2 h) following the HFHS test,
suggesting that those changes were meal-specific. Finally, we also explored the insulin (Akt) and
protein synthesis (eEF2α) signalling pathways in order to evaluate the capacity of PBMC to transduce
the nutritional stimuli from the meal into intracellular information able to regulate the glucose and
protein metabolisms (Figure 3). In both cases, their phosphorylation statuses increased following the
control meal (about +200% for both proteins), but no changes were observed after the HFHS test.
3.2. Long-Term HFHS Trial
After two months of HFHS feeding minipigs developed an obesity-like phenotype, with a
significant increase in body weight (from 31.5 ± 1.4 kg to 44.7 ± 1.7 kg), most likely as the consequence
of fat deposition at the visceral and subcutaneous adipose tissue [23]. The main metabolic features
associated to this phenotype are described in Table 1. No changes were observed in glucose and lactate
levels, while TG concentrations slightly increased between day 7 and 14. Insulin levels increased
significantly from day 7 (about three times from day 0), and remained elevated up to the end of trial.
In contrast, urea plasma levels were reduced from day 7 onwards (about 1.5 times) up to day 60.
Finally, the inflammation status of minipigs was evaluated by assessing the CRP circulating levels at
the beginning and at the end of the trial. CRP levels increased significantly from 0.52 ± 0.10 up to

















































































































































































































Figure 2. Hexokinase (HK), pyruvate kinase (PK), lactate dehydrogenase (LDH), glucose 6-phosphate
dehydrogenase (G6PD), malate dehydrogenase (MDH), branched chain amino-acid transaminase
(BCAT), glutaminase P-dependent, aspartate aminotransferase (AspAT) and glutamate dehydrogenase
(GDH) alanine transaminase activities in PBMCs from Yucatan mini-pigs fed either a control or a high
fat–high sucrose (HFHS) test meals. Enzyme activity units (mU) are defined as nmol of substrate
converted to product, per min, at 37 ◦C and per mg protein. Results are expressed as means + SEM
(n = 5) and were analysed using a repeated measures two-way ANOVA test. Different letters indicate
significant differences between sampling points for a given meal test. * Significantly different for a
given sampling point between the control and the HFHS meals (p < 0.05). PMBC: peripheral blood
mononuclear cell.
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Figure 3. Phosphorylation levels of Akt Ser473 and eEF2-α Thr56 in PBMCs and S6 Ser235/236 from
Yucatan mini-pigs fed either a control or a high fat–high sucrose (HFHS) test meals. Analysis was
made by Western blot and levels of phosphorylated protein were normalized to the levels of the
respective total protein (Akt Ser473 and eEF2-α). Results are expressed as means + SEM (n = 5) and
were analysed using a repeated measures two-way ANOVA test. Different letters indicate significant
differences between sampling points for a given meal test. *Significant different for a given sampling
point between the control and the HFHS meals (p < 0.05).
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Table 1. Plasma fasting metabolites in Yucatan minipigs fed a high fat–high sucrose diet (HFHS) over
2 months.
Time (Days)
1 7 14 30 60
Glucose (mM) 3.78 ± 0.28 3.54 ± 0.11 3.42 ± 0.12 3.56 ± 0.15 3.54 ± 0.07
Lactate (mM) 0.53 ± 0.07 0.51 ± 0.03 0.49 ± 0.03 0.48 ± 0.04 0.58 ± 0.06
Triglycerides (mM) 0.19 ± 0.03a 0.35 ± 0.06b 0.33 ± 0.07b 0.21 ± 0.03a 0.32 ± 0.05ab
Insulin (ng/mL) 0.05 ± 0.03a 0.17 ± 0.04b 0.16 ± 0.04b 0.17 ± 0.05b 0.14 ± 0.03b
Urea (mM) 5.38 ± 0.43a 3.41 ± 0.32b 3.79 ± 0.15b 3.92 ± 0.31b 4.06 ± 0.31b
Results are expressed as means + SEM (n = 5) and were analysed using a one-way ANOVA test followed by post-hoc
Holm-Sidak. Different letters indicate significant differences between the sampling points (p < 0.05).
Once the metabolic phenotype of minipigs evaluated during the 2 months of HFHS feeding,
we aimed at determining if the PBMC metabolism was able to respond to the modifications induced
by the diet at the circulating level. We explored the PBMC metabolism at both, the enzyme activity
and mRNA levels, as shown in Figures 4 and 5, respectively. Overall, most of the explored enzymes
increased their activities from day 7, recovering progressively their basal levels after 2 months of
feeding. Only glutaminase and AspAT activities were reduced by the HFHS feeding (−50%), also from
day 7. The tendency was conserved up to the end of the trial. Concerning the molecular analyses,
several genes resulted up-regulated by the long-term HFHS feeding, including acox, fasn, bckdhb and
bckdk, for which levels increased progressively with time. Only dld mRNA levels increased at day 7
and remained stable up to the end of the trial. Bcat and bckdhb mRNA levels were down-regulated by
the HFHS consumption, while no changes were observed on srebpf2 levels. Finally, srebpf1 levels were
transiently reduced between day 7 and 30 (−40%) but recovered the initial levels at day 60.
The third objective of the present study was to compare PBMC metabolic potential to those of
other organs, such as the liver, the skeletal muscle and the AT. We therefore explored the metabolism
of those tissues before and 2 months after HFHS feeding. As for the PBMCs, we choose a double
approach, including biochemical (glycogen levels, enzyme activities) and molecular (mRNA levels)
targets as presented in Figures 6 and 7, as well as in Table 2, respectively. At the hepatic level,
the HFHS feeding resulted in increased glycogen levels (+24-fold), and in enzymes participating at
the gluconeogenesis (FBPase, +3-fold), lipogenesis (FAS, +5-fold), lipid oxidation (Acox, +2.5-fold)
and amino acids catabolism (GDH, +3-fold). Other enzyme activities were inhibited by the HFHS
feeding, including those participating at the glycolysis (HK, PK, about −4-fold), the pentose phosphate
pathway (G6PD, −1.8-fod), and amino acid transamination (AspAT, −1.3-fod). Except for the AspAT
activity (which was inhibited (−2-fold)), all the explored enzymes were up-regulated in the adipose
tissue, including HK (+5-fold), G6PD (+3-fold) and GDH (+2-fold). At the muscle level, glycogen
levels increased by 2-fold after 2 months of HFHS feeding, while HK, GDH, and AspAT activities
were reduced.
Concerning the mRNA levels of proteins involved in glucose, lipids and amino acids metabolism
are at the hepatic level, the general tendency was the reduction of expression induced by the HFHS
feeding including those genes involved in glucose metabolism such as hk1 (−1.5-fold) and g6pc
(−2-fold), or in lipid oxidation like cptl (−5-fold) or lipogenesis (acly; −1.3-fod). The only exception
was another gene involved in lipogenesis, fasn, which mRNA levels were dramatically (+23-fold)
increased by the HFHS diet intake. Only minor changes were observed in the skeletal muscle,
with a 50% reduction it the mRNA levels of the cptm, involved in β-oxidation. Several genes were
up-regulated by the HFHS feeding in the AT, including those participating at the glucose transport,
like slc2a4 (+6-fold), hk1 (+1.4-fold), or lipogenesis, like acly (+10-fold) and fasn (+9-fold). In contrast,
the hepatic isoform of CPT (cptl) was down-regulated (−5-fold) the HFHS feeding.
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4. Discussion
In the present study we show for the first time that the metabolism of mini-pig PBMC can be
altered at the biochemical and molecular levels and that it was closely related to the AT profile,
at least in the context of a long-term HFHS feeding. Further, we showed that the PBMC metabolism,
particularly at the biochemical level, can be modulated at the postprandial level.
4.1. PBMC Metabolism Is Highly Reactive to the Meal, But Its Response Is Blunted by the Intake of a
HFHS Meal
After meal intake, the body must adapt to the greater influx of nutrients in a very short period
of time (from minutes to a couple of hours). Although several studies have previously explored the
postprandial response of PBMC, they were focussed on transcriptomics analyses only [20,21,27]. Given
the very short-term response needed after the meal, we choose to explore the postprandial metabolism
at the biochemical and signalling levels rather than at the molecular level, which as far as we are
aware has never been done before. The objective was therefore to elucidate if PBMC metabolism
could respond in the very short-term to a nutritional stimulus and provide valuable information
about changes at the whole body metabolism and metabolic flexibility that could not be visible at
the fasting state [16,28]. In our study, PBMC metabolism was indeed highly responsive to the control
meal challenge. The glucose phosphorylation potential and further channelling through the glycolysis
was strongly increased, highlighting the importance of glucose for fuelling PBMC metabolism [29].
This was further supported by the meal-stimulated phosphorylation of Akt, a major actor on the insulin
signalling pathway. Other metabolic processes were also stimulated by the meal, as the NADPH
production to support lipogenesis or nucleotide biosynthesis through the pentose phosphate pathway.
PBMCs not only rely on glucose as energy source, as glutamine utilization in these cells can be
even greater than that of glucose [8]. In our study glutaminase activity was significantly reduced
following the meal, in line with its increased activity in lymphocytes from starved rats [29]. The fact that
the AspAT activity followed the same profile than the glutaminase, further confirms that this enzyme
rather than GDH is mainly responsible of the glutamate to α-ketoglutarate conversion in PBMCs.
However, PBMCs do not only use glutamine for energy purposes, as the production of non-essential
amino acids (such as alanine and aspartate) via the transaminases for biosynthetic purposes is of
great importance for this kind of highly proliferating cell [8]. Following the meal, when circulating
amino acid levels increase, PBMCs would rather rely on them for biosynthesis processes, reducing
the demand from transaminases and resulting in an increase in the glutamate channelling through
the GDH reaction [30], explaining the increased GDH activity in our study. Finally, the fact that the
glucose utilisation was enhanced in response to the meal, whereas glutamine utilisation was reduced,
strongly suggests that during the fasted-to-fed transition a metabolic shift allows PBMC to switch from
glutamine to glucose utilisation [31].
During the HFHS meal test, we surprisingly found that the PBMC response was often blunted
or in some cases delayed when compared to the regular test meal. The postprandial trial aimed
at challenging the metabolic response of PBMC, which has been achieved with the control meal.
By providing for the first time an HFHS meal to the same animals, our goal was to further alter the
PBMC environment in terms of composition and time-course appearance of nutrients and hormones.
Thus, the kinetics of most of the plasma parameters were altered following the HFHS meal, most likely
due to the impact of the diet on gut physiology (motility, gastric emptying) and hormone release
(CCK, PYY, GLP-1) [32]. Thus, despite a higher content of sugar than in the regular meal, the HFHS
consumption did not result in a significant postprandial increase in blood glucose levels. Accordingly,
the same lack of responsiveness was observed in the insulin signalling pathway, resulting (together
with the low glucose available) in a non-stimulated glucose utilisation, and supporting the idea that
PBMC strongly depend on circulating substrates, particularly glucose. This could explained in part
by a delayed and reduced excursion of glucose and insulin mediated by a slower gastric emptying
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and reduced gut hormone secretion, as previously observed in humans subjected to high fat diet
tests [33–35].
Unlike after the control meal, following the HFHS intake we did not longer observe the
fasting-to-fed transition between glucose and glutamine utilisation. This suggests that PBMC
metabolism has adapted to the reduced glucose levels and continue to rely on glutamine, such as
during the post-absorptive period. In contrast to other circulating metabolites, BCAA levels
following the HFHS meal showed reduced levels during the postprandial period, which resulted in
a lower transamination potential as well, likely reducing the flux of ketoacids up to the Krebs cycle.
In agreement with this, the phosphorylation status of the protein eEF2α, responsible for determine
the end of the translation and sensitive to the leucine signal role, remained unchanged after the
HFHS meal. This may represent another sign of the altered response to the meal stimulus. Another
symptom of impaired normal metabolic activity after the HFHS meal was the reduction on MDH
activity. Since MDH plays crucial roles in the malate–aspartate shuttle, essential for coupling activation
of mitochondrial and energy production [36], a decrease in MDH activities may suggest a depression
of the transfer of NADH, and less ATP production in mitochondria.
4.2. Time-Course Changes in PBMC Metabolism during Long-Term High Fat Feeding
The second goal of our study was to evaluate if the metabolism of PBMC could be modified by
a long-term nutritional change, such as HFHS feeding-induced obesity. As in our previous study
focused on tissue/organ metabolism [23], we observed in the present study that the same major
metabolic changes occurred also in PBMC after only one week of HFHS feeding. However, unlike
during the short-term stimulation (postprandial period) PBMC do not seem to rely on available
circulating metabolites during the long-term HFHS imprinting. Thus, despite the lack of changes
in post-absorptive blood glucose levels, PBMC glucose metabolism was enhanced, as previously
shown in a PBMC transcriptome-based study comparing lean vs. obese subjects [20]. It is known that
alterations in postprandial glucose kinetic precedes those at the fasting state in the insulin resistance
installation [37]. The increased glucose metabolism at the fasting state observed in the circulating
PBMC may be the result of a long-term important glucose postprandial excursions (as supported by
the hyperinsulinemia), exposing the circulating cells to elevated postprandial glucose levels. If our
results are further investigated in future studies, alterations in these enzyme activities could constitute
early events signalling the beginning of glucose alterations leading to insulin resistance, even when
fasting blood glucose levels remain unchanged.
PBMCs seem to also have very active lipid metabolism [22]. Thus, genes involved in lipid
catabolism, such as acox and ppara, were up-regulated by the long-term HFHS feeding, suggesting that
minipig PBMC metabolism adapted to the increased dietary lipids, as previously observed in PBMCs
from obese rats fed on cafeteria diets [2,38]. On the other hand, markers of lipogenesis (fasn, srebpf1)
also resulted up-regulated. A recent study showed that lipogenesis was active in PBMCs and that was
highly dependent on glucose [39], a strong activator of lipogenic genes [40]. This effect of glucose on
de novo lipid synthesis represents a common feature for lipogenic organs, such as the liver or the AT
from HFHS-fed animals [28,41,42].
As far as we are aware, the metabolism of amino acids has never been explored on PBMC from
obese animals. After two months of HFHS feeding, both glutaminase and AspAT activities resulted
rapidly (one week) down-regulated, suggesting that amino acids use for energy was reduced in
detriment of other alternative fuels like glucose and lipids [23]. BCAA related-enzyme activities and
mRNA levels were also reduced by the end of the trial, supporting the idea of a progressively reduction
of BCAA catabolism from obese minipigs. We and other have shown that in obese and insulin resistant
animal models, BCAA circulating levels increased with time [25,43]. Interestingly, the increased
transamination potential during the first weeks of HFHS feeding could be the consequence of a
metabolic adaptation to the progressively increase in BCAA levels. However, by the end of the trial,
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the potential to catabolise BCAA was blunted, in agreement with a defective oxidative deamination
observed in the adipose tissue of HFHS-fed minipigs [25].
4.3. The PBMC Metabolism Rather Resembled that of the Adipose Tissue
As explained above, PBMC metabolism is different from any other organ, as these cells are
actually permanently stimulated by changes in circulating blood metabolites and hormones. Despite
this, we demonstrated that their metabolism has many common features with several major organs of
the body. The second objective of the present study was therefore to compare PBMC response to the
long-term HFHS meal to that of the liver, skeletal muscle and the AT.
We observed that an adaptive strategy was settled at the hepatic level in order to handle the
excess of nutrients and energy brought by the HFHS diet. Thus, those pathways involved in glucose
utilisation, such as glycolysis and pentose phosphate pathway were reduced, while lipid oxidation
potential increased, illustrating a metabolic switch aiming at giving the priority to the more abundant
energy substrates available. In accordance with this, we observed that the liver increased its capacity
to store the excess of energy in the form of lipids (lipogenesis) and glycogen. Of note, the increased
FBPase activity and reduced G6Pase potential strongly suggests that the glucose produced via the
gluconeogenesis was further stored as glycogen rather than being exported into the blood stream.
Unlike the liver, the overall metabolic features observed in the skeletal muscle and the AT suggest that
both organs enhanced the uptake, utilisation, and storage of glucose. Two other catabolic features were
also different from those of the liver, including lipids and amino acids oxidation pathways, that were
reduced in the muscle and the AT. As for the liver, lipogenesis potential was strongly up-regulated in
the AT. The integrative view of the HFHS minipig physiology suggests therefore that at the whole-body
level, inflammation was settled. Despite this, the metabolism seemed flexible enough to adapt and kept
blood glucose levels into within the physiological range. This was achieved through a coordinated
increased in glucose uptake, utilisation and storage from all the explored organs in order to remove
as much as possible glucose from the blood circulation. Further, the liver and the AT increased also
their potential of other highly consuming glucose pathways, such as de novo lipogenesis. Finally,
the lipid handling seemed to be organ-dependent, as the liver increased the oxidation potential of
lipids, while the muscle and the adipose tissue showed an opposite trend.
When compared to the results discussed above, the metabolic response observed in the PBMCs in
the obese minipig at the fasting state seems to be coherent with the adaptations reported in the major
organs involved in the intermediary metabolism. As in a previous study in hamsters [44] our results
show that PBMC metabolism does not reflect that of the liver. In contrast, the metabolic profile of
PBMC evaluated at the molecular and biochemical levels was particularly close to the one observed in
the AT. This is in line with similar conclusions draws in several studies in humans [45] and laboratory
animals [16,44], specially concerning lipid metabolism [46]. In contrast to this, other metabolic features,
like pentose phosphate potential seems to have a PBMC-specific behaviour, with a strong dependence
on glucose uptake and phosphorylation and a lower induction capacity when compared to the AT.
The responsiveness of PBMCs, particularly at the biochemical level could be then potentially used to
explore the whole body metabolism in response to different dietary interventions or to evaluate the
functional metabolic status of an individual with a single blood sample.
5. Conclusions
As a whole, the evaluation of the metabolic response to a control test meal of PBMC showed
for the first time at the biochemical level that these cells were able to modify and adapt in a very
short period (often < 3 h) their metabolic activity under the influence of circulating nutrient and
hormones. Most of the changes recorded showed that PBMCs relayed glutamine metabolism during
the post-absorptive period, and that they switched to glucose when quantity of carbohydrates from
the diet increased in the circulation. Interestingly, we showed that major and fast changes in the PBMC
environment induced by the HFHS during the postprandial period were able to trigger in PBMCs
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the necessary metabolic changes to adapt to this challenge. Finally, the exploration of the PBMC
metabolism in long-term HFHS feeding confirmed that the regulation pattern observed in PBMCs fits
with that expected in tissues involved in energy balance. It would be therefore reasonable to use them
to evaluate whole-body metabolism without the need to perform invasive organs biopsies, as they can
act as metabolic sentinels of nutritional-related changes. The common features observed between the
PBMC and AT metabolism in HFHS minipigs make these cells particularly attractive for exploring
metabolism and looking for biomarkers of dysregulation in obesity-related conditions.
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Abstract: A dysregulation of nutrient exchange between tissues (gut, liver, muscles, adipose) occurs
during overnutrition and could induce obesity and metabolic diseases. We aimed to evaluate how,
in overfed mini pigs, nutrients use and partition were regulated in the gut and liver. Net nutrients
fluxes were assessed in the fed (PP) and post absorptive (PA) states at 1, 14 and 60 days of adaptation
to overfeeding in five adult Yucatan female multicatheterized minipigs. Pigs PA glycaemia and
PP-induced hyperglycemia remained unchanged over the experimental period, suggesting that the
management of the excess of energy intake allowed the maintenance of glucose levels. This was
associated with (1) an increased PA plasma insulin, (2) an increased gut lactate production (increased
lactate net release +89%, 1 h PP, D1 vs. D60) probably from an increased glucose oxidation, (3) a
shift in utilization of gluconeogenic precursor (lactate, propionate) in the liver, and (4) a reduced gut
utilization of nitrogen moieties for energy purposes (glutamine), a nitrogen sparing effect at the whole
body level (decreased plasma urea in PA (−24% D1 vs. D60) and PP states) and a specific increased
level of AA involved in lipids handling and bile recycling in the gut lumen (taurine and glycine).
Keywords: liver; gut; obesity; amino acid; glucose; lactate; nutrient flux; short chain fatty acid; minipig
1. Introduction
Prevalence of overweight and obesity has increased dramatically over the last 35 years, as well as
the associated chronic diseases (diabetes, cardiovascular diseases, cancers) [1]. Obesity results from an
imbalance between energy supply and expenditure due to increased food intake and reduced physical
activity. This imbalance, when occurring over a long period of time, induces metabolic dysregulations
leading firstly to metabolic adaptations capable to maintain normal homeostatic state and later to the
development of metabolic disturbances such as low grade inflammation [2], insulin resistance [3] and,
ultimately, pathologies. These late perturbations occur when tissues and organs are no longer capable
to deal with the nutrient oversupply and maintain homeostasis compatible with a healthy status.
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The most deleterious effects of over-nutrition on tissues and organs are observed on liver
(development of non-alcoholic fatty liver disease) [4], subcutaneous and visceral adipose tissues [5],
muscle [6], inflammatory cells [7], etc. An altered gut profile of bacteria species [8] and richness [9]
have also been demonstrated in obese or overfed or diabetic humans and animals, which explains the
increasing interest on the impact of the gut (and its tightly connected microbiota) on the development
of insulin resistance and associated pathologies. Consequently, the gut-liver axis has recently regained
increasing interest [10]. Interestingly, it has been shown that the splanchnic area (and particularly
the liver) was metabolically disturbed early (i.e., within the first days) in streptozotocin treated
rats [11,12]. These disturbances at the splanchnic level occur before dysfunctions of peripheral tissues
are demonstrated. However, the interaction between gut and liver, although considered to be one of
the keys in the development of hepatic and whole body obesity-related pathologies [13–15], has been
relatively scarcely studied due to a lack of access to metabolites/factors present the portal vein which
is the only vascular link from the gut to the liver. In addition, the investigation of the gut-liver axis is
complex due to the combination of various metabolically intertwined tissues and organs in this area
(microbiota, gut, liver, visceral adipose tissues). On the top of this, the investigation of the adaptation
mechanisms stimulated to deal with excess of nutrients is also complex because gut and liver, but also
nutrients and metabolites are at the crossroad of various metabolic pathways leading to a competition
between tissues for metabolites utilization [14,16,17].
Consequently, from this analysis of the data obtained so far in the field, we focused on the
investigation of (1) the gut-liver nutrients utilization within the first steps of obesity/IR development
in a situation of overfeeding and (2) the major routes of exchange of nutrients between gut, liver,
and the periphery during obesity development. This approach will help to decipher what the gut
actually releases (as nutrients and signals) to the liver, what is taken up/released to the liver, and
what is finally available to peripheral tissues in the early phases of adaptation to overfeeding and
obesity development.
To address the point concerning the early steps of obesity development, we have recently
investigated the whole body and tissues metabolic adaptations by analyzing genes expressions
and activities of enzymes (in the fed state) involved in the major metabolic pathways of nutrients
utilization/synthesis in gut, liver, and adipose and muscle tissues in Yucatan mini pigs overfed for two
months with a high fat, high sucrose diet [18–20]. We have confirmed specific inter-organ metabolic
adaptations developed by the pigs to handle the sudden and massive dietary supply of nutrients and
we have shown the development of an obese phenotype (rapid weight gain, increased cholesterol,
and insulin plasma levels in the fasted state), as well as a reduced potential to phosphorylate glucose,
a decreased capacity for de novo lipogenesis and an increased arterial insulin and branched chain
plasma amino acids. The present work aims at investigating the adaptive dynamics of the net fluxes of
energy and nitrogenous nutrients (i.e., the consequence of the genes regulation) between tissues in
the splanchnic area both in the fasted and the fed states. The main objective is to understand how the
gut and the liver net uptake and release of major nutrients/metabolites in a situation of overfeeding
affects nutrients available to peripheral tissues.
To address this issue, multicatheterized (in artery, portal vein, and hepatic vein) Yucatan minipigs
were overfed for a period of two months as previously published [18,19]. Net fluxes of energy and
nitrogenous metabolites were measured across the gut and the liver in the fasted and fed states over
the several weeks of overfeeding.
2. Materials and Methods
2.1. Animals and Experimental Procedure
The study involved five female adult Yucatan mini-pigs (30 ± 1 kg). Three weeks before the
experimentation, the mini-pigs were surgically fitted with permanent catheters (polyvinyl chloride;
1.1 mm i.d., 1.9 mm o.d.) in the abdominal aorta, the portal vein, and the sus hepatic vein for blood
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sampling and in mesenteric vein for infusions. The animals were housed in subject pens (1 × 1.5 m) in
a ventilated room with controlled temperature (21 ◦C) and regular light cycle (L12:D12). They were fed
once daily with 400 g/d of a concentrate feed containing 17.5% protein, 3.2% fat, 4.3% cellulose, and
5.2% ash (Porcyprima; Sanders Centre Auvergne, Aigueperse, France) and had free access to tap water.
Catheters were flushed and filled with a saline solution containing heparin (1/10) three times a week
over the experimental period to avoid the formation of blood clots in the catheters. All procedures were
in accordance with the guidelines formulated by the European Community for the use of experimental
animals (L358-86/609/EEC, Council Directive, 1986; authorization 02090.01).
At least two weeks after surgery, the mini-pigs were fed a High Fat High Sugar (HFHS) diet
consisting in a regular pig diet enriched with fat (13% palm oil) and sugar (10% sucrose) (1 kg/day,
13.3 kJ/day) for two months. Lipids represent 27% of energy supply in the diet. This diet was
offered in two meals (500g each meal) at 8:00 am and 16:00 pm. Over the entire experimental period,
the animals ingested their meal in no more than 10 min and no refusal was observed. Samplings
were performed on D1 (1st day of HFHS exposure), D14 and D60. After an overnight fast, blood
samples were simultaneously withdrawn from the aorta, the portal vein and the sus-hepatic vein
on heparinized or EDTA treated tubes, before the meal, 30, 60, 120, 180, 240, 330, 420 and 510 min
post-meal ingestion. Blood was centrifuged at 4500 × g for 10 min, plasma rapidly collected and stored
at −80 ◦C until further analyses. Body weight was determined weekly.
For measurement of plasma flow, a solution of 0.185 M of sodium p-aminohippurate (PAH)
(pH 7.4) was infused in the mesenteric vein at a rate of 12 mL/h. The infusion started 1 h before
feeding and lasted over the entire post prandial sampling period. The plasma flows in each vessel was
calculated according to the Fick principle [21].
After the two-month experimental period, the mini-pigs were euthanized after an overnight
fast by intravenous administration of Dolethal® (pentobarbitone sodium 200 mg/L, Vetoquinol®,
Magny-Vernois, France).
2.2. Analytical Procedures
Glucose, lactate, urea, triacylglycerol (TG), High Density Lipoprotein (HDL)-cholesterol, Low
Density Lipoprotein (LDL)-cholesterol, total cholesterol, albumin, aspartate aminotransferase (AST),
alanine aminotransferase (ALT), and fructosamine concentrations were enzymatically measured using
commercial kits on an automotive ABX Pentra 400 (Horiba Medical, Montpellier, France) test system.
Plasma insulin levels were assayed using a commercial ELISA kit (Mercodia, Uppsala, Sweden).
Data at D1 and D60 for glucose, urea, triacylglycerol (TG), HDL-cholesterol, LDL-cholesterol, total
cholesterol, and insulin in artery have already been published [18]. Data for these parameters at D14
have been added to evaluate the short-term vs. longer term kinetics of adaptation to overfeeding.
For amino acid measurements, detailed procedures are described elsewhere [22]. In brief, plasma
samples were deproteinised with sulphosalicylic acid after adding norleucine as an internal standard.
The supernatant was diluted (2/3) with a lithium injection buffer containing glucosaminic acid as
an injection standard and amino acids concentrations were determined with an amino acid analyzer
(Hitachi L8900, Sciencetec, Villebon/Yvette, France) by ion exchange chromatography with postcolumn
derivatisation with ninhydrine.
PAH concentration in plasma was measured according to [23], 250 μL of plasma samples were
deproteinized with sulphosalicylic acid acid, thoroughly mixed and centrifuged at 10,000× g, 4 ◦C,
for 15 min. 80 μL of the supernanant was deacetylated by adding 20 μL of 5 M HCL, followed by an
incubation at 90 ◦C for 1 h [24]. Sodium nitrite (625 mg/L) was then added manually. The samples were
then inserted into the automotive ABX Pentra 400 (Horiba Medical, Montpellier, France) which added
successively ammonium sulfamate (0.64 g/L) and N-(1-Naphtyl) ethylenediamine dihydrochloride
(1 mg/mL). Concentrations were determined by comparison with PAH standard and read out at
600 nm.
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Short chain fatty acids (SCFA) in plasma were measured using 1-(tert-butyldimethylsilyl)
imidazole (MTBSTFA) derivatization and analysis by gas chromatography (GC) according to [25].
Shortly, to 500 μL of plasma was added 50 μL of a mixture of 13C labelled 1-13C-acetate (4 mM),
1-13C-propionate (1.5 mM), 1-13C-butyrate (0.6 mM) (Cortecnec, Voisins Le Bretonneux, France), and
10 μL of 37% (v/v) HCL solution. A total of 2 mL of diethyl ether was added to plasma and the mixture
was centrifuged (10 min, 2000 rpm). A total of 50 μL of MTBSTFA (Tokyo Chemical Industry, Tokyo,
Japan) was added to supernatant for SCFA derivatization. The mixture was injected in GC–MS system
7890A (Agilent Technologies California, USA) using the splitless mode equipped with a quadrupole
detector (5975C) and autoinjector (7683). The ionisation mode was operated in electron impact (electron
energy 70 eV). The GC system was fitted with a nonpolar capillary column DB-5 MS (J&W Scientific,
Folsom, CA, USA, 30 m × 0.25 mm i.d. × 0.25 μm film thickness) for chromatographic separation.
Quantification of the SCFA was performed using the Selected Ion Monitoring acquisition Mode by
measurement of the m/z ratios of the specific 13C and 12C ions of each quantified SCFA and comparison
to a standard curve: 117/118 (12C acetate/1-13C-acétate), 131/132 (12C propionate/1-13C-propionate),
145/146 (12C butyrate/1-13C-butyrate). SCFA content in the feces was determined by NMR following
a water extraction of feces samples.
2.3. Calculations
The HOMA2-IR (Homeostasis Model Assessment 2, Insulin-Resistance) was calculated from
arterial insulin and glucose levels by the program HOMA Calculator v2.2.3 (The Oxford Centre for
Diabetes, Endocrinology and Metabolism. Diabetes Trials Unit, Oxford University, Oxford, United
Kingdom; http://www.dtu.ox.ac.uk/ToolsSoftware/).
Net nutrient fluxes through the gut (viscera drained by the portal vein), the liver and total
splanchnic tissues (gut + liver) were calculated as described by Katz et al. [21]. The net nutrient fluxes
were calculated as differences between the efferent flux and the afferent flux. Consequently, a positive
net flux indicates a net release whereas a negative net flux indicates a net uptake.
Metabolite (MET) net flux across the portal-drained viscera was calculated as follows:
([MET]PV-[MET]A) × PFPV where PFPV is the portal plasma flow and [MET]PV,A the plasma
concentrations of the metabolite in the portal vein and the aorta, respectively. The net hepatic
flux of metabolites was calculated as follows: ([MET]HV × PFHV − ([MET]PV × PFPV + [MET]A
× PFAH) where [MET]HV, PV and A are the plasma concentrations of the metabolite in the hepatic
vein, portal vein and aorta, respectively and PF HV, PV and A are the plasma flows in the hepatic
vein, portal vein and artery, respectively. Lastly, the net flux of AA and urea across overall
splanchnic tissues was calculated as follows: ([MET]HV-[MET]A) × PFHV where PFHV is the plasma
flow in the hepatic vein and [MET]HV and A, the metabolite concentrations in the hepatic vein and
artery. Indispensable amino acids (IAA) included histidine, isoleucine, leucine, lysine, methionine,
phenylalanine, threonine, tryptophane, and valine; non-indispensable amino acids (NIAA) included
alanine, glutamate, glutamine, glycine, serine, tyrosine, cysteine, citrulline, ornithine, arginine, proline,
3-methylhistidine; and branched-chain amino acids (BCAA) included isoleucine, leucine, and valine.
Total amino acids (TAA) were the sum of IAA and NIAA.
2.4. Statistics
All data are expressed as means ± SEM. Comparisons of data between D0, D14, and D60 in
the fasted state were performed using a one way repeated measures ANOVA (SigmaPlot 12, Systat
software, San Jose, CA, USA) followed by a post hoc analysis using the Holm Sidak test. Comparison
of data between D1, D14, and D60 (adaptation to the diet) and between hours post test meal ingestion
in the fed state (t0 (fasted), t30, t60, t120, t180, t240, t330, t420, t510 min post meal ingestion) were
performed using a two way repeated measures ANOVA and followed by post hoc analysis using
the Holm Sidak test. Differences were considered significant if p < 0.05 and as a tendency (t) for
0.05 < p < 0.1.
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3. Results
3.1. Overfeeding, Impact on Pigs’ Weight, Insulin Levels, Alteration of Energy Nutrients Concentrations and
Net Splanchnic Uptake in the Fasted and Fed States: Data Presented in Tables 1–5 and Figure 6 (for Insulin)
3.1.1. Energy Nutrients
Overfeeding led to a 43% increase of pigs’ weight over the 60 days of the experimental period
(p < 0.05). At the plasma level and as already observed in a similar model of overfed animals [18],
lactate, total plasma cholesterol, HDL cholesterol, and LDL cholesterol were significantly (p < 0.05) or
tended to be increased over the experimental period (+54%, +44%, +58%, D60 vs. D1 for lactate, total
and HDL cholesterol, respectively; +34% D14 vs. D1 for LDL cholesterol) whereas no effect on glucose,
triglycerides, albumin, alanine aminotransferase, and aspartate aminotransferase was observed in
the fasted state at D14 and D60 relatively to D1 (Table 1). The stable glucose arterial levels observed
between D1 and D60, suggests that animals were still capable to maintain their glycaemia although
glucose content in the diet (supplied as saccharose or starch) and net plasma gut release of glucose is
higher at D60 vs. D14 and D1 in the fasted state after adaptation to overfeeding (4.9× between D1 and
D60, p = 0.06, Table 4). This active glucose utilization by the liver (net splanchnic release in the fasted
state not significantly altered between D1, D14 and D60, Table 4) can be associated with the increased
insulin levels (p < 0.05), as well as HOMA index (Figure 6) in the artery at D14 and D60.
Table 1. Animals’ weight, arterial concentration in the fasted state of glucose, lactate, urea,
triglycerides, total cholesterol, Low Density Lipoprotein (LDL)-cholesterol, High Density Lipoprotein
(HDL)-cholesterol, albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST) before
(D1) and after 14 days (D14) and 60 days (D60) of adaptation to High Fat High Sugar (HFHS) diet.
Average plasma flow in portal vein (PV), hepatic vein (HV), and hepatic artery (HA) from 0 to 8.5 h
post meal ingestion before (D1) and after 14 days (D14) and 60 days (D60) of adaptation to HFHS diet.
Parameter Vessel D1 D14 D60 ANOVA
Pig’s weight 31.52 ± 1.49 a 35.70 ± 1.51 b 45.16 ± 1.56 c <0.001
Kg
Glucose A 5.20 ± 0.35 5.46 ± 0.29 5.26 ± 0.11 0.85
mmol/L
Lactate A 0.55 ± 0.05 a 0.86 ± 0.94 b 0.85 ± 0.05 b(t) 0.03
mmol/L
Urea A 5.34 ± 0.43 a 3.83 ± 0.31 b 4.04 ± 0.31 b(t) 0.03
mmol/L
Triglycerides A 0.19 ± 0.01 0.25 ± 0.04 0.24 ± 0.05 0.15
mmol/L
Total A 1.76 ± 0.10 a 2.79 ± 0.09 b 2.53 ± 0.16 b <0.001
Cholesterol
mmol/L
LDL A 0.97 ± 0.03 a 1.30 ± 0.02 b 1.00 ± 0.08 a <0.001
Cholesterol
mmol/L
HDL A 0.67 ± 0.03 a 1.28 ± 0.09 b 1.06 ± 0.08 c <0.001
Cholesterol
mmol/L
Albumin A 536 ± 20 544 ± 14 537 ± 17 0.70
μmol/L
ALT A 29.7 ± 0.8 27.1 ± 1.8 25.4 ± 1.7 0.15
U/L
AST A 36.2 ± 4.2 37.9 ± 5.2 28.8 ± 2.3 0.36
U/L
Plasma flow PV 0.60 ± 0.05 0.69 ± 0.05 0.66 ± 0.03 0.37
L/min
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Table 1. Cont.
Parameter Vessel D1 D14 D60 ANOVA
Plasma flow HV 0.78 ± 0.03 0.82 ± 0.08 0.84 ± 0.01 0.80
L/min
Plasma flow HA 0.17 ± 0.02 0.13 ± 0.03 0.18 ± 0.03 0.34
L/min
Part of the data (D1 and D60) for glucose, lactate, triglycerides, cholesterol, and urea are published elsewhere [18].
Values are means ± SEM; for details on the statistical treatment of the data see Materials and Methods.
Lactate levels were severely altered in the fasted state, as previously shown in a study in a similar
model [18]: arterial, portal and hepatic vein concentrations increased significantly at D14 and D60
vs. D1 (+34% and +89% at D60 vs. D1 in the portal and hepatic vein, respectively, p < 0.05, data not
shown). Only an increased net hepatic lactate release between D1 and D60 was observed (p = 0.03)
(Table 4).
Fasting arterial short chain fatty acids levels (acetate + propionate + butyrate: C2 + C3 + C4)
were increased (+37%, D1 vs. D60, p < 0.05), essentially due to an increased acetate level (+38%, D1
vs. D60, p < 0.05), which is the only major SCFA significantly altered at the arterial level (Table 2).
Minor SCFA (isobutyrate and isovalerate) were also significantly modified over the experimental
period: their concentration decreased between D1 and D14 and significantly re-increased between
D14 and D60 (+32% for isobutyrate and +25% for isovalerate between D14 and D60) (Table 2). Except
for fasting propionate in the hepatic vein that tend to be increased at D60 (+23% D60 vs. D1 p = 0.06,
Table 2), the SCFA levels in the hepatic vein are not significantly modified. However, they tended to be
increased in the portal vein (+18%, D60 vs. D1 for C2 + C3 + C4, p = 0.09, Table 2). Concerning the net
overall splanchnic release of SCFA (Table 4), it was not modified by overfeeding even if the net gut
release of butyrate (+43%, D60 vs. D1, p = 0.05) and to a lesser extend propionate (+33%, D60 vs. D1,
p = 0.09) increased over the experimental period. Quantitatively, it also should be noted that except for
acetate, the net splanchnic release represents only a small percentage of what is released by the gut:
3%, 27%, 7%, 11% at D1 for propionate, butyrate, isobutyrate and isovalerate, respectively, implying
an important utilization of these molecules by the liver, whatever the diet (Table 4).
Table 2. Acetate (C2), propionate (C3), butyrate (C4), isobutyrate, isovalerate and C2+C3+C4
concentrations in the fasted state in artery (A), portal vein (PV), and hepatic vein (HV) before (D1) and
after 14 days (D14) and 60 days (D60) of adaptation to HFHS diet.
Metabolite Vessel D1 D14 D60 ANOVA
Acetate (C2) A 552.3 ± 14.5 a 572.1 ± 34.6 a 761.8 ± 50.0 b 0.02
μmol/L PV 844.8 ± 53.8 897.0 ± 54.7 1000.2 ± 25.5 0.07
HV 744.5 ± 53.1 861.3 ± 81.2 896.2 ± 41.0 0.33
Propionate (C3) A 22.7 ± 0.5 26.8 ± 4.4 27.1 ± 4.4 0.50
μmol/L PV 199.8 ± 22.6 232.0 ± 30.2 229.5 ± 16.7 0.50
HV 26.1 ± 1.2 a 28.0 ± 2.7 ab 32.0 ± 4.4 b(t) 0.05
Butyrate (C4) A 2.0 ± 0.6 5.0 ± 1.4 2.8 ± 1.1 0.30
μmol/L PV 63.0 ± 6.7 80.7 ± 11.1 81.0 ± 4.3 0.09
HV 14.4 ± 1.7 19.9 ± 6.5 15.4 ± 2.1 0.62
Isobutyrate A 2.3 ± 0.1 ab 1.9 ± 0.19 b 2.5 ± 0.2 a 0.03
μmol/L PV 15.3 ± 2.1 a 11.1 ± 1.2 b(t) 12.8 ± 0.2 ab 0.08
HV 3.0 ± 0.2 1.8 ± 0.6 2.8 ± 0.3 0.20
Isovalerate A 1.8 ± 0.1 a 1.6 ± 0.1 b 2.0 ± 0.1 c 0.002
μmol/L PV 8.7 ± 1.4 7.0 ± 0.6 8.3 ± 0.2 0.12
HV 2.3 ± 0.3 2.5 ± 0.5 2.6 ± 0.2 0.37
C2+C3+C4 A 577 ± 17 a 603 ± 40 a 792 ± 55 b 0.02
μmol/L PV 1108 ± 81 1210 ± 91 1311 ± 32 0.09
HV 851 ± 50 909 ± 88 944 ± 37 0.46
Values are means ± SEM; for details on the statistical treatment of the data see Materials and Methods.
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3.1.2. Nitrogenous Nutrients
Urea levels were strongly decreased in the fasted state in all blood vessels at D14 (−39%, −26%
and −27% at D14 vs. D0 in artery, portal vein and hepatic vein respectively, p < 0.05), and to a
lesser extent at D60 (Table 1). The small differences in concentrations between vessels did not allow
us to determine significant variations in net gut or hepatic uptake/release of urea throughout the
experimental period (Table 4) although sites or urea recycling and synthesis are mainly located at the
splanchnic level. Arterial BCAA, and particularly leucine levels, were significantly increased between
D1 and D60 (+14% and +18% for BCAA and leucine, respectively, Table 3), as already shown in a
previous paper, using other methodologies for assessment of total BCAA levels [19]. Other AA, such
as tryptophan, tended to increase (+28% D60 vs. D1, p = 0.09) as well as non-indispensable AA, such
as glycine (+26%, D60 vs. D1, p = 0.01), proline (+76%, D60 vs. D1, p = 0.003), and serine (+24%, D60 vs.
D1, p = 0.09) (Table 3). Taken together, arterial NIAA and TAA (but not IAA) were increased at D60 vs.
D1 (+26% and +17% for arterial NIAA and TAA, p = 0.03 and p = 0.07, respectively). On the contrary,
methionine, and to a lesser extent phenylalanine, decreased over the same period (−28% (p = 0.02)
and −17% (p = 0.06) between D1 and D14 for methionine and phenylalanine respectively). Except for
methionine and phenylalanine, the significant increased arterial concentration observed for leucine,
isoleucine, valine, tryptophane, glycine, serine, proline, NIAA, and TAA was (or tended to be) present
also in the portal and hepatic veins (Table 3).
Table 3. Amino acids concentrations (μmol/L) in the fasted state in artery (A), portal vein (PV) and
hepatic vein (HV) before (D1) and after 14 days (D14) and 60 days (D60) of adaptation to HFHS diet.
Metabolite Vessel D1 D14 D60 ANOVA
Leucine A 145.2 ± 8.3 a 146.9 ± 5.8 a 172.0 ± 9.6 b 0.03
μmol/L PV 149.0 ± 10.5 a 151.1 ± 7.3 a 204.0 ± 7.2 b 0.01
HV 150.2 ± 8.9 a 161.0 ± 9.8 a 190.8 ± 12.5 b(t) 0.06
Isoleucine A 102.9 ± 8.0 a 126.3 ± 2.6 b 120.8 ± 2.2 b(t) 0.03
μmol/L PV 103.8 ± 10.7 a 127.4 ± 2.5 ab 139.3 ± 5.6 b(t) 0.06
HV 104.2 ± 9.5 a 137.8 ± 7.5 b(t) 134.0 ± 7.0 b(t) 0.05
Valine A 275.2 ± 14.5 a 276.7 ± 12.0 a 302.8 ± 16.9 b(t) 0.06
μmol/L PV 276.0 ± 15.0 a 275.8 ± 11.8 a 336.5 ± 5.2 b 0.02
HV 279.8 ± 14.4 a 285.3 ± 10.0 a 323.4 ± 16.5 b(t) 0.06
Lysine A 139.5 ± 14.4 157.7 ± 18.5 166.4 ± 5.0 0.37
μmol/L PV 143.4 ± 18.5 164.2 ± 12.3 193.5 ± 10.0 0.24
HV 134.0 ± 15.7 167.8 ± 9.8 171.8 ± 9.9 0.08
Phenylalanine A 56.8 ± 2.1 a 47.2 ± 2.0 b(t) 53.0 ± 2.0 ab 0.06
μmol/L PV 58.8 ± 3.3 52.4 ± 3.7 66.0 ± 2.8 0.12
HV 54.4 ± 2.8 51.0 ± 3.0 53.2 ± 1.8 0.68
Methionine A 26.4 ± 2.3 a 19.0 ± 0.8 b 19.0 ± 0.4 b 0.02
μmol/L PV 26.0 ± 3.1 19.8 ± 0.9 22.8 ± 1.0 0.25
HV 22.2 ± 2.2 21.0 ± 1.5 19.8 ± 0.9 0.65
Threonine A 132.8 ± 13.2 123.2 ± 7.8 135.3 ± 4.9 0.43
μmol/L PV 129.8 ± 12.2 123.6 ± 5.3 151.3 ± 6.9 0.25
HV 129.4 ± 9.4 123.0 ± 5.4 130.8 ± 6.6 0.97
Tryptophane A 28.0 ± 2.0 a 30.8 ± 1.4 a 35.8 ± 1.9 b(t) 0.09
μmol/L PV 27.8 ± 2.2 a 27.6 ± 1.4 a 36.0 ± 2.8 b(t) 0.07
HV 27.0 ± 2.0 a 35.5 ± 1.0 b(t) 32.2 ± 2.7 ab 0.05
Histidine A 74.0 ± 4.2 69.4 ± 2.5 76.3 ± 1.4 0.34
μmol/L PV 75.0 ± 5.9 72.0 ± 2.2 84.8 ± 1.4 0.28
HV 71.0 ± 5.2 70.5 ± 1.0 78.0 ± 2.0 0.39
Alanine A 202.8 ± 31.5 216.4 ± 24.4 222.3 ± 19.6 0.93
μmol/L PV 233.0 ± 42.7 268.8 ± 26.4 286.0 ± 19.1 0.68
HV 158.0 ± 32.2 224.3 ± 21.5 215.4 ± 12.2 0.20
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Table 3. Cont.
Metabolite Vessel D1 D14 D60 ANOVA
Glutamate A 129.6 ± 15.4 156.8 ± 12.3 140.8 ± 15.7 0.48
μmol/L PV 120.2 ± 16.9 130.4 ± 9.5 131.0 ± 19.3 0.90
HV 280.8 ± 44.0 279.8 ± 53.2 357.4 ± 42.2 0.41
Glutamine A 244.5 ± 13.8 215.3 ± 24.2 213.5 ± 16.2 0.46
μmol/L PV 200.4 ± 12.6 179.4 ± 12.4 183.3 ± 15.6 0.50
HV 196.4 ± 11.7 190.3 ± 9.9 181.3 ± 15.3 0.75
Glycine A 624.4 ± 72.2 a 864.6 ± 51.9 b 785.3 ± 39.2 b 0.01
μmol/L PV 650.2 ± 84.0 a 977.2 ± 59.5 953.3 ± 19.5 0.007
HV 620.0 ± 78.2 a 894.3 ± 57.3 b 824.0 ± 41.5 0.001
Serine A 133.8 ± 7.2 a 149.8 ± 4.3 ab 165.8 ± 15.4 b(t) 0.09
μmol/L PV 130.4 ± 10.8 a 152.6 ± 5.7 b(t) 182.8 ± 13.0 c 0.009
HV 132.4 ± 11.1 156.5 ± 10.6 158.4 ± 11.5 0.11
Tyrosine A 66.4 ± 7.7 62.0 ± 7.5 76.5 ± 12.2 0.28
μmol/L PV 66.4 ± 7.0 a 66.2 ± 9.3 ab 79.0 ± 14.2 b(t) 0.09
HV 60.0 ± 7.2 69.3 ± 12.0 68.2 ± 9.0 0.17
Cystine A 24.4 ± 2.6 22.2 ± 2.1 26.0 ± 0.9 0.66
μmol/L PV 26.0 ± 3.8 25.2 ± 1.2 29.5 ± 0.5 0.74
HV 27.0 ± 3.3 23.0 ± 0.9 24.4 ± 2.3 0.75
Citrulline A 69.6 ± 5.9 77.4 ± 4.9 70.0 ± 4.3 0.38
μmol/L PV 86.2 ± 8.3 92.8 ± 4.7 97.5 ± 5.3 0.52
HV 78.6 ± 6.6 92.3 ± 6.4 89.8 ± 5.1 0.13
Ornithine A 54.6 ± 4.7 a 76.2 ± 7.6 b(t) 68.0 ± 4.3 ab 0.06
μmol/L PV 61.8 ± 6.3 83.2 ± 8.9 77.8 ± 5.1 0.17
HV 59.6 ± 6.1 a 86.5 ± 6.1 b 75.6 ± 4.2 ab 0.04
Arginine A 87.8 ± 6.0 87.4 ± 9.2 100.8 ± 4.6 0.60
μmol/L PV 86.0 ± 12.0 93.4 ± 8.7 114.5 ± 4.5 0.32
HV 80.6 ± 9.4 98.8 ± 7.0 102.0 ± 4.2 0.20
Taurine A 72.7 ± 2.3 75.1 ± 4.5 73.8 ± 2.4 0.85
μmol/L PV 76.3 ± 2.7 76.0 ± 4.3 74.0 ± 4.8 0.81
HV 77.1 ± 3.0 80.7 ± 5.6 74.8 ± 3.8 0.78
Proline A 215.8 ± 33.3 a 379.2 ± 10.7 b 379.0 ± 9.8 b 0.003
μmol/L PV 208.4 ± 26.5 a 381.4 ± 6.6 b 379.3 ± 40.6 b 0.006
HV 229.8 ± 35.7 a 394.8 ± 15.5 b 402.6 ± 7.7 b 0.002
3-methyl histidine A 24.2 ± 0.6 ab 21.2 ± 2.5 a 28.5 ± 2.2 b(t) 0.09
μmol/L PV 24.2 ± 0.8 24.2 ± 1.2 25.3 ± 5.0 0.99
HV 26.0 ± 2.2 22.0 ± 2.4 29.6 ± 2.1 0.13
Carnosine A 16.8 ± 1.9 20.2 ± 2.3 18.5 ± 2.2 0.17
μmol/L PV 17.8 ± 2.2 19.4 ± 1.5 18.0 ± 1.2 0.72
HV 20.6 ± 2.1 22.0 ± 2.9 20.4 ± 2.2 0.98
BCAA A 523.3 ± 29.2 a 549.8 ± 19.4 ab 595.6 ± 28.5 b(t) 0.07
μmol/L PV 528.8 ± 35.3 a 554.3 ± 20.0 a 679.8 ± 16.2 b 0.03
HV 534.2 ± 31.6 a 581.0 ± 24.3 ab 648.2 ± 35.0 b(t) 0.06
IAA A 985.9 ± 57.8 997.1 ± 41.8 1081.2 ± 32.9 0.22
μmol/L PV 989.6 ± 73.7 1009.9 ± 43.85 1234.0 ± 33.4 0.09
HV 972 ± 58.8 1044.5 ± 38.6 1107.8 ± 48.9 0.19
NIAA A 1877.9 ± 102.3 a 2330.3 ± 120.7 b 2276.2 ± 14.3 b(t) 0.03
μmol/L PV 1873.2 ± 145.9 a 2474.8 ± 123.8 b 2539.1 ± 85.7 b 0.01
HV 1929.2 ± 165.4 a 2530.5 ± 132.7 b 2528.7 ± 95.3 b 0.01
TAA A 2742.4 ± 147.0 a 3198.4 ± 157.4 a 3210.9 ± 44.8 b(t) 0.07
μmol/L PV 2771.0 ± 205.9 a 3352.3 ± 161.7 b(t) 3609.0 ± 88.2 b (t) 0.04
HV 2789.8 ± 207.2 a 3440.7 ± 160.5 b 3498.7 ± 139.7 b 0.03
Branched chain amino acids (BCAA): leucine + isoleucine + valine; Indispensable amino acids (IAA): leucine +
isoleucine + valine + lysine + phenylalanine + methionine + threonine + histidine + tryptophane; Non indispensable
amino acids (NIAA): alanine + glutamate + glutamine + glycine + tyrosine + citrulline + cystine + 3 methyl-histidine
+ ornithine + arginine + proline + serine; Total amino acids (TAA): NIAA + IAA. Values are means ± SEM; for
details on the statistical treatment of the data see Materials and Methods.
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Table 4. Net gut, liver and splanchnic (gut + liver) fluxes of acetate (C2), propionate (C3), butyrate (C4),
isobutyrate, isovalerate and C2+C3+C4 in the fasted state before (D1), 14 days (D14) and 60 days (D60)
of adaptation to the HFHS diet.
Metabolite D1 D14 D60 ANOVA
Glucose Gut 6.84 ± 6.67 a 22.45 ± 6.31 a 33.41 ± 5.78 b(t) 0.05
mmol/h Liver 29.78 ± 7.32 31.60 ± 2.65 36.31 ± 11.17 0.51
Splanchnic 34.72 ± 12.18 50.81 ± 10.23 59.54 ± 15.16 0.56
Lactate Gut 4.85 ± 1.49 1.45 ± 1.14 2.04 ± 0.73 0.17
mmol/h Liver −1.78 ± 3.08 a 2.90 ± 4.15 a 8.53 ± 0.63 b 0.03
Splanchnic 2.85 ± 2.36 3.63 ± 4.36 10.57 ± 0.77 0.09
Urea Gut 1.78 ± 0.89 5.74 ± 1.92 2.24 ± 3.49 0.47
mmol/h Liver 7.11 ± 2.45 3.36 ± 1.47 6.60 ± 2.57 0.49
Splanchnic 7.10 ± 1.55 9.69 ± 0.94 9.31 ± 2.29 0.32
Acetate Gut 10,645 ± 1736 12,921 ± 1738 8717 ± 1563 0.47
μmol/h Liver −722 ± 2416 689 ± 1607 −418 ± 1205 0.42
Splanchnic 9984 ± 1916 14,635 ± 3153 8299 ± 2739 0.26
Propionate Gut 6193 ± 688 8210 ± 1038 8227 ± 664 0.09
μmol/h Liver −6447 ± 817 −8822 ± 622 −8191 ± 1205 0.11
Splanchnic 164 ± 55 252 ± 119 35 ± 130 0.57
Butyrate Gut 2176 ± 296 a 3048 ± 295 b(t) 3121 ± 189 b(t) 0.05
μmol/h Liver −1583 ± 357 −2362 ± 280 −2515 ± 187 0.23
Splanchnic 581 ± 84 747 ± 216 607 ± 122 0.79
Isobutyrate Gut 465 ± 86 375 ± 46 414 ± 29 0.37
μmol/h Liver −428 ± 99 −386 ± 32 −409 ± 27 0.64
Splanchnic 31 ± 16 4 ± 29 5 ± 16 0.71
Isovalerate Gut 252 ± 51 218 ± 18 253 ± 13 0.56
μmol/h Liver −227 ± 53 −177 ± 15 −229 ± 20 0.54
Splanchnic 27 ± 15 44 ± 17 24 ± 9 0.85
C2+C3+C4 Gut 19,014 ± 2608 24,179 ± 2961 20,065 ± 816 0.50
μmol/h Liver −8476 ± 4498 −10,494 ± 961 −11,124 ± 1948 0.87
Splanchnic 12,173 ± 1550 15,634 ± 3346 8942 ± 2720 0.40
Values are means ± SEM; for details on the calculations and statistical treatment of the data see Materials
and Methods.
Although concentrations of several AA were modified between D1 and D60, an absence of impact
of adaptation to overfeeding on nearly all the net gut, hepatic and splanchnic amino acids fluxes in
the fasted state (Table 5) were observed. Only an increased glutamate net gut uptake at D14 (+ 180%,
p < 0.05), a tendency for an increased glycine release by the gut at D14 and D60 (+339% at D14, p < 0.1)
and alterations of tryptophan net plasma gut release and liver uptake (p < 0.05) occurred.
Table 5. Net gut, liver and splanchnic (gut + liver) fluxes of amino acids in the fasted state before (D1)
and after 14 days (D14) and 60 days (D60) of adaptation to HFHS diet.
Metabolite Area D1 D14 D60 ANOVA
Leucine Gut 147 ± 227 188 ± 133 793 ± 37 0.28
μmol/h Liver 152 ± 84 343 ± 566 −71 ± 167 0.93
Splanchnic 246 ± 182 620 ± 531 586 ± 194 0.86
Isoleucine Gut 37 ± 143 46 ± 83 423 ± 21 0.27
μmol/h Liver 71 ± 61 290 ± 367 −13 ± 141 0.84
Splanchnic 70 ± 116 388 ± 357 343 ± 120 0.76
Valine Gut 46 ± 265 −38 ± 71 619 ± 159 0.20
μmol/h Liver 291 ± 75 446 ± 625 54 ± 237 0.97
Splanchnic 238 ± 254 427 ± 592 623 ± 156 0.90
Lysine Gut 154 ± 218 248 ± 110 816 ± 47 0.22
μmol/h Liver −341 ± 90 −31 ± 407 −948 ± 111 0.24
Splanchnic −238 ± 186 280 ± 391 −160 ± 101 0.55
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Table 5. Cont.
Metabolite Area D1 D14 D60 ANOVA
Phenylalanine Gut 81 ± 142 230 ± 131 563 ± 104 0.37
μmol/h Liver −161 ± 89 −145 ± 207 −512 ± 27 0.36
Splanchnic −101 ± 110 −157 ± 125 −1 ± 75 0.51
Methionine Gut −9 ± 61 2 ± 24 121 ± 26 0.61
μmol/h Liver −157 ± 92 84 ± 71 −105 ± 62 0.53
Splanchnic −176 ± 108 110 ± 44 −1 ± 35 0.1
Threonine Gut −64 ± 198 −8 ± 119 359 ± 37 0.55
μmol/h Liver 20 ± 268 −6 ± 274 −639 ± 240 0.3
Splanchnic −97 ± 423 43 ± 328 −307 ± 106 0.76
Tryptophane Gut −3 ± 32 ab −123 ± 30 b 111 ± 68 a 0.03
μmol/h Liver −29 ± 10 ab 305 ± 136 b −328 ± 218 a(t) 0.05
Splanchnic −43 ± 31 166 ± 139 −189 ± 163 0.1
Histidine Gut 42 ± 114 105 ± 42 319 ± 37 0.34
μmol/h Liver −145 ± 30 −35 ± 129 −288 ± 90 0.38
Splanchnic −132 ± 110 97 ± 110 103 36 ± 110 58 0.47
Alanine Gut 1128 ± 583 2141 ± 447 2917 ± 719 0.23
μmol/h Liver −3106 ± 680 −2776 ± 1204 −2989 ± 1263 0.93
Splanchnic −2065 ± 837 −318 ± 965 −810.4 ± 863 0.33
Glutamate Gut −357 ± 268 a −1023 ± 228 b(t) −567 ± 72 a 0.04
μmol/h Liver 6387 ± 1315 7692 ± 2556 9063 ± 273 0.68
Splanchnic 5976 ± 1502 6531 ± 2759 8926 ± 434 0.61
Glutamine Gut −1545 ± 265 −1612 ± 547 −1628 ± 248 0.90
μmol/h Liver −468 ± 673 157 ± 413 −440 ± 395 0.53
Splanchnic −2106 ± 757 −1460 ± 1079 −1888 ± 208 0.89
Glycine Gut 1049 ± 884 a 4605 ± 978 b(t) 5072 ± 1916 ab 0.08
μmol/h Liver −1003 ± 373 −4675 ± 1412 −4549 ± 2028 0.31
Splanchnic −170 ± 669 744 ± 977 562 ± 232 0.74
Serine Gut −110 ± 211 70 ± 246 428 ± 64 0.52
μmol/h Liver 107 ± 84 −99 ± 421 −810 ± 193 0.32
Splanchnic −52 ± 288 103 ± 509 −430 ± 104 0.58
Tyrosine Gut 7 ± 150 151 ± 89 371 ± 62 0.29
μmol/h Liver −259 ± 96 −167 ± 238 −605 ± 160 0.51
Splanchnic −279 ± 141 21 ± 250 −251 ± 79 0.64
Cystine Gut 49 ± 123 120 ± 35 168 ± 47 0.79
μmol/h Liver 57 ± 137 −141 ± 101 −350 ± 135 0.39
Splanchnic 98 ± 208 −46 ± 114 −124 ± 93 0.94
Citrulline Gut 580 ± 107 662 ± 146 1029 ± 44 0.19
μmol/h Liver −161 ± 202 −88 ± 221 −167 ± 130 0.82
Splanchnic 396 ± 184 581 ± 405 920 ± 108 0.38
Ornithine Gut 230 ± 84 293 ± 77 366 ± 48 0.79
μmol/h Liver 5 ± 61 −99 ± 115 −68 ± 62 0.54
Splanchnic 261 ± 112 225 ± 61 315 ± 38 0.36
Arginine Gut −75 ± 231 234 ± 41 638 ± 74 0.14
μmol/h Liver −218 ± 120 −3 ± 181 −623 ± 96 0.18
Splanchnic −324 ± 192 226 ± 184 38 ± 119 0.34
Taurine Gut 149 ± 80 24 ± 44 132 ± 162 0.65
μmol/h Liver 144 ± 67 185 ± 170 22 ± 181 0.75
Splanchnic 223 ± 75 117 ± 121 225 ± 105 0.25
Proline Gut −237 ± 360 −14 ± 370 108 ± 2154 0.97
μmol/h Liver 955 ± 1483 555 ± 1110 695 ± 2464 0.21
Splanchnic 653 ± 1598 472 ± 1434 811 ± 376 0.95
3-methyl Gut 1 ± 20 47 ± 31 28 ± 14 0.27
histidine Liver 75 ± 97 −102 ± 108 22 ± 18 0.21
μmol/h Splanchnic 67 ± 94 −73 ± 73 38 ± 24 0.31
Carnosine Gut 39 ± 17 −17 ± 67 40 ± 79 0.63
μmol/h Liver 162 ± 144 101 ± 96 25 ± 73 0.77
Splanchnic 194 ± 147 44 ± 49 144 ± 57 0.47
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Table 5. Cont.
Metabolite Area D1 D14 D60 ANOVA
BCAA Gut 230 ± 629 196 ± 279 1834 ± 147 0.23
μmol/h Liver 553 ± 203 1079 ± 1556 −29 ± 544 0.93
Splanchnic 533 ± 543 1435 ± 1474 1552 ± 448 0.88
IAA Gut 432 ± 1166 549 ± 586 4123 ± 299 0.17
μmol/h Liver −300 ± 618 1120 ± 2610 −5185 ± 1781 0.28
Splanchnic −235 ± 1239 2026 ± 2115 −816 ± 1210 0.61
NIAA Gut 720 ± 2330 5674 ± 1476 8962 ± 5024 0.14
μmol/h Liver 2371 ± 2231 257 ± 4121 −821 ± 6378 0.93
Splanchnic 2409 ± 3985 7005 ± 3836 8118 ± 1275 0.64
TAA Gut 1307 ± 3243 6141 ± 1766 12,704 ± 5186 0.15
μmol/h Liver 2099 ± 1873 1542 ± 6094 −5203 ± 6534 0.80
Splanchnic 2400 ± 4524 8945 ± 5525 7822 ± 1020 0.77
Branched chain amino acids (BCAA): leucine + isoleucine + valine; Indispensable amino acids (IAA): leucine +
isoleucine + valine + lysine + phenylalanine + methionine + threonine + histidine + tryptophane; Non indispensable
amino acids (NIAA): alanine + glutamate + glutamine + glycine + tyrosine + citrulline + cystine + 3 methyl-histidine
+ ornithine + arginine + proline + serine; Total amino acids (TAA): NIAA + IAA. Values are means ± SEM; for
details on the calculations and statistical treatment of the data see Materials and Methods.
3.2. Overfeeding, Impact on Pigs’ Weight, Insulin Levels, Alteration of Energy Nutrient Concentrations, and
Net Splanchnic Uptake in the Fed State. Data Presented in Figures 1–6
3.2.1. Energy Nutrients
Even if arterial, portal, and sus-hepatic vein glucose concentrations were increased after meal
ingestion (PP time < 0.05), the duration of adaptation to overfeeding (D1 vs. D14 vs. D60) did not
modify the plasma postprandial glucose profile in artery, portal, or hepatic veins (Figure 1). These data
are consistent with what found in the fasted state. No significant “day effect” was found concerning
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Figure 1. (A) Glucose concentration (mmol/L) after meal intake (post prandial state, PP: 0 to 510 min)
in artery, portal vein, and hepatic vein. (B) Net glucose gut and splanchnic (gut + liver) fluxes (mmol/h)
after meal intake (Post prandial state, PP: 0 to 510 min) before (D1) and after 14 days (D14) and 60 days
(D60) of adaptation to HFHS diet. Two-way RM ANOVA, * D14 significantly different from D1, † D60
significantly different from D1, ‡ D60 significantly different from D14; Values are means ± SEM. For
calculations and statistical treatment of the data and for details, see Materials and Methods.
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On the contrary, and consistently to what observed in the fasted state, arterial plasma as well
as portal and hepatic veins lactate concentration were more elevated 60 min after feeding at D60
compared to D1 (PP time × day effect: p < 0.001 in the three vessels, Figure 3). This was accompanied
with a significant (PP time × Day: p < 0.002) increased net gut and splanchnic release of lactate. Lastly,
insulin was increased post-prandially (particularly 30 min after meal ingestion) to a similar extend at
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Figure 2. (A) Lactate concentration (mmol/L) after meal intake (Post prandial state, PP: 0 to 510 min) in
artery, portal vein and hepatic vein; and (B) net lactate gut, splanchnic (gut + liver) and hepatic fluxes
(mmol/h) after meal intake (post prandial state, PP: 0 to 510 min) before (D1) and after 14 days (D14)
and 60 days (D60) of adaptation to HFHS diet. Two way RM ANOVA, * D14 significantly different
from D1, † D60 significantly different from D1, ‡ D60 significantly different from D14; Values are
means ± SEM. For calculations and statistical treatment of the data and for details, see Materials
and Methods.
3.2.2. Nitrogenous Nutrients
Similarly to what observed in the fasted state, urea levels were lower in the fed state in all blood
vessels at D14 (p < 0.05), and to a lesser extent at D60 (Figure 3). Again, the small differences in
concentrations between vessels did not allow us to determine significant variations in net gut or
hepatic uptake/release of urea throughout the experimental period.
In the fed state, and as could be expected, a significant (PP time effect: p < 0.01) increased TAA,
IAA and NIAA concentration in the 3 vessels was observed with a peak 1 and 3 h post meal ingestion
(IAA data shown in Figure 3). In artery, only glycine and proline levels were not increased or did not
tend to be altered by meal ingestion (Figure 5, data not shown for Proline). Similarly to many other
AA, glutamine was increased in the fed state in all vessels (PP time effect: p < 0.001, p < 0.001, and
p = 0.079 in artery, portal vein, and hepatic vein, respectively) (Figure 4).
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Figure 3. (A) Urea concentration (mmol/L) after meal intake (Post prandial state, PP: 0 to 510 min) in
artery, portal vein and hepatic vein; (B) indispensable amino acids (AA) concentration (μmol/L) after
meal intake (Post prandial state, PP: 0 to 510 min) in artery, portal vein and hepatic vein; before (D1)
and after 14 days (D14) and 60 days (D60) of adaptation to HFHS diet. Two way RM ANOVA, * D14
significantly different from D1, † D60 significantly different from D1, ‡ D60 significantly different from
D14; Values are means ± SEM. For calculations and statistical treatment of the data and for details, see
Materials and Methods.
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Figure 4. (A) Glutamine concentration (μmol/L) after meal intake (post prandial state, PP: 0 to 510 min)
in artery, portal vein and hepatic vein; and (B) glutamate concentration (μmol/L) after meal intake
(post prandial state, PP: 0 to 510 min) in artery, portal vein and hepatic vein; before (D1) and after
14 days (D14) and 60 days (D60) of adaptation to HFHS diet. Two way RM ANOVA, * D14 significantly
different from D1, † D60 significantly different from D1, ‡ D60 significantly different from D14; Values
are means ± SEM. For calculations and statistical treatment of the data and for details, see Materials
and Methods.
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However, an important increased glutamine level in the portal vein was observed at D14 and
D60 relatively to D1 (PP time × day effect = 0.037) whereas PP effect is lower (p = 0.08) in hepatic
vein (Figure 4), suggesting an increased release by the gut associated with an increased utilization by
the liver. Glutamate followed the same pattern of change in the portal vein as glutamine, but only
at D14 (day effect: p = 0.003, PP time × day effect: 0.004) (D1 and D60 similar) (Figure 5). However,
the increased glutamate concentration observed in the portal vein was also present in the hepatic vein
(day: p = 0.001), suggesting a different role of the liver towards glutamate utilization relatively to
glutamine. Taurine concentration is, similarly to glutamate, increased (or tended to) in two vessels
in the fed state (PP time effect: p = 0.068 and p = 0.007 in artery and portal vein, respectively, not
significant in the hepatic vein) (Figure 5). In the portal vein, a more important post prandial increased
level of taurine is observed at D14 relatively to D1 (Day: p = 0.02) (Figure 5). No such profile existed
for taurine both in artery and hepatic vein. Lastly, glycine presented a very specific profile (not seen for
all other AA): an increased fasted level in the three vessels was observed both at D14 and D60 (p < 0.01
for all vessels) (Figure 5). Associated with this, in the fed state, glycine concentrations were decreased
at D14 and D60 whereas glycine levels at D1 increased in all vessels (PP time effect: p < 0.001, p = 0.08
and p < 0.001 in artery, portal vein, and hepatic vein, respectively) (Figure 5).
Figure 5. (A) Glycine concentration (μmol/L) after meal intake (Post prandial state, PP: 0 to 510 min)
in artery, portal vein and hepatic vein; and (B) taurine concentration (μmol/L) after meal intake (post
prandial state, PP: 0 to 510 min) in artery, portal vein and hepatic vein; before (D1) and after 14 days
(D14) and 60 days (D60) of adaptation to HFHS diet. Two way RM ANOVA, * D14 significantly
different from D1, † D60 significantly different from D1, ‡ D60 significantly different from D14; Values
are means ± SEM. For calculations and statistical treatment of the data and for details, see Materials
and Methods.
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Figure 6. (A) Arterial insulin concentration (μg/L) in the fasted before (D1) and after 14 days (D14)
and 60 days (D60) of adaptation to HFHS diet. (B) HOMA 2 IR (UA) in the fasted state before (D1) and
after 14 days (D14) and 60 days (D60) of adaptation to HFHS diet. (C) Insulin concentration (μg/L)
after meal intake (Post prandial state, PP: 0 to 510 min) in artery before (D1) and after 14 days (D14)
and 60 days (D60) of adaptation to HFHS diet. Fasted state: One way RM ANOVA: with different
letters: significantly different; (t): tendency. Fed state: Two way RM ANOVA, * D14 significantly
different from D1, † D60 significantly different from D1, ‡ D60 significantly different from D14; Values
are means ± SEM. For calculations and statistical treatment of the data and for details, see Materials
and Methods.
4. Discussion
In the present study we assessed the effect of two-month overfeeding on nutrients uptake/release
by the splanchnic area in the adult mini pig in the fasted state for a wide range of molecules and in the
fed state for selected metabolites/molecules (glucose, lactate, urea, insulin, amino acids). We mention
that the data presented in the fasted state at D1 represent the metabolic status of an animal adapted to
a diet providing energy and proteins capable to maintain body weight stable and the post prandial
state at D1 is the first day they receive the HFHS diet.
Although the animals did not present diabetes or fasting hyperglycemia at the end of the HFHS
overfeeding period (and as already shown in a previous work on other animals but a rather similar
diet [18]), their utilization of energy and nitrogenous nutrients at the splanchnic level was strongly
altered to handle the unusual nutrients overflow both in the fed and the fasted states due to overfeeding.
Some short term (after 14 days of overfeeding) and longer-term adaptive mechanisms are discussed in
the present study.
4.1. Metabolic Adaptations to Overfeeding in Pigs: Impact on Nitrogenous and Energy Nutrients at the Gut,
Hepatic, and Whole Body Levels
As the primary tissue in contact with the diet changes, the gut leaves large quantities of glucose
to reach the portal vein when animals are fed the HFHS diet. As could be expected following the meal
intake, the net plasma gut release is increased post-prandially as well as at the portal, hepatic and to a
lesser extend arterial level from D1 to D60. These kinetic patterns are not differentially altered between
D1 and D60, as shown by an absence of difference of significant net plasma gut release of glucose
between D1 and D60. This is not the case in the fasted state where glucose concentrations are not altered
in all vessels, but net plasma gut release increased, suggesting an intense utilization of glucose by
other tissues and possibly by peripheral tissues, as generally observed in the fasted state (e.g., muscle
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and adipose tissues). The fact that the net glucose release by the liver and splanchnic area (Table 4)
remains stable in the fasted state throughout time shows that contrarily to what generally occurs
in well installed IR, no increased hepatic glucose release/production occurs in our model [26–29].
Residual amounts of glucose released by digestion of carbohydrates from the previous meal can
be one of the explanations to the significant increased glucose net plasma gut release observed in
the fasted state at D60 compared to D1. As HFHS meal supplies important amounts of nutrients,
and particularly lipids, carbohydrates hydrolysis and digestion rate may be delayed between D1
(animals were adapted to the Control diet) and D14/D60 where the gut had been adapted to HFHS
diet. Another possibility is an increased gluconeogenesis by the gut due to the increased supply of
gluconeogenic precursors, as previously suggested [16], such as luminal amino acids (alanine for
instance), plasma lactate or even small amounts of short chain fatty acids produced by microbiota
from dietary fibers (tendency for an increased net gut release of propionate, suggesting an increased
synthesis of SCFA by microbiota in the gut, Table 4). It should be noted that the increased overall
food intake between D1 and D60 is associated with and increased supply of dietary fibers, potentially
capable to stimulate microbiota activity. The increased SCFA synthesis by microbiota observed in the
present study (as shown by net portal release of propionate) has already been reported in the literature
on obesity (and related diseases) and illustrates the complex role of SFCA in the relationship between
microbiota and host (SCFA increased both in fiber-supplemented [30] but also in obese individuals [31]).
Indeed, as suggested by [31], according to their signaling pathway or metabolic mechanism they are
involved in, they can either promote (via stimulation of triglycerides accumulation) or prevent (Histone
deacetylases inhibition and/or GPR 41 and 43 activation) hepatic steatosis. In the present work, our
hypothesis is that overfeeding (more than the relative oversupply of lipids) associated with an increased
overall supply of dietary fibers may have maintained the activity of carbohydrates degrading microbes,
leading to increased portal release of some SCFA.
To handle the important supply of nutrients, particularly glucose, and notably avoid even more
massive glucose release, the gut adapts by oxidizing it into lactate, which is then released into the
portal vein (more increased in the fed states (Figure 2) at D14 and D60 relative to D1). These increased
lactate levels are visible in all vessels including artery. Such an increased fasting lactate level is known
to occur progressively in obesity [32] and during IR installation [33], as observed in our model with
D14 values intermediate between D1 and D60. As glucose supply from the diet is important due
to overfeeding in the fed state, a conversion of glucose into pyruvate followed by its reduction into
L-lactate (anaerobic glycolysis [34]) is a mechanism that can limit hyperglycemia [35]. Aside from a
production in the gut, and as the portal vein also drains visceral adipose tissue, an increased lactate
production from adipose tissues located at the gut level cannot be excluded [14]. In the fasted state,
other mechanisms can explain the increased lactate levels. The sites of metabolic adaptation are also
different (located at the muscle/adipose tissues and liver levels). The lactate that reaches the liver
may not entirely be metabolized into glucose [35], and lactate net release from the liver has been
shown to increase between D1 and D60, suggesting a limited capacity for lactate uptake (notably
for gluconeogenesis).
The oversupply of food does not only disturb the energy metabolism but also amino acid
utilization for energy, protein metabolism, and urea synthesis/elimination. First, levels of urea
in all vessels are decreased both in the fasted state and the fed state. Such a decreased plasma urea
content has already been discussed in a previous paper [19], in rodents fed a cafeteria diet [36] and
corresponds to a nitrogen-sparing effect due to overfeeding [37]. The increased availability of all
nutrients (lipids, glucose, AA, other N-based products, like nucleotides) tend to limit AA oxidation
and, consequently, urea production. Due to this (and also the increased supply of proteins in HFHS-fed
animals), a relatively small, but significant, increased AA plasma level (TAA, and among them
particularly some NIAA (glycine) and BCAA) is observed. The reduced activity of the urea cycle
observed is supported by the increased level of fasting plasma ornithine which accumulates instead
of being metabolized into citrulline via carbamoyl-P synthetase and NH3 incorporation into the urea
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cycle. For technical reasons, we could not measure plasma ammonia levels but data from pigs fed a
similar diet (unpublished results) did not present significant alterations of ammonia levels throughout
the obesity development. This is also in line with the increased concentrations we observe for glycine
and serine known to be direct precursors for ammonia synthesis [38], and which accumulate instead
of being catabolized into ammonia (and later into urea). Hence, in absence of necessity to detoxify
ammonia, urea cycle remains at a low level. Our present model of oversupply of both energy and AA
ends up with a mechanism of decreased urea and probably ammonia synthesis and relative increased
level of certain AA. This lies a question un-answered: where and under what form the nitrogen excess
can be utilized? A stimulation of muscle growth and AA utilization for protein synthesis could occur
in our pigs (even if adults) associated with an increase in animal size (as previously shown in a similar
study [18]) and may help to avoid massive hyper-aminoacidemia. This could be mediated by insulin
that is highly responsive to meal intake at D14, suggesting that growth stimulation might be maximum
at D14 (very low urea/high AA levels at D14) and intermediate between D14 and D60 (insulin less
stimulated by meal and urea levels intermediate Figures 2 and 4). Other fates for nitrogen could be: N2
in expired air or urinary nitrates, nitrites, uric acid, peptides or amino acids. An increased N excretion
as AA in urine is possible as the presence of AA in urine has been spotted in a recent work on the same
model [18].
Looking at specific amino acids, a significant alteration of post prandial profile of the
glutamate/glutamine couple was observed in our study. Indeed, glutamine portal concentration
was increased both at D14 and D60 vs. D1 (Figure 4). This suggests that this major fuel for small
intestine (along with glutamate) [39] is replaced by other energy nutrients, a mechanism already
demonstrated elsewhere [40]. In parallel, glutamate post prandial concentration in the portal vein was
also significantly increased, but only at D14, whereas it was not altered at D1 and D60. One explanation
is that glutamine, used by the gut as a fuel at D1, could have been replaced by glucose as a fuel at
D14 and glutamate and glucose at D60. At D1, as it was the first time that the gut was challenged by
the diet, catabolism of all energy nutrients was stimulated. Due to the long term overfeeding, at D14,
a prioritization of glucose gut uptake and utilization may have occurred via a stimulation by insulin
(increased in PP state at D14 (Figure 6)), as glucose uptake may be at least partially regulated by insulin
receptors present in intestine epithelium, [41]. Lastly, the glutamate excess present in the enterocytes,
due to glutamate dietary supply and potentially glutamine excess, could ultimately lead to an increased
utilization of glutamate by the gut to limit overall hyperaminoacidemia. This increased utilization
of glutamate by the gut and activation of Krebs cycle [42] could lead to an increased production of
lactate, in absence of total catabolism, and concur to explain the increased lactate portal concentration
and net plasma gut release observed at D60. This could also explain why urea levels are less decreased
at D60 compared to D14 (D60 plasma concentrations were intermediate between D1 and D60).
Our dietary intervention was also characterized by an increased supply of lipids (palm oil) leading
to an increased arterial cholesterol level (Table 1). Interestingly, glycine and taurine, two amino acids
involved in recycling of biliary acids in human and pigs [43] presented an increased level in all vessels
in the fasted state for glycine and in the portal vein in the fed state at D14 for taurine (Figure 5). As they
combine to bile acids within the liver to be further recycled into the bile, their utilization in the liver is
increased when dietary supply of lipids is increased. However, the fact that the increased availability
is observed in the portal vein in the fasted state for glycine and in the fed state for taurine with a
probable utilization within the liver for both AA, the metabolic fate of these two AA in relation to
lipids intake should require further investigation. Interestingly, glycine has also been demonstrated,
when administrated in the diet of rats, to limit non esterified fatty acids and lipids accumulation in
adipocytes, via a stimulation of mitochondrial activity [44]. Aside from the already observed “buffering
effect” of adipose tissues to limit hyperlipidemia [18]. Could the increased plasma glycine observed in
the fasted state in our animals be another endogenous mechanism capable to counteract the increased
plasma lipids concentration (in our study, triglycerides are not altered)?
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4.2. Analysis of the Kinetics of Evolution of the Arterial Metabolites in Our Model of Overfed Mini Pigs
As already discussed in the present paper but also in previous published works [18], the metabolic
shifts observed in our model represents the early stages of development of obesity and diet-induced
metabolic disturbances ultimately leading to insulin resistance (IR). Increased arterial fasted cholesterol
(total, LDL and HDL), lactate, insulin and HOMA2 IR are observed between D1 and D60. In parallel,
short chain fatty acids (acetate, isobutyrate, or isovalerate) and several amino acids (AA): leucine,
isoleucine, valine, tryptophane, glycine, ornithine, and proline increased, whereas urea and methionine
decreased between D1 and D60.
However, the pattern of change of these parameters can differ. Some parameters are significantly
modified only at D14 (arterial isobutyrate, isovalerate, and LDL cholesterol) and represent a short
lasting diet-dependent adaptations. A second group of parameters are modified early (D14) and
remained stable at D60 (AA: methionine, proline, isoleucine, glycine, phenylalanine, lactate, urea,
fructosamine, insulin, HOMA, total and HDL cholesterol), suggesting that these alterations can be very
closely linked to the rapid shift from a “maintenance” diet to a “high fat high sucrose” diet but could
also be considered as very early markers of a metabolic shift and/or development of insulin resistance.
Looking at the potential regulatory role of glycine on lipids and cholesterol handling (see above),
this AA should be studied in detail. Lastly, some parameters (acetate, leucine, valine, tryptophane,
and serine associated with the progressive pigs’ weight) are also particularly interesting as they are
significantly (or tend to be) increased more progressively and more lately than the other parameters,
suggesting a progressive shift of their utilization/metabolism at the whole body level (less driven
by the direct impact of the change of diet and associated nutrients). Leucine and valine are already
considered as predictors of insulin resistance [45] and their slow increase over the entire experimental
period confirms their relevance in the development of insulin resistance/obesity phenotype [19].
Acetate is less studied but its concentration is increased in the caecum and plasma as well as its overall
turnover in insulin resistant or high fat fed animals/humans [46–48]. The role of the microbiota in this
increased acetate production of obese/IR states, particularly in the fasted state may be significant [46]
and may lead to altered glucose-stimulated insulin production, fat storage and could ultimately lead
to insulin resistance. Unfortunately, due to high variability between animals, no increased gut or
splanchnic net acetate production could be observed in the present study (Table 4) whereas it is the
case for propionate and butyrate. A reduction of acetate utilization by muscles for oxidation is a
possible explanation for the increased arterial acetate levels, as a significant part of acetate utilization
takes place in muscle [49]. The establishment of a resistance for acetate oxidation in muscle can be
hypothesized as acetate oxidation has been shown insulin-sensitive in rodents’ hindquarters [50].
Lastly, tryptophan has also been shown (among aromatic amino acids), to be increased and tightly
correlated to obesity, adiponectin and intrahepatic fat content [51–53].
In conclusion, we have shown that two months of overfeeding in pigs led to important metabolic
shifts which may have led to the maintenance of a relatively stable glycemia. This was achieved thanks
to important shifts in lactate and amino acids/urea metabolism. A progressive increased release of
lactate by the gut and the liver in the fasted and the fed state observed in the present study could trigger
other metabolic perturbations leading to nutritional-related pathologies and should be examined in
detail. The analysis of the profile of arterial metabolites throughout the experimental period showed, as
could be anticipated, a progressive increased BCAA levels (as detailed elsewhere [19]) but also acetate,
tryptophan and, potentially, glycine, which are less studied in the context of obesity development,
should require further investigation as potential markers of metabolic shift towards insulin resistance.
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Abstract: Background: When given in the long term, whey proteins alone do not appear to be an
optimal nutritional strategy to prevent or slow down muscle wasting during aging or catabolic states.
It has been hypothesized that the digestion of whey may be too rapid during a catabolic situation
to sustain the anabolic postprandial amino acid requirement necessary to elicit an optimal anabolic
response. Interestingly, it has been shown recently that the duration of the postprandial stimulation
of muscle protein synthesis in healthy conditions can be prolonged by the supplementary ingestion
of a desynchronized carbohydrate load after food intake. We verified this hypothesis in the present
study in two different cases of muscle wasting associated with anabolic resistance, i.e., glucocorticoid
treatment and aging. Methods: Multi-catheterized minipigs were treated or not with glucocorticoids
for 8 days. Muscle protein synthesis was measured sequentially over time after the infusion of a 13C
phenylalanine tracer using the arterio-venous method before and after whey protein meal ingestion.
The energy bolus was given 150 min after the meal. For the aging study, aged rats were fed the whey meal
and muscle protein synthesis was measured sequentially over time with the flooding dose method using
13C Valine. The energy bolus was given 210 min after the meal. Results: Glucocorticoid treatment resulted
in a decrease in the duration of the stimulation of muscle protein synthesis. The energy bolus given
after food intake was unable to prolong this stimulation despite a simultaneous increase of insulin and
glucose following its absorption. In old rats, a similar observation was made with no effect of the energy
bolus on the duration of the muscle anabolic response following whey protein meal intake. Conclusions.
Despite very promising observations in healthy situations, the strategy aimed at increasing muscle protein
synthesis stimulation by giving an energy bolus during the postprandial period remained inefficient in
our two anabolic resistance models.
Keywords: aging; catabolic state; anabolic resistance; protein synthesis; energy bolus
1. Introduction
Skeletal muscle size and function are directly related to the amount of muscle protein content
and quality. Muscle protein homeostasis is ensured by continuous turn-over, including the
degradation of non-functional muscle proteins which are replaced by the synthesis of new ones.
This equilibrium between muscle protein synthesis and breakdown varies throughout the day.
During the post-absorptive period, in the absence of food intake, muscle proteolysis exceeds synthesis
to provide essential amino acids to other organs, whereas an anabolic response is initiated when muscle
protein synthesis is higher than proteolysis after food intake [1]. It is now well-established that the
postprandial anabolic response in skeletal muscle occurs through the stimulation of protein synthesis
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initiated by increased essential amino acid bioavailability, whereas the decrease in proteolysis mainly
occurs through the stimulation of insulin secretion in response to feeding [2,3]. Although decreased
physical activity has been identified as a cause, muscle atrophy has also been explained by the presence
of anabolic resistance following food intake in several physio-pathological catabolic states as diverse
as aging, cancer, and disuse [4–10]. In each case, increasing dietary protein intake above the current
recommended dietary allowances (RDA at 0.8 g/kg/day) [11] has been proposed to overcome the
anabolic resistance observed. Among dietary proteins, rapidly digested and leucine-rich proteins (i.e.,
whey) have been shown to be the most efficient for the acute stimulation of muscle protein synthesis
during aging, disuse or glucocorticoid treatment when compared to casein, a protein with lower leucine
content and whose digestion rate is slower [9,12–14]. However, when given in the long-term, whey
proteins alone do not appear to be an optimal nutritional strategy to prevent or slow down muscle
wasting during aging [15,16] or catabolic states [10,17–19]. This could be explained by the nature
and intensity of the catabolic state but also by the fact that the digestion of whey may be too rapid
during a catabolic situation to sustain the anabolic postprandial amino acid requirement necessary
to elicit an optimal anabolic response [20]. Indeed, the stimulation of muscle protein synthesis has
a defined and limited duration during the postprandial period [21,22]. Atherton et al. showed that
whey ingestion is only able to stimulate muscle protein synthesis for 2 h [21]. The leucine content of a
complete meal drives peak activation but not the duration of skeletal muscle protein synthesis [23].
Interestingly, it has been shown recently that the duration of the postprandial stimulation of muscle
protein synthesis in healthy conditions could nevertheless be prolonged by maintaining the cellular
energy status with the supplementary ingestion of a desynchronized carbohydrate load after food
intake (±150 min) [24]. Such a prolongation would be very useful to slow down the loss of muscle
mass during aging, or in other catabolic situations. To our knowledge, the use of such an energy
bolus at a precise time after a meal has never been tested in catabolic situations. Thus, the present
study aimed to determine whether an energy bolus given 30 min after peak postprandial muscle
protein synthesis stimulation could also increase muscle protein synthesis during a catabolic situation.
We tested two catabolic situations: glucocorticoid treatment in young mini pigs, and chronic loss of
muscle mass during aging in the rat. Unfortunately, in both situations, the energy bolus was unable to
re-stimulate muscle protein synthesis.
2. Materials and Methods
In the present manuscript, we studied two different muscle wasting conditions for which we have
clearly described an anabolic resistance in skeletal muscle following food intake. In these two studies,
we showed that whey, a rapidly digested protein rich in leucine, was more efficient than casein at
the same protein content for (re)initiating an anabolic response, mainly by increasing muscle protein
synthesis postprandially [9,10]. Thus, some of these results which represent the “control” groups in
these manuscripts have been already published. In the present publication, the original results are the
results in the same conditions, but associated with the desynchronized energy bolus.
2.1. Glucocorticoid Treatment Study
2.1.1. Animal Housing, Surgery and Ethics Statement
The present study was approved by the Animal Care and Use Committee of Auvergne (CEMEA
Auvergne; Permit Number: CE 68-12) and the Ministère de l’Enseignement Supérieur et de la Recherche
(no. 02125.02) and described in full by Revel et al. [10]. For the study, 18 adult male Yucatan mini
pigs (averaging 20 kg) were housed individually in subject pens (1 × 1.5 m) in a ventilated room
with controlled temperature (21 ◦C). They were fed twice daily with 220 g/d of a concentrated feed
containing 16% protein, 1% fat, 4% cellulose, and 5% ash (Porcyprima; Sanders Centre Auvergne,
Aigueperse, France) and had free access to water. Three weeks before the experiment, the minipigs
went into surgery and were fitted with catheters in the inferior cava vein and the aorta. For the cava
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vein, the catheter was inserted just downstream of the junction with the iliac veins. A transit time
ultrasonic blood flow probe (6 mm probe, R-series; Transonic Systems, Inc., Ithaca, NY, USA) was
implanted around the distal aorta 1–2 cm before it splits into the iliac arteries. Catheters and probe
cables were exteriorized through the skin of the right flank of the animal. A minimum of 2 weeks was
allowed for recovery from surgery before initiating the experiment. Surgical procedures, as well as
post-surgical care, were described previously in detail by Rémond et al. [25].
2.1.2. Tracer Infusion Procedures
On the day of the experiment, after an overnight fasting period, the animals were separated into
3 groups (n = 6 per group): control group (WHEY CONTROL), glucocorticoid treated group (WHEY
DEXA), and the glucocorticoid group with a desynchronized energy bolus during the postprandial
period (WHEY DEXA BOLUS). For all groups, after basal blood samples were withdrawn from the
artery and iliac vein, a priming dose of labeled [ring U-13C] L-Phenylalanine (4.2 μmol·kg−1) was
injected and then [ring U-13C] L-Phenylalanine was infused (4.2 μmol.kg−1·h−1) for 550 min through
the hepatic vein. During the first 150 min, the animals remained deprived of food and samples of
arterial and iliac venous blood were simultaneously withdrawn at 90, 120, and 150 min, and represented
the post-absorptive period (PA). At t = 150 min, the animals consumed a test meal (250 g) containing
whey as a protein source (13%), as well as lipids (6%), and carbohydrates (57%). The meal was entirely
consumed within 10–15 min, arterial and iliac venous blood was sampled every 30 min during the
remaining 400 min (postprandial period, PP). The ultrasonic blood flow probe was used to record
blood flow continuously throughout the whole experiment. For the glucocorticoid-treated group
(WHEY DEXA), 8 days before the experiment, the animals received a dose of 0.4 mg/kg/day of
dexamethasone added to the feed every morning (0.15 mg/kg) and evening (0.25 mg/kg). Food intake
was not modified by the treatment. The animals were subjected to the same tracer infusion protocol
described above except that dexamethasone was consumed with the test meal. The WHEY DEXA
BOLUS group followed the same protocol except that 150 min after the test meal ingestion (30 min
after the expected peak of protein synthesis observed in our previous experiment [10]), the animals
were allowed to consume 100 g of glucose/ saccharose (50/50) to initiate an energy bolus similar to
70% of the carbohydrate content of the test meal, as described by Wilson et al. [24]. In the experiment
performed by Wilson et al., the bolus was similar to 100% of the carbohydrate content of the test meal
and was given 45 min after peak muscle protein synthesis.
2.1.3. Samples Analysis
The plasma 13C enrichment of phenylalanine was measured by gas chromatography–mass
spectrometry (GC–MS, model HP5975C/7890A, Agilent, Santa Clara, CA, USA) with the use of
tertiary-buthyldimethylsilyl derivatives and by ion monitoring with m/Z 336 and 342, as previously
described [10,26].
Plasma concentrations of amino acids were determined by ion exchange chromatography
on deproteinized samples [10]. Plasma glucose was assayed using an enzymatic method on an
autoanalyzer (Pentra 400, Horiba, Montpellier, France) and the insulin concentration was assayed by
ELISA (Mercodia, Uppsala, Sweden).
2.1.4. Calculations
Muscle protein synthesis was calculated using the arterio-venous differences method according to
the equations previously described by Bruins et al. [27] and Paddon-jones et al. [28]. Phenylalanine was
selected to represent amino acid kinetics because it is neither produced nor metabolized in skeletal
muscle [29]. In this tissue, the disposal and production of phenylalanine reflect protein synthesis and
protein breakdown. The complete and detailed equations used to calculate muscle protein synthesis
were described by Revel et al. [10].
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2.1.5. Statistics and Analysis of Results
Data are presented as means ± SE. Repeated time variance analyses were performed to test the
effect of time, status (WHEY CONTROL, WHEY DEXA, WHEY DEXA BOLUS) and interaction time ×
status. LSD post-hoc tests were used to compare mean values at each time (Statview, SAS Institute,
Cary, NC, USA).
2.2. Aging Study
2.2.1. Animals and Diets
The present study was approved by the Animal Care and Use Committee of Auvergne (CEMEA
Auvergne; Permit Number: C2EA-02) and the Ministry of Higher Education and Research (no.
2016101911586999). Twenty-month-old male Wistar rats (Charles River, L’Arbresle, France) were housed
individually and kept in a controlled environment (temperature maintained at 22 ◦C; 12:12 light: dark
cycle). The average weight of the rats was close to 600 g. After an adaptation period during which the
animals were fed regular chow (Safe A04, Augy, France), they were divided into 2 groups, fasted overnight
and fed the next morning with a meal (6 g). The majority of this amount (>60%) was consumed within the
first 30 min and withdrawn after 1 h if any food remained uneaten. One group received the meal made
with whey (13%) as a protein source (+ 6% lipids and 71% carbohydrates) and the second group received
the same meal but also 4.5 g of glucose/sucrose (50/50), which was similar to 104% of the amount of
carbohydrate in the test meal 210 min after the beginning of the meal. Once again, our aim was to mimic
the study of Wilson et al. [24] but in heavier and older rats. Our bolus was given 30 min after peak muscle
protein synthesis. The animals were then sacrificed before (0) and 90, 125, 180, 240 and 270 min (only for
the energy bolus group) after the beginning of the meal under 4% isoflurane anesthesia (n = 10/time point).
An abdominal incision was made and blood was withdrawn from the abdominal aorta with syringes
containing EDTA. The gastrocnemius muscles were rapidly removed, weighed and freeze-clamped in
liquid nitrogen, and stored at −80 ◦C. Regarding the muscle protein synthesis measurement, 40 min
before the sacrifice, animals were injected intravenously with L-valine (150 μmol per 100 g body weight)
containing 100% L-[1-13C] valine (Euriso-Top) (see [9] for the detailed protocol).
2.2.2. Analytical Procedures
Glucose concentrations were measured enzymatically using commercial kits (Horiba, Montpellier,
France). Plasma insulin levels were also assessed using a commercial ELISA kit (Mercodia, Uppsala,
Sweden). To measure protein synthesis, the muscles were powdered in liquid nitrogen in a ball
mill (Dangoumeau, Prolabo, Paris, France). A 200 mg aliquot of frozen muscle powder was
homogenized in 2 mL of 10% trichloroacetic acid (TCA). Proteins were hydrolyzed in 6 N HCl
at 110 ◦C for 48 h. HCl was removed by evaporation and amino acids purified by cation exchange
chromatography. The enrichment of [1-13C] valine in muscle proteins was measured on the basis of
its N-acetyl-propyl derivatives by gas chromatography–combustion-isotope ratio mass spectrometry
(GC–C-IRMS). The plasma 13C enrichment of valine was measured by gas chromatography–mass
spectrometry (GC–MS, model HP5975C/7890A, Agilent, Santa Clara, CA, USA) with the use of
tertiary-buthyldimethylsilyl derivatives (see [9] for the detailed protocol). The absolute synthesis
rate (ASR: total muscle protein synthesized) was calculated from the product of the protein fractional
synthesis rate (FSR) and the protein content of the tissue, and expressed in mg/d. FSR (in %/day)
was calculated from the formula: FSR = Sb × 100/Sa × t, where Sb is muscle protein-bound [1-13C]
valine enrichment (minus natural basal enrichment of protein), Sa is the mean enrichment of plasma
valine during tracer incorporation, and t is the incorporation time in days calculated between the time
of tracer injection and the time of muscle sampling, i.e., “PA” between −40 min and 0 min; “90 min”
between 50 and 90 min; “125 min” between 85 and 125 min; “180 min” between 140 and 180 min,
“240 min” between 200 and 240 min and “270 min” between 230 and 270 min. The mean Sa enrichment
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was the Sa (t1/2) value calculated from the linear regression obtained in the tissue between the time of
injection and time t.
2.2.3. Statistics and Analysis of Results
Data are presented as means ± SE. Separate groups of animals were used each time; thus a
repeated time variance analysis could not be performed. We used a two-way variance analysis to
discriminate between the effect of time of measurement, and the effect of nutritional status (WHEY or
WHEY BOLUS). The interaction was not testable since, by construction, the bolus was given at time
210 min and affected only time 240 and time 270. LSD post-hoc tests were performed to compare mean
values at each time (Statview, SAS Institute, Cary, NC, USA).
3. Results
3.1. Minipigs Treated with Glucocorticoids
3.1.1. Plasma Glucose, Insulin, and Arterial Amino Acid Concentrations
After the whey-based meal, an increase in both glucose and insulin was observed (Figure 1A,B).
Plasma glucose increased rapidly (1.2-fold between 180–240 min) and gradually decreased to the basal
values throughout the remaining postprandial period (300–550 min). Insulin was secreted rapidly
with maximum stimulation at 210 min (7–8-fold), and then insulin decreased back to the basal values
throughout the rest of the postprandial period.
Plasma insulin and glucose increased in WHEY DEXA minipigs during the early postprandial
period (150–300 min), when compared to the control situation. During the late postprandial period
(300–550 min), no significant differences were observed for either plasma insulin or glucose between
the WHEY CONTROL and the WHEY DEXA minipigs (Figure 1A,B). When the glucocorticoid-treated
mini pigs received the energy bolus at 300 min (WHEY DEXA BOLUS), a significant increase in both
plasma glucose and insulin was recorded in the late postprandial period (300–550 min) when compared
to the two other groups: WHEY CONTROL and WHEY DEXA (Figure 1A,B).
Plasma leucine also increased rapidly (approximately 2-fold) after the WHEY CONTROL meal
intake (Figure 1C). This difference was maintained during the first two-thirds of the postprandial
period, then finally decreased rapidly during the late postprandial period (>400 min) (Figure 1C).
The same pattern was recorded for the essential amino acids (EAA) (Figure 1D).
Post-absorptive leucine concentrations were significantly increased after the glucocorticoid
treatment (time 0, 90 and 120 min: +35–40%) (Figure 1C). By contrast, the glucocorticoid treatment
did not significantly alter plasma leucine and EAA kinetics following whey meal intake (Figure 1D).
When the energy bolus was given at 300 min, no significant changes were recorded in leucine or EAA
kinetics in the late postprandial period (300–550 min) in the WHEY DEXA BOLUS when compared to
the WHEY CONTROL and WHEY DEXA groups (Figure 1D).
3.1.2. Muscle Protein Synthesis
When fed the whey meal, muscle protein synthesis increased to a peak at 240 min after which it
decreased slowly until the end of the postprandial period studied (Figure 1E). In the WHEY DEXA
group, muscle protein synthesis was significantly lower in the post-absorptive state and was only
transiently significantly stimulated by the whey protein during the early part of the post-prandial
period (150–270 min) (Figure 1E). In the late post-prandial period, muscle protein synthesis remained
significantly lower in the WHEY DEXA group when compared to the WHEY CONTROL group.
When the energy bolus was given at 300 min, no modification of muscle protein synthesis was
recorded when compared to the WHEY DEXA group and it stayed significantly different to the values
recorded in the WHEY CONTROL group (Figure 1E).
141
Nutrients 2019, 11, 727
Figure 1. Plasma glucose (A), insulin (B), leucine (C) and essential amino acids (D) in control
(WHEY CONTROL), in glucocorticoid-treated (WHEY DEXA) and in glucocorticoid-treated with
the carbohydrates (CHO) bolus (WHEY DEXA BOLUS) minipigs. The areas under the curve (AUC)
for glucose and insulin are presented in inserts. Postprandial AUCs were calculated by subtracting
the post-absorptive values (t = 90–150 min) to each postprandial values. (E): Muscle protein synthesis
kinetics for the post-absorptive period (before t = 150 min) and after the meal (after 150 min) in
control (WHEY CONTROL), in glucocorticoid-treated (WHEY DEXA) and glucocorticoid-treated +
carbohydrate (CHO) bolus (WHEY DEXA BOLUS) minipigs. The CHO bolus was given at t = 300 min.
Data are presented as means ± SEM. (n = 6).
3.2. Aging Study
Plasma Glucose and Insulin
Plasma glucose increased significantly after the ingestion of the whey protein meal and glycemia
peaked 180 min after food intake (Figure 2A). Insulin was also significantly increased after food intake
to reach maximal values at 125 and 180 min (Figure 2B). When the energy bolus was given at 210 min,
plasma glucose remained elevated and was significantly increased when compared to the WHEY
CONTROL Group (Figure 2A). At 240 and 270 min, plasma glucose was 31 and 21% significantly
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higher, respectively, than at 240 min without the sugar bolus (Figure 2B). By contrast, insulinemia was
not significantly increased after the intake of the energy bolus and even tended to be lower (−31%)
than the value recorded at 240 min in the WHEY CONTROL (Figure 2B).
Figure 2. Plasma glucose (A), insulin (B) and muscle protein synthesis (C) in aged rats fed with whey
or with whey followed by an energy bolus (CHO) 210 min after food intake. Data are presented as
means ± SEM. (n = 10).
3.3. Muscle Protein Synthesis
Muscle protein synthesis was significantly stimulated after the ingestion of the whey protein
meal and maximum stimulation was recorded at 180 min (Figure 2C). After 180 min, muscle protein
synthesis decreased to become similar to the post-absorptive value at 240 min. When the energy
bolus was given at 210 min, it did not prevent a decrease in muscle protein synthesis in the Whey
Bolus group and its value was not significantly different from the values recorded in the Whey group
(Figure 2C).
4. Discussion
We previously showed that casein was unable to initiate the stimulation of muscle nitrogen
balance or muscle protein synthesis when given at the amount fulfilling healthy adult requirements in
the two anabolic resistant states presented, i.e., glucocorticoids treatment and aging [9,10]. The reason
for this anabolic resistance was explained by the lower sensitivity of the main signaling pathway (i.e.,
mTOR signaling pathway), which leads to the stimulation of muscle protein synthesis in response
to food intake and particularly to dietary leucine intake and availability [30–33]. These observations,
which are now well accepted, have led to recommending in such situations the preferential intake
of rapidly digested and leucine-rich proteins such as whey proteins. Indeed, when the availability
of essential amino acids and/or leucine is increased, the defect in the stimulation of muscle protein
synthesis is attenuated or reversed during both glucocorticoid treatment [33] and aging [34]. Long-term
supplementation of free leucine or leucine-rich proteins was therefore tested in both elderly humans
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and aged rodents. Verhoeven et al. [16] tested a 3-month leucine supplementation (7.5 g/day) and
showed that it did not augment skeletal muscle mass or strength in healthy elderly men. Animal studies
also showed no beneficial effect of leucine or whey protein supplementation on muscle mass in aged
rodents unless it was given in high amounts within a high protein diet [15]. In a recent review,
Woo et al. [35] concluded that to date, evidence suggests that nutritional intervention including
high-quality protein or leucine does have benefits in the elderly, but mainly if combined with exercise.
Similar conclusions could be drawn from glucocorticoid-induced anabolic resistance in which leucine
supplementation remained without effect against the deleterious effect of dexamethasone on muscle
fiber atrophy and strength loss [18]. We previously showed that whey proteins could initiate an
anabolic response in the skeletal muscle in glucocorticoid-treated minipigs, but that the response
remained transient and was only visible during the early post-prandial period (i.e., first 2 h), in contrast
to the 7 h-stimulated muscle protein accretion obtained in healthy conditions [10]. In other catabolic
states, with muscle wasting and anabolic resistance, such as bed rest and immobilization, leucine
supplementation and whey proteins supplementation have also been shown as not being optimal for
preserving muscle mass and strength [19,36–39].
Recently, it has been shown that muscle protein synthesis stimulation after feeding is of finite duration
even if amino acid availability is still high and mTOR signaling pathways remain activated [21,22]. It has
been postulated that muscles can sense they are “full,” and this phenomenon has been named the “muscle
full” effect [40,41]. Few studies have been carried out to elucidate the mechanisms involved in this
“muscle full” effect and whether it can be prevented in order to prolong the anabolic response after
food intake. They found that it was the decrease in muscle energy status associated with the increased
activity of the intracellular energy sensor AMPK, which leads to blocking the stimulation of muscle protein
synthesis [24,42]. However, when post meal supplements of carbohydrates (increased available energy)
were given, the activation of AMPK was prevented, and the post-prandial muscle anabolic response was
significantly extended in young growing rodents [24,42]. This could constitute a new strategy for slowing
down muscle loss during the catabolic state.
Therefore, for the first time, we tested this nutritional strategy in catabolic models:
glucocorticoid-treated young pigs and aging rats (a milder anabolic resistant state). In glucocorticoid
treated pigs, the carbohydrate bolus further increased plasma glucose and insulin levels but remained
without effect on the duration of muscle protein synthesis stimulation. Similarly, in aging rats,
no modification in the duration of this stimulation was recorded. We hypothesize that glucocorticoids,
which generate insulin resistance at the skeletal muscle level, had altered glucose uptake and
metabolism and then rendered the energy bolus inefficient for maintaining or increasing ATP during
the remaining postprandial period. In the aged rodents, it is noteworthy that our energy bolus
dramatically increased plasma glucose, as expected, but did not increase plasma insulin. Since this
increase of insulin was recorded in younger animals in which the energy bolus prolonged muscle
protein synthesis, it is possible that during aging the lack of insulin elevation after the carbohydrate
bolus did not allow simultaneous glucose uptake and metabolism in skeletal muscles and was unable
to correct the energy deficit and AMPK activation. This is consistent because it has been shown
that elderly subjects have a lower pulse amplitude and less responsive insulin secretion regarding
oscillations in glucose (see [43] for a review). Furthermore, as mentioned for the glucocorticoid
treatment, aging is also associated with glucose intolerance/insulin resistance, which may have further
prevented glucose uptake during the energy bolus intake.
In addition, specific defects in AMPK pathways are possible. Indeed, it was shown that
dexamethasone treatment caused intracellular ATP deprivation and robust AMPK activation [44].
This could explain the lack of effect of the energy bolus, which is assumed to increase ATP
availability and reduce AMPK activation. Similarly, aging can disrupt AMPK signaling. For instance,
mitochondrial biogenesis is reduced during aging in muscle, in particular in response to alteration in
initial signaling through AMPK [45].
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Other methodological differences exist between our study and the studies examining the effects
of leucine or carbohydrate supplements for regulating protein synthesis duration [23,24]. The young
mature rats were trained to consume three meals per day and were slightly food restricted (−20%).
Since AMPK is a major sensor of energy availability in tissues, this food restriction could stimulate
AMPK activity. Our older rats were not food-restricted and had much higher stores of energy than the
young adult rats, which could also explain the lack of effect of our energy bolus on protein synthesis.
Limiting Points of the Study
In the case of the glucocorticoid-treated minipigs, we may also hypothesize that, contrary to
rodents, the CHO bolus was unable to prolong the duration of the anabolic response to food intake
in healthy control animals fed a whey protein meal. We did not perform trials with this group in the
present study, so we cannot exclude that the lack of effect of the CHO bolus was not related to the
glucocorticoid treatment per se but was possibly also related to species-specific metabolic response
to this nutritional strategy. Another possibility is that since glucocorticoid treatment reduced the
overall response of muscle protein synthesis to feeding, and in particular led to an earlier peak of
protein synthesis, our energy bolus could have been given too late to achieve the stimulation of
muscle protein synthesis in this group. Finally, for technical reasons, we were unable to measure
AMP/ATP and/or P-AMPK/AMPK ratios, which would have been a beneficial addition to our study.
However, we had already shown that in both the models tested, resistance to the anabolic effect of
food intake was indeed correlated with a defect in the activation of the Akt/mTOR signaling pathway,
and thus the energy bolus was a pertinent strategy for trying to prevent this resistance and prolong
its duration [9,10]. Further studies are necessary to confirm that the “energy bolus strategy” is not
possible in catabolic situations.
5. Conclusions
The use of a simple energy bolus to prolong the anabolic response to a meal would have been
a very interesting tool for preventing muscle loss during catabolic states. The carbohydrate bolus
was indeed efficient in young rats fed whey protein meals to sustain muscle protein synthesis [24].
However, our attempt to prolong the already weak anabolic effect of whey in our catabolic model and
to increase the anabolic muscle response of whey during aging using a desynchronized carbohydrate
bolus during the postprandial period did not succeed. We emphasize that nutritional strategies aimed
at preventing the adverse effect of catabolic states on skeletal muscle requires additional studies and
would probably need a combination of several levers, including physical activity.
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Abstract: Not only are energy expenditure (EE) and the respiratory quotient (RQ) parameters of
the energy nutrient utilization and energy balance, they are also related to the development of
obesity. In this study, post-meal night-time energy metabolism was investigated following the oral
ingestion of wheat albumin (WA) with a late evening meal. A randomly assigned, double-blind,
placebo-controlled crossover trial for a single oral ingestion in healthy participants was completed.
The participants ingested the placebo (PL) or WA (1.5 g) containing tablets 3 minutes before
the late evening meal at 22:00 hour, and energy metabolism was measured using a whole-room
indirect calorie meter until wake-up. The participants were in bed from 00:00 hour until 06:30 hour.
Twenty healthy participants completed the trial and were included in the analyses. Night-time
RQ and carbohydrate oxidation were significantly lower following the WA treatment as compared
with the PL treatment. Although the total EE was not significantly different between treatments,
postprandial fat oxidation was significantly higher following the WA treatment as compared with the
PL treatment. In conclusion, WA has the potential to shift the energy balance to a higher ratio of fat
to carbohydrate oxidation during the night.
Keywords: energy expenditure; fat oxidation; human; respiratory quotient; wheat albumin
1. Introduction
Obesity is well known to result from an imbalance between energy consumption and expenditure.
Therefore, increases in physical activity or proper diet therapy are recommended to maintain
body weight. In addition, recent studies have reported that a lower respiratory quotient (RQ)
or ratio of fat to carbohydrate oxidation was associated with weight gain over several years in
non-diabetic Pima Indians [1] and non-obese Italian women [2], even after the adjustment for energy
expenditure (EE), suggesting that the RQ is an independent predictor against the development of
obesity. Moreover, in individuals with obesity, carbohydrate oxidation did not change while fat
oxidation was attenuated by aging [3]. Thus, in addition to the imbalance between energy consumption,
a lower ratio of fat to carbohydrate oxidation is a risk factor for weight gain.
A previous study showed that wheat albumin (WA), which has a long history of human
consumption as a natural food constituent, is a potential agent against postprandial hyperglycemia [4].
As carbohydrate overloading stimulates carbohydrate oxidation together with fat storage and reduced
fat oxidation [5], we hypothesized that carbohydrate loading during the night would induce a lower
ratio of fat and carbohydrate oxidation, even in healthy individuals, presumably due to the lower
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physical activity during the night. Based on our unpublished pilot study, we predicted that this
phenomenon would be improved by WA via its suppressive effect on the glucose response after meals.
Thus, we investigated energy metabolism during the night with or without a single oral ingestion
of WA with a late evening meal.
2. Materials and Methods
2.1. Ethics Approval and Consent to Participate
This study was performed in accordance with the tenets of the Declaration of Helsinki (2013) and
was approved by the Ethical Committee of the Kao Corporation (Tokyo, Japan). After receiving a full
explanation of the study, all participants provided written informed consent. The study was registered with
the University Hospital Medical Information Network (UMIN) clinical registry prior to the enrolment of the
first participant as UMIN000020151; registered 18 December 2015 at http://www.umin.ac.jp/ctr/index.htm.
2.2. Study Design
This study was a randomized, double-blind, placebo-controlled, crossover trial performed under
supervision by the physician in charge with a 5-day washout period. The study protocol is shown in
Figure 1. Between the screening and the second visit, the participants were instructed to maintain and
record their dietary, alcohol, and smoking habits, and level of physical activity. The participants were
prohibited from drinking alcohol and undergoing heavy exercise the day before the visits and from
smoking cigarettes on the days of the visits based on the report showing that the energy expenditure
was increased by exercise or smoking [6]. The participants consumed a designated meal (3310 kJ,
protein (P):fat (F):carbohydrate (C) = 14:25:61 as the energy value) for dinner in the evening until
21:00 hour one day before the trial, and had a designated breakfast (2249 kJ, P:F:C = 11:51:38 as the
energy value) at 08:00 hour and designated lunch (2887 kJ, P:F:C = 17:18:65 as the energy value)
at 12:00 hour on the day of the trial. The participants were not allowed any energy intake other
than the designated meals from after dinner on the day before the visit until after completion of the
visit. After bathing, the anthropometric parameters of the participants, such as body weight and
blood pressure, were measured, as shown in Table 1, and then they entered the whole-room indirect
calorie meter (chamber room) at 19:00 hour and underwent low-energy activities such as watching TV,
using the PC, or reading books in a sitting position until 21:00 hour to habituate to the conditions of
the chamber room (25 ◦C, 40% humidity). At 21:00 hour, the participants’ baseline energy metabolism
levels were measured in a sitting position for 30 minutes. Blood samples were obtained at 21:30 hour
via the specific window on the chamber door to collect samples with no air exchange between the inside
and outside of the room. The participants ingested PL or WA (1.5 g) containing tablets 3 min before the
designated late evening meal (Japanese style meal, such as rice, grilled fish, grilled chicken, and boiled
vegetables; 3423 kJ, P:F:C = 16:19:65 as the energy value) at 22:00 hour and their energy metabolism
was measured until wake-up. The participants slept from 00:30 hour until 06:30 hour and their sleep
quality was measured using an Actigraph (ActiGraph, Pensacola, FL, USA). Water consumption was
controlled during the measurement period. The treatment allocation was concealed throughout the
study (from screening to finalizing the dataset) from the people involved, including the participants,
the caregivers, the physicians, the manufacturers of the test tablets, the person in charge of the
allocation, and the outcome assessors.
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Figure 1. The study protocol.
Table 1. Characteristics of the participants.
Parameter Value
Number of participants (male/female) 20 (14/6)
Age, years 38 ± 10
Body weight, kg 62.4 ± 9.8(M, 67.7 ± 7.7; F, 51.9 ± 4.0)
Body mass index, kg/m2 21.8 ± 1.9
Fat mass, kg 12.5 ± 2.9
Fat free mass, kg 49.8 ± 8.2
Systolic blood pressure, mmHg 124 ± 18
Diastolic blood pressure, mmHg 73 ± 14
Glucose, mmol/L 5.36 ± 0.31
Insulin, pmol/L 19.2 ± 7.2
Triglyceride, mg/dL 0.894 ± 0.485
Data are means ± standard deviations. M, male; F, female.
2.3. Participants
A sufficient sample size for the primary outcome of postprandial fat oxidation was estimated to be
20 participants based on the outcomes of our unpublished pilot study outcome (power 0.8 and
type I error 0.05). In this study, potential participants were screened from men and women
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aged from 24 to 59 years. Participants were excluded if they met the following exclusion criteria:
(1) Presence of liver, kidney, or heart disease; respiratory, endocrine, metabolism, nervous system,
or consciousness dysfunction; diabetes; or other diseases; (2) previous experience of seizures based
on circulatory-diseases or under treatment for a condition of this type; (3) presence of arrhythmia;
(4) taking medications for hyperglycemia, lipidemia, or hypertension; (5) experience of seizures based
on a neural disease; (6) surgery within two months before the trial; (7) previous gastrectomy or
enterectomy; (8) allergies to any constituents in the test meal or tablets; (9) unpleasant feeling during
blood drawing; (10) claustrophobia; (11) insomnia; (12) chronic headache; (13) donation of 200 mL or
more of blood within one month before the trial or 400 mL or more of blood within three months before
the trial; (14) a habitual bed-time of after 1:00 a.m. on weekdays; (15) heavy smoker (>20 cigarettes);
(16) weight change of more than 2.0 kg one month prior to informed consent; (17) shift worker or
engaged in night work and shift operations three months prior to informed consent; (18) pregnant
or expecting pregnancy; (19) taking supplements or food for a specific use of health authorized by
the government; (20) were not checked by a doctor regarding their health condition or their health
examination results for the past two years prior to the trial could not be accessed; (21) did not disclose
their age and their latest health examination result; (22) did not reply to the questionnaire about living
situation and condition; and (23) could not indicate their menstruation situation. The participants
were randomly assigned to each sequence (ingestion order) with stratified randomization for glucose,
triglyceride, age, and sex using computer-generated random numbers under blind conditions.
2.4. Test Tablets
The test diet was three tablets containing a total of 1.5 g WA for a single oral administration.
The PL tablets did not contain any WA. These were prepared using identical ingredients including
flavors and preservatives except for the WA, with a weight of 1.1 g for each tablet. The energy value
of a single dose was 14.7 kJ for the WA tablet and 10.9 kJ for the PL tablet. The tablets could not be
distinguished by appearance, taste, or odor and were provided to the participants after concealment.
2.5. Whole-Room Indirect Calorie Meter
EE and substrate utilization for each participant were measured in the respiratory chamber.
Whole-room indirect calorimeter measurements were obtained by the previously described methods [7].
In brief, the room temperature, humidity, and fresh airflow were set to 25 ◦C, 40%, and 70 L/minute,
respectively. Oxygen consumption (VO2) and carbon dioxide production (VCO2) were calculated using
the method reported by Henning et al. [8]. VO2 and VCO2 were calculated across a 60-minute period
to obtain the values of EE, RQ, fat oxidation, and carbohydrate oxidation for the transient response
analysis [9,10]. Protein oxidation was estimated based on urinary nitrogen excretion. All urine samples
were collected and weighed while participants were in the whole-room indirect calorie meter and
measured in triplicate using a chemiluminescent nitrogen analyzer (TN-100, Mitsubishi Chemical,
Kanagawa, Japan).
2.6. Blood Samples
Collected blood samples for the measurements as shown in Table 1 were centrifuged at 1000× g
for 15 minutes at 4 ◦C to isolate the serum or plasma and were measured by SRL, Inc. (Tokyo, Japan)
or LSI Medience Co. (Tokyo, Japan).
2.7. Statistics
The primary outcome of this study was the difference in fat oxidation during the night between
PL and WA treatments. To determine the effect of WA on the primary outcome, the mean value during
the night from 22:00 hour to 06:30 hour was estimated and assessed using a mixed model adjusted
by order of the treatment (No significant effect of order of the treatment was observed). A two-sided
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p-value ≤ 0.05 was considered to be statistically significant. All statistical analyses were performed
using the IBM SPSS Statistics version 19 (IBM Co., Armonk, NY, USA).
3. Results
3.1. Characteristics of the Participants
Thirty-five individuals were screened, and 21 were recruited. Of those recruited, one participant
dropped out of the study right after the consumption of the PL tablet on the first visit due to an
unfavorable feeling due to the texture and flavor of the PL tablet. Twenty participants completed the
study and were included in the analyses. From screening until the second visit, no considerable habitual
changes were recorded. The characteristics of the participants are presented in Table 1. The dietary
records from the three days before the measurements are indicated in Table 2. There were no significant
differences in dietary status before the visits or percentage of sleep during the trial between treatments
(PL and WA, 92.9 ± 4.3% and 91.9 ± 3.5%, respectively, mean ± standard deviation).
Table 2. Dietary records of the three days before the treatment.
Parameter PL WA
Energy, kJ/day 8299 ± 1616 8464 ± 1610
Protein, g/day 72.1 ± 18.0 69.5 ± 17.6
Fat, g/day 64.2 ± 19.4 68.7 ± 22.7
Carbohydrate, g/day 249.2 ± 54.5 250.5 ± 46.1
Data are means ± standard deviations. There were no significant differences between treatments. PL: placebo,
WA: wheat albumin.
3.2. Substrate Utilization
In the study, the test tablets were ingested 3 minutes before the designated meals, and the substrate
oxidation was compared between treatments. The mean fat oxidation during the night increased
significantly following WA ingestion as compared with the PL, whereas the mean carbohydrate
oxidation significantly decreased. There was no significant difference in the mean protein oxidation
(Figure 2). Fat mass is reported to be associated with fat oxidation [11]. In this study, the fat mass
before the WA treatment was not significantly different compared with that before the PL treatments
(PL and WA, 12.5 ± 2.9 kg and 12.5 ± 3.2, respectively, mean ± standard deviation). The fat oxidation
on the fat mass during the WA treatment was significantly increased compared with that during the
PL treatment.
 
Figure 2. (Left) Fat oxidation. (Middle) Carbohydrate oxidation. (Right) Protein oxidation. Data are
means ± standard errors during the night from 22:00 hour to 06:30 hour. Significant differences between
the treatments were assessed with a mixed model adjusted by order of treatment.
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3.3. EE and RQ
There were no significant differences in the baseline EE (PL and WA, 1189 ± 182 kJ and 1150 ± 156,
respectively, mean ± standard deviation) and the baseline RQ (PL and WA, 0.816 ± 0.020 L/L/h and
0.805 ± 0.026, respectively, mean ± standard deviation). There was no significant difference in the
mean EE during the night between treatments; however, the mean RQ was significantly lower after WA
ingestion than after PL ingestion (Table 3), suggesting a trend in fuel utilization of greater fat oxidation
during the night following the WA treatment. Fat free mass change is reported to be associated
with EE [12]. In this study, the fat free mass before the WA treatment was not significantly different
compared with that before the PL treatment (PL and WA, 49.8 ± 8.2 kg and 49.8 ± 8.0, respectively,
mean ± standard deviation). The EE on the fat free mass was also not significantly different between
the treatments.
Table 3. Energy expenditure (EE) and respiratory quotient (RQ).
Parameter PL WA
EE, kJ/h 1148 ± 139 1142 ± 122
RQ, L/L/h 0.904 ± 0.027 0.890 ± 0.032 **
Data are means ± standard deviations during night from 22:00 hour to 06:30 hour. The asterisk denotes significant
differences between the treatments assessed with a mixed model adjusted by order of the treatment; ** p < 0.01.
4. Discussion
In this study, the effect of the WA treatment on substrate oxidation during the night was
investigated in healthy humans. Our previous unpublished study showed a moderate suppressive
effect of WA on the glucose response during the night. The underlying mechanism of the effect is
thought to be its inhibitory action on alpha-amylase activity [4], which induces a lower carbohydrate
absorption and may also accompany the lower glucose-dependent insulinotropic polypeptide (GIP)
response. Indeed, the plasma concentration of GIP was lowered significantly by the WA treatment
when compared to the PL treatment in our previous unpublished study. A higher postprandial
concentration of GIP, an incretin that stimulates insulin secretion from the pancreatic beta-cells, has been
directly associated with a lower metabolic rate [13] and stimulates fat accumulation in adipose tissue as
an exopancreatic function [14]. Additionally, higher blood GIP levels induced by chronic GIP treatment
were shown to reduce fat utilization in high-fat diet-fed mice [15]. Thus, the potential mechanism
underlying enhanced fat oxidation by WA treatment may be associated with the GIP lowering effect.
In the present study, fat oxidation was enhanced and RQ was lowered following WA treatment,
but EE was not changed. An imbalanced energy balance between energy consumption and the
expenditure is directly associated with obesity [16]. Therefore, the anti-obesity effect of tWA via acute
increased EE was not expected. However, a low ratio of fat to carbohydrate oxidation was reported to be
a predictor of future weight gain in several studies, such as in Pima Indians [1] and healthy women [2].
An assumable underlying mechanism was reported to be enhanced lipogenesis induced by the overflow
of carbohydrate metabolism [5]. Therefore, a lowering effect on the ratio of fat to carbohydrate
oxidation may reduce the overflow. Although we observed an acute effect on RQ, repeated nightly
treatment of WA might have an impact on body fat accumulation overnight. Thus, an intervention
study with a focus on weight gain in such patients with night eating syndrome [17] is of interest.
The difference of mean fat oxidation between the treatments was 0.35 g/h (PL and WA,
1.64 ± 0.73 g/h and 1.99 ± 0.79, respectively, mean ± standard deviation). Based on this, the estimated
cumulative fat oxidation during the night from 22:00 hour to 06:30 hour (8.5 hours) was 3.0 g.
The impact of this amount is estimated to be 1.08 kg as fat under simple calculation if the repeated
WA treatment was performed for one year. However, given that there was no difference in energy
expenditure, it remains unknown if this would result in any change in body weight or composition.
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The limitations and potential biases in this study were the imbalanced gender of the participants
(male:female = 14:6) and the use of a single race (Japanese). The included authors are employees of the
manufacturer of the test diet.
5. Conclusions
WA has the potential to shift the energy balance to a higher ratio of fat to carbohydrate oxidation
during the night.
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Abstract: Milk proteins have been hypothesized to protect against type 2 diabetes (T2DM) by
beneficially modulating glycemic response, predominantly in the postprandial status. This potential
is, amongst others, attributed to the high content of whey proteins, which are commonly a product of
cheese production. However, native whey has received substantial attention due to its higher leucine
content, and its postprandial glycemic effect has not been assessed thus far in prediabetes. In the present
study, the impact of a milk protein hydrolysate of native whey origin with alpha-glucosidase inhibiting
properties was determined in prediabetics in a randomized, cross-over trial. Subjects received a
single dose of placebo or low- or high-dosed milk protein hydrolysate prior to a challenge meal high
in carbohydrates. Concentration–time curves of glucose and insulin were assessed. Incremental areas
under the curve (iAUC) of glucose as the primary outcome were significantly reduced by low-dosed
milk peptides compared to placebo (p = 0.0472), and a minor insulinotropic effect was seen. A longer
intervention period with the low-dosed product did not strengthen glucose response but significantly
reduced HbA1c values (p = 0.0244). In conclusion, the current milk protein hydrolysate of native
whey origin has the potential to modulate postprandial hyperglycemia and hence may contribute in
reducing the future risk of developing T2DM.
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Abstract: Milk proteins have been hypothesized to protect against type 2 diabetes (T2DM) by
beneficially modulating glycemic response, predominantly in the postprandial status. This potential
is, amongst others, attributed to the high content of whey proteins, which are commonly a product of
cheese production. However, native whey has received substantial attention due to its higher leucine
content, and its postprandial glycemic effect has not been assessed thus far in prediabetes. In the
present study, the impact of a milk protein hydrolysate of native whey origin with alpha-glucosidase
inhibiting properties was determined in prediabetics in a randomized, cross-over trial. Subjects
received a single dose of placebo or low- or high-dosed milk protein hydrolysate prior to a challenge
meal high in carbohydrates. Concentration–time curves of glucose and insulin were assessed.
Incremental areas under the curve (iAUC) of glucose as the primary outcome were significantly
reduced by low-dosed milk peptides compared to placebo (p = 0.0472), and a minor insulinotropic
effect was seen. A longer intervention period with the low-dosed product did not strengthen glucose
response but significantly reduced HbA1c values (p = 0.0244). In conclusion, the current milk protein
hydrolysate of native whey origin has the potential to modulate postprandial hyperglycemia and
hence may contribute in reducing the future risk of developing T2DM.
Keywords: alpha-glucosidase inhibitor; biopeptides; blood glucose; glycemic control; hyperglycemia;
milk peptides; postprandial; prediabetes; pre-meal; type 2 diabetes
1. Introduction
Insulin resistance, a condition established by genetic and environmental factors, leads to impaired
glucose tolerance due to an imbalance between insulin sensitivity and insulin secretion. This so-called
prediabetic status plays an important pathophysiological role in the development of type 2 diabetes
mellitus (T2DM) and is a hallmark of obesity, dyslipidemias, and other major risk factors contributing
to the metabolic syndrome [1]. Over the years, our understanding of insulin resistance has improved
tremendously, while T2DM is expected to have increasing detrimental effects on the health of
populations and healthcare systems. Aside from preventive activities, to combat sedentary lifestyles
and unbalanced diets in particular, reducing postprandial glycemia is as important as lowering fasting
blood glucose levels to limit (or at least delay) the appearance of T2DM in at-risk individuals, and
even modest postprandial hyperglycemia may lead to β-cell dysfunction [2,3]. As such, numerous
studies have consistently demonstrated that pathophysiological abnormalities associated with an
increased postprandial hyperglycemia ≥155 mg/dL (value of 1 h postload glucose concentration)
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including impaired insulin sensitivity, β-cell dysfunction, and increased glucose intestinal absorption,
which are linked to an increased risk for future T2DM [2]. Most anti-diabetic agents that are
currently available reduce fasting blood glucose levels but have little impact on postprandial glycemic
excursions and thus do not normalize postprandial hyperglycemia [4]. In this context, simple dietary
modifications, proper nutrition, and exercise may modify postprandial derailments; also, there is
growing interest in food components that may beneficially modulate glycemic response, predominantly
in the postprandial status.
There are many scientific reports highlighting the role of biologically active peptides derived
from food proteins (e.g., milk, eggs, plant proteins), and clinical studies revealed that protein-rich
dairy products are beneficial for reducing the risk of developing T2DM due to their glycemic and
insulinotropic effect to improve glycemic status [5–8]. Thereby, the possible protective mechanism has
been ascribed to the protein fraction [9–11]. Such biologically active protein fragments are released from
parent proteins after enzymatic action (e.g., protein hydrolysis in the digestive tract) and positively
influence various functions of the human body by interacting with enzymes or receptors [12,13].
Moreover, it is assumed that milk proteins have more effects on metabolic response in subjects with
disturbed glucose metabolism [14]. Milk comprises two protein fractions, the slowly digestible
casein and the fast digestible whey fraction [15]. Whey from native origin is produced by direct
filtration of pasteurized skimmed milk and is therefore a more native protein compared to whey
protein from cheese production with more denaturated protein character and less leucine content
than native whey [16]. A further degradation of proteins is achieved by hydrolysis in mainly di-
and tri-peptides via proteolytic enzymes in the digestive tract, resulting in a complex mixture of
peptides of different length and free amino acids [17]. The hydrolysis process may change the
kinetic pattern of the specific protein fractions, as shown for casein with more rapid digestion
characteristics [15,18,19] and for whey with an improved absorption in a perfused human jejunum
model [20]. Milk-derived bioactive peptides can be encrypted in both casein (α-, β-, and γ-casein) and
whey proteins (β-lactoglobulin, α-lactalbumin, serum albumin, immunoglobulins, lactoferrin, and
protease-peptone fractions) [21]. Also, milk protein hydrolysates were previously analyzed for their
antidiabetic properties due to inhibition of alpha-glucosidase, a carbohydrate degrading digestive
enzyme [22,23]. Counteracting alpha-glucosidase action through inhibition delays carbohydrate
hydrolysis and consequently extends its digestion time (gastric emptying), which results in reduced
glucose absorption from the gastrointestinal tract. Thus, postprandial levels of blood glucose and
insulin are reduced [23,24]. The alpha-glucosidase inhibitor acarbose was shown to be an effective and
valuable option in delaying or preventing the progression to T2DM [25]. However, this oral antidiabetic
drug is known to cause gastrointestinal side effects when used as long-term therapy. Thus, in the last
few years, progress has been attained in the search for new peptide alpha-glucosidase inhibitors, either
synthetic or of natural origin.
The purpose of our study was to evaluate whether a proprietary milk protein hydrolysate
of native whey origin containing alpha-glucosidase inhibiting bioactive peptides might improve
postprandial glucose profile after single dosage or after a six week intervention period in prediabetic
subjects. Therefore, both glucose response and insulin secretion were assessed from individual
concentration–time curves. We used Pep2Dia® as an investigational product containing a bioactive
arginine-proline (AP) dipeptide with alpha-glucosidase inhibiting properties. Based on literature and
on proprietary in vitro studies according to Kang et al. [26] (European Patent EP 3,107,556), there is
evidence that the current milk protein hydrolysate acts on the inhibition of alpha-glucosidase with an
IC50 value of 0.0025 mg/mL and thereby reduces glucose absorption from the gastrointestinal tract [27].
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2. Materials and Methods
2.1. Study Subjects
From September 2018 to January 2019, a total of 21 subjects were included in the monocentric
study at BioTeSys GmbH (Esslingen am Neckar, Germany). Overall, 84 non-smoking female and male
people aged 30–70 years with a body mass index (BMI) of 19–35 kg/m2 were pre-screened for eligibility,
from which 30 subjects were screened to ascertain their eligibility. The main inclusion criteria were
prediabetic HbA1c values between 5.7% to 6.4% and/or fasting glucose ≥5.6 mmol/L (≥100 mg/dL) and
<7.0 mmol/L (<125 mg/dL), confirmed twice on two separate days if HbA1c value was <5.7%. The
subjects had to be in good physical and mental health represented by the medical history, physical
examination, electrocardiogram, vital signs, and results of biochemistry and hematology. Finally,
21 subjects (8 men, 13 women) were included and all completed the study successfully, as shown in
Figure 1.
Figure 1. Subject recruitment flow chart.
The main exclusion criteria were a relevant history or presence of any medical disorder potentially
interfering with this study (e.g., malabsorption, chronic gastro-intestinal diseases, severe depression,
cardiovascular disease occurrence within the last 3 months, etc.), regular intake of medications or
supplements known to affect glucose tolerance, diagnosed type 2 diabetics with medical treatment,
and drug, alcohol, and medication abuses. Medications for treatment of chronic diseases that do not
affect the metabolism of the study product were permitted and were judged individually regarding
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interference with the study by an investigator. Any concomitant chronic disease medication and
medication used for the treatment of adverse events (AEs) was documented.
With regard to the 84 subjects given information and pre-screened by phone interview, the
inaptitude was due to fasting glucose levels ≤100 mg/dL or >125 mg/dL in previous laboratory
reports from subjects’ physician, BMI >35 kg/m2, metformin medication, lack of interest/response, and
time collision.
This study was conducted in orientation towards the guidelines of the Declaration of Helsinki and
Good Clinical Practice. The protocol and all documents were approved by the Institutional Review
Board (IRB) of Landesärztekammer Baden-Württemberg with the reference number F-2018-062. A
written informed Consent Form was obtained from all participants prior to screening evaluations. The
present study was registered with ClinicalTrials.gov (ID: NCT03,932,695).
2.2. Study Design
The study was performed as a randomized, double-blind, placebo-controlled, monocentric,
3-way-cross-over study with 21 eligible subjects under fasted conditions at the study site of
BioTeSys GmbH, Esslingen, Germany. A CONSORT 2010 checklist of information is included
in the Supplementary Materials (Table S1). There was a wash-out period of 7 days between the study
days to assess postprandial glucose response after a challenge meal. Within the cross-over study
design, subjects received all interventions randomly allocated to 3 sequence groups.
Following an overnight fasting period of at least 10 h, a permanent venous catheter was inserted,
and baseline blood (time points were 10 min and 5 min prior to challenge meal) was examined at the
three visits within the cross-over study (kinetic days). Subjects received a single dose of placebo or
1400 mg (low dose) or 2800 mg (high dose) bioactive peptides from milk protein hydrolysate 15 min
prior to a challenge meal high in carbohydrates (consisting of white bread, jam, and butter standardized
to 75 g carbohydrates), and blood was further sampled at 15, 30, 45, 60, 90, 120, 150, and 180 min after
the intake of the challenge meal. All participants received the two dosages of the study product and
the placebo, and effects were compared to the placebo.
Additionally, an open-label single arm phase was performed with a daily intake of the low dose
milk peptide concentration for 6 weeks to estimate effects over a longer period. After the 6 week
intervention period, the postprandial assessment after the intake of 1400 mg bioactive peptides from
milk protein hydrolysate 15 min prior to a challenge meal was repeated comparable to the cross-over
phase. Subjects were encouraged not to change their food habits and physical activity during the
study. Therefore, nutrition habit questionnaires were filled in during screening after the single dose
cross-over study (= before 6 week intervention) and after 6 week intervention within the open-label
single arm design. Thereby, subjects were asked about their food habits using a semi-quantitative
short questionnaire assessing different food categories (fruit, vegetables, sausage, meat, intake of dairy
products, sweets including beverages).
Blood analysis comprised determination of glucose and insulin plasma concentration over time at
defined intervals besides blood routine parameters such as hematogram or total cholesterol. Subjects
were asked to avoid alcohol 24 h before each study visit and to consume standardized meals 24 h
prior to each visit to control for external confounding factors. In detail, breakfast was individually
standardized, and for lunch, tortellini with pesto was served. Furthermore, a standardized snack
(apple and cookie) was provided, and bread with cream cheese “Frischkäse” and cucumber had to be
consumed as dinner. Additionally, subjects were not allowed to consume food or drink anything other
than water for at least 10 h before testing, and no strenuous physical activity or endurance sports were
allowed within 24 h before the study visits. In the morning of the study visits, subjects were instructed
to drink a minimum of 200 mL water after waking up before they came to the study site.
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2.3. Intervention
The investigational product (Pep2Dia®) was a milk protein hydrolysate from native whey protein
containing a bioactive arginine-proline (AP) dipeptide (between 0.15% and 0.4%) with alpha-glucosidase
inhibiting properties. The proprietary compound was prepared by Ingredia S.A. (Arras CEDEX, France)
and was produced from native whey extracted by filtration according to Boutrou et al. [28]. Furthermore,
a protease was used to perform the respective procedure. The protein is composed of 100% soluble
protein with mainlyβ-lactoglobulin andα-lactalbumin. The profile of the peptides in the investigational
product was as follows: 94.5% with a molecular weight (MW) <5000 Da, 0.5% with 5000–10,000 Da MW,
and 5% with a MW > 10,000 Da. The products were provided in capsules (vegetable fiber) with 350 mg
of milk protein hydrolysate per capsule (which includes, on average, 0.96 mg AP peptide). Maltodextrin
with dextrose equivalent of 9 (DE9) was used as placebo with 350 mg per capsule. For single dose
intake, 4 verum capsules and 4 placebo capsules (low dose) or, for high dose, 8 verum capsules
were taken 15 min prior to a challenge meal. In the open-label single arm phase, subjects consumed
the investigational product (4 verum capsules) daily 15 min prior to lunch, and at the study visit,
subjects ingested 4 verum capsules after an overnight fasting period 15 min prior to a challenge meal.
Manufacturing and encapsulation were carried out in compliance with Good Manufacturing Practice
conditions, and all excipients as well as capsule shells met the current European food regulations. Size,
shape, color, odor, and secondary packaging were identical between verum and placebo capsules to
ensure double-blind conditions. Capsules were provided by Ingredia S.A. (Arras CEDEX, France), and
subjects received either placebo or low dose (1400 mg) or high dose (2800 mg) milk protein hydrolysate.
2.4. Sample Collection and Processing
Venous blood samples were taken at screening visits to assess safety parameters (differentiated
hematogram and clinical laboratory). At the same day, analyses with standard methods were performed
at an accredited laboratory (Synlab Medizinisches Versorgungszentrum Leinfelden-Echterdingen,
Germany). Blood samples were centrifuged at 3000× g for 10 min at 4 ◦C, and aliquots for spare
samples for the determination of glucose and insulin were taken. Plasma glucose was analyzed
using the Atellica® CH analyzer (Siemens Healthcare GmbH, Germany; assay: Atellica CH Glucose
Hexokinase_3, Ref. 11,097,592) with enzymatic UV detection based on the glucose hexokinase method.
Briefly, glucose-6-phosphate formed from glucose and ATP by hexokinase was oxidized by NAD+ in
a reaction catalyzed by glucose-6-phosphate dehydrogenase to give NADH, which was quantitated
spectrophotometrically at 340/410 nm. Serum insulin was analyzed using the Atellica® IM analyzer
(Siemens Healthcare GmbH, Germany; assay: Atellica IM IRI, Ref. 10,995,628) with insulin detection
based on a sandwich-type of electrochemiluminescence immunoassay using two monoclonal antibodies
against insulin. Thereby, insulin quantification was linked to the number of relative light units (RLUs).
Fasting blood glucose was controlled in finger prick samples using the HemoCue Glucose 201+
Analyzer (HITADO GmbH, Möhnesee, Germany) on the morning of each study day.
2.5. Methods for Safety (Adverse Events, Concomitant Medication, and Tolerability)
During the study intervention, the subjects documented any adverse events and concomitant
medication. The tolerability was assessed at the end of the study days. The subjects rated overall
tolerability to three categories from “well tolerated”, “slightly unpleasant”, or “very unpleasant”.
2.6. Data Analysis and Statistics
Based on previous data [29] reporting a reduction of postprandial glucose levels after a challenge
meal with different milk proteins with up to 18% reduction, a conservative assumption with a reduction
of 11% was applied for the prior sample size calculation, resulting in an effect size of d = 0.74. Based
on the following input details—alpha error problem of α = 0.05, actual power of 80%, correlation
between groups of 0.5—a sample size of n = 17 subjects was estimated, which was applied for the 3-way
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cross-over design in phase I. Considering a drop-out rate of 15% and equally sized sequence groups
for the 3-way cross-over design in phase I, the study was performed with n = 21 subjects. The part II
open-label phase was planned to be exploratory as a first proof of concept study to estimate long-term
effects and to gain first experiences for further clinical studies. Pharmacokinetic parameters were
individually calculated with the blood concentration–time curves. As the primary efficacy endpoint,
the incremental area under the observed concentration–time curve above the baseline (iAUC), more
precisely iAUC0–180 min, was calculated by applying the trapezoidal rule with the y-axis, defined by
glucose plasma concentration, and the x-axis defined via sampling time points. Secondary efficacy
target variables were iAUC0–180 min of insulin, total AUC0–180 min, and ΔCmax of glucose and insulin.
Primary and secondary endpoints were analyzed using a linear mixed model of iAUC with treatment
(3 levels), period (3 levels), sequence (3 levels), and baseline blood glucose level within study periods as
fixed effects and subject as random effect. Due to the 7 days wash-out period, examination of possible
carry-over effects was not foreseen. The residuals of this model were checked for normality using
the Shapiro–Wilk test with an alpha level of 0.05. If applicable, data were log transformed prior to
analysis. Multiple pairwise comparisons of least squares means of primary and secondary endpoints
were adjusted by the method of Dunnett–Hsu in order to assess differences between the two active
treatments and placebo. Data of the cross-over design are presented as least square means with 95%
confidence interval (CI).
Moreover, in the open-label study period, besides HbA1c values, the homeostasis model assessment
(HOMA) index and the Matsuda index were used to evaluate the impact of the study product intake
during a longer period on insulin sensitivity, and comparisons were performed between the baseline
and the end of intervention. Additionally, during the open-label study period of 6 weeks, the
pharmacokinetic endpoints after the challenge test were compared with placebo during the study
phase I. Data were evaluated using a paired t-test. In case of non-normal distribution of data, a
Wilcoxon signed-rank test was applied. Data of the open label phase are presented as means with
95% CI. All 21 subjects were included in the analysis. Statistical tests were performed two-sided,
and p values < 0.05 were statistically significant. Statistical evaluation, summary tables, and graphs
were generated using GraphPad Prism software (La Jolla, CA, USA) and SAS V9.4 statistical software
(SAS Institute, Cary, North Carolina).
3. Results
3.1. Subject Characteristics
The investigated study population was a non-smoking prediabetic study group, on average
62.4 years (95% CI: 60.0–64.9) old with a BMI of 28.1 kg/m2 (95% CI: 26.3–30.0). A total of 21 subjects
(n = 13 women, n = 8 men) completed the study.
Table 1 presents the participants’ demographic data and screening data. Vital signs and blood
routine parameters were within normal range. None of the subjects were vegetarian or vegan, and 52%
of the participants practiced sports on a regular basis.
Table 1. Demographic and screening data.
Variable Prediabetics (n = 21)
Mean 95% CI
Age (years) 62.4 (60.0–64.9)
BMI (kg/m2) 28.1 (26.3–30.0)
Systolic BP (mmHg) 134.7 (127.3–142.1)
Diastolic BP (mmHg) 83.9 (79.6–88.2)
HbA1c (%) 5.83 (5.69–5.97)
Fasting plasma glucose (mg/dL) 109.6 (105.3–113.9)
BMI: body mass index; BP: blood pressure; HbA1c: glycated haemoglobin.
164
Nutrients 2019, 11, 1700
Subjects were advised not to change their eating habits, which were controlled by a
semi-quantitative nutrition habit questionnaire comprising 24 food categories. There was no significant
change over intervention period (p = 0.2148). Fasting baseline values of glucose and insulin did not
differ among the single dose treatment days (p > 0.05). Regarding the homeostasis model assessment
of insulin resistance (HOMA-IR), a parameter that estimates insulin sensitivity considering the relation
between fasting insulin and fasting glucose, was—on average—clearly above the cut-off level of
two [30], indicating insulin resistance and not different among the testing days (placebo: 2.95; low dose:
2.80; high dose: 2.96; six week intervention: 2.84; Figure 2).
 
Figure 2. Distribution of homeostasis model assessment (HOMA) index at baseline at the testing days
before intake of placebo or milk protein hydrolysate containing bioactive milk peptides in low and high
doses. Data represent mean ±95% CI. Data represent mean ±95% CI. No statistical difference between
baseline conditions.
3.2. Milk Peptides and Their Postprandial Effect on Glucose Response after Single Dose Intake
There was a significant increase of plasma glucose concentration over time after the challenge
meal (p < 0.0001 after all study interventions). The concentration–time curves indicate that milk
peptides have an impact on postprandial blood glucose profile in prediabetic subjects (Figure 3). No
dose linearity between low dose (1400 mg) and high dose (2800 mg) milk peptides could be revealed,
and the effects were even slightly more distinct after single dose intake of low dose milk peptides in
comparison to the high dose.
Figure 3. Glucose responses to a single intake of placebo or low- or high-dosed milk protein hydrolysate
containing bioactive peptides consumed 15 min prior to a challenge meal. Data represent mean
±95% CI.
In terms of iAUC0–180 min glucose, single dose intake of low dose milk peptides resulted in
significantly reduced values compared to the placebo (3441.1 vs. 4312.0 mg/dL × min, p = 0.0472),
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whereas the high dose milk peptides were not statistically different to the placebo (p = 0.1749) (Table 2).
The secondary endpoint ΔCmax, the maximum increase of glucose above baseline, confirmed the
significant postprandial glucose lowering effect of the low dose milk peptides with a mean increase
in plasma glucose of 44.8 mg/dL (95% CI: 35.9–53.8) vs. 52.8 mg/dL (95% CI: 43.9–61.8) for placebo
(p = 0.0237) vs. 49.1 mg/dL (95% CI: 40.1–58.0) for high dose milk peptides (Table 2). In addition,
analyses of total AUC0–180 min and Cmax revealed statistical significance for the low dose milk peptides
in comparison to the placebo (low dose vs. placebo: AUC0–180 min: 21,931 vs. 23,073 mg/dL × min,
p = 0.0313; Cmax: 152.1 mg/dL (95% CI: 143.1–161.0) vs. 160.1 mg/dL (95% CI: 151.1–169.0), p = 0.0237).
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3.3. Milk Peptides and Their Postprandial Effect on Insulin Response after Single Dose Intake
The impact of milk peptides on insulin release as a response to the challenge meal was a minor
evident (Figure 4). There was a slight reduction of iAUC of insulin after an intake of low dose milk
peptides in comparison to the placebo [low dose: 6339.8 μU/mL ×min (95% CI: 4997.5–8042.5); placebo:
6844.5 μU/mL ×min (95% CI: 5396.5–8681.9)]; however, the difference was not significant (p = 0.4296).
No difference to the placebo was seen in the high dose milk peptides (7212.0 μU/mL ×min (95% CI:
5396.5–8681.9) vs. 6844.5 μU/mL ×min (95% CI: 5396.5–8681.9), p = 0.6606). The maximum increase in
plasma insulin (ΔCmax) after the challenge meal was lower for low dose milk peptides compared to
the placebo and the high dose milk peptides [low dose: 66.2 μU/mL (95% CI: 54.8–80.1); high dose:
74.1 μU/mL (95% CI: 61.3–89.5); placebo: 71.4 μU/mL (95% CI: 59.0–86.3)]. ΔCmax of both low and
high dose milk peptides were not different to the placebo (low dose: p = 0.5536; high dose: p = 0.8573).
These results indicate a negligible insulinotropic effect of the current milk protein hydrolysate.
Figure 4. Insulin responses to low and high dose milk protein hydrolysate containing bioactive peptides
consumed 15 min prior to a challenge meal. Data represent mean ±95% CI.
3.4. Six Week Intervention with Low Dose Milk Peptides
Plasma concentrations of fasting blood glucose and fasting insulin after six weeks of low dose milk
peptides intervention were comparable with the fasting conditions prior to the challenge meal with
single dose placebo intervention [baseline vs. six week intervention: 108.0 mg/dL (95% CI: 103.6–112.4)
vs. 106.8 mg/dL (95% CI: 102.4–111.1) for glucose (p = 0.5165); 11.01 mg/dL (95% CI: 8.68–13.34) vs.
10.67 μU/mL (95% CI: 8.22–13.12) for insulin (p = 0.3352)]. Approximation of whole-body insulin
sensitivity, which combines both hepatic and peripheral tissue insulin sensitivity, was performed by
assessment of the Matsuda index; 61.9% of subjects were in the pathological range with values <4,
9.5% in the borderline range with values between 4 and 6, and 28.6% were in the normal (healthy)
range with values of 6–12 at baseline, defined as the condition prior to the six week intervention period.
Daily intake of low dose milk peptides for six weeks did not result in a change of HOMA-IR (baseline
vs. six week intervention: 2.87 (95% CI: 2.28–3.45) vs. 2.84 (95% CI 2.14–3.53); p = 0.5202)), but resulted
in a slight increase of the Matsuda index by trend [baseline vs. six week intervention: 4.32 (95% CI:
3.21–5.43) vs. 4.59 (95% CI: 3.48–5.71); p = 0.0952)] (Figure 5a). There was a significant reduction of
HbA1c levels after a six week intervention treatment with low dose milk peptides resulting in HbA1c
values of 5.69% (95% CI: 5.58–5.79) compared to baseline values of 5.78% (95% CI: 5.67–5.89) with
p = 0.0244 (Figure 5b). Notably, 11 out of 21 subjects (52.4%) completed with HbA1c levels <5.7% after
the six week intervention period.
In accordance with the single dose treatment, the concentration–time curve of postprandial plasma
glucose concentration in response to the challenge meal after six week intervention with low dose milk
peptides was below the placebo intervention at all time points (0–180 min) (Figure 6). However, the six
week intervention period did not strengthen the acute postprandial glucose response in comparison
with the single dose intake of low dose milk peptides, as iAUC values of glucose were similar [single
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dose vs. six week intervention: 3423 mg/dL ×min (95% CI: 2181–4664) vs. 3577 mg/dL ×min (95% CI:
2305–4849); p = 0.6766)] but statistically different to placebo (p = 0.037).
 
(a) (b) 
Figure 5. Distribution of Matsuda index (a) and of HbA1c [%] values (b) after the six week intervention
period with low dose milk protein hydrolysate containing bioactive milk peptides. Data represent
mean ±95% CI. Statistical difference as indicated: * p < 0.05.
Figure 6. Glucose responses after six week intervention with low dose milk protein hydrolysate
containing bioactive milk peptides and after challenge meal. Data represent mean ±95% CI.
Moreover, glucose response analyses in terms of ΔCmax and total AUC0–180 min supported the
abovementioned primary endpoints and confirmed the significant postprandial glucose lowering
effects after low dose milk peptides intervention over a longer period of six weeks (placebo vs. six week
intervention: 53.1 mg/dL (95% CI: 44.1–62.1) vs. 47.5 mg/dL (95% CI: 39.2–55.9), p = 0.0399 for ΔCmax,
and 23,211 mg/dL × min (95% CI: 21,280–25,143) vs. 22,099 mg/dL × min (95% CI: 20,393–23,804);
p = 0.0408 for AUC0–180 min)).
Low dose milk peptides intervention over a period of six weeks had no impact on the insulin
response compared to the single dose intake regarding iAUC and ΔCmax. Again, although descriptively,
there was (on average) a slight reduction by trend of iAUC of insulin in comparison to the placebo
with p = 0.0952 for iAUC insulin (after six weeks: 7434 μU/mL ×min (95% CI: 5770–9097); placebo:
8163 μU/mL × min (95% CI: 5962–10,363)). This was confirmed by ΔCmax values of insulin (after
6 weeks: 76.7 μU/mL (95% CI: 61.4–92.1); placebo: 80.4 μU/mL (95% CI: 61.7–99.1), p = 0.3048)).
3.5. Safety Assessment
All subjects (100%) rated the tolerability of the study products as “well tolerated” during the
kinetic days of single dose intake and after the six week intervention period with low dose milk
peptides. During the assessment of postprandial glucose response after a challenge meal after single
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dose intake, no adverse events (AEs) were reported. In terms of the six week intervention period
with low dose milk peptides, a total of 14 adverse events were assessed by 10 subjects (predominantly
headaches (6 x) and common cold (5 x)). Of those AEs, one serious adverse event (SAE) was reported
on one surgery accompanied with hospitalization. None of the AEs were related to the study product.
4. Discussion
In the present study, we investigated the impact of a proprietary milk protein hydrolysate from
native whey origin containing a bioactive AP dipeptide on postprandial glucose and insulin responses
after a challenge meal in prediabetic subjects after a single dosage regimen or over a longer period
of six weeks. Based on literature and on proprietary in vitro studies according to Kang et al. [26]
(European Patent EP 3107,556), there is evidence that the current milk protein hydrolysate containing
bioactive AP dipeptides acts on the inhibition of alpha-glucosidase with an IC50 value of 0.0025 mg/mL
and thereby reduces glucose absorption from the gastrointestinal tract [27]. The amount of the
bioactive AP dipeptide per capsule is, on average, 0.96 mg and thus in line with the content of already
published bioactive peptides of whey protein origin [31], irrespective of the metabolic effects. The
concentration–time curves indicated that the study product has the potential to counteract postprandial
hyperglycemia in prediabetic subjects. After single dose application, effects on glucose response were
slightly more distinct by intake of low-dosed milk peptides (1400 mg) 15 min prior to a challenge meal
in comparison to the high dose (2800 mg) in terms of reduced iAUC glucose. Compared to placebo, a
significant difference was seen for the low dosage (p = 0.0472) but not for the high dose. Of note, no
linear dose–response relationship could be revealed. This might have been due to the multi-peptide
characteristics, and interactions of single components in different concentrations might have been
responsible for the limited dose–response. However, this needs further exploration in future studies.
In addition, the secondary endpoints ΔCmax, AUC0–180 min, and Cmax supported the findings for the
primary endpoint iAUC and confirmed the significant postprandial glucose lowering effects after
single dose intake of the low-dosed milk peptide.
Milk protein hydrolysates were previously analyzed for their antidiabetic properties with an
alpha-glucosidase inhibiting effect [22,23]. Thereby, potent peptide fractions of a whey protein
concentrate were identified with high biological activities of peptide fractions with a molecular weight
lower than 33 kDa [32]. In what way the biological activity due to molecular weight might be causative
for the postprandial glucose response exceeds the objective of the current study. Compared to already
published literature in which the pre-meal effect of milk proteins (whey proteins) were analyzed in
subjects with and without T2DM, an absent glucose response was demonstrated in both groups [14]
owing to the insulinotropic rather than the glycemic effect of whey protein, which has higher amounts
of lysine, threonine, tryptophan, leucine, and isoleucine [33]. Of note, recent in vitro data using
preadipocytes revealed that the tripeptides IPP (Ile-Pro-Pro) and VPP (Val-Pro-Pro), which are derived
from milk casein, enhance insulin sensitivity and contribute toward the prevention of insulin resistance
in the presence of tumor necrosis factor [34]. VPP-mediated improved insulin sensitivity was also
confirmed in diet-induced obese mice by decreasing pro-inflammatory cytokines in adipose tissue [35].
Further, it is known that whey and casein proteins differentially affect postprandial glucose and insulin
response. It was shown that insulin secretion was greater with whey protein than with casein, whereas
incretin responses in terms of GLP-1 tended to be lower with casein than with whey protein [36].
Analysis of iAUC of insulin release of the individual concentration–time curves revealed that the
study product’s impact on insulin release was minor, evident from the response to the challenge meal.
However, after single dose application there was, although descriptively, on average a slight reduction
of iAUC of insulin after intake of the low-dosed milk peptide in comparison to the placebo but without
reaching statistical significance.
One has to take into account that differential patterns in insulin response after milk protein intake
were reported between studies, which may be the result of a number of fundamental differences
in study design, such as preload design and the type of milk proteins, protein amount, or altered
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milk peptides/bioactive peptide sequences. Results of our study contrast with previous literature
demonstrating a significantly reduced glucose response with a concomitant increase in insulin AUC
by intake of 18 g milk protein (whey) to 25 g glucose [37]. This effect was ascribed to amino acid
availability, which may potentiate the increased insulin response since plasma amino acids also
increased in a dose-dependent manner. Similarly, a combination of whey and free amino acids induced
a rapid insulinotropic effect, which influenced early glycemia [38]. Further literature demonstrated
an insulinotropic effect of milk proteins or whey protein in terms of higher insulin release [14,39,40].
It is discussed that the insulinotropic properties appear to originate from a specific postprandial
plasma amino acid pattern with predominantly isoleucine, leucine, lysine, threonine, and valine, the
main amino acids of whey protein [38]. Whether the difference in the respective glycemic and/or
the insulinotropic responses of the current milk protein hydrolysate with bioactive peptides might
be related to a different incretin pattern or to changes in plasma amino acid concentration was not
clarified in the present study. However, one has to mention that the current milk protein hydrolysate is
of native whey origin, the cleanest and the least processed whey protein available, whereas most of
clinical trials used regular whey protein from cheese whey (e.g., [14,33,37,38,41]). Due to the process of
creating native whey, namely filtration of pasteurized skimmed milk, more proteins remain intact and
thus there is a higher leucine content than the more common whey protein concentrate from cheese
production [42]. Of note, it has been shown that intake of native whey protein induces greater leucine
blood concentrations than other whey protein supplements [16]. Whether the higher leucine content of
the native whey protein might be causative for the more glycemic than insulinotropic response after
the challenge meal is speculative but might be an explanation to already published data from other
groups using regular whey protein from cheese whey.
In addition, it may be considered that a glycemic response does not necessarily impact insulin
release. In this context, the inconsistency between glycemic and insulinotropic responses to fresh milk
and two fermented milk products in healthy subjects was previously addressed [39]. However, it is
known that whey protein in particular tends to be less glycemic and more insulinotropic [40], and
casein, another bioactive milk component, was reported to reduce the postprandial rise in blood glucose
by an increased insulin response and blood glucose disposal in T2DM subjects when coingested with
carbohydrates [43–45]. Interestingly, one study assessed the glycemic response following consumption
of liquid protein preloads of whey (55 g) and casein (55 g) in comparison with lactose (56 g) and glucose
(56 g) controls in overweight, prediabetic subjects [41]. Although a significant reduction in glucose
response was shown, insulin concentrations were not affected. Furthermore, no impact on post-meal
insulinaemia in accordance with a 16% reduction in post-meal glycemia over 360 min in overweight
subjects further supports observations of the current study product [46]. Thus, one might assume
that the current milk protein hydrolysate containing bioactive peptides may influence plasma glucose
via insulin-independent mechanisms. This is supported by in vitro experiments demonstrating the
alpha-glucosidase acting mode of action for the study product (unpublished data). Therefore, one
might speculate that the slight reduction in insulin release might be a secondary response due to lower
postprandial increase of glucose.
We further assessed the effect of the milk protein hydrolysate with bioactive peptides for a longer
period of six weeks with a daily intake of 1400 mg of the study product. Notably, this intervention
resulted in a slight improvement of whole-body insulin sensitivity (hepatic and peripheral tissue
insulin sensitivity) as assessed by the Matsuda index. The change was not significant (p = 0.0952),
which might be attributed to the limited samples size and needs further confirmation in future studies.
Additionally, one might assume that the current milk protein hydrolysate containing bioactive peptides
may influence whole-body insulin sensitivity secondary to its primary effects on alpha-glucosidase
inhibition, which were not obvious after the limited intervention period of six weeks. In addition, the
longer intervention period did not strengthen the postprandial effect on glucose response, as iAUC
values were comparable to those of single dose intake.
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In summary, the study product primarily influenced postprandial glycemia and secondarily
influenced insulin sensitivity in the whole body, suggesting rather insulin-independent mechanisms or
temporal changes in insulin sensitivity. Moreover, the six week intervention period accentuates the
more glycemic and less insulinotropic effect of the current milk protein hydrolysate, as the glycemic
marker HbA1c was significantly reduced (p = 0.0244). Notably, 52.4% of the subjects completed the
study with HbA1c levels < 5.7% after the six week intervention period, and the significant reduction of
HbA1c is worth mentioning in the short time period of six weeks, which has to be confirmed in further
studies with longer intervention periods.
Regarding study limitations, the current study was performed in cross-over design to control
for inter-individual variability. This variability cannot be estimated from the data, as study products
were only provided once to subjects. Nevertheless, data from the open-label single arm phase
performed with a daily intake of the low-dosed milk peptide concentration for six weeks suggest
minor inter-individual variability and overall confirmed the results of the three-way-cross-over study
with single dose intake regimen. Furthermore, one has to take into account that T2DM—and even the
prediabetic state—is a heterogeneous disease with multiple pathophysiologies. Both incretins and
microbiota in the gastrointestinal tract are known to be affected in prediabetics [47,48], which might
have an impact on the postprandial responses. Although these parameters were not assessed in this
study, the current results look very promising and should be confirmed in further investigations.
5. Conclusions
The objective of the current study was to assess whether alpha-glucosidase inhibiting bioactive
peptides from milk protein hydrolysate might improve postprandial glucose profiles in prediabetic
subjects. We demonstrated that low dose milk peptides had a significant impact on postprandial
blood glucose profile with more glycemic than insulinotropic properties in prediabetic subjects after
a challenge meal high in carbohydrates. This was confirmed after a single dose intake and after
a six week intervention period, whereas impacts on postprandial effects were not strengthened by
intervention over a longer period. Furthermore, the study product primarily influenced postprandial
glycemia and secondarily influenced insulin sensitivity in the whole body, as only a minor increase of
the Matsuda index and a slight but significant reduction of HbA1C levels were demonstrated after the
six week intervention period.
The investigated hydrolyzed milk-derived bioactive peptides (1.4 g/day) of native whey origin
seem to be promising and well-tolerated by prediabetic subjects to control postprandial glucose levels,
which should be confirmed in further clinical studies with longer intervention periods to ascertain the
benefits for glucose homeostasis.
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32. Babij, K.; Dąbrowska, A.; Szołtysik, M.; Pokora, M.; Zambrowicz, A.; Chrzanowska, J. The Evaluation
of Dipeptidyl Peptidase (DPP)-IV, α-Glucosidase and Angiotensin Converting Enzyme (ACE) Inhibitory
Activities of Whey Proteins Hydrolyzed with Serine Protease Isolated from Asian Pumpkin (Cucurbita
ficifolia). Int. J. Pept. Res. Ther. 2014, 20, 483–491. [CrossRef]
33. Kung, B.; Anderson, G.H.; Paré, S.; Tucker, A.J.; Vien, S.; Wright, A.J.; Goff, H.D. Effect of milk protein intake
and casein-to-whey ratio in breakfast meals on postprandial glucose, satiety ratings, and subsequent meal
intake. J. Dairy Sci. 2018, 101, 8688–8701. [CrossRef]
34. Chakrabarti, S.; Jahandideh, F.; Davidge, S.T.; Wu, J. Milk-Derived Tripeptides IPP (Ile-Pro-Pro) and VPP
(Val-Pro-Pro) Enhance Insulin Sensitivity and Prevent Insulin Resistance in 3T3-F442A Preadipocytes.
J. Agric. Food Chem. 2018, 66, 10179–10187. [CrossRef]
35. Sawada, Y.; Sakamoto, Y.; Toh, M.; Ohara, N.; Hatanaka, Y.; Naka, A.; Kishimoto, Y.; Kondo, K.;
Iida, K. Milk-derived peptide Val-Pro-Pro (VPP) inhibits obesity-induced adipose inflammation via an
angiotensin-converting enzyme (ACE) dependent cascade. Mol. Nutr. Food Res. 2015, 59, 2502–2510.
[CrossRef]
36. Tessari, P.; Kiwanuka, E.; Cristini, M.; Zaramella, M.; Enslen, M.; Zurlo, C.; Garcia-Rodenas, C. Slow versus
fast proteins in the stimulation of beta-cell response and the activation of the entero-insular axis in type 2
diabetes. Diabetes Metab. Res. Rev. 2007, 23, 378–385. [CrossRef]
37. Nilsson, M.; Holst, J.J.; Bjorck, I.M. Metabolic effects of amino acid mixtures and whey protein in healthy
subjects: studies using glucose-equivalent drinks. Am. J. Clin. Nutr. 2007, 85, 996–1004. [CrossRef]
38. Gunnerud, U.J.; Heinzle, C.; Holst, J.J.; Ostman, E.M.; Bjorck, I.M.E. Effects of pre-meal drinks with protein
and amino acids on glycemic and metabolic responses at a subsequent composite meal. PLoS ONE 2012, 7,
e44731. [CrossRef]
39. Ostman, E.M.; Liljeberg Elmstahl, H.G.; Bjorck, I.M. Inconsistency between glycemic and insulinemic
responses to regular and fermented milk products. Am. J. Clin. Nutr. 2001, 74, 96–100. [CrossRef]
40. Pasin, G.; Comerford, K.B. Dairy foods and dairy proteins in the management of type 2 diabetes: A systematic
review of the clinical evidence. Adv. Nutr. 2015, 6, 245–259. [CrossRef]
41. Bowen, J.; Noakes, M.; Trenerry, C.; Clifton, P.M. Energy intake, ghrelin, and cholecystokinin after different
carbohydrate and protein preloads in overweight men. J. Clin. Endocrinol. Metab. 2006, 91, 1477–1483.
[CrossRef]
174
Nutrients 2019, 11, 1700
42. Hamarsland, H.; Nordengen, A.L.; Nyvik Aas, S.; Holte, K.; Garthe, I.; Paulsen, G.; Cotter, M.; Børsheim, E.;
Benestad, H.B.; Raastad, T. Native whey protein with high levels of leucine results in similar post-exercise
muscular anabolic responses as regular whey protein: a randomized controlled trial. J. Int. Soc. Sports Nutr.
2017, 14, 43. [CrossRef]
43. Manders, R.J.F.; Wagenmakers, A.J.M.; Koopman, R.; Zorenc, A.H.G.; Menheere, P.P.C.A.; Schaper, N.C.;
Saris, W.H.M.; van Loon, L.J.C. Co-ingestion of a protein hydrolysate and amino acid mixture with
carbohydrate improves plasma glucose disposal in patients with type 2 diabetes. Am. J. Clin. Nutr. 2005, 82,
76–83. [CrossRef] [PubMed]
44. Manders, R.J.; Koopman, R.; Sluijsmans, W.E.; van den Berg, R.; Verbeek, K.; Saris, W.H.; Wagenmakers, A.J.;
van Loon, L.J. Co-ingestion of a protein hydrolysate with or without additional leucine effectively reduces
postprandial blood glucose excursions in Type 2 diabetic men. J. Nutr. 2006, 136, 1294–1299. [CrossRef]
[PubMed]
45. Manders, R.J.F.; Hansen, D.; Zorenc, A.H.G.; Dendale, P.; Kloek, J.; Saris, W.H.M.; van Loon, L.J. Protein
co-ingestion strongly increases postprandial insulin secretion in type 2 diabetes patients. J. Med. Food 2014,
17, 758–763. [CrossRef] [PubMed]
46. Pal, S.; Ellis, V.; Ho, S. Acute effects of whey protein isolate on cardiovascular risk factors in overweight,
post-menopausal women. Atherosclerosis 2010, 212, 339–344. [CrossRef]
47. Færch, K.; Torekov, S.S.; Vistisen, D.; Johansen, N.B.; Witte, D.R.; Jonsson, A.; Pedersen, O.; Hansen, T.;
Lauritzen, T.; Sandbæk, A.; et al. GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected
Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study. Diabetes 2015, 64, 2513–2525.
[CrossRef] [PubMed]
48. Allin, K.H.; Tremaroli, V.; Caesar, R.; Jensen, B.A.H.; Damgaard, M.T.F.; Bahl, M.I.; Licht, T.R.; Hansen, T.H.;
Nielsen, T.; Dantoft, T.M.; et al. Aberrant intestinal microbiota in individuals with prediabetes. Diabetologia
2018, 61, 810–820. [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution





Glucose Response during the Night Is Suppressed by
Wheat Albumin in Healthy Participants:
A Randomized Controlled Trial
Shinichiro Saito 1,*, Sachiko Oishi 1, Aiko Shudo 2, Yoko Sugiura 2 and Koichi Yasunaga 2
1 Biological Research Laboratories, Kao Corporation, 2-1-3 Bunka Sumida-ku, Tokyo 131-8501, Japan;
oishi.sachiko@kao.com
2 Health Care Food Research Laboratories, Kao Corporation, 2-1-3 Bunka Sumida-ku, Tokyo 131-8501, Japan;
shudou.aiko@kao.com (A.S.); sugiura.yoko@kao.com (Y.S.); yasunaga.kouichi@kao.com (K.Y.)
* Correspondence: saito.shinichiro@kao.com; Tel.: +81-3-5630-7456
Received: 25 December 2018; Accepted: 15 January 2019; Published: 17 January 2019
Abstract: Postprandial blood glucose excursions are important for achieving optimal glycemic control.
In normal-weight individuals, glucose tolerance is diminished in the evening compared to glucose
tolerance in the morning. Wheat albumin (WA) has the potential to suppress the postprandial glucose
response with a relatively small dose, compared to the dose required when using dietary fiber. In the
present study, the effect of WA on glycemic control during the night was investigated after a late
evening meal. A randomly assigned crossover trial involving a single oral ingestion in healthy male
participants was performed in a double-blind placebo-controlled manner. The participants ingested
the placebo (PL) tablets or the WA (1.5 g)-containing tablets 3 min before an evening meal at 22:00
hour, and blood samples were drawn during the night until 07:00 hour using an intravenous cannula.
The participants slept from 00:30 hour to 06:30 hour. Glucose response, as a primary outcome during
the night, was suppressed significantly by the WA treatment compared to the PL treatment, but the
insulin response was not. Plasma glucose-dependent insulinotropic polypeptide concentration during
the night was lowered significantly by the WA treatment compared to the PL treatment. In conclusion,
WA may be a useful food constituent for glycemic control during the night.
Keywords: glucose; human; night; postprandial; wheat albumin
1. Introduction
An estimated 425 million people worldwide had diabetes in 2017, and this number is projected to
reach 700 million by 2045 [1]. Many epidemiologic studies have demonstrated a complex association
between glycemia and cardiovascular risk [2,3], with evidence suggesting that an acute increase in
glycemia, particularly after a meal, may have direct detrimental effects on the cardiovascular system [4].
Until recently, there has been a strong emphasis on fasting plasma glucose, and the predominant
focus of therapy has been on lowering hemoglobin A1c (HbA1c) levels [5]. Although the control of
fasting hyperglycemia is necessary, it is usually not sufficient to achieve optimal glycemic control.
A growing body of evidence suggests that the reduction of postprandial plasma glucose excursions is
as important, or perhaps even more important for achieving HbA1c goals [6,7]. The use of a variety
of both non-pharmacologic and pharmacologic therapies is recommended to control postprandial
plasma glucose [7]. This is particularly relevant during the night, as glucose tolerance is diminished
compared to its level in the morning, even in normal-weight individuals [8–16]. Therefore, even in
healthy, non-diabetic people, the use of non-pharmacologic therapies, such as the control of dietary
and fitness habits, to protect against impaired glucose tolerance during the night is recommended.
Wheat albumin (WA) has a long history of consumption in humans as a natural food constituent
and is a potentially protective agent against postprandial hyperglycemia via its alpha-amylase
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inhibiting activity with no change in insulin secretion [17], suggesting that WA might improve
postprandial insulin sensitivity. Inhibitors of carbohydrate digestion and absorption have been
reported to improve blood glucose control with a low risk of hypoglycemia [18], so WA might be a
good candidate for night care. Additionally, WA has the potential to suppress the glucose response at a
relatively lower dose [17] than other food constituents like wheat or oat fiber (~6 g) [19,20]. Therefore,
it could be used in a wide variety of functional food products or incorporated easily into a habitual diet.
Thus, the primary objective of the present study was to investigate the potential effect of WA
as a dietary therapy agent to protect against the diminished glucose response during the night in
healthy individuals.
2. Materials and Methods
2.1. Ethics Approval and Consent to Participate
This study was performed in accordance with the tenets of the Declaration of Helsinki (2013)
and was approved by the Ethical Committee of the Oriental Ueno Kenshin Center (Tokyo, Japan).
After receiving a full explanation of the study, all participants provided written informed consent.
The study was registered with the University Hospital Medical Information Network (UMIN) clinical
registry, prior to the enrollment of the first participant, as UMIN000014533 (registered 15 July 2014 [21].
2.2. Study Design
This was a randomized, double-blind, placebo-controlled, crossover trial with a 1-week washout
period, performed under the supervision of a physician in charge. Between the screening and the
second visit, the participants were instructed to maintain and record their normal level of physical
activity and their normal dietary, alcohol, and smoking habits. As shown in Figure 1, during the
study, the participants were free-living, but were prohibited from drinking alcohol the day before
the visits to the clinic and from smoking cigarettes for 2 hours before the visits. The participants ate
designated meals for dinner in the evening at 21:00 hour one day before the trial, and for breakfast
at 08:00 hour and lunch at 12:00 hour on the day of the trial. The participants were not allowed any
energy intake after the designated dinner until the trial. The participants visited the clinic at 17:00
hour and were examined by the physician in charge. From 17:00 hour to 22:00 hour, anthropometric
parameters were measured, and for the rest of the time participants read books or watched TV for
naturalization in a sitting position with no energy consumption. Immediately after obtaining a blood
sample, the participants orally ingested a single dose of WA (1.5 g)-containing tablets or placebo (PL)
tablets 3 min before ingesting a designated evening meal at 22:00 hour. Blood samples were then
drawn every 30 min until 00:00 hour, and then at 01:00 hour, 02:00 hour, and 07:00 hour, using an
intravenous cannula. The participants slept from 00:30 hour to 06:30 hour, and their sleep quality was
measured using an ActiGraph (ActiGraph, Pensacola, FL, USA). The amount and timing of water
consumption during the visits were controlled. The study was conducted at Sumida Hospital, Tokyo,
Japan and managed by TES Holdings Co., Ltd. (Tokyo, Japan), a contract research organization (CRO).
The CRO managed the random allocation, enrollment, assignment of participants, and blinding of the
assignment, and assessed the outcomes under the supervision of the physician in charge. Throughout
the study (from screening to finalizing the dataset), the treatment allocation was concealed from
the people involved, including the participants, the caregivers, the physicians, the CRO members,
the manufacturer of the test tablets, the person in charge of the allocation, and the outcome assessors.
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Figure 1. The study protocol.
2.3. Participants
The appropriate sample size for the primary outcome of postprandial blood glucose was estimated
to be 20 participants based on the outcomes of our unpublished pilot study (power 0.8 and type I
error 0.05). In the present study, potential participants were screened based on the following inclusion
criteria: (1) 5.3 ≤ fasting blood glucose < 7.0 mmol/L, (2) 5.2 ≤ HbA1c < 6.5%, (3) 23 ≤ body mass
index (BMI) < 30, and (4) 30 ≤ age < 60 years. Participants were excluded if they met the following
exclusion criteria: (1) presence of liver, kidney, or heart disease; respiratory, endocrine, or nervous
system disorder; metabolism or consciousness dysfunction; diabetes; or other disease, (2) surgery
in the 2 months before the trial, (3) history of gastrectomy or enterectomy, (4) taking medications
for hyperglycemia, lipidemia, or hypertension, (5) taking supplements or food for a specific health
use authorized by the government, (6) allergies to any constituents in the test meal or tablets, (7) an
unpleasant feeling during blood draws, (8) donated 200 mL or more of blood in the month before the
trial, (9) habitual breakfast skippers, (10) heavy smokers (>20 cigarettes/day), or (11) shift workers.
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The conditions and procedures of the trial were reviewed with all participants before they signed the
informed consent form. The participants were randomly assigned to each sequence (ingestion order)
with stratified randomization for glucose, hemoglobin A1c, age, and BMI using computer-generated
random numbers under blind conditions.
2.4. Test Tablets and Meals
The designated 3 meals (the dinner on the day before the trial, and the breakfast and lunch on
the day of the trial) consisted of a Japanese-style diet, such as rice, miso soup, simmered vegetables,
grilled meats, and snacks with a total of 9142 kJ (protein = 14%, fat = 22%, and carbohydrate = 64% of
the total energy), were provided by the physician in charge before the trial. The test tablets contained
1.5 g WA in 3 tablets for a single oral administration. The PL tablets were prepared using identical
ingredients, including flavors and preservatives, but did not contain WA. Each tablet weighed 1.1 g.
The energy values were 14.7 kJ per WA tablet and 10.9 kJ per PL tablet. The tablets could not be
distinguished by appearance, taste, or odor, and were provided to the CRO after concealment by
the manufacturer. The CRO then re-concealed the test tablets and provided them to the participants.
The test evening meal on the trial day consisted of curry and rice with a total of 2579 kJ (protein = 7%,
fat = 11%, and carbohydrate = 81% of the total energy).
2.5. Laboratory Measurements
The blood samples collected for measuring glucose, insulin, and triglyceride were centrifuged
at 1000× g for 15 min at 4 ◦C to isolate the serum or plasma. The measurements were performed
by the Health Sciences Research Institute, Inc. (Yokohama, Kanagawa, Japan). Blood samples for
total glucose-dependent insulinotropic polypeptide (GIP) and active glucagon-like peptide-1 (GLP-1)
were collected into BD P800 tubes (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) on
ice and centrifuged at 1000× g for 15 min at 4 ◦C to isolate the plasma. Total GIP and active GLP-1
were measured using commercially available enzyme-linked immunosorbent assay kits obtained from
Immuno-Biological Laboratories, Co., Ltd. (Fujioka, Gunma, Japan).
2.6. Statistics
The primary outcome of this study was the difference in the area under the curve (AUC) of
the blood glucose response during the night (9 hours from 22:00 hour to 07:00 hour) between the
treatments assessed with the mixed model, adjusted by sequences and treatments as a fixed effect.
As an exploratory assessment, analysis of covariance was also performed on the slope of the changes
in the parameters using the linear mixed model, and the p-values for the time and treatment effect and
the treatment by time interaction were obtained. In addition, the Bonferroni correction for multiple
comparisons was applied to assess statistical difference on each time point between the treatments.
A two-sided p-value ≤ 0.05 was considered to indicate statistical significance. All statistical analyses
were performed using IBM SPSS Statistics version 19 (IBM Co., Armonk, NY, USA).
3. Results
3.1. Characteristics of the Participants
Eighty-five individuals were screened, and 22 were recruited. Of those recruited, one participant
missed the second visit for unknown reasons, and one dropped out due to feeling sick before
ingesting the test tablets on the day of the second visit. Based on an examination by the physician
in charge, there was no relationship between the reason for dropping out and the test tablets. Thus,
20 participants completed the study and were included in the analyses. The baseline characteristics
of these participants are presented in Table 1. From screening until the second visit, no considerable
habitual changes were recorded. The percentage of sleep did not differ significantly between the
treatments (88.1 ± 2.3% after PL treatment and 86.3 ± 3.0% after WA treatment).
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Table 1. Baseline characteristics of participants.
Parameter Value
Number of participants (male/female) 20 (20/0)
Age, years 51 ± 1
Body weight, kg 75.8 ± 1.7
Body mass index, kg/m2 26.0 ± 0.4
Systolic blood pressure, mmHg 116 ± 2
Diastolic blood pressure, mmHg 76 ± 2
Glucose, mmol/L 5.19 ± 0.05
Insulin, pmol/L 39 ± 4
Triglyceride, mg/dL 1.61 ± 0.16
HbA1c, % 5.6 ± 0.1
Data are mean ± standard error.
3.2. Effects of WA on Blood Glucose, Insulin, and Triglyceride Response during Night
A comparison between the PL and WA treatments revealed that the increase in blood glucose
concentration during the night was suppressed significantly by WA, as shown by the AUC. In the
exploratory analysis, the treatment by time interaction was also shown to be significant. WA only
suppressed the glucose response for 2 hours after the meal, but not after bedtime, suggesting that a
hypoglycemic risk by WA treatment was not observed (Figure 2).
Insulin response was not shown to be significantly different in the AUC and interaction
assessments, however, a significant treatment effect was observed (Figure 3).
Blood triglyceride was also measured during the night, but no considerable differences between
the treatments were observed (data not shown).
 
Figure 2. Changes in the blood glucose level during the night following the placebo (PL) (broken line,
n = 20) and wheat albumin (WA) treatments (solid line, n = 20). (Left) Changes in the blood glucose
response. (Right) The AUC of the blood glucose level for 9 h from 22:00 hour to 7:00 hour. Data are the
mean ± standard error. Significant differences between the treatments: * p < 0.05, *** p < 0.001.
3.3. Effects of WA on Incretins during the Night
The AUC of the GIP concentration in the blood was significantly lower following the WA treatment
than following the PL treatment, but the treatment by time interaction was unchanged. Interestingly,
the difference was large at bedtime, but there was no difference in the postprandial state for 2 hours
after the meal (Figure 4). There were no significant differences in the blood GLP-1 concentration in any
of the assessments (Figure 5).
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Figure 3. Changes in the blood insulin level during the night between the PL (broken line, n = 20) and
the WA treatments (solid line, n = 20). (Left) Changes in the blood insulin response. (Right) The AUC
of the blood insulin level for 9 h from 22:00 hour to 7:00 hour. Data are the mean ± standard error.
Significant differences between the treatments: * p < 0.05.
 
Figure 4. Changes in the blood glucose-dependent insulinotropic polypeptide (GIP) level during the
night between the PL (broken line, n = 20) and WA treatments (solid line, n = 20). (Left) Changes in the
blood GIP response. (Right) The AUC of the blood GIP level for 9 h from 22:00 hour to 7:00 hour. Data
are the mean ± standard error.
 
Figure 5. Changes in the blood active glucagon-like peptide-1 (GLP-1) level during the night between
the PL (broken line, n = 20) and the WA treatments (solid line, n = 20). (Left) Changes in the blood
GLP-1 response. (Right) The AUC of the blood GLP-1 level for 9 h from 22:00 hour to 7:00 hour. Data
are the mean ± standard error.
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4. Discussion
For healthy individuals, the recommended strategies to prevent an elevated glucose level at
night are non-pharmaceutical, such as diet and exercise. Dietary therapy is perhaps easier to achieve,
and thus may give more continuous efficacy, especially before sleep. Accompanied by the widespread
use of a non-invasive glucose monitoring system, nocturnal hypoglycemia and its mortuary risk have
been investigated in diabetic patients treated with insulin therapy [22]. However, in healthy individuals
and individuals with borderline high values, the risk of a nocturnal hypoglycemic state is also best
avoided. Therefore, the use of a food constituent with a moderate efficacy may be an alternative
strategy for night care. As previously reported, WA has a suppressive effect on the postprandial
glucose level via its inhibitory action on alpha-amylase activity [17], suggesting its potential as a low
risk strategy for glycemic control during the night. Therefore, this study investigated the effect of
WA on glucose response during the night in healthy individuals. As expected, WA contributed to a
lower glucose response during the night but showed no hypoglycemic effect when compared to the
PL (Figure 2). Thus, WA is a good candidate as a strategy for bedtime glycemic control in healthy
individuals, and perhaps in diabetic patients alongside insulin therapy; however, additional studies
are required for these patients to assess safety concerns.
An epidemiology study showed that the habitual intake of late-evening meals was associated
with a higher BMI and metabolic risk factors such as high triglycerides and lower high-density
lipoprotein cholesterol [23]. A potential explanation for this is the reduced metabolic rate and fuel
utilization that occur during sleep [24]. GIP, an incretin that stimulates insulin secretion from pancreatic
beta-cells, was reported to have a higher concentration postprandially that was directly associated
with a lower metabolic rate [25] and the stimulation of fat accumulation in adipose tissue as an
exopancreatic function. In contrast, GLP-1 did not show associations with these factors [26,27].
Moreover, higher blood GIP levels induced by chronic GIP treatment reduced fat utilization in high-fat
diet-fed mice [28]. Interestingly, a bigger difference in the total GIP response between the PL and the
WA treatments occurred after sleep than before sleep (Figure 4), with a moderate effect on insulin
(Figure 3). These findings indicate that WA affects the later phase of the blood GIP level or its secretion,
rather than the earlier phase. This might induce metabolic differences in the extrapancreatic actions
of GIP, as mentioned above. Therefore, WA might improve not only glucose metabolism, but also fat
utilization as energy by lowering the extrapancreatic actions of GIP during sleep. However, further
investigation of the effects of WA on metabolic rate or fuel utilization during the night is required.
Dietary intake in the late evening has been suggested to alter clock genes such as Bmal1 and
Clock [29]. Bmal1 knockout mice showed a higher blood glucose concentration than a wild type [30,31].
Circadian mutant mice, and both Clock [32,33] and Bmal1 [34] mutants, showed impaired glucose
tolerance, reduced insulin secretion, and defects in the size and proliferation of pancreatic islets that
worsened with age. Thus, habitual late-evening meals may induce impaired glucose tolerance and the
development of diabetes. As shown in our study, WA has the potential to reduce factors relating to
the development of metabolic disorders, such as higher glucose and GIP responses during the night,
through consumption in an evening meal, so WA can be expected to rearrange disordered circadian
rhythms. Thus, a further investigation into the effect of WA on glucose tolerance with a focus on
circadian rhythms or clock gene expression would be of great interest.
Overall, further studies to investigate the effects of WA on glycemic control during the night in
diabetic patients, on energy metabolism, and on circadian clock genes would be of considerable interest.
The limitations and potential biases in this study were the imbalanced gender of the participants
(only men), the use of a single race (Japanese), and the inadequate sample size for stratified analyses
based on the participants’ characteristics, such as BMI and fasting glucose level. In addition, all authors
in this study are employees of the manufacturer of the studied ingredient.
5. Conclusions
WA might be a useful food constituent for glycemic control during the night.
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Abstract: Sucrose overfeeding increases intrahepatocellular (IHCL) and intramyocellular (IMCL) lipid
concentrations in healthy subjects. We hypothesized that these effects would be modulated by diet
protein/fat content. Twelve healthy men and women were studied on two occasions in a randomized,
cross-over trial. On each occasion, they received a 3-day 12% protein weight maintenance diet
(WM) followed by a 6-day hypercaloric high sucrose diet (150% energy requirements). On one
occasion the hypercaloric diet contained 5% protein and 25% fat (low protein-high fat, LP-HF), on the
other occasion it contained 20% protein and 10% fat (high protein-low fat, HP-LF). IHCL and IMCL
concentrations (magnetic resonance spectroscopy) and energy expenditure (indirect calorimetry)
were measured after WM, and again after HP-LF/LP-HF. IHCL increased from 25.0 ± 3.6 after WM
to 147.1 ± 26.9 mmol/kg wet weight (ww) after LP-HF and from 30.3 ± 7.7 to 57.8 ± 14.8 after HP-LF
(two-way ANOVA with interaction: p < 0.001 overfeeding x protein/fat content). IMCL increased
from 7.1 ± 0.6 to 8.8 ± 0.7 mmol/kg ww after LP-HF and from 6.2 ± 0.6 to 6.9 ± 0.6 after HP-LF,
(p < 0.002). These results indicate that liver and muscle fat deposition is enhanced when sucrose
overfeeding is associated with a low protein, high fat diet compared to a high protein, low fat diet.
Keywords: sucrose overfeeding; hepatic steatosis; intramyocellular lipids; intrahepatocellular lipids;
dietary protein content; dietary fat content; energy expenditure; plasma triglyceride
1. Introduction
Consumption of hypercaloric high-fructose or high-sucrose diets can lead to the deposition of
fat in ectopic sites such as visceral adipose tissue, the liver (intrahepatocellular lipids, IHCL), skeletal
muscle (intramyocellular lipids, IMCL), the heart, and the pancreas [1]. Such ectopic fat deposition has
been associated with insulin resistance and increased risk of cardiovascular and hepatic disorders [2,3].
In addition, hypercaloric high-fructose diets have been shown to impair hepatic insulin sensitivity [4,5],
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to increase fasting and postprandial blood triglycerides [6,7] and uric acid [8] concentrations, and may
therefore be associated with a particularly ominous constellation of cardiometabolic risk factors.
Most studies that have documented metabolic effects of fructose or sucrose overfeeding have
involved either the addition of fructose or sucrose to a weight maintenance diet, or the substitution of
fructose or sucrose for dietary starch. In real life conditions, however, the addition of sucrose to an
ad libitum diet is expected to impact habitual food consumption and hence to alter both total energy
intake and the dietary macronutrient composition. It has indeed been reported that the addition of
fructose-sweetened beverages to the spontaneous diet of overweight subjects was associated with
a partial suppression of dietary fat and protein intake from solid foods [9]. One may therefore
hypothesize that the metabolic effects of overfeeding depend not only on the amount of excess sucrose,
but also on how it impacts other dietary macronutrient intake. Dietary sucrose and fat content may
have additive effects on IHCL [10]. Interactions between dietary sucrose and protein are also relevant,
since dietary protein intake has been shown to modulate overfeeding-induced ectopic lipid storage:
in rodents fed a high fructose diet, the increase in IHCL was lower when excess dietary fructose
was associated with a high, compared to a low, protein intake [11,12]. Similar observations were
reported for humans overfed with lipids and protein compared to lipids alone [13–15], and with
fructose and essential amino-acids compared with fructose alone [16]. In addition, a high protein
intake is associated with an increase in energy expenditure, and may thus reduce energy storage [17].
We therefore hypothesized that, in normal weight human subjects, a short-term sucrose overfeeding
associated with a high-protein, low-fat intake would blunt intrahepatocellular and intramyocellular
lipid storage compared to the same sucrose overfeeding associated with a low-protein, high-fat diet.
To assess this hypothesis, we carried out a randomized, cross-over controlled trial in 12 healthy male
and female subjects. We monitored IHCL and IMCL, postprandial energy expenditure (EE), and blood
metabolite concentrations at baseline, i.e. after 3 days on a 10% sucrose weight maintenance diet (WM),
and after 6-days overfeeding with 50% extra-energy added as 40% sucrose and 10% lactose with either
a high protein-low fat (HP-LF) or a low protein-high fat (LP-HF) content.
2. Materials and Methods
2.1. Subjects
Twelve healthy and non-obese volunteers (6 males, mean age 21 ± 1 years, weight 71.6 ± 2.3 kg,
BMI 22.5 ± 0.8 kg/m2; 6 females mean age 23 ± 1 years, weight 57.3 ± 0.8 kg, BMI 21.2 ± 0.7 kg/m2)
were included in this study. Volunteers were recruited through advertisements posted at the University
of Lausanne and the Lausanne University Hospital. All volunteers were sedentary (less than 2 h of
strenuous physical activity per week), were nonsmokers, had no lactose intolerance as documented by
a lactose hydrogen breath test [18], and did not take any medication, (except for contraceptive agents
which were used by all female participants). They all provided informed written consent.
2.2. Experimental Protocol
The experimental protocol was approved by the ethical committee (Commission d’éthique
pour la recherche humaine de l’Etat de Vaud, Switzerland), and was registered at clinicaltrials.gov
(NCT02168218). All procedures were performed in accordance with the 1983 revision of the Declaration
of Helsinki. The primary outcome of the study was whole body protein turnover using labelled leucine,
and will be reported separately. IHCL, IMCL and EE, which are the main focus of this paper, were all
secondary outcomes. The experimental protocol is presented in Figure 1.
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Figure 1. Experimental protocol. Each participant took part in two overfeeding periods according to
a randomized, cross-over design. WM: weight maintenance diet, LP-HF: hypercaloric (150% energy
requirement high-sucrose, low protein-high fat); HP-LF: hypercaloric (150% energy requirement
high-sucrose, high protein-low fat); MRS: magnetic resonance spectroscopy for measurement of IHCL
and IMCL; M. test: metabolic test, consisting of measurements of energy expenditure, plasma hormones,
and substrate concentrations after ingestion of WM meal providing 40% of total energy requirements
(D0), or LP-HF/HP-LF meals providing 60% of total energy requirements.
2.3. Dietary Interventions
All participants were studied on two occasions, each one consisting of a 3-day (D-3–D-1)
weight-maintenance (WM), low sucrose diet followed by 6-day of sucrose + lactose overfeeding
(D1–D6). On one occasion this overfeeding consisted of a 5% dietary protein and 25% fat content; on
the other occasion, it was comprised of 20% dietary protein and 10% fat content. The dietary conditions
were applied according to a randomized, cross-over design (Figure 1). Randomization was performed
according to a pre-defined sequence, which was generated using R, version 3.0.1. (R Foundation for
Statistical Computing, Vienna, Austria). The intervention was not blinded due to the nature of the
drinks consumed. The two interventions were separated by a washout period of four to eight weeks.
WM diets were prepared from market foods and provided 100% of energy requirements (estimated
from basal energy expenditure, calculated with the Harris-Benedict equation, times a physical activity
level of 1.5). Food intake was partitioned into 3 meals/day and 2 snacks/day. It contained 45% of
total energy as starch, 10% as sucrose, 33% as lipid, and 12% as protein and 22.6 ± 0.9 g dietary
fiber/day; beverages were provided ad libitum as water. Overfeeding was attained by adding an extra
50% energy to the weight-maintenance energy requirements, in the form of six drinks per day. Drinks
were prepared with skimmed milk and sucrose for the HP-LF condition or with water, lactose, and
sucrose for the LP-HF condition, and had a volume of 218 ± 52 ml each. Solid diets were adjusted to
obtain the same total energy (150% energy requirement): starch (29%), sucrose (34%) and lactose (7%)
in both diets, with 20% protein (2.7 g/kg/day) and 10% fat in HP-LF or 5% protein (0.8 g/kg/day)
and 25% fat in LP-HF. The addition of fat in LP-HF was mainly achieved by the addition of olive oil,
butter, sauces, and cereals bars. Water consumption was left ad libitum. The detailed compositions of
all three diets are shown in Table 1.
During each intervention, participants came to the metabolic unit of the Physiology Department
of the University of Lausanne to consume their breakfasts, lunches, dinners, and three supplemental
drinks under supervision. Every day, they also received two packages of snacks, together with three
supplemental drinks during the overfeeding periods to consume between main meals, and were
instructed not to consume any other food or drinks except plain water.
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Starch 1061 (45) - 1054 - 1054 (29) 1043 - 1043 (29)
Sucrose 249 (10) - 241 965 1206 (34) 246 964 1210 (34)
Lactose - - - 245 245 (7) - 246 246 (7)
Protein 274 (12) - 194 - 194 (5) 514 178 692 (20)
Fat 781 (33) - 886 - 886 (25) 357 12 369 (10)
SFA 263 (34) - 313 - 313 (35) 184 - 184 (52)
MUFA 280 (36) - 389 - 389 (44) 102 - 102 (29)
PUFA 202 (26) - 168 - 168 (19) 55 - 55 (15)
Total kcal 2365 - 2375 1210 3585 2160 1400 3560
WM: weight maintenance diet; LP-HF: high-sucrose, low-protein; HP-LF: high-sucrose, high-protein. Data are
expressed as kcal/day; values into bracket represent % of total energy intake. For SFA, MUFA and PUFA, values
in () are given as % total fat intake.
2.4. Measurements of IHCL and IMCL
For each intervention, IHCL and IMCL were measured at 4:00 pm on the 3rd day (D-1) on the
WM diet (WMLP-HF and WMHP-LF) and on the 6th day (D6) on the hypercaloric diets (HP-LF and
LP-HF). IHCL and IMCL content were determined by 1H-MRS using a clinical 3T MR system (Verio,
Siemens Medical, Germany) using methods similar to those described previously for IMCL [19,20]
and for IHCL [21]. For the latter, quantification was based on the unsuppressed water signal corrected
for transverse relaxation (characterized by the T2 value) as determined in each subject individually.
Since T2 values were found to be significantly different before (WMLP-HF, WMHP-LF) versus after the
diets (LP-HF, HP-LF), but did not differ between diets (LP-HF vs. HP-LF), individually averaged T2
values for pre- and post-diet sessions were used for IHCL quantification. Results were expressed as
mmol/kg ww.
2.5. Metabolic Tests
On days following IHCL and IMCL measurements (D0 and D7), participants were asked to
arrive in the fasting state at the Metabolism, Nutrition and Physical Activity Research Center of the
Department of Physiology of the University of Lausanne at 7:00 am for a metabolic test (schema shown
in Figure 2). They had performed a 24-h urine collection the day before.
Figure 2. Schema of metabolic tests at D0 and D7.
This metabolic test aimed at comparing their fasting and postprandial energy expenditure,
plasma hormones, and substrate profiles during periods of weight maintenance and overfeeding. At
their arrival, participants were asked to void and discard their urine. They were then weighed and
transferred to a bed where they remained in a semi-recumbent position for the next 7.5 h. A catheter
was inserted into an antecubital vein for blood collection. Subjects remained fasted for the initial 2.5 h.
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Four fasting blood samples and a urine collection were obtained during this period. Thereafter, they
received two meals, one at 150 min and the second one at 330 min. Meal composition corresponded to
the current intervention (i.e., WM on D0 and either HP-LF or LP-HF on D7). The sum of these two
meals contained 40% (30% in first and 10% in the second meal) of total daily energy intake, which
corresponded to 40% of energy requirements with WM, and to 60% of daily energy requirements
during overfeeding periods (HP-LF and LP-HF). Postprandial blood samples were collected at the
times 210 min, 270 min, 330 min, 390 min, and 450 min. Respiratory gas exchanges were monitored
throughout the experiment by open-circuit indirect calorimetry (Quark RMR, version 9.1b, Cosmed,
Rome, Italy), except for brief interruptions during meals. A second urine collection was obtained at the
end of the test (time 450 min). Energy expenditure (EE) was calculated using the equations of Livesey
and Elia [22].
2.6. Analytical Procedures
Plasma glucose, triglycerides (TG), lactate, and urine urea were measured by enzymatic methods
(Randox Laboratories, Crumlin, County Antrim, UK). Plasma fructose concentrations were measured
by GC–MS apparatus (Agilent Technologies, Santa Clara, CA, USA) [23]. Insulin and glucagon were
assessed by radioimmunoassays (Millipore, Billerica, MA, USA). Plasma lipoprotein subfractions were
separated by ultracentrifugation [24].
2.7. Statistical Analysis
All results are expressed as means ± SEMs. Postprandial results for all parameters (except for
IGF1 and glucagon, which were determined in fasting conditions at only 2-time points postprandial)
were expressed as the incremental area under the curve (iAUC (0-300 min)), which was obtained using the
trapezoidal method by subtracting the fasting value. As a preliminary analysis, the normality of data
was checked with Shapiro-Wilk tests for all parameters analyzed. Non-normally distributed data were
log-transformed (IHCL, fasting insulin, glucagon, TG, and postprandial glucagon). Two-way ANOVA
assessed the effects of overfeeding, protein/fat content (HP-LF vs. LP-HF), and interaction between
overfeeding x protein/fat content with repeated measures. Tukey post hoc tests were performed to
compare individuals when needed. All statistical analyses were performed using Prism 7 (GraphPad
Software, Inc., La Jolla, USA). The number of subjects included in the study was based on a power
analysis related to whole body protein turnover (not reported here).
3. Results
The recruitment and follow up of subjects took place between June 2013 and April 2016. All
volunteers completed the investigation and reported that they did not take any additional caloric drinks
and food during the study. One volunteer was not included in the calculation of postprandial fructose
due to missing plasma samples. Two volunteers were excluded from 24 h urinary concentration,
excretion, and clearance calculation due to missing urine collections. All other calculations were
performed with all 12 volunteers.
3.1. Fasting Condition
Fasting parameters are shown in Table 2. All fasting parameters were not significantly different
after WMLP-HF and WMHP-LF. Body weight increased by 0.7 ± 0.1 kg (males 0.9 ± 0.2 kg, females
0.6 ± 0.1 kg) between D0 and D7 after LP-HF and by 1.4 ± 0.2 kg after HP-LF (males 1.8 ± 0.2 kg,
females 0.9 ± 0.1 kg) (for the whole group: p < 0.001 for overfeeding, p > 0.999 for protein/fat content,
p = 0.009 for overfeeding × protein/fat content). Fasting EE increased from 1.11 ± 0.06 kcal/min
(WMLP-HF) to 1.12 ± 0.05 kcal/min (LP-HF), and from 1.10 ± 0.05 kcal/min (WMHP-LF) to 1.18 ± 0.05
kcal/min (HP-LF), (p = 0.018 for overfeeding, p = 0.126 for protein/fat content, p = 0.024 overfeeding
x protein/fat content). Fasting plasma glucose, fructose, lactate, TG, and insulin all increased to the
same extent with HP-LF and LP-HF (Table 2). Fasting plasma NEFA decreased to the same extent with
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HP-LF and LP-HF. In contrast, fasting glucagon concentration and IGF-1 concentrations increased with
HP-LF, but remained stable (glucagon) or slightly decreased (IGF-1) with LP-HF.









Overfeeding Protein/Fat Content OxP
Glucose (mmol/L) 4.56 ± 0.07 4.78 ± 0.07 4.46 ± 0.11 4.76 ± 0.09 <0.001 0.444 0.383
Fructose (μmol/L) 25.95 ± 1.41 27.15 ± 1.49 26.35 ± 1.37 28.0 ± 1.32 0.022 0.611 0.750
Lactate (mmol/L) 0.70 ± 0.06 1.22 ± 0.07 0.64 ± 0.04 1.16 ± 0.09 <0.001 0.107 0.935
Uric acid (mmol/L) 0.38 ± 0.02 0.38 ± 0.03 0.39 ± 0.02 0.30 ± 0.02 <0.001 <0.001 <0.001
TG (mmol/L) 0.68 ± 0.07 1.54 ± 0.22 0.66 ± 0.08 1.68 ± 0.19 <0.001 0.429 0.119
NEFA (mmol/L) 0.72 ± 0.05 0.44 ± 0.09 0.77 ± 0.04 0.37 ± 0.07 <0.001 0.779 0.097
Insulin (μU/mL) 8.42 ± 0.83 10.95 ± 1.02 7.82 ± 0.79 11.73 ± 1.54 <0.001 0.744 0.295
Glucagon (pg/mL) 72.42 ± 4.83 72.49 ± 4.94 68.67 ± 4.03 79.27 ± 5.35 0.059 0.276 0.036
IGF-1 (ng/mL) 212 ± 13 176 ± 12 174 ± 18 208 ± 13 0.901 0.712 <0.001
WM: weight maintenance diet; LP-HF: high-sucrose, low-protein; HP-LF: high-sucrose, high-protein. All values are
mean ± SEM, n = 12. A significant difference in each condition, p < 0.05 (2-way ANOVA with repeated measures).
OxP: Overfeeding x protein/fat content.
3.2. IHCL and IMCL Concentrations
IHCL and IMCL concentrations after WM and after LP-HF and HP-LF are shown in Figure 3.
No statistically significant difference was observed between WMLP-HF and WMHP-LF. Compared to
WM conditions, IHCL and IMCL concentrations increased significantly with both LP-HF and HP-LF
overfeeding. However, IHCL increased more importantly with LP-HF than with HP-LF (p < 0.001 for
effect of overfeeding, p < 0.001 for effect of dietary protein/fat content, and p < 0.001 for interaction
overfeeding x protein/fat content). IMCL also increased more with LP-HF than with HP-LF (p < 0.001
for overfeeding, p = 0.025 for protein/fat content, and p = 0.002 for overfeeding x protein/fat content).
  
(a) (b) 
Figure 3. Intrahepatocellular (IHCL) (a) and intramyocellular (IMCL) lipids (b) in response to weight
maintaining diet (WMLP-HF and WMHP-LF) and overfeeding with LP-HF and HP-LF. n = 12; significant
responses from WMLP-HF and WMHP-LF were measured by 2-way ANOVA for repeated measures
with interaction. *: p < 0.001, interaction overfeeding × protein/fat content. $: p < 0.005, Tukey post
hoc tests.
3.3. Postprandial Parameters
Postprandial metabolic parameters were not significantly different after WM diets. Postprandial
EE and diet-induced thermogenesis were both significantly higher with LP-HF and HP-LF than under
their respective WM conditions. Furthermore, EE increased more after HP-LF (from 1.23 ± 0.05
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to 1.55 ± 0.06 kcal/min) than after LP-HF (from 1.24 ± 0.05 to 1.41 ± 0.06 kcal/min) (p < 0.001 for
overfeeding, p = 0.013 for protein/fat content, and p < 0.001 for overfeeding x protein/fat content).
The postprandial iAUCs for blood metabolites and hormones are shown in Table 3. Postprandial
blood glucose did not significantly change with HP-LF and LP-HF compared to their respectively WM
conditions. Postprandial fructose, lactate, TG, and insulin iAUC were significantly higher in HP-LF
and LP-HF than in the respective WM conditions.
Table 3. Metabolites and hormones at postprandial states.
Postprandial WM (LP-HF) LP-HF WM (HP-LF) HP-LF
p Value
Overfeeding Protein/Fat Content OxP
iAUC Glucose (mmol/L*300min) 504.0 ± 40.5 495.3 ± 69.2 560.3 ± 43.7 471.4 ± 57.2 0.242 0.616 0.189
iAUC Fructose (mmol/L*300min) 4.2 ± 0.3 30.3 ± 2.9 4.8 ± 0.5 23.4 ± 2.2 <0.001 0.005 0.003
iAUC Lactate (mmol/L*300min) 78.8 ± 12.8 239.8 ± 24.5 92.2 ± 15.1 139.3 ± 15.7 <0.001 0.001 0.001
iAUC TG (mmol/L*300min) 29.3 ± 6.8 121.3 ± 15.3 24.2 ± 8.0 126.7 ± 16.9 <0.001 0.986 0.471
iAUC NEFA (mmol/L*300min) −162.6 ± 12.5 −86.7 ± 23.2 −173.1 ± 11.0 −76.6 ± 17.2 <0.001 0.984 0.051
iAUC Insulin (μU/ml*300min) 11378 ± 1232 19228 ± 1708 11138 ± 1488 24123 ± 2790 <0.001 0.061 0.028
WM: weight maintenance diet; LP-HF: high-sucrose, low-protein; HP-LF: high-sucrose, high-protein. All values are
mean ± SEM, n = 12. A significant difference in each condition, p < 0.05 (2-way ANOVA, with repeated measures).
OxP: Overfeeding x protein/fat content. In the calculation of iAUC fructose (n = 11) one volunteer was excluded for
reason of missing plasma data.
HP-LF and LP-HF nonetheless differentially altered postprandial insulin, fructose, and lactate
concentrations: HP-LF increased postprandial insulin concentrations more than LP-HF, but decreased
postprandial fructose and lactate (see Table 3 for detailed statistics). Postprandial plasma uric acid
concentration, measured at time 450 min, decreased from 0.38 ± 0.02 (WM) to 0.30 ± 0.02 mmol/L
with HP-LF, but increased from 0.38 ± 0.03 (WM) to 0.42 ± 0.04 mmol/L with LP-HF (p = 0.283 for
overfeeding, p = 0.001 for diet, p < 0.001 for overfeeding × protein/fat content). Plasma glucagon,
measured at time 450 min, increased from 62.6 ± 3.3 to 87.9 ± 8.4 pg/mLwith HP-LF, but did not
change with LP-HF: 65.1 ± 4.4 vs. LP-HF: 70.6 ± 4.8 pg/mL, (p < 0.001 for overfeeding, p = 0.026 for
protein/fat content, and p = 0.001 for overfeeding x protein/fat content).
24-h urinary excretion and clearance of creatinine and uric acid are shown in Table 4. LP-HF and
HP-LF did not significantly change 24-h urinary excretion and clearance of creatinine. HP-LF increased
urinary excretion of uric acid and uric acid clearance while LP-HF decreased it. Compared to LP-HF,
HP-LF significantly increased urinary creatinine and uric acid clearance; it also increased total 24-h
uric acid excretion.








Overfeeding Protein/Fat Content OxP
24-h urinary excretion
Creatinine (mmol/24h) 13.6 ± 1.8 12.6 ± 1.2 13.0 ± 0.8 12.7 ± 1.1 0.264 0.450 0.638
Uric acid (mmol/24h) 3.5 ± 0.2 3.3 ± 0.2 3.3 ± 0.2 4.1 ± 0.4 0.049 0.238 0.022
Urinary clearance rate
Creatinine (ml/min) 129.8 ± 9.4 133.7 ± 9.7 135.1 ±10.8
153.0 ±
13.0 0.279 0.309 0.282
Uric acid (ml/min) 6.9 ± 0.6 6.5 ± 0.6 6.1 ± 0.4 10.0 ± 1.4 0.005 0.015 0.004
WM: weight maintenance diet; LP-HF: high-sucrose, low-protein; HP-LF: high-sucrose, high-protein. All values are
mean ± SEM, n = 10 as two volunteers were excluded because of missing samples. A significant difference in each
condition, p < 0.05 (2-way ANOVA, with repeated measures). OxP: Overfeeding x protein/fat content.
4. Discussion
This study was designed to assess whether the consequences of sucrose overfeeding differ
according to concomitant changes in daily protein and fat intake. Our main findings were that both
HP-LF and LP-HF increased IHCL, IMCL, and blood triglycerides concentrations, but increments
were reduced on average by 78% for IHCL and by 59% for IMCL with HP-LF compared to LP-HF.
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In addition, fasting and postprandial EE were significantly higher with HP-LF than LP-HF. However,
blood triglyceride concentrations were not significantly different with HP-LF and LP-HF. Finally, blood
uric acid concentrations were increased with LP-HF, but decreased with HP-LF.
Our experimental design compared the effects of two hypercaloric high sucrose diets, one
with a high protein-low fat content and the other with a low protein-high fat content, to that of
a weight maintenance control diet. All three diets contained an amount of starch equivalent to
approximately 45% total energy requirements, and the two hypercaloric diets contained 150% of
daily energy requirements, with about 50% of energy requirements as sucrose, and 7% of energy
requirements as lactose. Lactose intake was higher in HP-LF than in WM because of a high milk
protein intake and was balanced by lactose addition in LP-HF in order to have equal carbohydrate
amounts and composition in both diets. Dietary saturated-monounsaturated and polyunsaturated
fatty acid proportions were also different in each diet.
The dietary composition had a profound effect on the amount of ectopic lipids being deposited
during overfeeding. HP-LF and LP-HF both increased lipid storage in the liver and muscle, two
sites in which ectopic lipid deposition is known to be associated with adverse long-term effects [1].
Several short-term studies had previously documented that excess energy intake from fructose or
glucose increased IHCL [10,25,26] and IMCL [26–28]. In our study, this effect was most notable in
the liver, where IHCL increased by 542 ± 105% after LP-HF. It was milder in skeletal muscle, where
we nonetheless observed a significant increase of +24 ± 3% after LP-HF. In both sites, the increases
induced by HP-LF were significantly lower than those induced by LP-HF. Excess energy intake from
sugars is thought to increase IHCL by enhancing hepatic de novo lipogenesis and inhibiting intrahepatic
lipid oxidation [29]. Several hypotheses can be proposed to account for the differential effects of HP-LF
and LP-HF. First, LP-HF contained more lipids than HP-LF. Previous experiments have shown that fat
overfeeding increases IHCL synthesis from intestinally derived TG-rich lipoprotein particles and/or
circulating NEFA [13,30,31]. It has also been shown that fructose and fat have additive effects on
IHCL during combined fructose-fat overfeeding [10]. It is therefore likely that, with LP-HF, the high
dietary sugar and fat intake had additive effects on IHCL. Second, dietary protein may decrease IHCL
independently of dietary fat or energy intake. In support of this hypothesis, a former study reported
that IHCL were increased in healthy subjects fed a hypercaloric, high fat diet containing 130% energy
requirements. However, the addition of protein to this high fat diet resulted in a similar daily fat and
carbohydrate intake, but also in a higher total energy and protein intake with significantly reduced
IHCL [13]. The mechanisms by which an increased protein intake may reduce IHCL remain unknown.
Inhibition of de novo lipogenesis has been postulated [13], but fractional hepatic de novo lipogenesis
was stimulated to the same extent in healthy subjects overfed with fructose alone or with fructose and
proteins [16]. A stimulation of hepatic VLDL-TG secretion and extrahepatic VLDL-TG clearance [16],
or a protein-induced increase in plasma bile acid concentrations [13] have also been proposed to play
a role. In contrast, no effect of dietary protein intake on IMCL has been reported to our knowledge.
Finally, changes in dietary fatty acids composition may modulate diet-induced hepatic fat deposition
(reviewed in reference [32]). Hepatic steatosis in animal models is readily produced by consumption of
a high saturated fat diet with low PUFA content. In contrast, there is evidence that PUFA or oleic acid
supplementation may actually blunt diet-induced hepatic steatosis [32]. In the present study, dietary
protein intake in HP-LF was increased through the consumption of skimmed dairy products to avoid
an increase in SFA, and dietary fat intake in LP-HF was increased by consumption of vegetable oils
(mainly olive oil). As a result, total daily SFA intake was only slightly higher in LP-HF than in HP-LF
(34.7 ± 1.5 vs. 20.4 ± 0.9 g/day) while MUFA+PUFA intake was markedly increased. It is therefore
unlikely that the higher IHCL observed with LP-HF can be explained by the differences in dietary
fat composition.
The postprandial increases in plasma TG concentrations were 5-fold higher with HP-LF and 4-fold
higher with LP-HF than with WM. Several studies have reported that fructose and sucrose overfeeding
increases fasting and postprandial blood triglyceride by increasing hepatic de novo lipogenesis and
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VLDL-TG secretion and by decreasing the postprandial clearance of triglyceride-rich lipoprotein
particles [27,33,34]. It is therefore likely that an upregulation of lipogenic enzymes with sucrose
overfeeding contributed to this hypertriglyceridemia. However, the meals administered during the
metabolic tests contained 50% more total energy in overfeeding than in weight-maintenance control
conditions, and, therefore, contained also more sucrose and fat, which makes it difficult to sort out
the relative role of sucrose and other macronutrients. Globally, the increase in postprandial TG
concentrations was not significantly different in HP-LF and LP-HF.
The effect of overfeeding on energy expenditure was also markedly dependent on dietary
composition. Postprandial EE increased significantly with both HP-LF and LP-HF, mainly due to the
fact that the test meals ingested in both conditions had a caloric content 50% higher than in the control
weight-maintenance condition. Postprandial EE increased more with HP-LF than LP-HF. This is most
likely explained by the high energy cost of amino-acid metabolism [35].
We also assessed whether dietary composition had significant effects on postprandial blood
metabolic markers during overfeeding. The total carbohydrate and sucrose content of meals ingested
during the metabolic tests were higher in overfeeding than in the WM control condition, and
postprandial increments in blood fructose, lactate, and insulin were accordingly enhanced. Similarly,
postprandial NEFA was decreased to lower levels in overfeeding than in WM conditions. However,
postprandial blood glucose responses were not significantly altered. Most postprandial parameters
were not significantly different in HP-LF and LP-HF overfeeding. However, postprandial glucagon
increased more with HP-LF than with LP-HF, as expected due to the well-known stimulation of
glucagon secretion by circulating amino-acids after protein ingestion [36]. Surprisingly, blood fructose
and lactate concentration increased less with HP-LF than LP-HF. It is possible that the lower lactate
concentration was secondary to glucagon stimulating hepatic lactate uptake [37]. The lower fructose
response was unexpected, however, and may suggest that hepatic fructose extraction was enhanced
when consumed with proteins. Nutrient- or glucagon-mediated changes in portal blood flow may also
be implicated [38]. Alternatively, it is possible that gastric emptying was delayed with HP-LF meals,
thus accounting for a slower fructose absorption [39]. Finally, compared to WM, postprandial increases
in uric acid were higher with LP-HF, but lower with HP-LF, while urinary uric acid excretion and uric
acid clearance were significantly increased with HP-LF. This suggests that both HP-LF and LP-HF
increased uric acid production, possibly due to the fructose component of sucrose [40], and that an
increase in glomerular filtration rate, possibly mediated by glucagon [41], increased uric acid excretion,
thus preventing an increase in blood uric acid. Elevated lactate concentrations are also known to
impair renal uric acid clearance [42], and it is, therefore, possible that lower lactate concentrations
during HP-LF than LP-HF overfeeding also played a role. Our data, however, do not allow accurate
comparisons of uric acid production and excretion between HP-LF and LP-HF.
The present study limitations need to be acknowledged. First, we did not include isotopic
measurements of de novo lipogenesis and VLDL-TG kinetics, and therefore cannot identify the
mechanisms by which HP-LF decreased IHCL and IMCL compared to LP-HF. Second, not only
total dietary fat intake, but also the proportions of SFA-MUFA-PUFA were different between diets,
and we cannot exclude the possibility that this may have impacted IHCL or IMCL storage. Third, in
HP-LF condition, dietary protein content was increased by addition of dairy products; whether the
observed effects are generic to dietary proteins or specific to dairy products remains to be evaluated.
Finally, our study was of short duration and was limited to a small group of healthy male and female
subjects, and results may not apply to other subgroups of the population (e.g., overweight subjects or
subjects with the metabolic syndrome).
5. Conclusions
In summary, our data indicate that overfeeding with a high sucrose, high protein/low-fat diet
markedly reduces ectopic fat accumulation in the liver and muscle, and increases energy expenditure,
compared to an isocaloric overfeeding with high sucrose, low protein/high-fat diet. This may be due
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to an additive effect of sucrose and dietary fat and/or a protective effect of dietary protein on ectopic
fat accumulation.
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